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1.0 INTRODUCTION 
The major theme in this project was to conduct as broad a series 
of studies as possible in areas relevant to the manned space effort 
utilizin9 the expertise and facilities available within the Section on 
Pharmacology of the Medical Sciences Pr09ram in conjunction with 
informational input from various NASA sources. Several aspects can be 
sinqled out for specific impetus, such as studies of the effects of 
amphetamines (which were accessible during various NASA space missions); 
examination of brain biogenic amines systems and stress phenomena 
(extremely relevant to the stresses of space fli9ht); and the effects 
. of commonly used therapeutic aQents on a basic physio1oqical drive 
such as deprivation-induced fluid consumption. In addition, many of 
these projects qenerated spin-off projects in related areas that yielded 
valuable data with siqnificant relevance to aspects of the space proqram 
or to mankind. 
2.0 EFFECTS OF DRUGS ON DEPRIVATION-INDUCED FLUID CONSUMPTION 
A number of previous publications from this laboratory had utilized 
a standard test system for examinin~ the effects of druos on fluid con-
sumption of deprived animals. In this system, rats are deprived of fluid 
for 23 hours of each day, then Q;ven access to an unlimited (but measure-
able) quantity during the remaininQ 60 minutes. Temporal drinkinq patterns 
and volume consumed are recorded; druqs are administered 15 minutes prior 
to the start of a test session. This test system was used to test a 
number of sedative-hypnotic druqs and tricyclic antidepressants, as well 
as to examine tolerance and taste phenomena. 
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~ Effects of Various Depressant Drugs on Deprivation-Induced 
Water Consumption. 
The volume of water consumed in the standardized test system was 
siqnificant1.y increased by barbiturates (amobarbital, hexobarbital, 
methohex1tal, phenobarbital), sedative-hypnotics (~lutethimide, metha-
qualone, methyprylon), and anxiolyt;c agents (chlordiazepoxide, diazepam, 
meprobamate), but not by the antipsychotic aqent, promazine. This latter 
findinq confirms earlier studies with promazine and other phenothiazine 
derivatives. The results wit~ the depressant druqs 5uggests that all of 
these agents (includinq the anxiolytics) are capable of causinq physical 
dependence in rqan, since the only other clru~s showing a similar cfipsogenic 
action in rats are the opiate narcotics. (A-2, B-3) 
2.2 Taste Phenomena Influences on Stimulation of Deprivation-Induced 
Fluid Consumption of Rats. 
The d1pso~enic action of barbital and chlordiazepoxide were found 
to be selectively influenced by the taste of the consummatory fluid 
presented to deprived rats. In the case of barbital, the potency of the 
drug (as a consummatory stimulant) is reduced when a more pleasant-tasting 
fluid (aqueous saccharin) is substituted for distilled water, while no 
alteration of efficacy is seen when the consummatory fluid is chanGed 
from water to an unpleasant-tastinq solution (aqueous tartaric acid). 
Promazine, althouqh its effect is to reduce, rather than increase, fluid 
consumption by deprived rats, has a similar effect in that its potency 
is reduced when the consummatory fluid is saccharin solution. In contrast, 
the potency of chlordiazepoxide as a dipsoqenic agent was markedly red~ced 
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when the taste of the consummatory fluid was altered to either more 
pleasant or less pleasant. (B-11) 
2.3 Lack of Tolerance Development to the Dipsoqenic Actions of 
Barbital. 
Previous studies had confirmed the dipsogenic actions of barbital 
when Qiven in acute dosage to rats in the test system utilized tn this 
laboratory. Daily dosage of rats with barbital for 14 days produced a 
chronic dipsogenic state with severe overhydration. No tolerance could 
be seen to this effect; on withdrawal of dru~ dosage, the water intake of 
the rats (when computed on a body weight basis) fell to below normal 
levels. In contrast, when the daily intake of fluid was restricted 1> 
during the period of barbital dosage, Dverhydration did not occur and 
drinking durina the withdrawal phase was increased. These results su~qest 
that the release of ADH by barbiturates could be a manifestation of an 
interaction involving the renin-angiotensin system. (B-8) 
2.4 Interactions of Tricyclic Antidepressant Drugs with Deprivation-
Induced Fluid Consumption by Rats. 
A series of tricycl ic antidepressant drugs, represent'inq both secondary 
and tertiary side-chain amines, as well as four different ring systems. 
were examined for their effects on deprivation-induced fluid consumption 
in the standardized test system. All of the compounds reduced fluid 
consumption; the potency ranking was in the order: desipramine> amitrip-
tyline > doxepin > nortriptyline> imipramine> protriptyline. Pretreat-
ment of rats with n-methyltyrosine (in a dosage regimen that lowered brain 
norepinephrine by 50% with no effect on brain serotonin) reduce~ fluid 
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ll~ consumption; in such animals, a dose of protriptylfne had its usual 
effect. Pretreatment of rats with p-chlorphenylalanine had a t1me-
dependent effect on both brain amines and fluid consumption. At 1 day, 
brain serotonin was 40% of normal brain norepinephrine was lowered by 
35%, and fluid consumption was reduced. At 8 days after dosage, brain 
serotonin was 50% of normal, but brain norepinephrine and fluid consump-
tion had returned to normal. By 15 days after dosage, brain amines and 
fluid consumption had all returned to normal. Administration of ;ro-
triptyline had no effect on fluid consumption on day 1, but had its usual 
magnitude of effect on days 8 and 15. (B-19) 
l{ ~ 
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2.5 Pharmacological and Toxicological Effects of Alkali and Alakline 
Earth Metal Ions as Measured by Deprivation-Induced Fluid 
Consumption. 
Two series of ions were selected: alkali metals (Li+, Na+, K+, Cst) 
and alkaline earth metals (Mg++, Ca++, Sr++, Ba++). The anionic component. 
was kept constant as the Cl- ion, and all dosages were by i.p. injection 
as solutions in distilled water. Dose-response data were collected over 
ranges of 0.02 - 0.06 m moles/kg (Ba++) to 1 - 10 m moles/kg (Na+, K+) 
depending on the toxicity of each ion. Dose related stimulation of 
deprivation-induced fluid consu"~lption was evoked by Na+, K+, Ca++. and 
Sr++, while the other ions, except for Ba++, had variable actions. 
Ba++ showed only a depressant action on deprivation-induced fluid con-
sumption and was the most severely toxic. Differential effects of the 
ions on fluid consumption and overt behavior were clearly observable. 
(A-18) 
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·c··,· { '--, 3.0 STUDIES ON BRAIN BIOGENIC AMINES. 
There is little doubt that many druCls can influence mammalian behavior 
by virtue of interaction(s) with bioqenic amine neurotransmitter systems 
in the brain. Thus, alteration of these neurotransmitter systems by 
admin';tration of compounds with specific actions prior to administration 
of a test druq may cause the expected action of that test druq to be 
perturbed. In addition, selective alteration of brain bioqenic amine systems 
by specific aqents may yield relevant information regardinq the systems 
themselves or the agents that influence them. 
3.1 Differential Effscts of Monoamine Oxidase Inhibitors. 
Daily dosage of rats for 20 d~ys with non-toxic amounts of various 
monoamine oxidase inhibitors had clearly differential actions on levels 
of brain bio~enic amines and spontaneous motor activity. Open field 
activity was initially depressed by isocarboxazid, but was elevated by 
the 6th day of treatment and remained up throuqhout the dosaqe period. 
Parqyline caused increased activity on the 6th and 9th dosaqe days and 
Su-ll,739 increased activity on the 6th dosaae day; both of these compounds 
had no other actions. Tranyleypromine consistently decreased activity 
over the entire dosaqe course. Brain levels of norepinephrine and sero-
tonin (on day 20) were elevated by all compounds. The effects on norepine-
phrine were: Su-ll ,739 > parqyline, tranyleypromine > ;socarboxazid; the 
effects on serotonin were: tranyleypromine> Su-l1,739 > parqyline > ;so-
carboxazid. Su-ll,739 and tranyleypromine decreased brain levels of 
5-hydroxyindole-3-acetic acid, while isocarboxazid and tran.vleypromine 
were without effect. (B-10) 
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3.2 On the Rol.e of Brain 8ioqenic Amines in the Control of Pituitary-
Adrenocortical Activity. 
Pretreatment of rats with a monoamine oxidase inhibitor such as pargyline 
prevents the metabolic destruction of serotonin and norepinephrine rE!leased 
from brain stores. Administration of a subsequent dose of reserpine will 
thus markedly elevate the ratio of free:bound amines in the brain. Under 
these conditions, the ACTH hypersecretion usually evoked by reserpinE! 
does not occur, suggesting that the lowering of brain amine levels by 
reserp1ne is the mechanism of action for that drug1s effect. The elevated 
levels of brain serotonin and norepinephrine produced by the inhibition 
of monoamine oxidase did not cause ACTH hypersecretion themselves, nor 
did they prevent the ACTH hypersecretion caused by exposure to cold or 
administration of sedative doses of chlorpromazine. (B-16) 
3.3 Comparative Effects of 5,6-Dihydroxytryptamine and Its Benzo[b]-
thiophene Analogue on Biogenic Amines in the Rat. 
Administration of a single i.p. dose of either compound to rats 
caused a significant reduction in levels of norepinephrine in heart and 
spleen. In contrast, only 5,6-dihydroxytryptam;ne reduced spleen levels 
of serotonin, and neither compound had any effect on brain norepinephrine 
or serotonin. When administered directly into the lateral ventricle of 
the rat brain, both compounds reduced the levels of norepinephrine for 
a period of less th~n 24 hours. The 5,6-dihydroxytryptamine caused a 
prolonged lowerinq of brain levels of serotonin and 5-hydroxyindole-3-
acetic acid; in contrast, its benzo[b]thicphene analogue was completely 
without effect on brain serotonin levels. (A-16, A-24, 8-20, C-3) 
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3.4 Structure-Activity Relationships 1n Analoques of 5,6-0ihydroxy~ 
tryptamine. 
Studies of a variety of compounds related to 5,6-dihydroxytryptamine, 
including 5-hydroxy-6-methoxytryptamine. 6-hydroxy-5-methoxytryptamine, 
5.6-dimethoxytryptam1ne, and 3-(a-aminoethyl)-5,6.,.isopropylidenedioxy-
benzo[b]thiophene demonstrated a wide variety of behavioral and biochemical 
differences related to specific structural entities. For example, the 
key structural factor in selective neurotoxic actions toward serotonergic 
systems appears to be the abO ity to form a quinone-type structure, 
while the requisite component for affecting catecholaminer9ic systems 
appears to be the catechol mority. The isopropylidenedioxy compound 
appears to have extreme biological stability and unique toxicological 
actions. (A-20, A-23, 0-1, 0-2) 
4.0 BIOCHEMICAL RESPONSES TO STRESSFUL STIMULI 
When the mammalian organism is subjected to stressful stimuli, a 
host of mechanisms are activated, providinq a diversity of response 
phenomena. Many measurable changes occur in biochemical parameters, 
some of which are directly relevant to the stress imposed, while others 
are second order or incidental. In addition, responses may differ 
dependinq upon the type of stress and whether it is of an acute, repetitive, 
or chronic nature. Exploration of a number of parameters in response to 
different stress situations could lead to a descriptive characterization 
of the stress process in animals ann indicate appropriate parameters to 
measure in man. 
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4.1 Development of a Model Stress System for Repetitive Daily ~tress. 
Usin~ mice as the test system for three differentially unique stressors 
(cold exposure, forced immobilization, drug-induced stimulation). the 
effects of single and repetitive stress application were measured on a 
variety of biochemical parameters: plasma corticosterone, glucose, and 
free fatty acids, and brain norepinephrine, serotonin, and 5-hydroxyindole-
3-acetic acid. In a single exposure, all three stressors elevated plasma 
corticosterone; amphetamine elevated plasma glucose, while cold exposure 
and immobilization produced a hypoqlycemia; plasma fatty acids were 
elevated by cold exposure, depressed by immobilization, and unaffected 
by amphetami ne. \1hen the acute stress was repeated daily for two weeks, 
adaptation was seen in plasma corticosterone in the repeatedly immobilized 
mice, while amphetamine and cold exposure continued to evoke elevated 
levels; plasma glucose levels were depressed in amphetamine-treated and 
immobilized mice but normal in mice exposed to cold; and plasma fatty acid 
levels were normal in all animals. When animals were subjected to an 
acute stress after two weeks of repetitive stress, the deqree of respondin~ 
was reduced for all combinations; the effect was greatest for repetitive 
cold exposure and least for repetitive amphetamine dosaqe. 
Acute amphetamine was without effect on brain bioqenic amines, 
although repetitive amphetamine for two weeks caused lowered levels of 
brain norepinephrine. Acute cold exposure or immobilization elevated 
brain levels of serotonin and 5-hydroxyindole-3-acet;c acid; on repetitive 
exposure, siqnificant decreases were seen in both compounds. No effects 
were seen on brain norepinephrine with either cold stress or immobilization 
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after single or repetitive exposure. Repetitive cold stress enhanced 
the increased serotonin and 5~hydroxyindole-3-acetic acid caused by all 
three acute stresses and reduced the effects of acute amphetamine on 
brain norepinephrine; repetit1ve amphetamine enhanced the effects of a 
subsequent cold exposure on brain norepinephr1ne; repetitive immobil-
ization was virtually without effect on subsequent acute stresses. (B-7, p-5) 
4.2 Stress Effects on Conversion of Glucose to CO2 in Mice. 
Administration of 14C-labeled glucose to mice under various acute 
stresses leads to differential excretion of 14C02, Cold stress increases 
the rate of conversion of C-l or C-U, decreases the rate of conversion 
of C-2, and has no effect on C-6. Immobilization stress has no effect 
on the rate of conversion of C-l glucose to CO2, but causes a decreased 
rate for C-2, C-6, and C-U. Amphetamine stress increases the rate of 
conversion for C-U glucose to CO2, but results in a decreased rate of 
conversion for C-l, C-2, and C-6. (0-6) 
5.0 BIOCHEMICAL AND BEHAVIORAL PHARMACOLOGY OF AMPHETAMINES 
Amphetamine and a variety of analogues and congeners are extremely 
interesting and cogent to this overall research proqram for several 
reasons. First of all, supplies of amphetamine, alone, or in combination 
with another aqent, were available to the astronauts on space fliqhts 
for use as antifatique and antimotion sickness aQents. Sp.condly, the 
amphetamines represent a class of pharmacoloqical agents with intriguinq 
actions on a variety of body sy~tems that involve biogenic amines such 
4' 'It.. ..... 
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-- as dopamine and norepinephrine. Thirdly, the known behavioral and 
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pharmacological effects of the amphetamines suggest that these drugs 
interact with a number of basic drive systems including arousal, hunger, 
and sleep. Finally, the structure-activity relationships of th~ amphet-
amines are most amenable to a variety of manipulations and inve~t1qat1ve 
studies. 
~ Differential Effects of aMT on Anorectic and Stimulatory Actions 
of Amphetamines. 
Pretreatment of rats with a dosage regimen of aMT (a-methyl tyrosine) 
that reduced brain levels of norepinephrine by 40-60% had a sliqht anorect~r. 
effect, but no effect on continuous avoidance respondinq. Such pretreatment had no effect on the anorectic action of a single dose (2 mq/kg) of 
d-amphetamine or methamphetamine, but markedly reduced the increased 
continuous avoidance responding usually evoked by those compounds. In 
contrnst, similar pretreatment with aMT had no effect on the actions of benzphetamine in either test system. (8-15) 
5.2 Interactions of Caffeine ~/ith Various Amphetamin~s on Rat Food 
Consumption and Avoidance Respondinq. 
Pretreatment of rats with caffeine potentiated the actions of the p-chloro- and p-methyl-analo~ues of amphetamine and penzphetamine as 
depressants of deprivation-induced food consumption, althouQh no such 
effects were seen with the unsubstituted compounds. Similar caffeine 
pretreatment completely antagonized the stimulant effect of d-amphetamine 
and its p-chloro analoque on continuous avoidance respondinq. In contrast • pretreatment with caffeine potentiated the ability of the p-methyl analogues 
of amphetamine and benzphetamine to decrease avoidance responding, 
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and converted the normally modest stimu1ator.y action of benzphetamine 
on avoidance responding to that of a depressant action. (8-18) 
5.3 Drug Interactions on BodX Temperature Maintenance in the Mouse. 
Exposure of mice to an environmental temperature of 4° C leads to 
a loss of body temperature and death in 5-6 hours. Intraperitoneal 
injection of water or solutions of d-amphetamine exacerbates this effect, 
while caffeine has a modest antagonistic action. The combination of 
d-amphetamine plus caffeine is synergistic; a rapid fall in body temper-
ature causes death to occur in less than 3 hours of cold exposure. (C-5) 
5.4 Differential Effects of d- and l-Amphetamine on spontaneous 
Motor ActivftX in Mice. 
The effects of s1nqle doses of'd- and l-amphetamine on motor activity 
in mice differed in both quantitative and qualitative aspects. At loW 
doses (0.5 mg/kq, i.p.) and at high doses (8.0 mg/kg, i.p.) both isomers 
were stimulants of spontaneous motor activity, differing only in potency. 
However, at intermediate doses (2.0 - 4.0 mg/kq, i.p.) the l-isomer 
caused a significant depression of spontaneous motor activity, while 
the d-isomer was stimulatory. (A-14, 8-9) 
5.5 Influence of Drugs Altering Brain Bioqenic Amines on the Effects 
of Amphetamine Isomers on Locomotor ActivitX. 
In mice, doses of d-amphetamine of 1.0 or 4.0 mg/kg, i.p. both produced 
a markedly increased level of spontaneous motor activity. Pretreatment of 
the animals with cxMT reduced the duration of the stimulatory effect while 
pretreatment with pargyline reduced the maqnitude of the amphetamine effect. 
Pretreatment with p-chlorophenyla1anine reduced the stimulatory effect of 
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t,... the lower dose of d-amphetami nf! but increased the acti on of the hi qher 
dose. Pretreatment of the mice with reserpine amplified the stimulatory 
effects of d-amphetamine as compared to animals given only reserpine. 
Administration of a sin~le dose of 1.0 mg/kq of l-amphetamine had 
only a transient depressant action on spontaneous motor activity in mice, 
while a larger dose (4.0 mg/kg, i.p.) caused a marked depression for 
30 minutes. These effects were not significantly changed by the aMT 
pretreatment but were altered by pretreatment with p-chlorophenylalanine, 
pargyline, or reserpine. The results suggest actions of the amphetamine 
enantiomers occur through different biogenic amine systems. (A-14, C-6) 
5.6 Differential PharmacoloCJY of Amphetamine Enantiomers. 
In rats, a single i.p. dose of 2.0 mg/kg of d-amphetamine induces 
a significant increase in navel spontaneous motor activity, while a similar 
dose of l-amphetamine induces a decrease in that activity. Chronic pre-
treatment with aMT blocks the stimulatory effect of the d-;somer blocks 
the stimulatory effect of the d-isomer but prolongs the depression induced 
by the l-;somer. Chronic pretreatment with pargyline induces a depression 
of spontaneous motor activity that is qualitatively, but not quantitativelyo 
reversed by d-amphetamine; the parqyline pretreatment has no effect on the 
depressant action of a subsequent dose of l-amphetamine. Pretreatment with 
p-chlorophenylalanine has no major influences on the stimulatory actions 
of d-amphetamine, but alters the maqnitude and duration of the depressant 
actions of l-amphetamine. The results suq~est that d-amphetamine influences 
only catecholaminergic systems while l-amphetamine also influences seroton-
ergic systems. (A-22. D-4) 
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6.0 BIOCHEMICAL STUDIES OF ANALOGUES TO BIOLOGICALLY ACTIVE INDOLE 
COMPOUNDS 
The continuing interest of this laboratory in biologically active 
indole compounds and the key roles of tryptophan as an essential amino 
acid in mammalian nutrition, a key component in active protein molecules, 
and a precursor of the biogenic amines serotonin and melatonin, led to 
a number of studies of compounds structurally similar to tryptophan. 
In particular, this area of research was particularly fertile ground for 
studies of molecular' structure relationships to biological activity, 
using the principles of selective molecular modifications. 
6.1 Intestinal Transport of Tryptophan and Its Analo~ues. 
A comparative study of the intestinal transport of DL-tryptophan 
and its l-methylindole and benzo[b]thiophene analogues was performed 
ill vitro, using the everted intestinal sac preparation of the rat and 
hamster. Both tryptophan and its benzo[b]thiophene analogue were actively 
transported by this preparation, while l-methyltryptophan was not. The 
active transport of tryptophan was competitively inhibited by the benzo[b]-
thiophene analogue, but not by l-methyltryptophan, suggesting little or 
no interactions of the latter with the carrier process, The transport 
of tryptophan and its benzo[b]thiophene analoque was depressed by high 
concentrations of either compound (> 10 mM); all three amino acids produced 
subtle alterations 1n the barrier properties of the sacs as evidenced 
by increased diffusion rates observed for tetraethylammonium bromide. 
(A-8, B-14) 
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6.2 Bioisoster1c Inhibition of DOPA Decarboxylase. 
Using an 1n vitro test system of purified hog kidney aromatic-~-amino 
. ----
.. 
acid decarboxyla~e, the benzo[b]thiophene analogue of 5-hydroxytryptophan 
was found to be an effective inhibitor of DOPA decarboxylation, with a 
potency almost twice that of a-methyl-DOPA. When administered to mice 
prior to a dose of labeled L-DOPA, the compound led to Significantly 
elevated brain levels of DOPA, dopamine, and DOPA metabolites, suggesting 
that sufficient inhibition of peripheral decarboxylation had been achieved 
to effectively increase the amount of DOPA that entered the brain. (A-4, 
A-17, C-l) 
6.3 The Metabolic Fate of the Benzo[b]thiophene Analogue of Tryptophan 
in the Rat. 
In mammals, the amino acid tryptophan is metabolically degraded via 
a number of pathways, including decarboxylation, transamination, and 
ring cleavage via tryptophan pyrrolase. However, when the benzo[b]thio-
phene analogue of tryptophan was administered to rats, no evidence was 
seen for decarboxylation or rinq opening. Instead, > 90% of the excretion 
products could be identified as unchanged compound and the benzo[b]th1o~ 
phene analogues of indole-3-1actic acid, indole-3-pyruvic acid, indole-3-
acetic acid and indole-3-acetylqlycine. (A-19, C-2) 
7.0 PHARMACOLOGICAL STUDIES OF ANALOGUES TO BIOLOGICALLY ACTIVE INDOLE 
COMPOUNDS. 
Following the aspects of bioloqically active indole analoques discussed 
!.J; in 6.0 (above) studies have also been carried out of the comparative 
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'~ structure-activity relationships of analoques of tryptamine in various 
~ vivo and in vitro systems containing responsive tryptamine receptors. 
The results obtained are compatible with a structural specificity for the 
unsubstituted indo11c nitrogen. 
7.1 Pressor Effects of Tryptamine Analogues. 
Methylation of tryptamine in the l-posit;on had little effect on the 
potency of the drug as a pressor agent in the intact anesthetized rat, 
while the benzo[b]thiophene analogue of tryptamine had a markedly decreased 
pressor activity. Pretreatment of the animals with the a-sympatholytic 
agent, phenoxybenzamine, reduced the pressor effects of all three compounds. 
In contrast, pretreatment of the animals with reserpine reduced the pressor 
effects of tryptamine and its benzo[b]thiophene analogue, but increased the 
pressor effects of l-methy1tryptamine. (A-9, B-17). 
7.2 Contractile Responses to Tryptamine Analogues in Isolated Smooth 
Muscle. 
Tryptamine and its benzo[b]thiophene and l-methYlindole analogues had 
a lower affinity for receptors in rat stomach fundus than did serotonin; 
the interaction between methyser0ide and serotonin in this system was 
competitive, while the interactions between methyserqide and tryptamine 
and its analogues were noncompetitive. In contrast, the affinity of 
tryptamine and l-methyltryptamine for receptors in rat aortic strips was 
greater than the affinity for serotonin; all compounds showed noncompetitive 
interactions with methysergide in this preparation. (A-2l, C-4) 
8.0 STUDIES IN CHEMICAL PHARMACOLOGY - DRUG DISPOSITION AND DRUG METABOLISM. 
In the course of carrying out a coordinated program of studies in 
biochemical pharmacolo~y, a number of occasions arise when studies of the 
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physiological disposition and/or metabolic fate of chemical compounds 
is relevant to other aspects of the pharmacology of such substances. 
8.1 Inability of Rat Brain Homogenate to Oxidize Amphetamine. 
Incubation of rat brain homogenate with labeled amphetamine failed 
to produce any decrease in the amount of amphetamine or any significant 
metabolites. The conversion of neotetrazolium chloride to diformazan 
by the tissue extract occurred with or without the presence of amphetamine. 
It was concluded that the literature report on metabolism of amphetamine 
by brain homogenate in vitro was erroneous. (8-6) 
8.2 Metabolism of 3-(2-Dimethylaminoethyl)benzo[b]thiophene ln~ 
and .I.n lli.Q. in the Ra t • 
The metabolism of 3-(2-dimethylaminoethyl)benzo[b]thiophene has been 
studied in vivo and in vitro in rats. The results indicate the major 
pathways of metabolism to be 6-hydroxylation, N-dealkylation, and oxidation 
by monoamine oxidase. No evidence for sulfoxidation was found. Metabolites 
were identified by combinations of mass spectrometry, nuclear maqnetic 
resonance spectroscopy, thin-layer chromatography, and liquid scintillation 
counting, (A-7, B-4) 
8.3 Comparative Physioloqical Disposition of Melatonin and Its Benzo-
[b]thiophene Analogue in the Rat. 
Melatonin and its benzo[b]thiophene analog were labeled by acetylation 
of the corresponding 5-methoxyarylethylamines with tritiated acetic 
anhydride. The benzo[b]thiophene analogue had a much hiqher lipid solu-
bility as measured by partition between neutral aqueous solution and 
organic solvents. When administered to rats, both compounds disappeared 
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from plasma and tissues by first-order decay. The dispositions were 
similar, with the higher lipid solubility of the benzo[b]thiophene analogue 
resulting in higher tissue:p1asma ratios, especially in adipose tissue, 
kidney, and liver, and a longer half~life in plasma and tissues. (A-l1, 
B-12) 
8.4 Physiological Disposition of Atropine in the Rat. 
The physiological disposition of atropine was studied in rats, using 
tritium-labeled drug and a specific assay method. At doses of 1.25 to 
10 mg/kg, i.p., the greatest localization was seen in kidney and liver, 
with t;ssue:plasma ratios of > 10:1. Tissue half-lives over the period 
0.5 - 4 hours ranged from 40-46 minutes in plasma to 97-106 minutes in 
adipose tissue. (A-10, B-5) 
9.0 STUDIES IN TOXICOLOGY 
Another facet of an overall project in biochemical pharmacology involves 
the need for testin~ various compounds of interest for their toxicological 
profiles or examination of specific toxicological phenomena. In some cases, 
such studies yield significant data that has relevance in a much broader 
scope than merely descriptive characterization of a compound. 
~ Pharmacological and Toxico10qical Studies on 1,4-Butanediol. 
1,4-Butanediol is a widely used aqent in the manufacture of a number of 
polymeric materials. The LD50 in rats was found to be 1328 mg/kq, i:p. 
The compound had a si~nificant sedative effect at dosages> 300 mg/kg. 
Effects of the drug on spontaneous motor activity were biphasic; doses of 
50-200 mq/kg significantly reduced spontaneous motor activity, while doses 
> 300 mq/kq caused loss of the rightinq reflex. No increase in 1ive~ 
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triglycerides was seen even after 14 days of dosage at 1000 mg/kg daily. 
(A-15, B-13) 
9.2 Hepatotoxic Effects of Iproniazid. 
Iproniazid represents a loss of monoamine oxidase inhibitors that are 
derivatives of hydrazine and thus have toxic biochemical effects by virtue 
of their ability to chemically react with carboxyl groups in the mammalian 
organism. Studies in mice chronically dosed with iproniazid indicated 
that significant strain differences exist with regard to the ability of 
the drug to influence liver triglycerides of animals on normal or pyri-
doxine-deficient diets. The effects of acute iproniazid dosage in Swiss-
l~ebster mice on a control diet were manifested by hypoglycemia; in animals 
on a pyridoxine-deficient diet, the drug induced both hyperglyceinia and 
and hyperlipemia. In addition, the administration of tryptophan or its 
benzo[b]thiophene or l-methylindole analogues to mice pretreated with 
iproniazid led to a marked hepatotoxicity. (A-6, A-12, A-13, 0-3) 
10.0 CHEMICAL METHODOLOGY 
In any project of this type, a variety of situations arise in which 
analytical or synthetic·chemical methodol09Y is required as a supportive 
effort. Several of these efforts resulted in significant productivity 
independent of, but related to, projects described elsewhere. 
~ Nass Spectra of CarcinoQenic 4-Hydroxylaminoguinoline N-oxides. 
The mass spectra of carcinoqenic 4-hydroxylaminoquinoline N-oxide and 
some methyl substituted derivatives have been determined. Fragmentation 
of the parent compound proceeds from M to M-2, M-16 and M-17. The M and 
M-2 ions are particularly valuable. (R-l) 
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10.2 Isotopic Procedures in Biomedical Analyses. 
The use of radioisotopes in analytical chemistry is widespread, 
although the applications to biomedical problems are somewhat limited. 
Of particular interest is the potential use of radiolabeled deY'ivatizing 
agents to permit the quantitative estimation of submicrogram quantities 
of organic compounds in biological materials. Several examples may be 
cited: (1) the use of 3H-acetic anhydride to determine primary and 
( ) 
lit • 
secondary amines, and steroids; 2 C-methyl iodide to determine tertlarY 
amines; and (3) 63Ni+ 3 to determine 3-ethoxy-2-ketobutyraldehyded1thio-
semicarbazone. In addition, enzymatic procedures utilizing transferase 
enzymes and IltC-S-adenosylmethionine have been developed for the deter-
mination of catecholamines. The potential applications of these approaches, 
'. 
using labeled derivatization reagents of classical semi-micro organic 
functional group analysis and/or purified transferase enzymes with labeled 
cofactors are an almost virgin field of research with tremendous potential. 
(A-l) 
10.3 Physicochemical Properties of Renzo[bJthiophene and l-Methylindole 
Analoques of Indolic Compounds of Biological Interest. 
Within a series of structures, i.e., indole, benzo[b]thiophene. 
l-methylindole. lipid solubility was determinerl by the side chain, ranking 
in the order: -CH2CH20H > -CH2CH2N(CH3)2 > -CH2CH2NH2 > -CH2COOH, -CH2CH-
(NH 2)COOH. Within a given series of constant side chains, i.e., -CH2CH2-
NH 2, -CH2CH2N(CH 3)2' -CH2CH(NH2(COOH, or -CH2COOH, the lipid solubility 
ranked in the order: benzo[b]thiophene > l-methylindole > indole. The 
influence of molecular alteration on pKa values of the compounds are correlated 
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with lipid solubility. The results are significant in relation to the 
biological activities and physiological disposition of the various compounds. 
(A-5) 
10.4 Site-Specific Deuteration or Trit1at1on of Benzo[b]thiophene 
and 1-Methy1indo1e Analogues of Biologically Active Indole 
Compounds. 
The site-specific deuteration and tritiation of l-methylindole and 
benzo[b]thiophene analogues of biologically active indole derivatives 
has been achieved by the use of the facile metalation of these hetero-
cycles with n-butyllithium and subsequent reaction with 2H20 or 3H20 • 
Metallation occurs at the 2-position and site and extent of deuterium 
incorporation was determined by NMR. The use of sim11ar procedures with 
3H20 led to ready incorporation of tritium into these heterocycles. 
(A-3, B-2) 
11.0 BIBLIOGRAPHY 
Research supported by this grant has yielded a variety of published 
materials. These have been categorized as follows: 
I. Abstracts of papers presented-at scientific meetinqs (listed in 
Section 11.1). 
"= II. Published papers that have appeared or are in press in the open 
scientific literature (listed in Section 11.2). 
III. Manuscripts that have been completed and have been submitted 
for publication (listed in Section 11.3). 
IV. Manuscripts that are in process and have not yet been submitted 
for publication (listed in Section 11.4). 
20 
A complete set of items in categories II and III is included as 
an Appendix to this report. 
11.1 Abstracts 
A-l Maickel, R.P.; Isotopic procedures 1n biomedical analyses. 
Eastern Analytical Symposium, Atlantic City, NJ, November 1-3, 
1972. 
A-2 Maloney, G.J. and Maickel, R.P.: Effects of depressant drugs 
on deprivation-induced fluid consumption in rats. Society for 
Neuroscience, Second Annual Meeting, Houston, TX, November 8-11, 
1972. 
A-3 Bosin, T.R. and Rogers, R.B.: Chemisal pharmacology of benzo[b]-
thiophene derivatives. VIII. Facile H labeling of compounds of 
pharmacological interest. The Pharmacologist ~:244, 1973. 
A-4 Buckpitt, A.R., D'Amico, D., Maickel, R.P., Hegeman, S.L. and 
Bosin, T.R.: Studies on the substrate specificity of aromatic 
amino acid decarboxylase. The Pharmacologist ~:204, 1973. 
A-5 Chiu, P., Harrison, S.D., Jr., Maickel, R.P. and Bosin, T.R.: 
Chemical pharmacology of benzo[b]thiophene derivatives. XI. 
Physicochemical properties of benzo[b]thiophene and l-methyl-
indole analogs of indolic compounds of pharmacological interest. 
The Pharmacologist li:184, 1973. 
A-6 Fedynskyj, N., Buckpitt, A.R. and Maickel, R.P.: Hepatotoxic 
effects of iproniazid in combination with tryptophan or analoqs 
of tryptophan. The Pharmacologist ~:261, 1973. 
A-7 Harrison, S.D., Jr., Maickel, R.P. and Bosin, T.R.: Chemical 
pharmacology of benzo[b]th;ophene derivatives. IX. Metabolism 
of the benzo[b]thiophene analog of N,N-dimethyltryptamine. The 
Pharmacologist ~:244, 1973. 
A-8 Hathaway, D.R., Maickel, R.P. and Bosin, T.R.: Studies on the 
intestinal transport of tryptophan. The Pharmacologist ~:205. 
1973. 
A-9 Hixson, J., Bos;n, T.R.,-Zabik, J.E. and Maickel, R.P.: Effects 
of benzo[b]thiophene and l-methylindole analogs of indolealkyl-
amines on rat blood pressure. The Pharmacolo~ist ~:180, 1973. 
A-l0 Long, R.J. t Maickel, R.P. and Harrison, S.D., Jr.: Correlation 
of physiological dispositioQ and behavioral effects of atropine 
in the rat. The Pharmacoloqist ~:2n6, 1973. 
,1 
1 
I 
1 
l 
1 
1 
l 
! 
= 
'¥1.1:41i ~-~~ ~T~r:;:-~--~~,,!w:~~~ ~-- ----~~'l~~ -~- -~~ "T "':'I:1~~l 
~. . . . .-.......... ' ~ ~ r 
A-l1 Riddle, M., Bosin, T.R., Harrison, S.D., Jr. and Maickel, R.P.: 
Comparative physiological disposition and metabolic fate of 
melatonin and its benzo[b]thiophene analog. The Pharmacologist 
12.: 257, 197~. 
A-12 Ryan, M.P., Snodgrass, W.R. and Matckel, R.P.: Studies on 
iproniazid. II. Biochemical chan~es evoked by iproniazid in 
mice on normal and pyridoxine-deficient diets. The Pharmacologist 
12.:261, 1973. 
A-13 Snodgrass, W.R., Bowman, n.R., Ryan, M.P., Seeger, J. and Maickel, 
R.P.: Studies on iproniazid. III. Physiological disposition of 
iproniazid in normal and pyridoxine-deficient mice. The Pharmacolo-
gist 15:261, 1973 . 
. -
A-14 Zabik, J.E., Levine, R.M. and Maickel, R.P.: Comparative pharma-
cology of amphetamine isomers. The Pharmacologist }i:219, 1973. 
A-15 Zabik, J.E., Van Dam, n.p. and Matcke1, R.P.: Riochemical 
toxicology of 1,4-butanediol. Toxicol. Appl. Pharmacol. 25:461, 
1973. 
A-16 Donelson, A.C., Bosin, T.R. and Maickel, R.P.: Possible structural 
specificity for the neurotoxic actions of 5,6-dihydroxytryptamfne. 
Soc. of Neuroscience, 4th Annual Meeting, St. Louis, MO, Oct. 20-23, 
1974. 
A-17 Maickel, R.P., Baldwin,J.R., Campaigne, E. and Bosin, T.R.: 
Studies on the inhibition of aromatic-L-amino acid decarboxylase. 
Fed. Proc. 34:293, 1975. 
A-18 Zabik, J.E., Fritsch, B.R. and Maickel, R.P.: Pharmacological 
and toxicological effects of alkali, and alkaline earth metal 
ions as measured by deprivation-induced fluid consumption. 
Toxicol. Appl. Pharmacol., 1l:128, 1975. 
A-19 Bickers, R.G., Basin, T.R., and Maickel, R.P.: The metabolic 
fate of benzo[b]thiophene-3-alanine in rats. The Pharmacologist 
li:1 61,1976. 
A-20 Donelson, A.C., Manian, A.A. and Maickel, R.P.: Behavioral and 
biochemical pharmacology of 5,6-disubstituted tryptamines. The 
Pharmacologist 1[:200, 1976. 
A-21 Hixson, E~J., Lehrmann, G.J. and Maickel, R.P.: Contractile 
responses to tryptamine analoques in isolated smooth muscle 
systems. The Pharmacologist 1[:200, 1976. 
A-22 Liqht. K.E., Zabik, J.E. and Maicke1, R.P.: Differential 
pharmacology of amphetamine enantiomers in the rat. The Pharma-
cologist 18:198, 1976 . 
. -
22 
1 I 
f 
_',~'-"':;"r.;--'t"~-_"'~~"-~""T'T"--- -.---..,.. ••• -,.-.~ -~~ •.• --~...,... ...... ~ ~;\~J~ ·.,, ____ u-.. -·,,,,=,o~~_w.,_·_ ~c_.,~~~~,~ ________ .• ___ ~.n_. __ ._. 
.... 
A-23 Maickel, R.P., Bosin, T.R., Campaigne, E. and Donelson, A.C.: Behavioral, biochemical, and toxicological studies of 3-(a-amino~ ethYl}-5,6~isopropylidenedioxybenzo[b]thiophene (IPST) in the rat. The Pharmacologist ~:200, 1976. 
A-24 Maicke1, R.P. and Donelson, A.C.: Structure-activity relation-ships in compounds analgous to 5,6-dihydroxytryptamine. New York Academy of Sciences Conference on Serotonin Neurotoxins. New York, NY, March 3D-April 1. 1977. 
11.2 Papers Published or in Press. 
8-1 Basin, T.R. and Maickel, R.P.: Mass spectra of carcinogenic 4-hydroxyl ami noqui no1 in,e-N-oxides. Res. Comm. Chem. Patho 1. Pharmacol. ~:813-820, 1973. 
B-2 Bosin, T.R. and Rogers, R.B.: Site-specific deuteration or tritiation of benzo[b]thiophene and l-methylindole analogs of biologically active indole derivatives. J. Labelled Cmpds. 9:395-403, 1973. 
B-3 Maickel, R.P. and Maloney, G:J.: Effect of various depressant drugs on deprivation-induced water consumption. Neuropharmacol. 1£:777-782, 1973. 
8-4 Harrison, S.D., Jr., Bosin, T.R. and Maicke1, R.P.: Metabolism of the benzo[b]thiophene analog of N,N-dimethyltryptamine in vivo and in vitro in the rat: Appl ication of organic chemical and--spectroscopic techniques to problems of drug metabolism. Drug Metab. Disposition ~:228-236, 1974. 
B-5 Harrison, S.D., Jr., Bosin, T.R. and Maickel, R.P.: Physiological disposition of atropine in the rat. Pharmacol. Biochem. & Behavior ~:843-845, 1974. 
8-6 Maickel, R.P. and Harrison, S.D., Jr.: Inability of rat brain homogenate to oxidize amphetamine. Biochem. Pharmacol. 23: 1146-1147, 1974. 
B-7 Maickel, R.P. and Qu;rce, C.M.: Development of a model stress system for repetitive daily stress. Proc. 1972 NASA Manned Spacecraft Center Endocrine Program Conference, 1974. 
8-8 Ma;ckel, R.P. and Maloney, G.,).: Lack of tolerance development to the dipsogenic actions of barbital. Pharmacal., Biochem. & Behavior ~:431-434, 1974. 
A-9 Maickel, R.P., Levine, R.M. and Quirce, C.M.: Differential effects of d- and l-amphetamine on spontaneous motor activity in mice. Res. Comm. Chem. Pathol. Pharmacol. ~:711-714, 1974. 
23 
::. ~ .... J h -""TP"' 
j 
1 
§ i 
" . ..,..... 
6-10 Maicke1, R.P., Rompalo, A.M. and Cox, R.H., Jr.: Differential 
effects of monoamine oxidase inhibitors. Res. Comm. Chem. 
Patho1. Pharmaco1. ~:727-730, 1974. 
B-11 Maicke1, R.P. and Maloney, G.J.: Taste phenomena influences 
on stimulation of deprivation-induced fluid consumption by rats. 
Neuropharmacology }1:763-768, 1974. 
B-12 Maickel, R.P., Bosin, T.R., Harrison, S.D., Jr., and Riddle, M.A.: 
Comparative physiological disposition of me1ato~in and its 
benzo[b]thiophene analog in the rat. ~ife Sci. 14:1735-1739, 1974. 
- -
B-13 Zabik, J.E., Van Dam, D.P. and Maicke1, R.P.: Pharmacological 
and toxicological studies on 1,4-butanedio1. Res. Comm. Chem. 
Patho1. Pharmaco1. ~:83-90, 1974. 
8-14 Bosin, T.R., Hathaway, D.R. and Maickel, R.P.: Intestinal 
transport of tryptophan and its analogs. Am, J. Physio1. 
228:496-500, 1975. 
B-15 Cox, R.H., Jr. and t·1aicke1, R.P.: Differential effects of 
aMT on anorectic and stimulatory actions of amphetamines. 
Res. Commun. Chern. Patho1. & Pharmaco1. 1£:621-626,1975. 
B-16 Maicke1, R.P.: On the role of brain biogenic amines in the control 
of pituitary-adrenocortical activity. Proc. 1973 lyndon B. 
Johnson Space Center Endocrine Program Conference, NASA-TM-X-
58155, pp. 7-1 - 7-10, June 1975. 
8-17 Bosin, T.R., Hixson, E.J; and Maicke1, R.P.: Pressor effects 
of tryptamine analogs. Brit. J. Pharmacol. 56:25-27, 1976. 
B-18 Cox, R.H., Jr. and Maicke1, R.P.: Interaction of caffeine with 
various amphetamines on rat food consumption and avoidance 
responding. Neuropharmaco1. }i:767-771, 1976. 
8-19 Zabik, J.E., Levine, R.M., Spaulding, J.H. and Maickel. R.P.: 
Interactions of tricyclic antidepressant drugs with deprivation-
induced fluid consumption by rats. Neuropharmacol., in press, 
1977 . 
B-20 Maickel, R.P., Bosin, T.R., Donelson, A.C., Campaigne, E., and 
Rogers, R.B.: Structure-activity relationships in compounds 
ana1~ous to 5,6-dihydroxytryptamine, Ann. NY Acad. Science, in 
press, 1977. 
lJ~ Papers Submitted for Publication. 
C-1 ~osin, T.R., Baldwin, J.R. and Maickel, R.P.: Rioisosteric 
inhibition of DOPA decarboxylase. Biochem. Pharmacol. submitted 
for publication, 1977. 
24 
i 
1 
I 
i 
1 
1 
l 
i 
I 
1 
1 
1 
~ 
1 
-i 
I 
1 
i 
1 
, 
L C-2 Basin, T.R., Bickers, R.G. and Dinner, A.: The metabolism of 
2_(3_benzo[b]thi enyl)-1-aminopropionic acid in the rat. Drug 
Metab. & Disposition, submitted for publication, 1977. 
C-3 Donelson, A.C., Bosin, T.R., Campaiqne, E., Rogers, R.B. and 
Maicke1, R.P.: Comparative effects of 5,6-dihydroxytryptami ne 
and its benzo[b]thiophene analogue on biogenic amines 1n the 
rat. Biochem. Pharmacol., submitted for publication, 1977. 
C-4 Hixson, E.J., Lehrmann, r,.V. and Maickel, R.P.: Contractile 
responses to tryptamine analogues in smooth muscle. Arch. 
Inter. Pharmacodyn., submitted for publication, 1977. 
C-5 Quirce, C.M., Levine, R.M. and Maickel, R.P.: Drug interactions 
on body temperature maintenance in the mouse. Res. Comm. Chem. 
Pathol. & Pharmacol., submitted for publication, 1977. 
C-6 Zabik, J.E., Levine, R.M. and Maickel, R.P.: Influence of drugs 
altering brain bioqenic amines on the effects of amphetamine 
isomers on locomotor activity. Pharmacol., Biochem. & Behavior, 
submitted for publication, 1977. 
11.4 Papers in Preparation. 
0-' Donelson, A.C. and Maickel, R.P.: Behavioral pharmacology of 
5,6-dihydroxytryptamine analo~ues. 
0-2 Donelson, A.C. and Maickel, R.P.: Pharmacolo~y and toxicoloqy 
of 3_(a_aminoethyl)-5,6-isopropylidenedioxybenzo[bJthiOPhene. 
0-3 Maickel, R.P., Bowman, D.R., Fedynskyj, N., Snodqrass, W.R. 
and Ryan, M.P.: Strain differences in effects of iproniazid 
on mouse liver triglycerides. 
0-4 Maickel, R.P., LiQht, K.E., and Zabik, J.E.: Differential behavioral 
pharmacoloQY of amphetamine enantiomers in the rat. 
0-5 Quirce, C.M. and and Maickel, R.P.: Some biochemical correlates 
of stress. 
0-6 Quirce, C.M. and Maickel, R.P.: Oxidative conversion of glucose 
to CO2 in the mouse .!n vi vo.: effects of stress. 
25 
r 
12.0 APPENDIX II 
PAPERS PUBLISHED OR IN PRESS 
" 
1 ". 
:1 
j 
1 
1 
J 
I 
• ~ 
~ ~ 
J 
i 
j 
I 
1 
1 
~ 
J 
a 
l 
A 
~ i,j 
~ 
26 
~~ ________________________________________________ J~ 
E'!' 
r', 
;.: 
, ' 
11: 
,"'1 
VOL,6, No.l 
NOVEMBER 1973 
. Research Communications in 
Chemical Pathology and Pharmacology 
MASS SPECTRA OF CARCINOGENIC 4-HYDROXYLAMI!IOQUINOLINE N-OXIOES 
T.R. Bosin and R.P. Ma;ckel 
Department of Pharmacology 
Medical Sciences Program 
Indiana University 
Bloomington, Indiana 47401 
Received Sept. 10, 1973 
ABSTRACT .. 
The mass spectra of carcinogenic 4-hydroxy1aminoquino1ine N-oxide and 
some methyl substituted derivatives have been determined. The diagnostic 
value of these fragments may be a facile means to study the metabolism and 
mechanism of carcinogenesis of these compounds. 
INTRODUCTION 
The known chemical carcinogens are composed of a multitude of structural 
types, including 4-nitroquino1ine N-oxides. This class of chemical carcinogens, 
first preparecl by Ochiai ancl co-wo"kers (1943), was demonstrated to be 
carcinogenic by Nakahara et. a1., (1957). Following this demonstration of 
~ -- 1: 
carcinogenicity, a number of papers have appeared describing the physical, 
chemical, and spectral characteristics of 4-nitroquinoline N-oxide and its 
derivatives; this data ancl the mechanism of carcinogenicity has been summarized 
in a recent monograph (Endo et. ~" 1971). 
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Sugimura et. ~. (1966) demonstrated that mammalian cells metabolically 
transform 4-nitroquinoline N-oxide to 4-h¥droxylaminoquino1ine N-oxide, a more 
potent carcinogenic moiety considered to be the prox.imate agent. In an earlier , 
paper (Basin and Maicke1. 1972) we reported on the mass spectral fragmentation 
patterns produced by carcinogenic methyl substituted 4-nitroquinoline N-oxides. 
As a continuation of that problem. we now report the mass spectral fragmentation 
patterns produced by methyl substituted 4-hydroxylaminoquinoline N-oxides. 
MATERIAL AND METHODS 
The structures of the compounds studied in this report are presented in 
Table 1. 
Table 1 
Structures of Compounds Subjected to Mass Spectral Studies 
R3 NHOH 
R4~R2 
R5V().Rl 
R6 0 
Substituent Position R, R2 R3 R4 R5 R6 
Ring Position II 2 I 3 5 6 7 8 
Compound Name Compound # 
4-Hydroxylaminoquinoline 
N-oxide I H H H H H H 
2-Methyl-I la CH3 H H H H H 
5-Methyl-I Ib H H CH3 H H H 
6-MethYl-I Ic H I H H CH3 H H 
7-HethYl-I Id H I H H H CH3 H i 
.. -
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The precursor methyl substituted 4-nitroquinoline N-oxides were prepared as 
previously described (Bosin and Maickel, 1972) and were reduced to the 
corresponding 4-hydroxylamino derivatives by known procedures (Kawazoe 
and Tachibana, 1967). Melting points were in agreement with those reported 
(Endo et. ~ .• 1971). Analytical purity was confirmeQ by thin-layer 
chromatography on silica gel G plates (Analtech, precoated, prescored, 
thickness 0.25 mm) using two solvent systems: methanol, and chloroform: 
methanol (1:4. V:V); visualization was accomplished py ultraviolet light 
(35Q nm) or alkaline permanganate spray. 
The mass spectra were determined on Varian MAT CJi-7 and AEI MS-9 
mass spectrometers at an io'nizing potential of 70 ev. The direct probe 
method was used in all cases. 
RESULTS AND DISCUSSION 
Figure 1 gives the complete spectra and Table 2 selected ions of 4-
hydroxylaminoquinoline N-oxide and some methyl substituted derivatives. 
The identification of the aromatic hYdroxylamine group by mass spectro-
metry has been reported (Coutts and ~lukherjee, 1970) and the diagnostic 
value of M, M-2. M-16, and M-17 emphasized. The diagnostic value of the 
M-16 ion, in the present case, is complicated by the possibility fer loss of 
oxygen from both the N-oxide and the hydroxylamino groups. In the mass spectra 
of methyl substituted 4-hydroxylaminoquinoline N-oxides, there is no M-17 
fragment, in contrast to simple al'omatic hydroxylamines and methyl substituted 
4-nitroquinoline N-oxides (Bosin and Maickel, 1972). In the latter case the 
M-17 ion was indicative of a methyl group adjacent to either the M-oxide or 
nitro group. Thus, for diagnostic purposes, the M and M-2 ions in combination 
with the select ions in Table 2 provide ready spectral characterization of these 
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Table 2 
Selected Ions of 4-H~droxl1amino9uino1ine N-oxide Derivatives 
COMPOUND Ia Ib Ie Id 
Fragment % Relative Intensity 
M 16 11 71 0 13 
M-1 20 30 19 27 38 
M-2 30 58 17 100 71 
M-16 35 76 38 68 68 
M-18 28 0 53 53 36 
M-32 18 37 43 93 62 
M-33 0 58 45 43 25 
M-47 29 49 36 28 54 
M-48 61 70 48 93 89 
M-60 62 100 17 68 100 
M-62 35 47 40 27 46 
M-75 67 52 40 73 89 
M-87 75 99 17 68 66 
Base Peak. mle 75 130 155 188 130 
compounds. Figure 2 provides a proposed rationalization for the mass spectral 
fragmentation of Id via the M-2 pathway. 
This mass spectral characterization described should be applicable to 
further studies of the metabolism of methyl substituted 4-hydroxylamino-
quino1ine N-oxides in relation to their carcinogenic effects. 
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SUflMARY 
The site-specific deuteration and tr>itiation of ]-methyZindole 
and benzol bl-thioph(m~ analogs of biologicqHy active indole der>i-
-vati1les has been achieved by use of the faaiZe metaZatiol1 of 
these heter>ocyaZes with n-butyZlithium and subsequent reaction 
with 2820 or 3820' Metalation occUr>S at the :;-poshion and site 
and extent of deuterilml inaorporation Lias detel·mined by N.M.h. 
The use of similar proaedur>es with 3820 Zed to r>eady inaorporation 
of tritiijm into these heteroayaZea. 
The demand for specifically labeled organiC molecules has resulted in 
the development of selective procedures for the incorporation of deuterium 
(3), .ritium (4), and carbon-14 (5) into organic compounds. Specifically, 
radiolabeled molecules are extensively used in mechanistic and biomedical 
research (6); in addition, the applicat~n of stable isotopically labeled 
molecules to metabolic studies has recently been described (n. 
As a result of our study of the chemical pharmacology of tryptophan 
and its isosteres, it became necessary to prepare suitably labeled 
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benzo[bJthiophene and I-methYl indole analogs of biologicallY active indole 
derivatives. The method which was employed ~tilizes the facile metalation 
of benzo(IIJthiophene (8) and l-methylindole (9) with !l-butyllithium and 
subsequent reaction with 2HzO or 3HzO. Metalation has been shown (8.9) 
to occ~r at the Z-posit-jon due to the inductive effec~ of the heteroatom. 
and is therefore the active site for introduction of the deuterium or 
tritium atom. 
RESULTS AND DISCUSSION 
A. Exchange Studies Using Deuterium 
The general procedure for deuterium incorporation is as follows: 
The compound to be labeled was dissolved in dry. freshly distilled tetra-
hydrofuran (THF) and the resultant solution cooled to DO for l-methyl-
indole and -780 for benzo[b]thiophene derivatives. The reaction Solution 
was treated with !l-butyllithium and allowed to stir for 30-75 minutes at 
the low temperature prior to reaction with 2H20. The nmr spectra of l-methyl-
indole and benzo(b]thiophene derivatives possessed a characteristic absorption 
for the H-2 proton, and therefore, the decrease or loss of the H-2 absorption 
provided a ready means of determining th8 percent exchange. The compounds 
labeled in this study and the nmr data appear in Table I. 
Table I 
Compounds and Percent Exchange Based on NMR 
W Z 
Compound Substituents NMR Data 
% H-2 Name X I 6H-2§ Exchanged 
3-(Z-Aminoethyl)benzo(b]-
thiophene S CH2CH2NH~ 7.07 80 
II Benzp[b]thiophene-3-acetic S CH2COOH 7.26- 70 acid 7.48* 
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Site-specific deuteration OP tpitiat~on of benzo (bJ th~ophene 
III 3-(2-Dimethylaminoethyl)_ 
benzo[b]thiophene s 7.10 100 
IV ]-Methyl-3-(2-dimethylamino_ N-CH3 CH2CH2N(CH3)~ 6.71 ethyl )indole 
§ These oH-~ values are those for the parent unexchanged compo~nd. 
* This proton is part of a multiplet. 
The exchange labeling of the sulfur analog of trYptamine (f) was 
complicated by its extreme sensitivity to air. Preparation of the free 
base from its hydrochloride salt and subsequent handling under an inert 
atmosphere were required. 
The metalation of the sulfur analog of indole-3-acetic acid (II) 
with rr-buty1ljthium resulted in 70% exchange of the H-2 proton and 35% 
exchange of the methylene protons. Increa,sing the molar ratio of rr-
butyllithium and/or the reaction time fai'Jed to significantly alter the 
extent of methylene proton exchange. 
75 
In order to facilitate the exchange of the H-2 proton in the l-methy1-
indole derivative (IV) it was necessary to elevate the reaction temperature 
to 00 and extend the reaction time to 75 minutes; further elevation of the 
reaction temperature or increase of the reaction time led to degradation 
of the compound. 
B. Exchange Studies USing Tritium 
The use of 3H20 as the quenching agent for the meta1ated heterocYcles 
allows for the facile preparation of specificallY labeled Cow?ounds. The 
specific activities of the compounds so labeled appear in Table fl. The 
chemi ca 1 purity of each compound was demons trated py thi n-1 ayer chroma to-
graphy using several different solvent systems and the radiochemical 
purity wa~ verified by radioscanning of the thin-layer plates, 
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Table II 
Specific Activity of Exchanged Compound56 
Compound No. 
II 
III 
IV 
Specific Activity (yCi/mmo1e) 
518 
729 
431 
176 
Reactions were run as per the experimental using 
3HZO (2 mCi/mmole). 
Compound II Was selected for a study of the effects of the volume and 
the specific ~ctivity of the quenching 3HzO on the rate of tritium incor-
poration. These data appear in Table III. 
The study of the effect of 3H20 volume used to quench 3.0 mmo1es of 
base reveals the highest rate of tritium incorporation occurred when 1.5 
mmo1es of 3H20 and the lowest when 6.0 mmoles of 3H20 were used to quench 
the reaction. The decreased tritium incorporation observed upon utilization 
of excess 3HZO may reflect a tritium isotope effect and/or the greater 
availability of IH vs. 3H atoms. 
Table III 
Effects of Volume and Specific Activity of the Quenching 3H20§ 
Volume (pll nunol es 3H20 
3H20 Specific 
Activity (mCi/mmole) 
Specific Activity 
of Compound II (mCi/mmolej 
27 1.5 2 2.15 
54 3.0 2 1.76 
108 6.0 2 0.91 
27 1.5 10 5.18 
27 1.5 20 11.10 
Reactions were run using 1.0 mmole of compound II and 3.0 mmoles of 
~-butYlljthium as per the experimental. 
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Site-Bpecific deutepqtion or tritiation of benao (bJ thiophene 
Thil stl!dy of the effect of the specific activity of the quenching 
3H20 on the rate of tritium incorporation was undertaken using 1.5 mmoles 
of 3HZO. The rate of tritium incorporation was a linear function of 
the speci:"ir: activity of the 3HZO. Studies are presently in progress to 
develop appropriate exchange procedUres for heterocycles containing NH 
groups, i·~·. indole, imidazole, thiazole, etc., and should greatly 
extend the versatility of this method. 
EXPERIMENTAL 
Melting points were measured on a Mel-Temp capillary melting point 
apparatus. UV data were obtained on a Unieam SP1800 UltraViolet Spectro-
photometer and concentrations of solutions used in specific activity 
determinations were obtained via UV. Radioactivity was measured in a 
Packard Tri-Carb 4322 liqUid Scintillation System, using the scintillation 
solution described by Maicke1. et!l (10). Nmr spectra were run on a Varian 
Associates Model HA-lOO spectrometer using deuteroch1oroform as the 
solvent and tetramethylsilane as the internal standard. Aromatic proton 
assignments were made by analogy to compounds previously reported (11.12). 
One dimensional thin-layer chromatography was carried out on Analtech 
silica gel ~ precoated plates (Analtech, Inc., Newark. Delaware). The 
solvent systems used in thin-layer chromatography were: A. methyl acetate-
2-propanol-ammonia (45:35:20); B. chloroform-methanol-acetic acid (60: 
35:5); and C. methanol-ammonia (98.5:1.5). All thin-layer chromatograms 
were developed 12 cm anq visualized with one or more of the following 
reagents (13): Van Urk reagent, alkaline potassium permanganate, ninhydrin, 
and iodine vapor. The developed thin-layer plates containing radioactiVe 
material were scanned on a Packard Hodel 7200 Radiochromatogram Scanner. 
All exchange reactions were conducted with oven-dried .glassware which 
Was assembled and placed under a continuous fl,)W of dry nitrogen gas, 
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prior to the introduction of any reaction component. 
3-(2-Aminoethyl)benzo[b]thiophene-2-2H or 3H. (I). 3-(2-Amino-
ethy1)benzo[b]thiophene hydrochloride (0.213 9. 1.0 mmo1e) was dissolved 
in 15 m1 of 1 li NaOH and extracted with 2 x 25 ml of diethy1 ether. The 
combined ether extracts were dried over anhydrous MgS04 and the ether removed 
under reduced pressure. The free base was unstable in the atmosphere neces-
sitating handling in an inert atmosphere. The free base was dissolved in 
60 ml of freshly distilled (from LiA1H4) THF, cooled to -780 in a C02/ 
acetone bath. and treated with ~-butYl1ithium (1.5 ml of a 2.~ M solution, 
3.75 mmoles). The solution was stirred for 30 min at -780 prior to quenching 
with either 2H20 (0.1 m1. 5 mmo1es) or 3H20 (0.1 m1, 5.0 mmo1es). The quenched 
reaction was dried with anhydrous MgS04' The dried and filtered THF solution 
was treated with dry HCl gas to produce the amine hydrochloride. Recrystal-
lization from methanol/ethyl acetate gave 0.176 g (S3%) of large colorless 
plates, m.p. 220-2210. TLC using solvent systems A, B, and C gave Rf's 
0.S2, 0.59 and 0.24 respectively. Nmr of 2H-exchanged I: 0 1.22-1.60 
(m, 2H, NH2). 2.97 (broad 5, 4H. CH2CH2). 7.09 (5, 0.20H, H-2). 7.20-7.46 
(m. 2H. H-5,6), 7.62-7.90 (m, 2H, H-4.7). Using 2H20 (99%) as the quench-
ing agent gave SO% deuterium incorporation at the 2-position, while using 
3H20 (2 mCi/mmole) gave a specific activity of 518 ~Ci/mmole. 
Benzo[b]thiophene-2-2H or 3H-3-acetic acid. (II). Benzo[b]thiophene-
3-acetic acid (0.192 g. 1.0 mmole) was dissolved in 60 m1 of freshly distil--
led (from LiA1H4) THF and the reaction vessel cooled to -780 in a CO2/ 
acetone bath qnd treated with ~.buty1lithjum (1.28 m1 of a 2.34 tl solution. 
3.0 rrmoles). The reaction was allowed to stir for 30 min at -780 and 
quenched with 2H20 (0.108 ml. 6.0 mmoles) or 3H20 (0.108 ml. 6.0 mmoles). 
Upon removal of the THF under reduced pressure, the residue was dissolved 
in 20 m1 of 1 li He1 and the aqueous phase extracted with 2 x 25 m1 of ether. 
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Removal of the ether and recrystallization of the product from H20 gave 
0.155 (81%) of long colorless needles, m.p. 110-1110. TLC using solvent 
systems A and B gave Rf's 0.68 and 0.91 respectively. Nmr of 2H-exchanged 
II: Ii 3.82 (5, 1.3H, CH2). 7.25-7.50 (m, 2.3H, H-2,5,6), 7.64-7.94 (m, 
2H, H-4,7l, 11.50 (broad 5, lH, OH). Using 2H20 (99%) as the quenching 
agent gave 70% deuterium incorporation at the 2-position and 35% incorpora-
tion at the methylene ~osition. Quenching with 3H20 (2 mCi/mmole) gave a 
specific activity of 719 ~Ci/mmole. 
3-(2-0imethYlaminoethyllbenzo[!l!hiophene-2-2H or aH. OIl). 3-(2-
Pimethylaminoethyl)benzo[b]thiophene (0.2059,1.0 mmole) was dissolved 
in 60 ml of freshly distilled (from LiA1H4) THF and the reaction vessel was 
cooled to -78° in C02/acetone prior to treatment with ~-butYl1ithium (1 ml 
of 2.5 !i solution, 2.5 mmoles). The reaction was illl.owed to stir for 30 
min at -780 before quenching with either 2H20 (0.1 ml, 5 mmolesl or 
3H20 (0.1 ml, 5 mmo1es). The THF was removed under reduced pressure, the 
free base was dissolved in 50 101 of diethyl ether and the ether dried over 
anhydrous I1g504 prior to treatment with dry HCl gas to produce the hydro-
chloride. Recrystallization of the hydrochloride from methanol/ethyl acetate 
gave 0.20 g (83%) of long colorless needles, m.p. 260-2610. TLC using 
solvent systems A, a',and C gave Rf's 0.92, 0.42 and 0.36 respectively. 
Nmr of the 2H-exch<!nged lII: <I 2.31 (s, 6H, N(CH3)2)' 2.52-2.76 (m, 2H, 
CH2N), 2.85-3.10 (m, 2H, Ar~H2)' 7.18-7.43 (m, 2H, H-5,6), 7.63-7.86 (m, 
2H, H-4,7). Using 2H20 (99%) as the quenching agent gave 100% deuterium 
incorporation at the 2-position. while using 3H20 (2 mCi/mmole) gave a 
specific activity of 431 ~Ci/mmo1e. 
1-t1ethyl-3- (2-d imethyl am t!Lo(! tj1ylli.ndo 1 e-2::H or3H. (IV). Hlethyl-
3-(2-dimethy1aminoethyl)indole (0.203 g, 1.0 mmole) was dissolved in 60 m1 
of freshly distilled (from LiA1H4) THF, was cooled to 00 in an ice bath, 
and treated with ~-buty11ithium (0.8 m1 of 2.5 ~ solution. 2.0 mmoles) . 
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The reaction was allowed to stir for 75 min at 00 prior to quenching 
wfth either 2H20 (O.l ml, 5.0 mmoles), or 3H20 (O,l ml, 5.0 mmoles). The 
THF Was removed under reduced pressure, the free base was dissolved in 50 ml 
of diethyl ether and the ether was dried over anhydrous MgS04 prior to 
conversion to the hydrochloride with dry HCl gas. Recrystallization from 
ethanol/dlethY1 ether gave 0.176 (74%) of colorless needles, m.p. 169-1700 . 
T~C using solvent system C gave Rf 0.31. Nmr of 2H-exchanged IV: 2.30 
(s, 6H, N(CH3)2), 2.49-2.74 (m, 2H, CH2N), 2.80-3.04 (m, 2H, ArCH
2
), 3.64 
(s, 3H, NCH3), 6.80 (s, 0.25H, H-2), 6.97-7.26 (m, 3H, H-4,5,6), 7.49-
7.63 (m, lH, H-7). Using 2H20 (99%) as the quenching agent gave 75% 
deuterium incorporation at the 2-position, while using 3H20 (2 mCi/mmole) 
gave a specific activity of 176 ~Ci/mmole. 
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EFFECTS OF VARIOUS DEPRESSANT DRUGS 
ON DEPRIVATION-INDUCED WATER 
CONSUMPTION* 
R. P. MAICKEL and G. J. MALONEVt 
Department pf Pharmacology, Medical Sciences Program, Indiana University, Bloomington, 
Indiana 47401 
(Accepl(!d 4 January 1973) 
SummarY-The volume of water consumed in a 60 min period by rats deprived of water for 23' .1)( 
was increased by a variety of sedative drugs such as barbiturates, glutethimide, meth<1qualol1,;. 
and methyprylon. The antipsychotic agent, promazine, decrel\sed water consumption unJc:t 
similar conditions, while antianxiety agents such as chlordiazepoxide and meprobamate had a 
stimulatory effect similar to the barbiturates. The results may be significant in consideration of 
the use of liquid reinforcement in punishment allenuation studies. 
The role of central mechanisms in the control of fluid intake has been the subject of consider-
able study, as evidenced by a number of symposia, reviews. and books (MILLER. 1965; 
GROSSMAN, 1967; MORGANE, 1969). Previous work from this laboratory has demonstrated 
that a variety of cholinergi. blocking agents, cholinergic stimulants. antihistamines and 
amphetamines all reduce deprivation-induced fluid consumption by rats (GERALD and 
MAIC'KEL, 1969; MAICKEL, Cox, KSIR, SNODGRASS and MILLER, 1970; GERALD and MAIC'KEL. 
1972; MAIC'KEL and WEBB, 1972). 1n contrast to' this diversity of pharmacological agents 
that reduce deprivation-induced water consumption, one specific group of drugs, the bar-
biturates, have been shown to stimulate fluid intake by deprived rats (SCHMIDT, 1958. 
] 969). In addition, several antianxiety agents have been reported to stimulate consumption 
of fluids that might be considered aversive in tasle. For example FALK and BURNIDGE (1970) 
reported increased consumption of 1·5 % saline solution by rats treated with chlordiaze-
poxide. Similarly, MARGULES and STEIN (J 967) reported that oxazepam increased the 
consumption of milk made bitter-tasting by the addition of quinine. 
The present p&per reports on the actions of v&rious sedative-hypnotic drugs, both barbi-
turate and non barbiturate, and several antianxiety agents on deprivation-induced fluid con-
sumption by rats. 
MATERIALS AND METHODS 
Adult (300-350 g) male, Sprague-Dawley rats (Murphy ~reeding Laboratories, Plainfield, 
Indiana) were ~sed in all experiments. The animals were maintained on tap water and Purina 
Rat Chow ad lib. for at least I week after arrival in the laboratory. All solutions for injec-
tion were made in glass distilled water such that a dose volume of 0·1 ml per 100 g body 
·Supported by USPHS grants MH-14658 and K02MF-41083 (to R. P. MaickeJ) and by NASA grant NGL· 
15-003-117. 
tTaken in part from a thesis SUbmitted by G. J. Maloney for the M.S. degree in Pharmacology, Indiana 
University, 1972. 
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weight contained the desired dose; all injections were given intraperitoneally, 15 min prior 
to placing the anim&ls in the drinking cages. 
The procedures used to measure deprivation-induced water consumption were basically 
those of GERALD and MAICKF.L (1969). Rats were placed in cages, 7 x 7 x 14 inches. identi-
cal to the home cages ofthe animals. The cages were suspended in individual compartments 
of a sound-proofed box with uniform fluorescent lighting. Constant circulation of &ir by 
blowers maintained uniform temperature in the compartments; the noise level of blowers 
served as a .. white noise". Each cage contained a drinking tube connected to an external 
50 ml buret filled with distilled water at the start of each test run &nd stoppered. As the 
animal consumed water, the change in volume was measured visually to the nearest 0'1 mi. 
The front door of each compartment was equipped with an eye-piece lens to permit visual 
observation of the rats without disturbing their behavioral performance. For at least I week 
prior to testing drug effects, rats were deprived of water daily for 23 hr prior to testing, then 
placed in the" drinking cages" and allowed to drink for I hr. Food was available ad lib. in 
the home cages but was not available in the drinking cages. 
Drug trials were started only after the animals demonstrated stable baselines (less than 
5 % daily variation) of water intake. The schedule for drug studies was arranged so thai the 
rats were run daily, with drugs administered every fourth day, and. placebo doses on the 
intervening days. Water intake was recorded at 15, 30 and 60 min of the consummatory 
sessions; the greatest proportion of drinking occurred in the first 15 min in all cases. 
Groups of 8 rats were run in each test system; an n of <8 rats indicates that a value or 
values was discarded because of equipment malfunction. AU data are repNted as mean 
± S.D. Statistical comparisons were carried out by the correlated t-test for paired scores. 
The day prior to each drug day was used as the pre-drug value for that drug run. Each 
animal served as its own control; per cent of pre-drug values are the mean of values calcu-
lated for each animal. 
RESULTS 
Effects oj barbiturates on deprivation-induced water consumption in rats 
The data in Table J indicate that the short-acting barbiturates, amobarbital, hexobarbital 
and. methohexital, had no significant effect on the volume of water consumed by deprived 
rats, except for the highest dose or methohexital. ,.\lith the longer-acting barbiturate, pheno-
barbital, increased water consumption was observed at all dose levels, a finding similar to 
that previoU3ly reported for barbital (1\1AICKEL and MALONEY, ) 972). 
Effect oj various sedative drugs on deprival ion-induced water conswnp(iol/ 
The data in Table 2 are those obtained with three sedative drugs, glutethimide, methaqua-
lone, and methyprylon as well as the antipsychotic agent, promazine. With the exception of 
the lowest doses of glutethimide and methypry)on, a significant elevation of water consump-
tion was seen with all three sedatives. In contrast, promazine, at all three doses tested, 
produced a significant decre~se in d:!privation-induced water consumption, a finding that 
is in agreement with a previous publication from this laboratory (MAICKEL, GERALD, WAR-
BURTON and MMUU, 1968) examining several phenothiazine tranquilizers. 
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Depressant drug,; and water consumptioq 
Table I. Effects of barbiturates on deprivation-induced willer consumption in 
rats 
Dose (Lp.) Volume consllmed 
n (/Lmollkg) Pre-drug Drug 
(ml) 
%of P 
(/01) Pre-drug 
Amobilrbitill 6 1'9 14-9± 1·6 16'0 ± Jo6 109± UO 
8 JoB 16'2± Jo9 17'3±4'3 108 ± 23-8 
8 7-6 10·5 ± 3-4 1O·9±N lJ) ±37·2 
8 3·6 12'5 ± 2-1 IH ±N 105 ± 20·9 
7 7-2 J6'1 ± 2'7 17-8 ± 3'2 109 ± 17-4 
8 14.4 15'7 ± 4'l 16·8 ± Jo9 JlO± 1504 
Hexobarbital 
8 Jo6 1l·9± H 14·0±4·2 )20± 30'S 
8 3-2 13-9 ± 3'2 15'1 ± Jo9 )09 ± 18·7 
Methohexitill 
8 6'4 12-7 ± 2·9 14·9 ± 2'S ]21 ± 23·2 • 
Phenobarbitill 8 1·95 14'7 ± 2'5 18'7 ± 2'5 129± 19'8 • 8 3'9 13'5 ± 1'6 18·3 ± 3-3 137 ± 24·6 • 8 7-8 ;2-9 ± 1'9 20·0 ± 3'3 158 ± 38·8 • 8 1506 1I'2 ± 2'5 18·6 ± 1'8 172 ± 40·5 • 
Animals were treated as described in Material, and Methods section; drug was 
administered )5 min prior to start of drinking session. Results are expressed as 
mean ±S.D. of the values obtained. Statistical comparisons were made by the 
correlated I-lest for paired scores; significant differences from the corresponding 
pre-drllg val lies (P < 0'05) are indicated by .• 
Table 2. Effects of various sedative drugs on deprivation-induced water con-
sumption in rats 
Dose (Lp.) Volume consumed 
Drug n (It mol/kg) Pre-drug Drug % of p 
(ml) (ml) Pre-drug 
Glutethimide 7 4·6 15-8 ± 2·6 15-4 ± 2·2 99 ± )),3 
8 9·2 12-4±1'5 15·0 ± Jo9 121 ± 26'3 • 8 18-4 13-31 3'4 IH±3'4 PI ± 21-4 • 
fI.-fethaqualone B 2·0 15'1 J: 2·3 17'1 ± 7-8 116 ± 20·1 • 8 4·0 14'3 'J: 2'7 18'5 ± Jo6 )34 ± 23'1 • 
Methyprylon 8 2·7 1204 ± 2-J 13·2 ± 1-4 109 ± 19-7 
8 5-4 11·8 ± 2-8 15'2±H 142 ± 37-3 • 
7 10.8 12·4 ± 2-2 16·2 ± 3·2 133 ± 26·4 • 
Promazine 7 0·78 15'1 ± 3'1 12·9± 3'7 85 ± 16'4 • 8 1'56 10·2 ± JoJ 8·J ± 2-8 47/:: 14'7 • 
8 3-J 14-4 ± 3·3 6·3 ± 3·7 40:1: 24'7 • 
Animals were treated as described in Materials and Methods section; drug was 
administered 15 min prior to start of drinking session. Reslllts are expressed as 
mean ±S.P. of the values obtained. Statistical comparisons were made by the 
correlated I-test for paired scores; significant differences from the corresponding 
pre-drug values (P< 0'05) are indicated by.-
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l:..1{ect of various antianxiety drugs on deprivalion .. induced ",(lIer consumption 
In Table 3 are presented the data obtained when chlordiazepoxide, diazepam, and mepro-
bamate were administered to deprived rats prior to the start of the drinking session. Except 
for the lowest dose of meprobamate, significant increases in water consumption were 
observed in all test situations. 
Table 3. Effect of antianxiety drugs on depri'/ation-induced water consumption 
. in rats 
Dos~ (i.p.) Volume consumed 
Drug 
" 
(mol/kg) Pre-drug Drug ~~ of , 
(ml) (ml) Pre-drug 
Chlordiazepoxide 8 H IH ±2-4 16·4± 2-8 125 ± 15-1 
-8 2-2 1O·7±2·2 15'5 ± "2 15O±2')03 
-8 4.4 12-5 ± 2'9 18'S± 2'5 IS2±3)oJ • 
Diazepam 8 1·8 14·3±H 18'4 ± 3-5 133 ± 30'6 • 
8 3·6 14·2 ± 2-l 19·9 ±]oS 136 ± 32·7 .. 
7 7·2 12·S± 1'9 18·7 ± 3-2 lSI ± 26·0 
-
Meprobamate 8 9'2 12·6±2·2 IH±H 106± 18'5 • 
8 18·4 13-4±2-3 16·7 ± 3'5 124 ± 11-7 It 
8 36·8 10'6± 2'S 13-7::1:3'0 132 ± 21'7 • 
Animals were treated as described in Materials and Methods section; drug was 
administered 15 min prior to start of drinking session. Resu Its are expressed as 
mean ±S.D. of the values obtained. Statistical comparisons were made by the 
correlated I-test for paired scores; significant differences from the corresponding 
pre-drug valucs (P < 0'05) are indicated by.-
A comparison of the slopes of the dose-response curves for all the drugs tested is seen in 
Table 4. The slopes of chlordiazepoxide, phenobarbital, melhyprylon, lind meprobamate 
are similar, as are those of diazepam and glutethimide. Promazine is dissimilar to all others 
in sign since it causes a reduction i!1 fluid intake, while amobarbital, hexobarbital and melho-
hexital did not yield dose-response curves. 
Table 4. Slopt.'S of dose response 
plols of drug effects on fluid 
consumptiol\ 
Compound 
Amobarbilal 
Chlordiazepoxide 
Diazepam 
Glutethimide 
Hexobarbital 
Meprobamate 
Methaqualone 
Methohcxital 
Mcthyprylon 
Phenobarbital 
Promazine 
47 
Slope ~ 
3-4 0'64 
43-4 0·90 
21),9 0'93 
36'5 0·87 
8·3 0'94 
43·0 0'98 
28-2 0·99 
1·7 0'08 
]5-4 0'67 
49·8 0·99 
74-7 0'93 
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Depressant drugs and waler consumption 781 
DISCUSSION 
In many reports of the effects of sedative drugs on fluid consumption, a lack of standard-
ization of procedures, dose schedules, and thirst-inducing stimuli has made comparisons 
difficult. In the present study, the stimulus wa~ constant (23 hr deprivation of fluids), the 
pretreatment time was constant (15 min), all drugs were studied in dose-response schedules, 
and all experiments were run at the same time of day to minimize the effects of circadian 
rhythm variables. . 
The results obtained are consistent with the hypothesis that sedative-hypnotics and anti-
anxiety agents stimulate water consumption in deprived rats. The sedative action of the 
barbiturates cannot be responsible for this phenomena since promazine, like other pheno-
thiazine tranquilizers (MAICKEL et al., 1968) decreases fluid consumption in a similar test 
system. 1n addition, previous work from this laboratory has demonstrated that antihist-
amines, despite their having sedative actions in humans, also reduce fluid intake in a similar 
test system (GERALD and MAICKEL, 1972) 
In a recent publication (MAICKEL and MALONEY, 1972) we have shown that careful atten-
tion must be paid to time- and dose-response characteristics in order to separate the sedative 
and dipsogenic actions of barbital. Such restriction hold true for all sedative drugs; the 
depressed animal may not be able to drink even though the thirst drive is present. In this 
regard, the use of combination test system such as actopho(ometers and water consumption 
tests (MAICKEL and MALONEY, 1972) may be a requisite for suitable interpretation of the 
data obtained. 
The implications of the findings reported in the present manuscript towards the mode of 
action of antianxiety drugs merits special aHention. According to the hypothesis of Geller 
(GELLER and LEIFTER, 1960, 1962; GELLER, H ULAK and LEIFTER, 1962), the responsivenesll 
of rats on a bar pressing schedule for fluid reinforcement is suppressed by punishment. 
Administration of Chlordiazepoxide, meprobamate, or phenobarbital increases the rate of 
responding during the punished period, leading to the interpretation that these drugs have 
abolished the effect of punishment. In view of the present findings demonstrating the 
increased water intake in response to these drugs, one must pose the question of whether this 
dipsogenic action is sufficient to "override" the inhibition of behavior due to punishment. 
In view of evidence in the literature on increased food consumption elicited by sedative 
drugs (RANDAL,L, SCHALLEJ(, HEISE, KEITH and BAGDON, 1960; OPITZ and AKINLAJA, 1966) 
and the present findings on fluid consumption, the possibility of a motivational component 
in the explanation of consummatory behavior suppressed by punishment should receive 
further study. 
....,. 
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METABOLISM OF 
3-(2-DIMETHYLAM IN OETHYL)BE NZOlb ITH IOPH EN E 
IN VITRO AND IN VIVO IN THE RAT 
STEADMAN D. HARRISON. JR .. I TALMAGE R BOSIN. AND ROGER 1>. MAICKEL 
Department 01 Pharmacology. Medical Sciences Program. Indiana University 
(Aecelved October 11. 1973) 
ABSTRACT 
The metabolism of 3-(2-dimethylaminoethyllbenzolblthiophene has been studied in vivo and in 
vitro in rats. Thll results indicate the major pathways of metabolism to be 6.hydroxylatlon. 
N-dealkylatlon. and oxidation by mnnoamine oXidase No evidence for sulfoxidation was obtained 
Metabolites were identified by combinations of mass spectrometry. nuclear magnetic resonance 
spectroscopy. thin-layer chromatography. and liqUid sCintillation counting. 
Benzo[bJthiophene derivatives constitute a 
growing class of biologically active compounds (I). 
Despite the large number of benlolbJthiophene 
derivatives thai have been synthesi7ed. metabolic 
studies have hccr! reported fer only one compound. 
4-ben/olb]thiophene methylcarhamate. a pesti-
cide. in the rat (2), and in dair) gouts and a 
lactating cow (3). Of particular interest was the 
identification, by infrared spectroscopic tech-
niques, of benzolblthicnyl-4-sulfate-l-oxide. as a 
urinar~ metabolite in the goat and cow (3). 
Continuing interest in the biochemical pharma-
cology of benzo[blthiophene derivatives has led 
[his laboratory to investigate several compounds 
analogous to b;ologically active indoles (4 -9). No 
information is available on the metabolism of' 
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3-substituted ben7olblthiophenes, and because 
many of the naturally occu rring indoks of phar-
macological interest arc J-,ubslitutcd derivtltives. 
3-{2-dimethylaminoet h~ I)ben/olb ]thiophene {II, 
the befllolb]thiophcne analog of N. N-dimethYI-
tryptamine (tJMl). \\llS cho~en a~ a Illodel com-
pound for the present stud}. 
1 /"""""'- 11 "1 '·r 1 
J"ev ·i1 )1- ;\ .~ / ('H, t'II, 
I 
In view of the reported sulfoxidation of 4-ben-
zolbJthiophene methyl ctlrbamate (2, 3). it was of 
interest to determ inc \\ hether I m igh t undergo 
sulfoxidation. Other metabolic pathways for I 
might be predicted on the basis of the structural 
analogy between I and DMT.2 Metabolites of 
DMT result from N-dealkylation. N-oxidation. 
aromatic hydroxylation. llnd u-xidative dcamina-
lion (10. II). Jaccarini and Jepson (12) reported 
that the positional specificity of indole hydroxyla-
tion by liver microsomul enzymes \\a~ the same 
regardless of substrate, species. or atlempted in-
duction. The 6-hydrox) derivative was the only 
hydroxylated product formed. When incubated 
with the IO.OOOg supernatant fraction of rat liver 
hotnugenate (no pre! rea t men! with ind ucing 
agent). bMl was found to yield 1.5 ,umol of 
6-hydroxy-DM't per g. of liver per hr (12). 
2 The abbreviations used are DMT. N. N·dlmethyltrypta-
mine; NMA. nuclear magnetic resonance. TLC. thin, layer 
chromatography. 
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We report here the identification of metaholites 
of'1 hy hil,!h resolution N M R and mass ~pectromc­
try. Thc quantitativc metaholic profile of I is 
presented in \'11m and itt \'im in the ral. 
\1atcrial~ and :\Iethods 
Liver 5amplc~ \to ere obtained from adult male 
Sprague-Da\\ley rats. 300 -400 g (Murph) Breeding 
Laboratories. Plainfield. Ind.). Rats were fasted over-
night before use. 
The follO\\ Ing compounds \lere generousl) supplied by 
Dt. E. E. Campaigne. Department ol'ChemistTY. Indiana 
Unh'ersity. Bloomington. Ind.: 3-(2-dimcthylarnino-
ethyllbenzol b )thiophene 'hydrochloride. 3-(2-mcthyl· 
aminoethyl}bcnwlbjthiophene hydrochloride. benzolb)-
thiophene-3-acetic acid. 3-{2-hydroxycthyl )benzolb)t hio· 
phenc. and 5-hydroxy-3-(2-dimethylaminocthyl)benzo· 
Ibjthiophene picrate. 2-Tritio·3.(2-dimethylamino-
ethyl)benLOlb)thiophene hydrochloride. 8,9 mCi/mmol. 
was prepared b)' the method of Bosin and Rogers (13). 
The radiochemical purity of this compound was shown 
by thin-layer chromatography to be greater than 99.5%. 
Liter Microsomal Incubation. Preliminary studies 
were performed with the crude microsomal frnc\i':l0 of 
rat liver prepared and incubated by the method I',. Ma7e! 
(14). Optimum conditions for the microsomal ~·hydrox­
ylation of indlliealkylamines ill virro "ere established by 
Jaccarini and Jepson (11); these condition!. "ere em-
ployed in all experiments performed for the purpose of 
quantitating metabolites. Appropriate bufiers (12. 14) 
were prepared according to Stauff and Jaenicke (15). All 
experiments employed the 10.000g supernatant fraction 
of rat liver homogenate. Cehtrifugation was carried out 
at 5°C for 10 min in an I EC model B-20 refrigerated 
centrifUge. Incubations were carried out in 25-ml glass 
vials at 37°C with an Aminco-Dubnoff shaking ihcubator 
operated at 125 cpm. Reaclions were terminated after I 
hr b) immersing the viliis in a Dry Ice-acetone bath. 
1~()lation of Metabolites. For preliminary TLC studies. 
0.5-1.0 ml of incubation mixture. pH 1.2. was added to a 
glass-stoppered 15-ml centrifuge tube containing 6.0 ml 
of ethyl ether. Sufficient solid NaCI was added to 
saturate the aqueous phase, Tubes were mechanically 
shaken for 10 min and cehtrifuged for 10 min. The ether 
phase was then transferred to a disposable culture tube 
from which the ether was evaporated under a stream of 
N,. The residue was taken up in methanol and subjected 
to TLC on Silica Gel G plates (Anallech. ptecoated. 
prescored Uniplate; 0.25-mm thickness) in one or mote 
of the following solvent systems: A. chloroform! 
methanol/acetic acid (60: 35: 5): B. methanol/ammonia 
(50:0.75); C. methyl acetate/isopropanol/ammonia 
(45:35:20). A spra) of lo/c potassi~tTi permanganate in 
5% aqueous sodium carbonate was t:tTiployedfor visuali-
zation. 
To obtain a given metubolite in l! quantity sufficient 
for spectroscopic stud). 2.0 ml of ihcubation mixture 
"ere added to c~ch of at least 30 60·ml gla~s-stoppered 
51 
tuhe, <:ontJinlng. :!S 1111 of etll\ I ether and ~ufficicnt solid 
NaCI to ~;lturalc the aqueou, phase. Amines \\cre 
extracted after :\djustment of the aqueous phase to pH It 
with ,ulid Na,CO,. Acid~ wcre extracted after adjust-
ment of the aqueous phase to pH I "ith O.S ml of 5 N 
HCI. After .. haking and centrifugatIOn. the pooled ether 
extract, wcre evaporated under reduced pressure, The 
residue was taken up as an lIqueous solutiun at appropri-
ate pH (pH I for an amine. pH II for an acid), 
transferred to a 60·ml glas,.stoppered tube. diluted to a 
final volume of 6 mi. and "ashed with 2· 3 10·ml portions 
ofben7cne The aqueous phase was then adju~tcd to pH 7 
with solid Na,CO. or 0.5 N HCI as appropriate. 
saturated with NuCI. shaken with 30 ml of ethyl ether. 
and centrifuged. The ether was evaporated. and the 
residue was taken up in methanol. This methanolic 
solution WJS applied. by means of a I -ml glass syringe 
and 30·gaug.e hypodermic needle. as a streak to a Silica 
Gel H (Brinkmann) layer (20 x 20 em. 0.7S-mm 
thickness). which was then developed in one of the three 
solvent systems dcscribed ahove. A band of silica gel at 
an apprupriate Rr was scraped into a sintcred glass filter 
funnel and washed with 0.5 N HCI if the metabolite was 
an amine or 0,2 N NaOH if the metaholite was un acid. 
The filtrate was adjusted to pH 7. saturated with NaCI. 
shaken with at least 2 volumes of ethyl dher. and 
centrifuged. The ether phase was transferred to a clean 
sample vial ahd c"upornled. The residue was then 
c.,;mined b~ NMR and/or mass speclrllmetty. NMR 
s('icctra. 220 MHz. were ohtained using a Varian HR-220 
N M R spect romeler and. when nece~sary. were time-
averaged with a Nicolet Instrument Corp. 1080 com-
puter. Ma,~ spectra were obtained using a Varian Mat 
CH7 ma~s spectrometer using an ion current of 70 cV. 
Quantitation of Metabolites. [2·'H)3-(2·Dimeth-
ylaminoelhyl)benzolbjthiophene was used. Radioactiv-
ity was measured in a Packard Tri-Carb model 2425 
liquid scintillation spectrometer. with polyethylene vials 
and a scintillation medium consisting of 14 g of 2.5-bis-
[l-(S-lerl-butylbcnldxazolyll]thiophcne and 280 g or 
naphthalene in a mixture of2100 ml of toluene and 1400 
ml of ethylene glycol monorncthyl ether. A counting 
system of 15 ml or this mcdium, 0.5 ml of 0.5 N HCI. and 
silica gel (vide infra) was used for these determinations. 
A 4-/11 <Drummond Microcap) aliquot of incubation 
mixture or urine was applied to a Silica Gel G (Brink-
mann) layer (20 )<. 20 em. 0.50-mm thickness). The 
chromatogram was developed in either one or two 
dimensions. as appropriate, with one or more of the three 
solvent systems already described. The layer was then 
divided into I x I-em squares. and each square was 
scraped into u pol}cthylene counting vial. To each vial 
was then added 0.5 Inl of 0.5 N HCI. and after thorough 
mixing the counting system was completed with 15 ml of 
scintillation Inedium as dc'cribcd ahove. This system 
give~ 24% erticiency for tritium with a background of 19 
cplll. Results for this procedure allow the constrUction of 
two· and three-dimensional histograms for graphic pres-
entation of the quantitative metabolic prufile, Recovery 
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of lahdcd llllllp"UIHJ, In~uhJted In the al"cllcc 01 lI"ue 
ur in the rrC-l·lIe.: ,'I huiled ti"ue \\as :. YO', "11 a /l(J.nlln 
incuhJIII'n. lullol'cd b~ e\lracliun and TLC as dewrihed 
ahole 
Radiuchrnnl!ltu(!ram Scanni/ll( and I hin-l.lI.\cr .\!JIII. 
radiul!raph~. \\h~11 sulTlelenl rildi(laClilll~ \\J~ prc'enl. 
the 10raiIOn 01 'I I IJ\ctaholiles "II thlll·l;ncr Chllll1lat{l. 
f!rums (Silica (,el G. Brinl..mann 'iM·rlll~f!ralll. pre. 
coated plas"" sheet' 5 > 20 CIll. 0.25'111111 lu)er thid-
ness) lIas delcrIlllncd uSing a Packard model 7~OO 
radiochromJt')~i am scanner. Thln·lill er IIUllIrudlO!!ramS 
,",ere produLed'llI expOSing chrullIiI'togralm III ~od.lk 
RP RlI)lIl X-Orn.Jl medical X·rJI film fllr 4 lIed, 
hlm~ \\ere procc"ed in a "(,da~ X-Omat processor 
III 1'/"0 l\\l'tabulic,m.lh II tYPical e\pcfllllcnl. a ral \\ilS 
injecled II ilh 'H-I (30 mg/kg and 125 pCi/l..g ip) lind 
placed In a mClaholism clige (Mar) Illnd Plastics. 1\Jc .... 
York. N.Y.) for collection of urine and fcccs. At 5. 24. 
48. 72. and 96 hr aller Injection. urine was collected and 
~tored under t(,IUelle at 5°C. and feces \\ere ctllk~lcd and 
fWlen. The Ilnllnal \las killed and e,sanguin;lIcd. and 
samples of ria sma. livcr. kidney. and brain "'~re col. 
lected and fro/en. 
The I'olllmcs of Ihc urine and toluene phases .... ere 
measured. DlIrlic:lle uli4uots (0.1 ml) of each tolucne 
phase lIerc u,unlcd directl). Durlic<1le aliquolS co. I 1111) 
of each urine ph,,,c "erc digcslcd b) the perchlurlc aCid 
mel hod of I\t'na),,,hi and MaudslcI [161 heforc cuunt-
inf!o 
Thc IOlal kces LllJlcclcd lIerc homogcni/ed in loa ml 
of 0.5 N HCI Duplicale aliquals (1.0 ml) \\ere digested 
with rcrchluric acid (16). and 0..1 ml of each digesl was 
counted 
Tissues were homugellized in J \'olumt~ orO.1 N He/. 
Duplicate aliquol' 10.1 tnl) of each homogenale were 
digested,", ith perchloric acid (16) and cuunted. 
Urine .... as examined b) two methods for the presenc!: 
of rlldioactivlt). Ali4uots (5.0 ml) of urine at pH I (1.0 
ml of 5 N HCI added) and pH II (solid Na,CO, added) 
were saturated wilh solid NaCI and shaken wilh 30 ml of' 
ethyl ether in a flO'1ll1 glass-stoppered tube. After cenlrii'. 
ugalion. the ether phases \\ere transferred tv disposable 
culture lubes. and the ether was evaporated. The residue 
was taken up in methanol and chromatographed on a 
Silica Gel G (Brinkmahn thin layer 0.25 mm). The 
chromatogram \\US Ihen scanned fur radiuactivity. 
A second methud cntuiled the apnlication of 4 pI of 
II·hole urine to a Silica Gel G (Brinl..rnann) layer 1O.:'iO 
mm). After de\elopment in soilenl system A. a histo. 
gram W('S produced as descrihed earlier. 
Results 
Identification of Ihe itl Vilro Metabolites of 
3-( 2-0i melh~ I aminocthyl )bcnzol b jthiuphcnc (II. 
The presence of amine tne[ab(}lite~ \\a5 delllon-
~lt:lled without lhe aid of 3H_1. Extraction of the 
incubation mi.\IUre at pH I. 7. and J I I'olltl\\cd b) 
TLC e~amin;[tion of the organic ph:l~e relcaled 
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t\\(1 amllle ... ·J 1.(' clL'I,lLtefl~tic~ ofilll'/lrtJ nH:tab. 
lllite~ or I arc prewl I:d In table I. 
PIt:!'aratll e TU fI' \I,ll ent ~) stelll .\ ) lelded 
appro\imatel) I Ill!;! .d the maJor anllne meta h l1lite 
Irom an e\[ract 01 the incuhdtion f111\ture. A 
lirne-alcraged :!()(J· ... IHI NMR \peLlrum 01 the 
metaholite lIas obtained. and the anllllJIIC rt!!!llIn 
is pn: .. ented in ng. I The spcctrum .. hows that 
either the 5- or the (j'proton of I has been rt!placcd. 
II nne compares thiS spectrum with the same 
re!!ion Irom that of Ihe bcnlo[hjthiophene analog 
of burolenll1e. 5-h~drt1xy.J-(2-dimeth) IJmino-
cthyl)benlolbjthiopht!ht! (17), shown 111 Fig. 2. a 
strikin!;! dil'krencc is apparcnt. Tht! chemical 
shirts of the 2-prolons .Ire quilc dissimilar. lead-
ing to the t'lJllclusion lhat the amine metabolite in 
question is a 6.suhslituted-J-(2-dimethylamino_ 
dh) I)bcnllllbjthiophene. The possibility of 4- or 
7-,uh~titulion was ruled out after a consideration 
or [he aromutic splitting paltern. 4.H!droxyla-
tion for example. as scen in the spectrum or the 
benlolhjthiophene analog or psilocin (18). does 
not give rise to the \\ell re~olved multiplets that 
occur in a :;. or 6-~ubstituled henlO[bjthiophene. 
The mass spectruln or thi .. sal1lple is pre~enled in 
fig. 3, It exhibits a molecular ion III/e 221. in-
dicalin!! that the metaholilc rcprc\ents [he incor-
portltion of an o\ygt!n atom into the parent com-
pound. Fragmellt~ lII!e 16~ and m/e 91 are at-
trihutable to this metaholite. bUI the ,;ample was 
not sufficient to yield a 'rcctrum upon which a 
meaningful intt:r!1tctation of mass fragmentation 
could be hased. This evidence does, ho\\ ever. sup-
TABLE I 
TLC ciwractcristicJ oj in \'itro 1I/t'Iaho/ites oj 
3·(2·dillll'tltr/CJlllillocth I'/)hen:o[ h ]lhlOl'hclle 
Compound 
1\ B 
. __ ._-
3·( J. Dimcth) la mi noethyl)bel110- 0.38 0.50 
lbjthiophcnc" 
6· H\droxy-l-(~.dlmethy lamino. 0.20 0.42 
ethyl )heniO[ bjlhlllp~cnc" 
3·(2·M elh~la m inocthyl )l1en70' 0.43 0.29 
lblthiophcne" 
C 
Ben7u[bjthinphene-3·;lcctit: acid' U.62 0.45 0.47 
___ .~ __ L _ ____ ~_~'". 
U A. chloroformjmcthanolttlcetil acid (60: 35: 5); B. 
methanol/ammonia (50:0.75): C. methyl ucelulejiso. 
rroplll1ol/ummonia (45:35: 20) 
h Determined on Silica Gel G (Alwllcch!. 
, DelCtmincd on Silica Gel (j (Brlllkillahnl: authentic 
sample wa~ mi,ed with exlraCI of il1cuballon mixture 
berore chtomulogtaph). 
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FIG. I NMR speC1rum (220 M Hz) O/6-hydroxr-3-(2-dimelh.l'lalllilloe1hy/lbell:o[bj/hiophe"e_ 
Solvent; COCl,: intcrl'al ref.: CHCI,; 1'10_ of scans: () I. Chcrnieal ~hifls uf aromatic protuns arc prc~cnted in table 4. 
HO~ ~ I I 1 
::::... S CH" 'cH 
3 J 
fl2 
H7 
FIG. 2. N MR Spel'ftUIII (:!20 M H=) o/5-hrdrox\'-3-(2-dimt'1hrltJl/lill()f'fhyl)h,"I:O[b)lhiophelle 
Solvent: CDCI,; intervul ref.: trimcthylsilyl: Nu. of scans: I. Chemical shifts of aromatic protons are pre,ented in 
table 4. 
port the conclusion IhM the ma,ior umine metabo-
lite of I is 6-hydroxy-3-(2-dimethylaminoethyll 
benzol bJthiuphene. 
The second amine metaholite Was well separated 
----- ----~ --- ~ 
from I and 6-hydrox).' by soh'ent system B (table 
I). Prepal'atil'e TLC of ah extract of the incuhation 
mixtures yielded ,{ sample of mass spectral unaly-
sis. Spectral duta were cunsbtent with 3-(~_ 
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FIG. 3. Mass 'f'eelrum of 6-hrdroxy-3-(2 .dillJelhrfaflllll(}('tlryl)bell=olb Jllriof1helle. 
This sample was obtained from a liver incubation mixture. 
methyl a minoethyl)benlolblthiophene. This con-
clusion was confirmed by chromatog.raphic and 
spectroscopic comparison of synthetic 3-(2-
methyluminoethyl)hehzolbjthiophene with the in-
cubation mixture. 
When 3H_1 was incubated with the 10.000g 
supernatant rraction of rat Ih'er homogenate. 
radiochromatogrum scans and thin-layer autnradi-
agraphy revealed the presence of one acidic and 
one neutral metabolite. The mass spectra or these 
metabolites were consistent with benzolblthio-
phene-3-acetic acid and 3-(2-hydrox~ ethyllhen-
zolbJthiophenc. These conclusions were confirmed 
by comparison with authentic samples. 
Quantitalion of the in Vitru !\1etabolites of 3H_1. 
The radioactivity present in a given ineubation 
vessel was determined by digesting duplicate ali-
quots (0.1 011) of incublltion mixture with per-
chlotic acid as described ih Materillls and Methods 
and counting. Aliquots of incubation mixtute were 
diluted with water and SUbjected to rractional 
distillation to show that the tritium label was 
biologically and chemically stable. An aliquot (4 
Ill) of incubation mixture was then chromato-
graphed in two dimensiuns. first in solvent system 
A. and then in solvenl system B after rotation or 
the plale through a 90° angle. Histogram analysis 
ofthis chromatogram provided a direct determina-
tion of the amount of each metabolite produced. 
The results are presented in table 2, It was round 
that greater than 99% of the radioactivity applied 
to the plate was recoveted in four ~pots. 
Metabolism of 3H_I in Vivo. The urinary excre-
tion of radioactivity after an ip injection of 3H_1 
(30 mg/kg and 125 /lei/kg) in the rat is presented 
54 
TABLE 2 
Produclioll 0/ 
12-' Hj3-(2-dimelhylalllilloelhy/)"el/:v[ b jrhiof1helle 
metaboliles ill l'ilfO 
('ompound 
.'-r 2-I)inrcltl\ larnin!)cth, Ilhcnm· 
Ihlthiophe'lIe -
6· H \ drll., -.1-( 2·dimcth, lamino-
ct-h) I th~nlol b Ithioph~nc 
3-( 2-Methvlarn IlIllct hI Ilhenzo· 
Ibjlhiophenc -
Bell701 h JI h illphcnc-J-acc! ic 
ucid 
"mol 
PllldUCI"/!! Per ('cnl' 
t i,er/hr 
82.5 
U 4.8 
LI 4.2 
U Based on 10 "mol of suhstrate: not corrected for recoYen, 
" Percentage of total radioactiYity presenL . 
TABLE 3 
Urinan' excrelion of radiaaelil'ilt" a/ler ip adminirlratlOlI 
of [2_ 3 Hj3-(2-dilllethylamilloerhy/)bell:o[" JlhlOpilelle ill 
the ral 
-------r---- -------... -----
Timc 
ht 
5 
24 
48 
72 
96 
---j----
Urill'H) Radiouctivit) 
d(lm/ml x /OJ 
473 
564 
14 
8 
7 
in table 3. Urine was collected under toluene. and 
the possible loss of 3 H metabolites into the toluene 
was considered. The data indicate that 45')}, of the 
injected dose was excteted in the urine in 96 hr. 
From data derived as described in Materials and 
Methods. it was determined that 2';;, oflhe injected 
dose was excreted in the feees ill 96 hr. An 
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cxamimllion of brain. liver. kidnc~. ,Ind plasma at 
9(, hr failed to revcal a cunt:cntration or radinactil-
it)' in these tis~ucs, Radioacti\'it~ was unil"rml~ 
distrihuted in brain. liveI'. and kidne~ tll thc ntent 
of 13 " 103 dpm/g.. when:a5 thc pla~ma Ielel .... a~ 
6KOO dpm/ml. 
Radiochromatogram scans of urir.e extracts 
showed that although no radioactivit) was ex-
tracted rrom pH I I into ether. extraction from pH 
I yielded a single acidic metabolite, It, chromato-
graphic characteristics. based upun pre\'ious expe-
rience with benzo[bJthiophene-3-acetic acid in I'i-
Iro. suggested thtl! t he major in I'il'o metaholite 
was identical to tht: minor acidic metabolite pro-
duced in I'i"o. TLC comparison in all three solvent 
systems (A. B. and C) confirmed the identity of the 
urinary acid as benzolbJthiophene-3-acetic acid, 
Histogram analysis of whole urine confirmed the 
presence of [2_ 3 H lbenzolbJthiophene-3-acctic acid 
as the major metabolite. The Rr by histogram was 
identical to that obtained by a radiochromatogram 
scan. 
As described earlier. urine was collected under 
toluene. and in the first 5 hr of collection. 4% of the 
excreted radioactivity was round in the toluene, 
TLC examinlllion of this toluene fraction rcvealed 
the presence of [2-3HJ-6-hydroxy-1. It accounts for 
0.7o/r of the total radioactivity excreted in 96 hr. 
Alkaline permanganate revealed a trace or un-
changed I that was not detected b) a radio-
chromatogram scan, 
Discussion 
This study extends observations of the hepatic 
microsomal hydroxylation of 3-substitutcd indoles 
to the analogous benzo[bJthiophene ring system. 
High resolution N MR and mass spectroscopic 
methods were used td investigate hydroxylation 
and other biotransformations of 3-(2-ditnethyl-
aminoethyl)benzo[bJthiophene (I), 
The product ion of benzo[hjthiophene-3-llcetic 
acid reported in table 2 is a sum of the amounts of 
acid and 3-(2-hydroJlyethyl)benlO[bjthiophene 
produced. Because the latter is not readily sepa-
rated from the acid by TLC (19). direct quantita-
tion of 3-(2-hydroxyethyl)benzo(bjthiophene was 
not llccomplished, 3-(2-Aminoethyl)benzolbjthio-
phene ..... as not detected in this 5t udy. This is not 
surprising when one considers the comp:Hative 
mtes of oxidative N-demethYlation of tertiary 
amines vs. secondary amines (20) and the substrate 
specificity of monoamine oxidase (21). a contami-
nant in crude liver preparations such as the 
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10.OOOg supernatant u .. ed in this study. Incubation 
of' 3-(2-mcth~ lal11inoeth~ Ilbelllolblthiophene and 
e\umination h~ TI C indicated that this compound 
is also h~ dnl\~ lated. prc~unHlhl~ in the 6-position. 
but no pril11ar~ amine \\a~ detected. The occur-
rence of benzo[hlthiophene-3-acetic acid as the 
major urinar) metabolite of I is similar to the 
case of [)I\1T (22), No sulfoxidation was observed 
either in rim) or itl I'il'o. 
Fllilure to account for more than 47% of the 
administrated rlldioactivit) in a 96-hi' collection of 
e\creta prompted an investigation of a limited 
number of tissues. After 96 hr. radioactivity was 
uniformly distributed in hrain. liver. and kidney. 
The plasma level of radioactivity was about one-
half that of the other three tissues examined. 
Fractional distillation of diluted plasma og,!lggested 
that the pla~ma radioactivity was attributable to 
3H 20, A definitive study of the tissue distribution 
of I and its metabolites has not been completed. 
Compounds of high lipid solubility are often 
sequestered in tissues other than brain. liver. or 
kidney (23). Robbins el al. (2) noted that 4-ben-
lo[bjthiophene methykarbamate was highl~ con-
centrated in rat lung. 
Detailed analyses 01 the N 1\1 R spectra of a wide 
range of bcnlolbjthiophene derivatives have been 
presented (24- 26). A background for discussion is 
pro\'ided by the chemical shift data presented in 
figs. I and' 2 and table 4. The entries in table 4 
show that when the 5-position of the benzo[bJthio-
phene ring is SUbstituted, the chemical shifts of the 
4- and 6-ptotons ate comparable and fairly con-
stant. The signal from the 2-proton occurs down-
field from the center of the 4, 6-multiplet but 
overlaps the 4, 6-multiple\' When the 6- position is 
substituted, the chemical shifts of the 5- and 
7-protons are comparable and fairly constant, but 
the signal from the 2-proton is now shifted upfield 
and well separated from the 5, 7-multiplet. This 
characteristic of the chemical shift of the 2-proton 
is well illustrated in figs. I and 2. The method by 
which the 6-hydroxy derivative was obtained is 
presented in Materials and Methods, The 5-hy-
d roxy-3 -(2-d j met hyla min oethyl )benzo[b ]thio-
phene was obtained by liberating the free base 
from the picrate according to the method of Fieser 
and Fieser (27). From a consideration of the data 
presented in table 4, It is cleat that the microsomal 
enzymes hydroxylate lin the 6-position as they do 
the analogous indole. Hydroxylation in the 4- or 
the 7-position was tuled out in advance by consid-
ering the overall characteristics or the aromatic 
splitting pattern (see, for example, the NMR 
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spectrum of psilocin-S (IS). a 3. 4-disuhstit uted 
benLO(b lthiophcnel. 
Very IiUh: systematic" ork has heen done in the 
area of benzoiblthiophene mass spectrometry. A 
brief review has appeared (14). but no "ork has 
been rerorted on derivatives similar to those of 
interest here. and one is forced to dnl" analogie~ 
with the mass spectrometry of indolealkylumines. 
Couch and Williams (18) reccnt!) reported work 
that provides an excellent summary of the mass 
spectrometry of tr)ptamines. Qualitative and 
quantitative difrerences in the mass fragmentation 
of indoles and beni'o[b]thiophenes have heen ob-
served and have been presented in detail else-
where (29). With few excertions. the benzolbJthi-
ophene derivatives pertinent to the present work 
conformed to the rragmentation pathways that 
would be predicted from a consideration of indole 
mass spectrometry (28). The low relative abun-
dance or m/e 163 in fig. 3 represents a possible 
exception. but the sample was not sufficient to 
yield a spectrum from which definitive conclu-
sions about the mass fragmentation of 6-hydroxy-
3-(2-dim ethylam inoethyl)benzo[ b )thiophene can 
be drawn. 
Inasm uch as the 5-hydroxylation of tr) ptophan 
by a highly specific enzyme (30) is a widel) known 
reaction. it seems appropriate to consider the 
apparently unique nature of the 6-position of' 
indoles and benzo[blthiophene. 7r-Electron densi-
ties (I) at positions 4.5.6. and 7 of benzo[bJthio-
phene decrease in the order 6 > :; > 4 > 7. The 
order for indole is 5 = 6 < 4 = 7. In additIOn. 
evidence drawn from ultraviolet and N M R spec-
tral characteristics of indole ahd bcnl.O[bJthio-
phene derivatives suggests that 7r-elcctron conjugu-
lion into the ring may be more facile throu!lh the 
'---'" .. ,.,." ::'~.-- -..........-~ ~ ~,-+-~.~-.- -'" ~-~, 
O-pllsition ihan through any other. .1epson £'/ at. 
(31) hare reported on the formation ofa ch:lracter-
istic red color when u 6-hydroxy-3-substit uted 
indole reucts with diazoti/ed SUlfanilic acid. They 
found that a free 2-positilln \\as necessary for the 
reaction to occur. and it .Ippeared that the reaction 
product was a :!-alO derj\'ative . .1accIJrini and 
Jepson (11) reported absorption l1l:Jxima for a 
series Df hydroxytt)ptamin(!s coupled with diazot-
i/cd sulfanilic acid. ihe ahsorrtion maxima in-
crease in the order (by position of h:-droxyl grouP) 
4 < :; < 7 < 6. It is \\ell known (31) that 
7r-eleclron conjugation shifts the absorption max-
imum of a given chromorhore to a longer wave-
length. The shift to longer wavelength that is 
apparent in the series of hydroxytryptamines (14) 
suggests that 7r-electron conjugation is maximum 
in the 6-hydroxytr) ptamine derivative. 
Long-range coupling bet ween the 2-rroton and 
the 6-proton is a well documented characteristic of 
N M R spectra of benzo[b lthiophenes (24). Our 
N M R data revealed another consequence of the 
apparent electronic communication between the 
2- and the 6-positiol1s. Jackman und Stern hell (33) 
point out that the local diamagnetic shielding of a 
given proton is dependent upon the electron den-
sity about that proton. Ample evidence supports 
the conclusion that. in general. increasing the 
electron density about a ptoton will result in an 
up field shift of thut proton's resonance. This is 
exactly the behavior c~hibited by the 2-proton 
"hen one progresses from 5-h),droxy-1 to 6-
hydroxy-I (figs. I lind 2). This up field shift of the 
2-proton resonance in 6-hydroxy-1 may be inter-
preled as tesulting from an increased electron 
density at the 2-position as u cunsequence of an 
electron-donating group in the 6-position. 
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SCI II 'II I (J-1I1 dro.\ "Ialltm III <I 3-I/I".HlIII1£,d 1>1'11:011> Jlhiophl'fll!. 
The r1(1ssihility of lI'-l!leL:tron L:onjugatilll1 in 
indole~ llnd henwlbjthiophenes ~ugg.ests a reason 
for hepatic mixed-function oxidation of these ring 
systems in the 6-Pll~it ion as opposed to an.\ other. 
Resonance stahiliZlltion L:an nlntriollte tll :.1 !\1\\cr 
energy for 6-hydroxylation. This possihility is 
illustrated in scheme I. derived from a consideru-
lion of the; currently favored intermediatc~ of 
microsomal aromatic hydroxylation (34). No com-
parable resonance stabilization can be envisioned 
for intermediates of 5-hydroxylation. Allhough 
electronic considerations may not he divorced 
from the steric and kinetic innuences of an enzyme 
and its environment. the spectroscopic observa-
tions in our study that bellr more directly on the 
question of positional specificity of :Jrotnatic hy-
droxylation are eh:clronic in nature and are re-
ported with the hope ot stimulating further investi-
gations of this question. 
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Physiological Disposition of Atropine in the Rat I 
S. D. HARRISON. JR .. : T. R. BOSIN AND R. P. MAIC'KEL 
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(Received 13 June IY74) 
HARl\,30N, S. D., JR., T. R. BaSIN AND R. P. MAICKEL. Pilysi%}:ica/ disposilioll o[alropill£, ill I"!! '\71. PHAI{MAC. 
BIOCHEM. BEHAV. 2(6) 843-845, 1974. - The physioJlogical disposition of atropine was studied in rats 
using 3 H-Iabeled drug and a specific assay method. At d().~es of 1.25 to 10 mg/kg. i.p .• the greatest localization was 
seen in kidney and liver, with tissue: plasma ratios of > 10: I. Ti~~lIe half-lives over the period 0.5 to 4 hr ranj!cd from 
40-46 min in plasma to 97-106 min in adipose tissue. 
Atropine Tissue levels Physiological disposit ion 
ALTHOUGH pure atropine was first isolated in 1931. and 
its medical use dates back many centuries, few detailed 
studies of the physiological disposition of this compound 
have been published. As mentioned by Evertshusch and 
Geiling [31, suitable analytical methodology did not exist 
until the availability of radiolabeled atropine. These authors 
used randomly labeled 14 C-atropine and followed the time 
course of radioactivity in various tissues with 110 attempt to 
separate metabolites. Albanus et al. [11 used 3 H-atropine 
to study the disposition of the drug in mice, with a com-
bination of radioautography and paper chromatography to 
correct for metabolites. Werner and Schmidt [12] used a 
combination of 3 H- and t 4 C-attopine and specific proce-
dures in a detailed study of the disposition and metabolism 
in mice. In addition, Albanus et al. [21 used 3 H-atropine to 
study the disposition of total radioactivity in the dog, again 
ignoring metabolites. 
In addition to these studies, a number of reports have 
appeared describing the metabolic fate of atropine in a 
variety of animals. As early as 1949, Godeaux and 
Tonnesen [51 used a bioassay procedure to confirm the 
metabolism of atropine in rabbit blood and by cat, rabbit 
and rat liver in situ. Gosselin et al. [71 used 14 C-atropine to 
study disposition of radioactivity and excretion of the 
tropic acid metabolite in mice. Finally, Gabourel and 
Gosselin [4] examined the Urinary excretion of t 4 C-
atropine in mice and rats, and Gosselin et af. [6] studied 
the urinary excretion of t 4 C-attopine in man. Most 
recently, Kaiser and McLain [9) have examined the ex cre-
tion of t 4 C-atropine in man, including studies of the 
plasma decay curves. 
Despite the fact that atropine is widely used in hehav-
ioral. research, primarily in rats [8,10]' no attempts have 
been made to compare blood or tissue levels of the drug 
with behavioral effects. Indeed, the physiological disposi-
tion of atropine has not been reported in any detail in the 
rat. The present paper reports on the time course of physio-
logical disposition of 3 H-atropine in the rat over a range of 
doses commonly used in behavioral studies. 
METHOD 
Adult, male Sprague-Dawley rats (290-350 g) were 
obtained from Murphy Breeding Laboratories, Plainfield, 
Indiana and maintained on Purina Lab Chow and tap water 
ad lib for 7-10 days prior to experimental use. Tritiated 
atropine (labeled in the para position of the phenyl ring of 
the tropic acid moiety) was obtained from New England 
Nuclear Corporation. 
Groups of rats were stunned, then decapitated and 
exsanguinated at various times lifter i.p. administration of 
aqueous solutions of various doses of 3 H-atropine diluted 
with unlabeled atropine sulfate so that the dose of radio-
activity per rat was 60 IlC of 3 H. Blood was collected in 
heparin treated tubes and centrifuged immediately. Tissues 
were removed immediately; plasma and tissues were stored 
at -10° C until assay . 
Radioactivity was measured in a Packard Tricarb Model 
'This research was supported by USPHS Grants MH-18852 and K02-MH·41083 and by NASA Grant NGL 15-003-117. A preliminary 
report has been rre~eJ1ted: Pharmacologist 15: 206,1973. 
J Present address! SoutlJ(~rn Rc~('arch Institute, 2000 Ninth Ave., South. Birmin)!ham. Alabama 35205. 
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TABI I· I 
TIME COURSE OF LEn.LS 01 'H·A'IIWI'INE IN v.\Iuaus RAT )'ISSUES 
Plasma 
Brain 
Fat 
Heart 
Kidney 
Liver 
Dose 
(mg/kg, i.p.) 
1.25 
2.5 
5 
10 
1.25 
2.5 
5 
10 
1.25 
2.5 
5 
10 
1.25 
2.5 
5 
10 
1.25 
2.5 
5 
10 
0.05 
231 ; 37 (4) 
430± 78 (3) 
857± !;,t (4) 
2243 (J) 
329± 47 (3) 
887:! 42 (4) 
1901± 76 (3) 
3639 (I) 
944±HI (4) 
1983± 274 (3) 
3742±681 (31 
8011 (I) 
60b 93 (3) 
1210t97(4) 
2514± 271 (3) 
5279 (1) 
2917t 168 (31 
56121409(4) 
132061930 (3) 
26645 (1) 
2606± 93 (3) 
5828t 306 (4) 
91; 12 (4) 
163± 37 (3) 
423± 82 (4) 
1015t <)6 (4) 
218i 39 (3) 
539:'- 57 (3) 
1226:: 109 (3) 
2!i52± 191 (4) 
453; 91 (4) 
1(,451 194 (3) 
34·~4± 6UI (3) 
7219.\ 697 (4) 
257, 33 (3) 
508+ 66 (4) 
997± 59 (4) 
2360± 537 (4) 
lOIS! 57 (4) 
2404± 360 (3) 
5880i 397 (4. 
1168H 944 (4) 
11781 111 (41 
2407± 371 (41 
2 
48± 10 (4) 
93± 12 (3) 
209± 36 (4) 
375± 71 (3) 
85i 31 (3) 
309± 37 (3) 
794± 26 (3) 
1403±111 (3) 
406± 47 (3) 
974± 93 (3) 
2191±278 (3) 
4667±494 (4) 
102± 12 (3) 
219± 46 (3) 
430i 58 (4) 
808±106 (4) 
488± 57 (4) 
995± 93 (4) 
1955!216 (4) 
3674±378 (3) 
718t 76(3) 
1611±134 (4) 
4 
5.6± 1.9 (4) 
11± 5 (3) 
21 ± 5 (4) 
63± 9 (3) 
54;. 17 (3) 
145± 12 (3) 
296± 20 (3) 
476± 28 (4) 
209;!: 27 (4) 
511± 78 (3) 
J 019± 93 (3) 
23121174 (3) 
39± 13 (3) 
96± 41 (4) 
207t 60 (3) 
458± 57 (4) 
1991. 27 (4) 
411; 78(4) 
822+302 (4) 
14061271 (4) 
346:1. 39 (4) 
649;. 79 (4) 
t1/2 
min 
43 
45 
46 
40 
82 
79 
71 
71 
106 
97 
100 
103 
53 
54 
56 
52 
58 
56 
50 
53 
74 
72 
1.25 
2.5 
5 1075]:!912 (4) 4911:' 4(18 (4) 30?9±475 (4) 1607±138 (4) 72 
10 26544 (I) 12988±1012 (4) 6214.'ti12 (4) 3240i319 (4) 76 
Each value (ng/pS.D.) is the mean of values obtained from (N) rat~. 
4322 liquid scintillation specttometer, with polyethylene 
vials and a cocktail consisting of 14 g of 2,5-bis-2-{5-
tert-butylbenzoxazolyl)-thiophene and 280 g of naphtha-
lene in a mixture of 2100 ml of toluene and 1400 ml 
ethylene glycol monomethyl ether [ I I). A counting system 
of 15 ml of this cocktail and 0.5 ml of aqueous solution 
gives 18% efficiency for 3 H with a background of 10 to 
15 cpm. 
Atropine was determined as follows. Tissues were 
homogenized in 3 volumes of 0.05 N NCI, using a motor 
driven Teflon pestle and glass homogenizer. Aliquots of 
tissue homogenate (1.0 ml) or plasma (1.0 mt) were added 
to glass stoppered (g,s.) 50 mt shaking tubes containing 
25 tnl of benzene and 2.0 ml of a saturated aqueoUs solu-
tion of potassium carbonate. After mechanical shaking for 
5 min, the tubes were centrifuged. Aliquots (10 mt) of the 
benzene phase were transferred to g.S. 50 ml shaking tubes 
containing 2.0 mt of 2.0 N HCl j and the tubes were stop-
pered, shaken for 5 min, and centrifuged. The benzene 
phase was removed and discarded. Aliquots (0.5 ml) of the 
acid phase were then transferred to polyethylene vials con-
taining 15 ml of the liquid scintillat ion cocktail. The 
specificity of the method was confirmed by thin-layer 
chromatography using the system methanol: NH4 0H 
(l 00 ; 1.5) and silica gel G plates. Under these conditions, 
only a single radioactive St10t was found in the extracts, 
with an Rrcorresponding to authentic atropine. Recovery 
of authentic atropine was 85·- 90%. 
RESULTS AND DISCUSSION 
The results obtained after admini~tration of 3H-atropine 
in i.p. doses of 1.25. 2.5, 5,0 ot 10.0 mg/kg to rats are 
shown in Table I. Half-life values were determined from the 
slopes of the decay curves as estimated 1:Jy the method of 
least squares. Several facets are of particular interest. 
Plasma has the shortest half-life (40~46 mit.) while adipose 
tissue (97 -106 min) has the longest. Localization is seen in 
all tissues with tissue: plasma ratios relatively c!'JIlstant over 
the first 2 hr, thell increasing rapidly at 4 hr as pl.'lsma levels 
continue to fall rapidly. Tissue levels decay at a slower rate. 
In fact, the levels of atropine In tissues appear It.: have a 
biphasic decay curve on the basis of selected analyse~ done 
at 8 and j 2 hr after the larger doses. Plasma values were 
below the level of detection at all doses after the 4 hr time 
point. 
It 
. -
:~ 
AllWPINE :~IETABOUS:,1 )~,; RATS H45 
REFERENCES 
1. Albanus, L., L. Hammarstrom, A. Sundwall, S. Ullber and B. 
Vangbo. Distribution and met~butiSr11 of' H-atrupinc in mice. 
Acraphysiol. sCQ/ld. 73: 447-456.1968 . 
1. Albanus, L., A. Sundwall. B. Vangbo and B. Winbladh. The 
fate of atropine in the dog. Acta pharmacal. tax. 26: 
571-582.1968. . 
3. Evertsbusch, U. and E. M. K. Geiling. Studies with radioactive 
atropine. I. Distribution and excretiun pa tlcrns in the mouse. 
Arc/lsint. Pharmacodyn. 105: 175-192,1956. 
4. Gabourel, J. D. and R. E. Gosselin. TIle mechanisms of atro-
pine detoxication in mice and rats. Archs ill I. Pharmacodyn. 
115: 416-432, 1958. 
5. Godeaux, J. and M. Tonnesen. Ihvestigations into atropine 
metabolism in the animal organism. Aera (lharmac. loX. 5: 
95-109,1949. 
6. Gosselin, R. E., J. D. Gabourel and J. H. Wills. The fate of 
atropine metabolism in man. Clin. i'harmac. Ther. t: 597-603, 
1960. 
7. Gosselin. R. E., J. D. Gabourel. S. C. Kal~er and J. H. Wills. 
'OIC metabolism of 14 (,-labeled atropine and tropic acid in 
mice.!. Pharmac. expo Ther. 115: 217-229, 1955. 
8. Grossman. S. p, A Texlhook of Physiological Psychology. New 
York: John Wiley and SOilS. 1967. 
9. Kaiser. S I. and P. Mclain. Atropine metabolism in man. Gin 
Pharmar. ",er. 1 t: 214 - 227. 1970. 
10. Longo. V. G. Behavioral and electroencephalographic effects of 
atropine and related compounds. Pharmac. ReI'. 18: 965-996, 
1966. 
11. Maickel. R. P., R. H. Cox, Jr., F. P. Miller, D. S. Segal and R. 
W. Russell. Correlation of brain levels of drugs with behavioral 
effects.). Pharmac. expo Ther. 165: 216-224, 1969. 
12. Werner, G. and H. L. Schmidt. Chemical analysis of atropine 
metabolism in the mouse Hoppe·Seyler's Z. physiol. C!Jrm. 
349: 677-691,1968. 
r 
(1: 
'~ 
I 
~ 
f . [ [ 
I .,. r Ii ,I: ." ';.,il ~;;; 1"<'. ):;'1 ~I 
r ~: 
J t , 
! 
~: 
; tl A 
. , 
'.-
W~'I'!,~~;:or;=--""",~~~""·";~",-:,-~,.,,:~,,, 
. . . ~·'r"~~~>····''''·''''''1P''I~~ 
, r • 
J 14(1 "Ill 'n C', 'llll11llllh;.lt loll' 
r.:p"rI~d that rabbit alddl~dL' (I\ld,hL' \,ildch:de "\~';!Lnll\l<k'rcdll~ta~~. 1 l 1.2.~ Ili,.I> til.: "hilll: to oxi~ 
dllt: ;III"rurinol illlnipurllHlI '" """ 11Inh~nll(lk JllIll ,'1 "I • ~11tI\\,d Ih,1I IlwI'L' ;,.1 'c\ dmL'lentl' 
(If ;Jllkh, de oxida~c acti,il\ ill nlll~ " h"11 .\ -111t:th, Illkll\!IWlIlide II as u,ed a~ SlIostnl It: Tllet'dol C 1\ e are 
nOli in\~stigatin!! the n'laiioll~hlp hL'tl",,'1l alll1plI'lIlll1ll1\lllllillg cn/:I11C and aldehyd,' ,,\!da~c in IllICe 
[Iiun ", ,,/.:." rerorted that i1I1I'puruwl i, raridly ",idi/ed ill ritll to mipuflnol ,\hkh aisil inhihits xan~ 
thint: oxidase. Prel iousl~ II L' rt'!'ortcd tha t the '"( -cl,mpI1llnds disarpear much Slllll \'r in male than \11 
female mice after lahdcd alloplll inol treatment Thus II s,ems thut thi> ~C\ difference ill :ilillpllrinol oxi~ 
diLlllg aclilil: nUl). to Sllmc c\tent. h,' cl'nccrncd with i1L:lItc Ill.\icit). 
Further \lork is llL'cdcd to clarif: thl~ problem 
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hmhility ur rat hrain hUmlJ~l'lHlle tu uxidize amphl'1:ltniltl' 
(Rec{'il'l'd 10.1111.1' 11)73: ,,((epted 17 Scpll!lllber 1973) 
HrITAIWH IWATA 
ITARL' YA~IA~10TO 
KEt;!\ HUH 
IN A RECENt series of papers in this JOllrnal Gulw and Mitta' 3 have rcporlcdthat homogt!lllltcs of rat 
and guinea pig brain catalyze the reduction ofnco-tctra7olium chloride(NTCI in the prescnce of atnpheta-
mine. Thc system has been described as tin amphetamine dch)drogenase: the most rccent report suggests 
Ihaltranylcyptomfne is also actively dehydrogenated b,,· this systcm.J However. the activity of the Cn7)mC 
system has been estimated by measuring the production of difotmazan from NTC. The authors havc not 
determined that a degradation product of a mphetaminc is produced in thc course of the reaction. 
Hucker4 and Parli and McMahon~ have reccnti) rcpor',ed on the metaholism of amphetamine with 
no el'idcncefor a dehydrogenase rathwa:. Furlicr \lark frolTi'l~ls Iliborator), using I?HJlabc1cd ampheta-
mine_ had shoWillhat rutsconvcrl the d\'ug 1111';\'(1 b~ p-hydrp;ylation and o\idativc dC:lminatron." The 
pre~cnt colilmunication reports on attempts to l11easure therlroduction of lIlct;lholitcs of [3HJarnphcta-
mine hy the rat brain dch~drogenasc system as described h) Guha and Mitra.!-3 
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Braln~ \lcr ... r,'llhl\CU Iwlll 'ldull r~()tI 4fJOgi male, Sprdgllc- Da\lle\ rat; plitcilil,eU fHII1l :-'Iurph~ 
BrL'cuing Labllralll"lcs,l'bmfil'ld. Inu .• and hlll1logl'nalc, pr~p<lred Hcctlrdlllg to :'\1Jlra and Guha,; d-Am-
phctanlml' I'hmpht,te \\a, ,upl'lo,d h~ lhe I'enn\\all (mp,. l:IIJd'<Irllphd,tllline sU![.Jtc' \\;l' !,urcha,cd 
fr"1ll the Nt'll [J1gland ~lldcar ( "'1' .. NTC !WIll lhe SlgmH Chcmical Co ilnu Ji!orrnai,tn from Nlltn-
ti,Jllal Diodwrnil'ah lorp. 
Inclibalilln' \\cr,' j'erll1rnwd "'l.Hciing II' \litra and Guha \ Diformalan pr(llitrClrJ1:1 \Ia' I1h\I'llrcd h~ 
the mel hod of Lagnado and Sl'ur~c,' (bin)! a Gilf,'rd model ~llll(l :iI."orbance rccorder wrth a Beckman 
!ll<,del Dl' mllnl1chfllmolor. ['H jalllphct.JJ11inc \I<I~a,sa}eJ a' d ... "rihcll b! 1'>laickel ('r erl.!' using a Pack-
i1rJ Tri-Carb l1](ldcl 2425 liquid ,clntillatinu '~'t ... m 1\ktabolites oj ['H]amphc'tllmlllL' \Icrc separated b} 
TLC on Silica gel G plales fli~5111111, AllnhrllilllJl \1'-P"IH!ramt in the s!stetn described b\ Hucker.~ 
Phenyl-2-prl1r"n(ll1~ was l'i'U,lill"J h~ 'fHil~ing \llth I'" /.:"nO. in ~"" alju~ous Na:(·O .•. rL(' plales 
lIerc scanned for radioaclhc 'I"'h 111 a 1',1c'h.,rJ Illlllki :21111 radilllill'lnlatllgram <;c:Jnn~J. 
The «lnlcrsiol1 of NTC tl' J,f,q lila/ali In thL' ~"t~1lI "f Gulw alld '.litru' (lCCUlrcll Ilith or withoul 
lhe addition ofamrhct3minc. III an ;Jlll'IlI!,II" I'rcl;arc a ,t,lIldald L"une IClr the absorhance of diflll'mawll 
at520 nm. it was found that ahs,'rh,lIlcc i, Ill't linear Olt:r the c'tlnccntl.Jtinn range repolted h~ Guha and 
Mitra,1 3 Nu amphetamine mctalwlile, lIere tlb,clled IIhen Ihe incllb;lt~ \\as extracled wilh methylene 
chloride and examined by TLC· II1l:ubalinn of' ['HJal1lph,·trlllJlnc lIilh the hOJllogcn~le and NTC. fol-
lowed b~ extraction. TLc and nldiocilll1l1lHlC1gralll ,.:an1!lng Illdiculed that gl'eater lhan 9~ per cent of 
lhe radioacti\,jt~ present \las c(1nwined in a 'p"1 l'tlrrcspl1ntling 1(1 linchilnged ['H):1lllphcll1J11ine. In a 
dcfinilht: e\periment. incubation Illixlul'l:s II ere pll'pilled \lilh and l\ithouII1l1nll1g,·nalc. Duplicate mix-
lures of each l~ rc \1 ere either incuha t~d and e\ lraclt:d illter<1l rnin or IlIlt incubated. I.e, t:\ tr:lcted a I I = O. 
['H)amphct<lmine was c\lractcd b~ a specific prllccuurc al\d rl1~<lsured b;. liquid ,t:inlillatillJl spectro-
melry." Neither [he presence of bwin hOlll,'gcnatc nur incuballon at.F fot ~n min re,ulted in any reduc-
lion in the a nl(1unt of eH)amphelanline th:lt could he ex lmelcJ. Bascu l'n thc I'a te of difl1rlll<l7:ln produc-
tion reported b~ Mitra and Guha.' OIlL' \Iould IHl\'c c\rectcu :It least R:, per ccnl conlt:1sion of ampheta-
mine, A, litlle as 10 per ccnlmetabl1lism ofamphelamln(' II "lild haw heen easily delecleu, 
Man~ suhslancc<; ute known ((1 reduce neo-tctra/l,lium chiliride. HlJ1ging from simple alkaline pH to 
u,"urbic ;Icid. reducing sugars ;Ind na\Opr"lCinl'n/)mes,~ Indeed. il Ila~ ,'bserved thai during an earl) 
slep in lhe amphetamillc ntractillil prnt:cdure" ;11 \I hich thc llljueou' pllil~c II:\S made alkaline, the color 
charactcrislit: of diform:llan arpearcd in lIIi\tUICS c(ll1lain1l1g NTC :l1ld IWI11l1gcIHIlc wilh (lr II ithoul 
amphetamine: mi\lures (Containing llnl~ al11phela mine alld NTC tk\t'lopcd IJO colur The rcciuctilln of 
NTC under Ihese conditions uppean; to be a function (ll 11lL' 1'1 eSC'ne(' of brain hUIIll'gellatc alld not of 
a mphela l11i ne wneenlra tion. 
In ~l1mmar~. un attel11pl was lIH1ue 10 IlICaSlire the pmduclionof ['H)alJ1phetatnine melaboliles by lhe 
ra I brain a/llphetamine.dch~drugellltsc s~ SI('Ill of Milrn and Guha J No mctabolic COllI crsion of ampheta-
mine \Ias ob~etl'ed. 
AcI'illII\r!"dliCmeJll$ This \\ork lin_ supporled by L'SPHS granls KO:'\1H-41083 alJd 1\IH-1885~ and by 
NASA grant 15-003-1 17. 
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DEVELOPMENT OF A MODEL STRESS SYSTEM FOR REPETITIVE DAILY STRESS 
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The concepts of homeostasis, which views ~iving organisms as actively 
o maintaining an optimcil internal environment or "mi1lieu interior", was 
(J) 
largely developed from the work of Claude Bernard (1). Since the 
development of the various concepts of "stress" by Selye (2,3), many people 
have considered stress to represent any state of the organism in which 
-,.. 
reactions to stimuli have distributed the normal homeostasis by perturbation 
of biochemical or physiological mechanisms. stress may thus be considered 
as an abnormal state of the organism, and, in the terminology of Selye (4) 
proceeds through three sequential phases: shock, resistance, and exhaustion. 
In this framework, shock is the initial phase, in which the organism is 
moved into a state of homeostatic imbalance by the action of the stressful 
stimuli. The second phase, resistance, is characterized by reactions 
of the organism as it attempts to regain its initial homeostatic state. 
The final phase, exhaustion, occUrs when the organism is exposed to 
repeated or continued stressful 'stimuli, and, because of repeated or 
continued attempts to maintain homeostasis, the organism becomes unable to 
respond fUrther or otherwise proceeds to a completely non-homeostatic 
state. The net result of the exhaustion state is generally expressed as 
one or more pathological phenomena; in the most severe case, irreversible 
damage or even death may ensue. 
The general characteristics of mammalian response to stress include 
emergency responding of two body systems: the sympathomedullary system 
and the pituitary-adrenocortical system. The response of the sympathomedul-
1ary system is manifested in increased peripheral sympathetic hervous activity 
and consequent biochemical and physiological responses to the surging release 
of norepinephrine: increased heart rate and respiration, contraction of 
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blood vessels, piloerection, heat consevation, and kipolysis in adipose tissue. 
,tJI At the same time, adrenal medull ary di scharge of epi nephri ne evokes a 
mobilization of glucose from the liver glycogen stores. Meanwhile, the 
anterior pituitary is secreting large quantities of ACTH, causing increased 
production of glucocorticoids from the adrenal cortex and causing further 
imbalances in normal body functional systems. 
In humans, elevated catecholamine outputs have been seen in response 
to a variety of psychological (5) or psychophysiological stimuli (6). 
Similarly, increased adrenal corticoid secretion has been evoked by fear (7), 
perceptual disturbances (8), emotional disturbances (9-10), and competitive 
sports (11). These findings seem most appropriate in view of the likeli-
hood of similar types of stressful situations occurring on a repetitive 
basis during space flight - especially since the duration of manned space 
flights are getting longer. 
Unfortunately, the ideal test system to examine the consequences of 
repetitive stresses does not as yet exist. Human test systems are extremely 
limited in that only a feW measurement parameters can be used; no tissues 
are available, and sarm1es other than urine are restricted in terms of 
the number that can be obtained. Animal test systems are readily available 
and permit ready sampling of almost anything, but, no appropriate animal 
model for repetitive stresses has yet been examined in sUfficient details. 
tn addition, while a large number of variables has been measured in a 
diversity of stresses and experimental animals, no one has been able to 
select the most appropriate variables to measure or the most useful stress 
to examine on a dose-response basis. 
In this report, we present preliminary studies comparing three 
stresses: cold exposure (a predominantly physiological stress), immobiliza-
tion (a predominantly psychological stress), and d-amphetamine (a predominantly 
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pharmacological stress). The experimental design permitted cOlllparison of 
if.::.,: s i n91 e stress with repetiti ve stress on primary (pl asma corti costerone L 
secondary (plasma glucose, plasma FFA), and tertiary (brain norepinephrine 
i, and serotonin) parameters of the stress response. 
f 
1; 
~, 
"' 
METHODS 
Adult, male, Swiss-Webster mice weighing 25-30 grams were used in 
all experiments; Cold exposure occurred in individual screen wire cages 
in a room at 40 C; immobilization was performed by restraining individual 
animals in wire mesh tubes; d-amphetamine was administered by i.p. injection 
at a dose of 4 mg/kg. Animals were killed by decapitation and blood was 
collected into heparinized tubes. Tissues were removed immediately and 
frozen; plasma was also prepared immediately by centrifugation and frozen. 
Plasma corticosterone, plasma glucose, and plasma FFA were determined as 
described by Maickel, et a1_ (12); brain 5HT, 5HIAA, and NE by the method 
of Mi 11 er, et a 1 (13). 
RESULTS 
,Effects of a Single Stress on Parameters. The time course of an acute 
stress (4 hours) was measured; the data are shown in Figures 1, 2, and 3. 
At all times, and with all three stressful stimu1i~ the plasma corticosterone 
values were significantly elevated (p <.05) above control values (Fig. 1); 
cold exposure seems to reach the highest level at 0.5 hr, as well as to 
produce a longer elevation. The picture of plasma glucose is quite different. 
Only d-amphetamine evokes a significant elevation in this parameter, although 
this effect falls to non-sighificant values at the 4 hr. time point. In 
contrast, both cold exposure and immobilization show a pattern of an initial 
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insignificant rise, followed by a fall to lower than control values (p <.05) 
at 2.0 and 4.0 hours. In the case of plasma FFA, cold exposure produces a 
significant elevation at 1 to 4 hours, while immobilization causes a 
significant depression at 1 hour and amphetamine has no significant effects 
although the value at 0.5 hour is almost significantly (.10>p>.05) lower 
than control. 
Effects of Repetitive stress on Parameters. The data presented in Figure 
4 were those obtained by exposing mice to chronic daily stress: 2 hrs 
of cold exposure, 2 hours of immobilization, or 4.0 mg/kg, i.p. of d-
amphetamine, for 14 days. The animals were sacrificed at the termination 
of the 14th stress session. Control animals were handled daily at the 
same times and to approximately the same extent as the experimental mice. 
The results indicate that cold exposure and amphetamine were similar in 
that plasma corticosterone values were significantly elevated after the 
14th session, while immobilization animals had normal values. In the case 
of plasma glucose, levels were depressed in chronic immobilization and 
amphetamine, but were normal with repetitive cold exposure. No differences 
from control were seen in plasma FFA levels with any of the stressfu1 
stimul i . 
Effects of Repetitive stress on Response to Acute Stress. In order to 
determine whether repetitive exposures to stressful stimuli might influence 
the ability df an organism to respond to a subsequent 'acute stimulus, 
an experiment testing this situation was devised. Animals were repetitively 
stressed (as described in the preceeding section) by either cold exposure, 
if~ immobilization, or d~amphetamitle; on the next day, an acute "challenge
ll 
stress was applied. The results (Figures 5, 6, 7) indicate that the 
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repetitive stresses, in general, tend to reduce the ability of the animals 
L to respond to a subsequent acute stress. This is most noticeable in the 
( ) 
'...,..' 
case of repetitive cold stress and least noticeable for repetitive amphetamirle 
dosages. 
Effects of Acute and Repetitive Stresses on Brain Biogenic Amines. In 
addition to the plasma biochemical parameters, measurements have also been 
rnade of the levels of brain serotonin (5HT), norepinephrine (NE), and 5-
hydroxyindole-3-acetic acid (5HIAA) in the various stress conditions. The 
effects of an acute stress or repetitive stresses on these amines are shown 
in Figure 8. The acute cold and immobilization stresses evoke significant 
(p <.05) increases in both SHT and 5HIAA, with increases, though !Jot 
significant in NE; acute amphetamine fails to cause any significant changes. 
Repetitive stress by cold or immobilization evokes significant decreases 
in 5HT and SHIAA, with no change in NE; repetitive amphetamine fails to 
influence SHT or SHIAA, but causes a fall in the level of NE. 
In the case of an acute stress "cha 11 engel! tested a Her the 1 4th 
repetitive stress, the results differ with each stress. Repetitive cold 
exposure enhanced the increased 5HT and SHIAA caused by a11 three acute 
stresses (Figure 9). No effect was seen with NE except in the case of 
acute amphetamine, where the repetitive cold exposures caused the animals 
to be less r@~ponsive. Repetitive immobilization had virtUally no effect 
on the brain amine alterations caused by a subsequent acute stress (Figure 
10), while repetitive amphetamine dosages enhanced the effects of a subsequent 
cold exposure on NE, and decreased the responsivity of all three brain 
substrates to a subsequent dose of amphetamine (Figure 11). 
, 
~. 
) 
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DISCUSSION 
(t- The results presented here should be considered as only preliminary 
in that they are studies in a single species of animal, with a minimal 
number of variables and parameters. However, several interesting points 
for further study have been clearly demonstrated. First of all, the 
effects of an acute stress of limited duration must be considered in the 
framework of a subject's prior experience as well as in the light of the 
sensitivity of the parameter of interest. Thus, a "classical" stress marker 
such as plasma corticosterone, while extremely sensitive and useful as an 
indicator of acute stress, becomes almost valueless when the same stress 
is applied repetitively (cf. Figures 1, 4,5). Plasma glucose responds 
nicely to cold exposure or immobilization in both acute and repetitive 
situations (Figures 2, 4), but is not suitable as an indicator of a 
subsequent acute stress (Figure 6). Plasma FFA responds in a useful manner 
only to acute cold exposure; however, in the repetitive situation (Figure 7), 
the effects are useful only in the cold exposure situation. 
In summary, these preliminary studies indicate the need for more 
detailed examination of potential stress "markers". An animal model would 
be most usefu1; if space flights of long duration are to be successful, 
repetitive stress must be considered. However, the search for a suitable 
animal model must be expanded to examine new possibilities for measurable 
markers. 
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LEGEriDS 
t.t FIGURE 1: Mean values of plasma corticosterone in control mice 0 (N=50), 
at various times of cold exposure ~ (N=20), immobilization ODD 
(N=lO), or after administration of d-amphetamine ~ (N=lO). 
Vertical bars indicate + S.D. 
FIGURE 2: Mean values of plasma glucose in control mice c=J (N=200) 
at various times of cold exposure B (N=20), immobil ization []] 
(N=20), or after administration of d-amphetamine ~ (N=lO). 
Vertical bars indicate + S.D. 
FIGURE 3: Mean values of plasma FFA in control mice c=J (N=200), at 
various times of cold exposure § (N=20), immobil ization lIJ] 
(N=20), or after administration of d-amphetamine [;8j (N=lO). 
Vertical bars indicate + S.D. 
FIGURE 4: Mean values of plasma corticosterone, glucose, and FFA in control 
mice 0 (N=24), or mice after repetitive cold exposure § 
(N=12), immobilization [J] (N=12), or amphetamine ~ (N=l2). 
Vertical bars indicate + S.D. Animals were killed 2 hrs after 
the last dose of amphetamine or immediately following the final 
2 hr immobilization or cold exposure. 
FIGURE 5: Mean values of plasma corticosterone response ratios (repetitive 
stressed + non-stressed )i 100%) to acute cold exposure f:§ (N=l2), 
immobilization ITll (N=12), or amphetamine t;§ (N=l2) in 
animais subject to repetitive prior stresses. Vertical bars 
indicate + S.D. Acute stress was applied 24 hrs after the 14th 
repetitive stress. Animals were killed as in Figure 4. 
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(N=12), 
i-jean va 1 ues of p1 asma gl ucose response J':l ti os (repetiti ve 
stressed 1 non-stressed x 100%) to acute cold exposure ~3 
ill1mobil ization lID (N=12), or amphetamine l~ (N=12) in 
animals subject to repetitive prior stresses. Vertical bars 
indicate + S.D. Acute stress was applied 24 hrs after the 14th 
repetitive stress. Animals were killed as in Figure 4. 
t,lean va 1 ues of plasma FFA reponse ratios (repetitive stressed .;. 
non-stressed x 10m~) to acute cold exposure B (N=12), 
immobil i zati on ITIJ (N=12), or amphetamine ~ (N=12) in 
animals subject to repetitive prior stresses. Vertical bars 
indicate + S.D. Acute stress was applied 24 hrs after the 14th 
repetitive stress. Animals were killed as in Figure 4. 
Mean va 1 ues of bra in 5HT 0 5HIAA [1 ,and NE CJ in 
animals after a 2 hr acute stress or at the end of the 14th 
repetitive stress, expressed as percent of control values of non-
stressed anima1s. Vertical bars are ~ S.D.; N=24 (controls), 
N=12 (each experimental group). 
Mean values of response ratios (repetitive stressed.;. non-stressed 
x 100%) of brain 5HT D 5HIAA [] ,and NE I·~!.:I in animals 
after a 2 hr acute stress 24 hrs after the 14th repetitive co1d 
exposure. Vertical bars are + S.D. Animals were killed as in 
Figure 4. 
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FIGURE 10: Mean values of response ratios (repetitive stressed f non-stressed 
'c x 100%) of brain 5HT 0 ,5HIAA [] ,and NE Ird ; n animals 
after a 2 hr acute stress 24 hrs after the 14th repetitive 
immobilization. Vertical bars are + S.D. Animals were killed 
as in Figure 4. 
FIGURE 11: Mean values of response ratios (repetitive stressed f non-stressed 
x 100%) of brain 5HT 0 5HIAA D and NE I~:~::] in animals 
after a 2 hr acute stress 24 hrs after the 14th repetitive 
amphetamine dose. Vertical bars are + S.D. Animals were killed 
as in Figure 4. 
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Lack of Tolerance Developlnent to the 
Dipsogenic Actions of Barbital 1 
ROGER P. MAICKEL AND GREG J. MALONEy2 
Department of Pharmacology. Medica! Sciences Program. Indiana University. Bloomington, IN 47401 
(Received 19 February 1974) 
MAICKEL, R. P. AND G. J. MALONEY. Lack of tolerallce development to thc dipsogellir actions o[barb;lal. PHARMAC. 
BIOCHEM. BEHAV. 2(3) 431 ·-434, 1974. - Chronic do~age of rats with barbital produced a dipsogenic state with 
overhydration. No tolerance could be seen to this effect in fourteen days; on withdrawal of drugs, the water intake of the 
rats fell to below normal levels, on a weight basis. When daily intake of fluid \'Ie; restricled during the period of barbital 
dosage, overhydration did nol occur and drinking during the withdrawal phase v'~s increased. 
Barbital Drug induced drinking Tolerance 
SCHMIDT and co-workers [11-19) have studied the 
effects of a variety of barbiturates on water consumption 
induced in rats by various means. In general, the com-
pounds had a dipsogenic action, a finding corroborated by 
us for a variety of depressant drugs (7). In addition, this 
laboratory recently reported an exhaustive study of factors 
involved in the dipsogenic actions of barbital (6) . 
Schmidt, et al. [16,18) administered phenobarbital to 
deprived rats daily for 30 days and measured water intake; 
no indication of tolerance to the dipsogenic effect of the 
drug was observed. Upon withdrawal of the drug from these 
anim"l~, and also upon withdrawal of a group given drug for 
14 days, the rats consumed less water than a saline control 
group for several days. This was later interpreted as the 
development of a hypersensitivity to the dipsogenic effect 
after a 15 day phenobarbital treatment and a 10 day with-
drawal (191. As evidence of hypersensitivity the authors 
cited the fact that the response to the second phellobarbital 
treatment, that is, after IS days treatment and 10 days 
withdrawal, was greater than the initial response to the 
same dose. 
The present paper reports on the effects of chronic daily 
dosage of barbital on the fluid intake of rats with restricted 
or unlimited access to water. 
MATERIALS AND METHOD 
Adult (280-290 g) male, Sprague-D~wley rats (Murphy 
Breeding Laboratories, Plainhcld, Indiana) were used in all 
experiments. The animals were maintained on tap water 
and Purina Rat Chow ad lib for at least 1 week after arrival 
in the laboratory. All solutions for injection were made in 
glass distilled water such that a dose volume of 0.1 ml per 
I aO'g body weight contained the desired dose; all injections 
were given intra peritoneally, 15 min prior to placing the 
animals in the drinking cages. 
The procedures used to measure deprivation-induced 
water consumption were basically those of Gerald and 
Maickel [51. Rats were placed in cages, 7 X 7 X 14 in., 
identical to the home cages of the animals. The cages were 
suspended in individual compartments of a sound-proofed 
box with uniform fluorescent lighting. Constant circulation 
of air by blowers maintained uniform temperature in the 
compartments; the noise level of blowers served as a white 
noise. Each cage contained a drinking tube connected to an 
external 50 ml buret filled with distilled water at the start 
of each test run and stoppered. As the animal consumed 
water, the change in volume was measured visually to the 
nearest 0.1 ml. The front door of each compartment was 
equipped with an eye-piece lens to permit visual observa-
tion of the rats without disturbing their behavioral perfor-
mance. For at least I week prior to testing drug effects, rats 
were deprived of water daily for 23 hr prior to testing, then 
placed in the drinking cages and allowed to drink for I hr. 
Food was available ad lib in the home cages but was not 
available in the drinking cages. In the restricted intake 
studies, rats were given only a fixed volume of water, 
14.0ml. 
Drug trials were started only after the animals demon-
strated stable baselines (less than 5% daily variation) of 
I Supporkd in part by L'SPIIS Gran1~ :'1H-18852 and IW1-~1.I·I-4l 083 and by NASA Grant NGL l5-D03-117. 
'Taken in part from a the'is ,ubmincd by Greg L \!.?!oney for the M.S. degree in Pharmacology, Indiana Onivcrsity.1971. 
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FIG. 1. Effects of barbital on fluid consumption-unrestricted intake. Each sym!:"J is the 
mean of values obtained from 8 rats as described in Materials and Method. Vertical bars 
indicate 1 S.D. Solid circles indicate days of dosage with barbital (80 mg/kg, i.p.); open 
circles are placebo dosage. 
water intake. The schedule for drug studies was arranged so 
that tne rats were run daily. Water intake was recorded at 
15, 30, and 60 min of the consummatory sessions, the 
greatest proportion of drinking occurred in the first 15 min 
in all cases. 
Barbital sodium was used in all experiments, dosages are 
reported as weight tlf barbital administered in mg/kg body 
weight. Groups of 8 rats were TUn in each test system; data 
are repo~ted as mean ± S.D. 
REsuLTS 
Effect of Chronic Daily Dosage of Barbital on Fluid Con-
sumption of Rats with Unlimited Voluml' A vailabk 
As shown in Fig. 1, chronic barbital (80 mg/kg, i.p.) 
increased daily fluid consumption above baseline for the 
duration of drug administration. There is a trend suggesting 
development of tolerance to the dipsogenic effect over the 
14 days of drug treatment, seen when consummatory vol-
ume was plotted as ml/100 g body weight. The animals 
gained an average of 100 g of body weight during the 
course of this experiment. Substitution of saline for bar-
bital resulted in a decrease in fluid consumption on the 
second day after drug withdrawal with a return to normal 
on the third and subsequent days. A weight loss of ) 8 g was 
also observed dUring this withdrawal period. Of particular 
interest is the fact that administration of a single dose of 
ba~bilaJ on the ninth day after drug withdrawal (Day 33) 
gave a normal dipsogenic response (Table 1). 
Effer .. of Chronic Daily Dosage of Barbital. orl Fluid Con-
sumption of Rats will! Limited Voilime A l'ailable 
Figure 2 shows the effect of limiting fluid intake during 
the drug treatment period of 14 ml/rat/day. Here, over-
drinking. and the weight gain during the dnlg period are 
r , 'I-'"'~'""~~' .,~'--' 
~t . 
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Dll'SOC;ENIC' ACTIO~S OF BARBITAL 
T.\BLE I 
IHI'SClGENIC E)·rEeTS OF BAIUJITAL BE.I·ORE AND AFTER 
CHIWNIC ·I1U.·\l!11ENT 
Volume Consumed 
Day of Schedule Drug total ml 
ml/1 00 g 
1-10 Saline 16.9 t 1.0* 
5.3 i 0.4* 
11-24 Barbital 24.5 ± 1. 7* 
6.7 ± 0.6* 
25-32 Saline 16.0 ± 1.5* 
4.3 ± 0.4* 
33 Barbital 23.2 ± 1.8t 
6.4 :!. 0.7t 
Data are presented as volume consumed by 8 animals. Barbital 
(80 mg/kg, i.p.) was given as described in Materials and Methods. 
*mean ± S.D. of 8 animals per day for number of days indicated 
t mean ± S.D. of 8 animals on a single day 
433 
prl'vented with the result that now there is no withdrawal 
d~crease in fluid intake nor weight loss. The period 01 WIth-
drawal shows a significantly greater fluid intake h) tilt! 
animals. 
DISCUSSION 
From a consideration of the data presented in thiS paper, 
it seems likely that the earlier work of Schmidt and co· 
workers [16, 18, 19) suffers from several defects. First, no 
recognition was made of the large weight gain during the 
period of the study. It is possible that the increased intake 
attributed to hypersensitivity after a period of drug trials 
119) may merely reflect the fact that heavier animals con-
sume more fluid. When fluid consumption by our animals is 
expressed in ml consumed/ I 00 g body weight, the daily 
intake decreases slightly over the drug period of 14 days. A 
transient weight loss and decrease in fluid consumption are 
present during the withdrawal period as previously reported 
by others [14,15). 
Schmidt et al. [12,15) also considered the chronic over-
hydration of the animals during the drug period as inconse-
IWwITAL (3.) t1i/1IG, I,P,) 
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FIG. 2. Effects of barbital on fluid consumption-restricted intake. Each symbol ;~ the 
mean of values obtained from 8 rats as described in Materials and Method. VertiCl,1 lars 
indicate 1 S.D.; no S.D. is seen for total fluid consumed on Days 11-24 when fluid was 
restricted. Solid circles indicate days of dosage with barbital (80 mg/kg, Lp.); open circles 
arc placebo dosage. 
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ljlll'nt;.ti 1;, til,' -:harac/t'ristics of th.e withdrawal state. In 
tht' prt:'!'l':ll Sl\ldy, when oYt'rhydratlOn was prevented, the 
d"al';I~e in fluid consumption and body weight during 
withdr:lwal did not occur. The increase in fluid intake over 
ra~eline on the first day of withdrawal may reflect the 
presence of barbital in the animal since the drug is not 
appreciably metabolized and is excreted slowly (6). It is 
unlikelv. however, that this drug carryover would ('x plain 
the inc~~ased consumption on subsequent days. 
It is reasonable, in light of the changes in neurosecretory 
material in the neurohypophyseal system d'uring overhydra-
tion [I], that prolonged overhydration in itself could lead 
to a decrease in fluid consumption upon removal of the 
stimulus for overdrinking. The animal is in a state of posi-
tive water balance and will restore his fluid balance by con-
suming less fluid. The post-drug weight loss appears directly 
related to the decrease in fluid consumption since the ani-
mals did not lose weight if thr-y were prevented from over-
drinking prior to withdrawal. The dipsogenic response 
during the post-drug treatment period by the Iimited-
volume animals may reflect an alteration in fluid balance 
svstems induced by the drug treatment. 
- A direct central action upon neurons involved in the 
regulation of water balance may caUse the dipsogenic effect 
by depression of inhibiting centers. Animals with lesions in 
the septal area and in the anterior hypothalamus show an 
increased fluid consumption [2,10). These drug effects 
!'oUICKEL AND MALONEY 
L'ould hL' du~ to chemical ll·,jnm \ 1;1 a (ll'pression of the 
septal area or hypothalamus. Intt'rfL'It'IH.:e with the hypo-
thalamm neurohypophyseal ~ystcIl1 lIlay also be involved in 
the dips(lgL'nic action. Barbiturates Jre known to release 
ADH from the posterior pituitary I :11, The depression of 
o~moreCl'ptor cells in the eNS. pos·dbly those near the 
ADH secreting neurons, may alter an animals preception of 
his actual state of hydration and cause him to continue 
drinking longer than usual. The conslimmatorv act itself 
may become pleasurable if the drug has depr~ssed inhib-
itory brain areas. 
In the rat satiation precedes restoration of the osmotic 
imbalance and comes about via impulses from nerves in the 
oral cavity traveling along cranial nerves to brain regions 
involved in fluid consumption [41. If drugs were to inter-
fere with the transmission of information as to the nature 
and amount of the fluid the rat is consuming, the animal 
might ingest larger amounts or cease earlier depending on 
the nature of t.he interference. Evidence for the involve-
ment of the peripheral nervous system [5) suggests that 
depression of these neurons may interfere with the regula-
tion of fluid intake. Another peripheral action could be 
drug interaction with the renin-angiotensin system. The 
release of ADH by barbiturates could also be a manifesta-
tion of the mediation of angiotensin since angiotensin itself 
releases ADH (8). 
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DIFFERENTIAL EFFECTS OF d- AND l-At~PHETAr~lNE ON SPONTANEOUS 
MOTOR ACTIVITY IN MICE 
Roger P. Maickel, Richard M. Levine and Carlos M. Quirce 
Department of Pharmacology 
Medical Sciences Program 
Indiana University 
Bloomington, IN 47401 
ABSTRACT 
The effects of single doses of d- and l-amphetamine on motor activity 
in mice differed both in quantitative and qualitative aspects. At low doses 
(0.5 mg/kg, i.p.) and at high doses (8.0 mg/kg, i.p.), both isomers were 
stimulants of SMA, differing only in potency. However, at intermediate doses 
(2.0,4.0 mg/kg. i.p.) the l-isomer caused a significant depression of SMA 
while the d-isomer was stimulatory. 
I NTRODUCTI ON 
Since the first reports (Alles, 1933) of the stimulant actions of 
amphetamine, a large volume of literature has accumulated on the differential 
actions of the d- and l-isomers. While the generally held opinion is that 
they differ merely in quantitative potency (Goodman and Gilman. 1970), several 
recent reports support the possibility of qualitative differences as well. For 
exaIDple, Bainbridge (1970) reported that d,l-amphetamine, in doses of 1-5 mg/kg, 
had a depressant effect on spontaneous motor activity (SMA) in mice, while doses 
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of 10 mg/kg or greater were stimulatory. Snyder', et ~ (1970) and Taylor and 
Snyder (1970) reported differential effects of the d- and l-isomers on norepine-
phrine and dopamine in brain areas. Phillips and Fibiger (1973) showed that 
d-amphetamine was seven to ten times more effective than the l-isomer in inducing 
self-stimulation when electrodes were located in the hypothalamus of rats, whil~ 
the two isomers were equipotent when electrodes were in the sUbstantia nigra. 
The present paper compares the effects of the two isomers of SMA in mice, and 
shows both qualitative and quantitative differences. 
MATERIALS AND ~1ETHODS 
Adult, male Swiss-Webster mice (Murphy Breeding Laboratories, Plainfield, 
IN) were used in all experiments. Drugs were administered as aqueous solutions 
by i.p. injection in volumes such that the required dose was contained in 0.1 
ml/10 g body weight. All doses were given 5 min prior to placing the animals 
(3 per cage) in Woodward Actophotometers. Counts were recorded at 10 min 
intervals for 40 minutes. Statistical comparisons were made by multiple "t" 
tests. ~ 
RESULTS AND DISCUSSION 
The data, as presented in Table 1 clearly demonstrate that the actions of 
the two isomers of amphetamine on SMA are both qualitatively and quantitatively 
different. Thus, d-amphetamine, at all doses tested and in all time periods, 
caused a significant increase in SMA when compared to ~nimals given distilled 
water. The results with l-amphetamine were quite different. At the lowest 
dose (0.5 mg/kg) and the highest dose (8.0 mg/kg), the l-isomer significantly 
increased SMA over all time points, although the magnitude of the increase was 
less than that seen with the corresponding dose of the d-isomer. At a dose of 
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TABLE 1 
Effects of Amphetamine Isomers on SMA of Mice 
Drug Dose N Counts per Interval + S.D. 
mg/kg 0~10 min 11-20 min 21-30 min 31-40 min 
Control 21 q9fi~147 609+ 60 
590+ 58 348+ 42 
d-Amphetamine 0.5 4 1232+191
b 758+113c 1007+161a 764+129a 
l-Amphetamine " 8 1 177+104
a 762+ 62a 634+ 62d 456+ 55a 
d-Amphetamine 1.0 4 1387+156
a 1320+147a 1606+152a 1 470+209a 
1-Amphetamine " 6 756+142
g 617+ 81 690+ 60b 451+ 44a 
d-Amphetamine 2.0 4 1932+ 192
a 2350+263a 1697+224a 1461+157a 
l-Amphetamine " 8 550+107e 395+ 87
e 464+100f 506+ 81 e 
d-Amphetamine 4.0 4 1641+284
a 1852+320a 1545+257a 1 767+232a 
1-Amphetamine " 8 739+1859 331+10g
e 425+123f 480+104b 
d-Amphetamine B.O 4 1609+255a 1448+210
a 1440+143a 1430+144a 
l-Amphetamine " 6 1189+210c 1069+125
a 1340+334a 672+ 86a 
Values significantly greater than control: a = p <.001. b = p <.005, c 
p <.02. d = P <.05. 
Val Lies significantly less than control: 
e = p <.001, f = P <.005, g = p <.05. 
1 mg/kg, 1-amphetamine caused a significant decrease of activity relative to 
control in the first 10 minute period; by t~e 20-30 minute period. this became 
a stimulatory effect. At doses of 2 and 4 mg/kg, the effects of l-amphetamine 
were clearly depressant over the first three 10 minute periods. While the 
30-40 minute period showed SMA to be increased relative to control mice. the 
activity did not differ significantly from that seen in the 20-30 minute period 
with the 1-isomer. At a dose of 8 mg/kg, the 1-isomer was clearly stimulatory 
at all time intervals. 
From these data it seems evident that the isomers of amphetamine differ 
in both qualitative and quantitative characteristics. In view of the recent 
report by Phillips and Fibiger (1973) on differential behavioral potencies of 
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the isomers, it seems possible that this effect on SMA may reflect actions on 
differing neurochemical systems, possibly norepinephrine and dopamine (Snyder, et 
!l, 1970; Taylor and Snyder, 1970). Other possibilities must also be 
considered. For example, Siva Sankar (1970) showed that 1-amphetamine was a 
potent inhibitor of liver alcohol dehydrogenase, while the d-isomer was, at 
best, a weak inhibitor. In conclusion, the possibilities of pharmacological 
differences because of isomeric differences in the amphetamines warrants 
further study. 
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DIFFERENTIAL EFFECTS OF MONOAMINE OXIDASE INHIBITORS 
Roger P. ~!aickel, Anne M. Rompalo, and Raymond H. Cox, Jl'. 
D~partment of Pharmacology 
Medical Sciences Program 
Indiana University 
Bloomington, Indiana 47401 
ABSTRACT: Chronic dosage of rats for 20 days with non-toxic doses of 
different monoamine oxidase inhibitors had clearly differential 
effects on brain biogenic amines and spontaneous motor activity. No 
correlation could be seen between behavioral and biochemical effects 
of the drugs. 
INTRODlICTION 
Although the enzyme monoamine oxidase [MAO, E.C. 1.1.3.4, 
monoamine:02 oxidoreductase (deaminating)] has been known for almost 
50 years, the role(s) it plays in various body functions are still 
only poorly understood, ,1S evidenced by a recent sympsoium (Costa 
and Sandler, 1972). The discovery of the antidepressant potency of 
iproniazid, and its subsequent introduction into clinical medicine 
in the therapy of depressed states was a major pharmacological 
development of the 1950's (Pletscher, 1968), leading to the production 
of a host of drugs acting as monoamine oxidase inhibitors (~~OI). 
One of the most perplexing aspects of the MAOI drugs has been an 
inability to explain their actions on behavioral phenomena in terms 
of the changes they produce in brain levels of serotonin (5HT) and 
norepinephrine (NE) .(Longo, 1972). In the present paper, we have 
compared the effects of 20-day chronic dosage to rats of four chemically 
different ~~OI's on brain levels of NE, 5HT, and 5-hydroxyindole-3-
acetic acid (5HIAA). In addition, behavioral activity in an open 
field was sampled throughout the dosage period. 
W.TERIALS AND METHODS 
Experimental subjects were 20 adult, male Sprague-Dawley rats 
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(Hormone Assay Laboratories, Chicago, IL) weighing 320-350 grams at 
the start of the experiment, and maintained in single cages on Purina 
lab chow and tap water ad libitum. 
Drugs were administered as solutions in distilled water made to 
concentrations such that 0.1 ml/lOO g. body weight contained the 
d¥sired dos~. Injections were made subcutaneously at the same time 
(0930-1030 hrs) each day. 
Body weights were recorded daily prior to each dosage. Estimation 
of open-field activity was made in 15 minute periods prior to dosage, 
using the procedure of Maickel and Johnson (1973). Animals were 
sacrificed by decapitation on the 21st day, 24 hours after the last 
dose of MAOI. Brains were removed and stored at _100 C until assayed 
for NE, 5HT and 5HlAA by the method of Miller et ~ (1970). All data 
is reported as mean ~ S.E.M.; statistical comparisons are by the 
student "t" test. 
RESULTS 
The doses of drugs were selected for use based on lack of toxicity 
observed in other studies in this laboratory. Body weight measurf!-
ments over the course of the experiments show no significant effects, 
nor did gross observation of the body organs at sacrifice show any 
obvious pathology. 
Effects of the chronic dosage with ~~OI's on open field behavioral 
activity are demonstrated by the data shown in Table 1. Animals 
treated with isocarboxazid exhibited significantly greater activity 
than control animals from the 6th day of treatment until the end of 
the experiment. Pargyline-treated animals showed elevated activity 
on the 6th and 9th days of dosage only, while the animals treated 
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with SU-11,739 were unaffected. Tranylcypromine-treated rats showed 
a generally decreased activity as compared to controls, significantly 
lower only on the 9th and 18th days. 
Table 1. Behavioral and Biochemical Effects of Chronic Dosage of 
MAOI's to Rats. 
Open field activity measured as described in Materials and Methods. 
Animals were tested on days 3, 6, 9, 12, 15, 18 prior to daily dosage, 
and killed 24 hours after the last (20th) dose of drug. Values are 
mean + 5.E.M. of values for 4 animals. 
Test Day Control Isocarboxazid Pargyline 5u-ll,739 Tranylcypromine 
3 
6 
9 
12 
15 
18 
Brain 
NE 
SHT 
SHIM 
106+ 7 
79+ 4 
77+ 4 
62+ 8 
66+ 8 
65+10 
0.52+.02 
0.63+.03 
0.62+.04 
80+14 
110+14a 
106+ 9a 
97+12a 
103+ Sa 
98+ 9a 
0.71+ .04a 
- a 1.03+.06 
0.62+.03 
105+ 4 
129+l0a 
128+l5a 
69+ 5 
66+10 
66+ 6 
0.95+.04a 
- a 1.17+.13 
0.56+.09 
103+ 6 
95+18 
77+ 5 
72+ 5 
69+ 4 
73+ 4 
1.04+.09a 
1.77+.l8a 
0.36+.02b 
: = Significant elevation (p <.05) compared to control. 
5~gnificant depression (p <.05) compared to control. 
88+14 
86+10 
59+ 2b 
55+ 9 
54+ 4 
47+ 3b 
0.95+.03a 
1.86+.09a 
- b 0.30+.02 
The brain levels of NE, 5HT and SHIM on the 21st day are also 
shown in Table 1. Isocarboxazid and pargyline both elevated brain NE 
and SHT significantly with decrease in SHIM. In contrast, both Su-
11.739 and tranylcypromine not only elevated brain levels of NE and 
5HT but also significantly reduced the levels of SHIM. Of particular 
interest is the observation that an increase of brain SHT of 60-90% 
(as produced by isocarboxazid and pargylin\!) is l~Ot reflected in a 
significant decrease in SHIM, while increase~ of urain 5HT of 180-
200% (as produced by 5u-ll,739 and tranylcypromine) are accompanied by 
reductions of 40-50% in SHIM levels. 
DISCUSSION 
The behavioral effects of the drugs were quite dissimilar and 
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could not be correlated to changes in brain amines. The effects of 
isocarboxazid and pargyline on SHT and SHIAA were not significantly 
different; however, pargyline-treated animals had a significantly 
higher level of NE. While the increases in NE produced by pargyline, 
Su-ll,739 and tranylcypromine were virtually identical, the latter two 
compounds had a m~~kedly greater effect on SHT. In fact, while iso-
carboxazid and pargyline did cause a significant elevation of brain SHT, 
neither compound showed an associated depression of SHlAA, as did Su-
11,739 and tranylcypromine. EVen though the inhibition of MAO was only 
sufficient to reduce SHIAA levels by SO% or less, elevations of as much 
as 200% in SHT levels were observed. 
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TASTE PHENOMENA INFLUENCES ON STIMLILATION 
OF DEPRIVATION-INDUCED FLUID 
CONSUMPTION OF RATS* 
R. P. MAIC'KEL and G. J. MALONEYt 
Department of Pharmacology. Medical Sciences Program. Indi,:na University. Bloomington. Indiana 47401 
{Accepled 27 JUIII/Q/'.I' 19741 
Summary-The dipsogenic actions or barbital and chlordiazepoxide are selectively influenced by 
the taste of the consummatory fluid presented to deprived rats. The potency of barbital as a con· 
summatory stimulant is reduced relative to distilled water or tartaric acid by the use of a pleasant 
tasting fluid. saccharin. The potency of chlordiazepoxide as a dipsogenic agent was reduced by the 
use of either tartaric acid or saccharin as a consummatory fluid as compared to water. Promazine 
depressed deprivation.induced fluid consumption with a similar potency regardless of the consum· 
matory fluid used. 
A previous paper from this laboratory (MAIC'KEL and WEBB, 1972) described the influence;! 
of con summa tory fluid taste on the reduction of fill id consumption by deprived ra ts. Both ( + )-amphetamine and methapyrilene were less effective in reducing consumption of a 
pleasant-tasting fluid (saccharin) and an unpleasant tasting fluid (tartaric acid). compared 
with the reduction in consumption of "nelltral" tasting distilled water. In contrast, atropine 
was more effective against the pleasant taste and less effective against the unpleasant, taste 
when compared to distilled water. In all cases the drugs had a similar action. that is, a 
reduction in the volume of fluid consumed as compared to baseline consumption. regard-
less of the taste of the consummatory fluid. 
More recently, this laboratory reported on the effects of a variety of depressant drugs 
on deprivation-induced fluid consumption (MAJC'KEL and MALONEY, 1973). In contrast to 
the earlier studies with cholinergic agents (GERALD and MAIC'KEL, 1969), antihistamines 
(GERALD and MAICKEL, 1972), amphetamines (MAJC'KEL, Cox, KSJR, SNODGRASS and 
MILLER, 1970), and phenothiazine tranquilizers (MA](,KEL, GERALD. WARBURTON and 
MAHJU, 1968), the depressant drugs stimulated consumption of water by deprived rats. The 
present paper describes studies of the actions of three depressant drugs; barbital, chlordia-
zepoxide, and promazine, as influenced by the taste of the consumma tory fluid. 
MATERIALS AND METHODS 
Adult male Sprague-Dawley rats (300-350 g) (Murphy Breeding Laboratories, Plain-
field, Indiana) were used in all experiments. The animals were maintained on tap water 
and Purina Rat Chow ad lib. for at least 1 week after arrival in the laboratory, All solutions 
for inj,~ctjon were made up in glass distilled water such that a dosage volume of 0·1 ml 
* Supported by USPHS grants MH-146Sg and K02-MH-41083 and by NASA grant NGL-JS·003-117. 
t Taken in part from a thesis submitted by G. J. Maloney for the M.S. Degree in Pharmacology. Indiana Uni· 
versity (19731. 
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per 100g body weight contained the desired dose: all injel.:tiLms wcre given intra peri-
toneally. J 5 min prior to placing the animals in the drinking cage~. 
Fluid consumption was measured basically as descrihed b~ Gl RALD lind MAICKEL 
(1969). Rats were placed in cages. 17·6 x 17·6 x 35·2 cm. identical to their home cages. The 
test cages were suspcnded in individual compartments of a sound-proofed box with uni
· 
form fluorescent lighting. Constant circulation of air by blowers maintained uniform tem
-
perature in the compartments; the noise output of the blowers served as uniform whit
e 
noise. Each cage contained a drinking tube connected to an external 50 ml burette filled 
with the appropriate fluid at the start of each run. As the animal consumed the
 
fluid. the change in volume was recorded by visual observation to the nearest 0·1 ml
. 
The front door of each compartment was equippcd with an eyepiece lens to permit visua
l 
observation of the rats without disturbing their behavioural performance. Rats were
 
deprived of water for 23 hr prior to testing and then placed on the drinking cages and 
allowed to drink for 1 hr. Food was available ad lih. in the home cages, but was not avail-
able in the drinking cages. 
Drug trials were started only after the animals d~monstrated stable baselines (less than 
5~/~ daily variation) of water intake. The schedule for drug studies was arranged so that 
the rats were run daily. with drugs administered every 4th day and placebo doses on the
 
intervening days. Fluid intake was recorded at 15, 30 and 60 min of the consummatory 
sessions; the greatest proportion of drinking occurred in thc first 15 min in all cases. 
Consummatory test fluids were distilled water or solutions of saccharin (0'2%), or tar-
taric acid (0·5~~) in distilled water. Three groups of eight rats were run first on distilled 
water. and all three drugs were tested. When a baseline had bccn re-established for each
 
group on one of the other test fluids. the effects of all three drugs were tested on that con
-
summatory system. For each drug. 11 = 6-8: an 11 of less than th~ maximum value indicates 
a malfunction of the apparatus or sickness or death of an animal. AlI results are expressed
 
as the mean ± S.D. of the volume consumed in the drug test session divided by the volum
e 
consumed on the pre-drug day x 100. i.e. the percent consumption. Thus. each anima
l 
served as its own control. 
Dose-response curves Were fitted for each drug on the test fluids by the method of "least 
squares". The slopes of the lines were determined by linear regression and the value of 
the RD25 was obtained. This value is an estimate of the dose of a 
particular drug which 
would be required to produce a 25% change in fluid intake during the test session. Values 
for slopes and RD25 values and statistical comparisons were determined as de
scribed by 
Cox (1970). 
RESULTS 
Effects of consummatory flUid taste on barbital actiol1 
The data in Table 1 are those obtained when dose-·response studies of the dipsogenic 
actions of barbital were performed using water. saccharin. or tartaric acid. All three dose
s 
of drug exerted a significant dipsogenic effect. regardless of the consummatory fluid. The
 
RD25 values for barbital were similar with values for water or t
artaric acid. but were sig-
nificantly higher (P < 0·05) for saccharin. fhe slopes of the log dose-response curves for 
water and tartaric acid were similar; that for saccharin was significantly lower (P < 0'05). 
Effect q{ cOl1sul1lml/torr.flllid tastl! 011 chlordiazepoxide action 
In this test system. chlordiazepoxide. like barbital. also had significant dipsogenic action 
at all doses tested. The data in Table 2 show that chlordiazepoxide was most effective a
s 
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Tabk I. Effect of taste phl!nonJl!na on barbilal elleCI, on deprh'ation-inducl!d fluid ctlfl,umption 
f ,,, Barbital Prl!-drug Drug Percentage of RD1~ 
:t Fluid consumed /1 (mgikg. i.p.) Iml:: S.D.I (ml ± S.D.I Pre-drug Il11g'kgl Slope 
Water 8 10 15·5 ± ),5 18·5 ± 3·2 '119 ± 12'2' 
8 40 17-7 ± ::1 23-0 ± 2-6 DO± R'4- 27·3 +78·1 
7 80 14·6 ± 2·7 22-7 ± 1·5 166 ± 12,8-
Tartaric acid 8 20 11·4 ± 2·2 14'() ± 1·7 125 ± Ilhl-
(0'5%) 8 40 11·4 ± 2·3 15·1 ± 2·~ 136 ± 3304" 24'1 +63-1 
7 80 10'2 ± 0·83 16·5 ± 2·3 163 ± 32'3" 
Saccharin 8 10 23·7 ± 3-6 2!)'5 ± 3'1 120 ± 9·9-
(0,2%) 8 40 23-9 ± 3·7 30'0 ± 5'3 126 ± 13·1" 35-6 +23·3 
7 80 21·8 ± 3·1 277 ± 6'3 134 ± 28-S-
Animals were treated as described in Methods section: drug was administered 15 min prior to start of drinking 
session. Results are expressed as mean ± S.D. of the values obtained. Statistical comparisons were mad~ by the 
correlated t-test for paired scores; significant differences from the corresponding pre-drug values (P < O·OS) are 
indicated by". 
Table 2. Effect of taste phenomena on chlordiazepoxide effects on dcpri\'ation-induc~d fluid consumption 
----~.-------
Chlordia-
zepoxide Pre-drug Drug Percentage of RD1~ 
Fluid consumed n (mglkg. i.p.) (ml ± S.D.I (ml ± S.D.) Pre-drug {mg'kgl Slope 
>---_ .. - ~ ~.+ 
Water 8 3·7S 14·0 ± 2-4 18·2 ± 4·0 130 ± 18'4-
" 8 7·5 14-8 ± 2·0 21'5 ± 2·1 - 145 ± 2S'8* 2'6 +38·2 ~ 8 15·0 15·3 ± 1·8 2304± I·g 153 ± 21'1* 
Tartaric acid 8 3·75 10·0 ± 2·5 12·0 ± 2'3 120 ± IN-
(0'5%) 8 7·5 104 ± 1'5 13-3 ± 2·0 12H ± 24-1' S'5 +33·2 
8 15'0 10·3 ± 1·8 14·4 ± 3·0 140 ± 1:'·5· 
Saccharin 8 3-75 21·8 ± 2-6 26'8 ± 3'2 114 ± 19·0· 
(0'2%) 8 7·5 21·9 ± 5-6 2% ± 6·1 145 ± 14,9- 4-7 +91·4 
8 15·0 22·9 ± z.s 40·6 ± 5·7 179 ± 3()'1" 
Animals were treated as described in Methods section: drug was administered 15 min prior to start of drinking 
session. Results are expressed as mean ± S.D. for the values obtained. Statistical comparisons were made by the 
correlated t-test for paired scores; significant c~fferences from the corresponding pre-drug values (P < 0'05) are 
indicated by". 
I Table 3. Effect of taste phenomena on promazinc effects on deprivation-induced nuid consumption Promazine Pre-drug Drug Percentage or RD2 $ Fluid consumed n (mg/kg. i.p.) (ml ± S.D.) (ml ±S,D.) Pre-drug (mg/kg) Slope 
__ • __ ~_._ ~ ____ ~. __ ~ __ ••• ____ .:;- ____ "_T _ . ~ 
Water 8 2·5 19-2 ± 2-6 17'0 ± 2-3 89 ± 8'5 U 
8 5·0 19-2 ± 2-2 IN± 2·6 74 ± 7'0* 4·7 -48-2 11 
8 10·0 16·7 ± 2·2 10'1 ±H 60 ± 9'S- iI 
Tartaric acid 8 2-5 11·4 ± 2·0 10'0±H R6 ± 14·4 ;~ 
(0'5%) 8 5·0 11·7 ± 1·2 9·0 ± 1'6 77 ± 14'1* 5'() -39·9 ., 
8 10·0 IH±2'2 7-8 ± 1-4 64 ± 8'6* I Saccharin 8 2·5 24-2 ± 4'1 22'5 ± 4'6 93±1O'1 I (0'2%) 8 5·0 24·4 ± 4'5 20'7 ± S'4 85 ± 8,6- 6·4 -40·7 8 10·0 23·1 ± 2·8 14'5 ± 6'7 62 ± 2'5" Animals were treated as described in Methods section; drug was administered 15 min prior to start of drinking session. Results are expressed as mean ± S.D. of the values obtained. Statistical comparisons were made by the 
correlated t-test for paired scores; significant differences from the corresponding pre-drug values (P < 0'05) are 
, 
indicated by· . 
. {. 
-.. ~ 
100 
! 1 ," I . . 
:;;;:_:_,o~,-".,;L; -.- -,,--,,-'cc -,. '=_:;:'=::=~:'C:==-'~-="-===:::=:::;:-_=;:;:-~"=-~"''''=';;;:=:''''--==-~----:-':-':=~_:::'':=-===:::;='."'_.,----::::'-" -____ -l--~ 
ill 
<--
766 R. P. MAICKI-L and G . .l MALO'I!')" 
a stimulus for water and considerably less eflective for solutions of tartaric acid and sac-
charin. The RD2 , values for tartaric acid and saccharin do not diner significantly from
 
each other, but both are significantly diflerent from that of water. As with barbital. the 
slopes of the dose-response curves were para lIel for water and tartaric acid: saccharin 
solutions were significantly different (P < 0'05). 
Effect of COIlSlIlIlIllaIOI'J.f/lIid lasle on pl'Ol1la:;lle action 
In the case of promazine. the drug depressed deprivation-induced fluid consumption. 
regardless of the fluid offered (Table 3). The efficacy for all three consummatory fluids is 
basicall} similar. Slopes of the dose-·response curves are parallel. and RD2 s values are not 
significantly different for all three fluids. 
. DISCUSSION 
A number of previous reports from this laboratory have indicated that a variety of drugs 
depress deprivation-induced fluid consumption by rats (MAICKEL I!t al .. 1968: GERALD and 
MAICKEL, 1969; MAICKEL. el al., 1970; GERALD and MAICKEL, 197:!). More recently. we 
have shown that a variety of sedative, hypnotic and anxiolytic drugs have an opposite 
effect, i.e. they stimulate fluid consumption by deprived rats (MAICKEL and MALONEY. 
1973). In addition, a previous report also described the effect of taste phenomena on the 
action of several drugs that depress deprivation-induced fluid consumption. 
In the present report. the effects of three drugs are examined for their ability to alter 
the deprivation-induced consumption of distilled water, 0'5'10 tartaric acid or 0.2
0
0 sac-
charin. These three consummatory fluids represent a range of tastes 11'om pleasant (sac-
charin) through neutral (distilled water) to unpleasant (tartaric acid); the volume con-
sumed by deprived rats is increased about 42~'~ (relative to water) by the use of saccharin. 
and decreased about 33~0 (relative to water) by the use of tartaric acid. The drugs chosen 
for this study also represent a diversity of pharmacological activities ranging from barbital. 
a long acting sedative. through chlordiazepoxide, an anxiolytic agent. to promazine. a mild 
antipsychotic. 
The results obtained with the various drugs on deprivation-induced consumption of dis-
tilled water are similar to those previously reported i.e. barbital and chlordiazepoxide 
stimulate consummatory behaviour, while promazine depresses it. When barbital was 
tested with other consummatory fluids, the results (see Table 1) demonstrated that the 
effects of the drug were influenced by pleasant taste. Thus. the slopes of the dose-response 
curves for barbital with water and tartaric acid solution was similar: the doses requ ired 
to elicit at 25% increase in volume consumed were virtually identical. By contrast. when 
the pleasant tasting sacchariri solution was used as a consummatory fluid, the dose-re-
sponse curve was much shallower, and cL'nsequently the RD 25 dose was higher. suggesting 
that the stimulatory action of the drug wa:; less effective. 
In the case of chlordiazepoxide, the dose-response curves for water and tartaric acid 
were again paraIlel, although the RD25 dose required for tartaric acid was more than 
double that required for water (Table 2). However, when the saccharin solution was used. 
the slope of the dose-response curve was much steeper, although the RDz5 dose fell 
between those for water and tartaric acid. In the case of promazine. all three consumma-
tory fluids behaved in a similar manner. with dose--response slopes and RD25 values not 
differing from each other. 
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Fluid CllIl,umptl(11l and ta5te 
In view of the plc,ious report from this laboratory on taste phcnomcna (MAI('KEL and 
\VUlI!. 1972). the present work adds a further dimension emphasizing the importance of 
standardizing conditions when lIsing behavioural test systcms involving fluid consumption 
or the thirst drive. While thesc drug cfTccts do not delineate gus1atory phenomena as 
oppost..'d to drug effcds 011 the thirst drive or on satiety centrc. they certainly demonstrate 
the nccessity for uniformity in tcst !\ystems. GROSSMAl\ (1967) reported a number of diver-
gent conclusions on thirst-associated phenomena or consummatory behaviour: a variety 
of consummatory fluids of varying tastes were used. 
Of particular interest is the observation (Table 21 that chlordiazcpoxide works best whcn 
the consummatory fluid is the plcasant-tasting saccharin solution. This must be considered 
in discussing the punishmcnt attenuation hypothcsis proposed for screening anxiolytic 
agents (GELLER and SEIFTER. 1960. 1962: GELLER. Hn:.AK and SUfTER. 19621. In view of 
the dipsogenic action of anxiolytic agcllts (MAICKEL and MALONEY, 1973). and this stimu-
latory effect of chlordiazepoxide on a pleasant tasting fluid. the possibility of a simple over-
ride of the punishment must be considered. 
ArhIIO\r!"dyr/lIl'llt.I·-The authors wish to thank the following manufacturers for gencrousl~ supplying thc drugs 
used in thb study: chlordiazep,1\ide (Lihrillm~f . Hoffmann La-Roche. Inc. and promazine hydrochloride 
(Sparine@}-W;.cth Labora tories. 
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COI1PARATIVE PHYSIOLOGICAL DISPOSITiON OF MELATONIN 
ArlO ITS BENZO[b]THIOPHENE ANALOG IN THE RAT.1£! 
H:rgamon Press 
Roger P. Maickel, Talmage R. Bosin, Steadman D. Harrison, Jr. 
and Mark A. Riddle 
Department of Pharmacology, Medical Sciences Program 
Indiana University, Bloomington, Indiana 47401 
(Received in final form 26 March 1974) 
SUMMARY 
Melatonin and its benzo[b]thiophene analog Were labeled by acetylation of 
the corresponding 5-methoxyarylethylamines with 3H-acetic anhydride. 
The benzo[b]thiophene analog had a much higher lipid solubility. When 
administered to rats, both compounds disappeared from plasma and tissues 
. by first-order decay. The dispositions were similar, with the higher 
lipid solubility of the benzo[b]thiophene-analog resulting in higher tissue: 
plasma ratios, especially in adipose tissue, kidney and liver, and longer 
half-lives in plasma and tissues. 
Melatonin (N-acetyl-5-methoxytryptamine, MLT) was first identified by 
Lerner and collaborators in 1959 (1). It has been found in the pineal 
glands of a variety of mammalian and avian species (2) and in the peripheral 
nerves and urine of humans (3).. More recently, several papers have reported 
the fate of exogenously administered MLT in cats (4) and rats(5). In the 
present paper, we report on the comparative physiological dispOSition of 
, ~ 
MLT and its benzo[b]thiophene analog (5-methoxy-3-(a-acetaminoethyl)benzo .. 
[b]thiophene, MLT-S) in rats. 
MATERIALS AND METHODS 
~lL T and ML T -S were prepared from thei r respecti ve 5-methoxyaryl ethyl ami nes 
:f.' . 
1 A preliminary report has been presented. The Pharmacologist ]E.:257 (1973). 
2 This research was supported in part by USPHS grants K02MH-41083 and NS~09762 
and NASA grant NGL 15-003-117. 
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by reaction with 3H-acetic anhydride as described by Campaigne and Dinner (6); 
the specific activities obtained were 4.1 mCi/mmole. The compounds were 
administered by i.v. injection in aqueous solution (0.5 mllrat, containing 
50 uCi of 3H and 12 umoles of compound) to 16 adult, male, Sprague-Dawley 
rats weighing 300 grams. Four animals were sacrificed at 0.25,0.5,1.0 and 
2.0 hrs. after dosage, and blood and tissues were collected and frozen until 
analysis. 
3H-MLT and 3H-MLT-S were determined by a modification of the procedure 
described by Kopin, et ~ (4). Tissues were homogenized in 3 volumes of 
0.05 N NaOH; pla.;ma was diluted 1:1 with 0.05 N NaOH. Homogenate or diluted 
pla!.ma (2.0 ml) were added to 50 ml gl:ss-stoppered centrifuge tubes contahdng 
15 ml of reagent grade toluene. The tubes were stoppered, shaken for 5 min. 
then centrifuged for 10 min. The aqueous layer was removed and discarded. 
and duplicate 5.0 ml aliquots of the toluene were removed and added to 
scintillation vials containing 7 ml of toluene, 8 ml of ethylene glycol 
monomethyl ether. 1.6 g of naphthalene and 80 mg of BBOT. The samples were 
counted in a Packard TriCarb r·lodel 4322 Liquid Scintillation System. Results 
~Iere converted to nglg ti ssue. Decay curve slopes were determi ned by 1 i near 
regression. 
Randomly selected aliquots of the final toluene phase from various tissues 
and times ~Iere evaporated to dryness, the residues were taken up in a small 
volume of methanol and applied to Analtech Silica Gel G precoated plates. 
One-dimensional TLC was carried out using the solvent system B as reported 
by Bosin and Wehler (7). Radiochromatogram scanning of the plates, using a 
Packard Model 7200 Scanner, revealed that >85% of the radioactivity applied 
to the plate resided in a single spot corresponding in Rf to authentic MLT or 
MLT-S. No other peaks of radioactivity were observed that were significantly 
greater than the background level of noise. 
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~ Time Course of Disposition of ~ILT and MLT-S in Rat Tissues ! 
i 
ng Compound/g TissuetS.D. 
Tiss\:~ ComEound 0.25 hr 0.5 hr 1.0 hr 2.0 hr tl/2 
min. 
Plasma HLT 1806+ 120 746+121 82+ 14 6.9+ 2.8 12 ~ 
1650+ 223 731+152 MLT-S 228+ 39 21 + 6.4 18 i J , l 
11 
Adrenal MLT 2036+ 123 1096+258 294+ 42 33 +}O 18 (1 
.. :;; MLT-S 3970+ 579 1911+293 803+159 81 +15 20 
• ~ 
,! 
~ Brain MLT 1311+ 200 
707+ 82 104+ 20 8.2+ 2.6 14 
'I 
.~ 
" 
~ MLT-S 2467+ 218 927+194 348+ 90 34 + 9.1 16 
lj 
, 
I] 
, 
i 11 ! Fat MLT 613+ 106 334+ 97 
37+ 16 2.1+ 0.5 13 
I MLT-S 1988+ 354 17l3+318 7&4+116 158 +16 29 ~ , , ! MLT 1840+ 136 856+102 l Heart 113+ 18 6.9+ 2.3 13 
MLT-S 2671+ 490 1156+260 484+ 97 44 + 9.7 17 11 CJ , 
l 
Intestine 
(Duodenum) MLT 2064+ 300 1194+205 285+ 77 16 + 5.0 15 
~ 
l 
MLT-S 2140+ 281 1167+267 628+118 166 +29 20 1 
Kidney MLT 3606+ 230 2281+390 245+ 41 20 + 5.8 14 
! j 
, 
MLT-S 11694,:.1713 5168+762 2566+440 240 +76 19 ~ 
f Liver MLT 
2270+ 332 1272+208 192+ 47 18 + 4.6 16 1 
I.; E MLT-S 6313+ 524 2878+367 1097+184 196 
+48 35 
Lung MLT 1388+ 262 847+125 145+ 11 33 + 5.1 
18 
MLT-S 2736+ 361 1201+135 505+108 78 +16 21 
Muscle MLT 2212+ 241 788+155 112+ 12 5.5+ 2.1 
13 
MLT-S 1543+ 229 750+132 229+ 37 25 + 3.5 19 
ill Spleen MLT 1286+ 190 770+241 82+ 16 7.2+ 3.5 14 
~j MLT-S 1350+ 153 662+127 317+ 50 26 + 7.8 
)9 
if; It 
Testes MLT 1687+ 179 1230+ 32 321+ 17 
45 + 5.6 15 
tl 
~; , 
-, MLT-S 2101+ 379 1487+294 558+ 35 73 +19 22 
i; 
'.1 !! 
11 
it i <~ ~ \~ 
_.".;ii 
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RESULTS AND DISCUSSION 
The data obtained for the tissues examined are presented in Table 1. 
Of particular interest fs the fact that the tissue levels achieved by the 
benzo[b]thiophene analog at 15 minutes after dosage are higher for every 
tissue except muscle; this is reflected in a lower plasma level at that time. 
Kidney, liver and fat show the highest I~LT-S/MLT ratios at 15 minutes. The 
half-life values are longer for MLT-S than for MLT in plasma and all tissues. 
Statistical comparison of the slopes of the decay curves for MLT and MLT-S 
indicate that fat, liver, muscle and plasma are different for the two analog. 
These results suggest that both the endogenously occurring indolic compound 
and the foreign benzo[b]thiophene analog are handled in a similar manner by 
the body, the differences presumably being due to the higher lipid solubility 
(benzene: pH 7.4 distribution values were MLT = 8.2, MLT-S = 610) of the MLT-S. 
Ruffin, et ~ (8) have shown that MLT can be bioassayed by its ability to 
produce distinctive night coloration in the pencil fish, Nannostomus beckfordi 
~n_()malus. ~lore recently, Reed (9) found that MLT-S I'{as about one-tenth as 
potent as MLT in this test system, although both compounds had a similar 
toxicity. The biological activities of the two analogs have not yet been 
examined in mammals. 
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PHARMACOl.OGICAL AND TOXICOLOGICAL STUDIES ON l,4-BUTANEDIOL 1 ,2 
Joseph E. Zabik, David P. Van Dam and Roger P. Maickel 
Department of Pharmacology 
Medical Sciences Program 
Indiana University 
Bloomington, Indiana 47401 
ABSTRACT 
1,4-Butanedio1 had a significant sedative effect on rats at i.p. dosages 
>300 mg/kg. The LD50 was 1328 mg/kg. Effects of 'the drug on spontaneous 
motor activity was biphasic; doses of 50-200 mg/kg significantly reduced 
activity, while doses of 300-400 mg/kg produced loss of righting reflex. 
No increase in liver triglycerides was seen even at doses of 1000 mg/kg/day 
for 14 days. 
INTRODUCTION 
The compound l,4-butanediol (1,4-BD) has numerous uses, for example, 
in the manufacture of polyurethanes and polyvinylpyrrolidone (Freife1d and 
Hart, 1966) as a curing agent in vulcanization (Athey, 1959), as a plasticizer 
1 A preliminary report of this material has been presented to the Society of 
Toxicology (Toxicol. Appl. Pharmacol. 25:461, 1973). 
2 
Supported in part.:.bY,'USPHS grants MH-18852 and K02-MH-41 083, and by NASA 
grant NGL 15-003-117~ .' ',. 
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for thermoplastic polymers (Farbenindustrie, 1943) as a softener and moistener 
for gelatin, cellophane and speciality papers (Aniline, 1964), as a mold-inhibiting 
humectant in tobacco products (Drucker, 1962), a component of cigarette 
filters (Toney, 1969), and in the preparation of flavoring and perfume solutions 
(levinson, 1968) and suppositories (Kawamura et. ~., 1968). In fact, l,4-BD 
has such widespread use that it has been considered by Knyshova as an environ-
mental pollutant (1968). 
Despite this widespread usage, the literature contains little information 
on the pharmacology and toxicology of l,4-BD. Sprince et. ~. (1966) have 
reported the i.p. lDSO in rats to be 1.00 g/kg, while Rowe (1963) reported a 
p.o. lDSO in rats of 1.78 g/kg. Hinricks et. ~. (1948) reported toxic 
effects of l,4-BO in man, but Sprince et. ~. (1966) suggest that this may 
have been due to a contaminant, 2-butyne-l,4-diol, the raw material used in 
the manufacture of l,4-BO. 
l,4-BD has been demonstrated to have a significant depressant action on 
the central nervous system, presumably through the action of a metabolite, 
a-hydroxybutyri c aci d (GHB ) (Maxwell and Roth, 1972; Roth and Ga i rman, 1968); 
both the parent compound and GHB have effects on the rat EEG (Sprince et. ~., 
1966). Guidotti and Ballotti (1970) have reported that loss of righting 
reflex correlated better with brain cOhcentrations of GHB than l,4-BD. 
The present paper reports on some preliminary pharmacological data 
obtained with l,4-BO in rats. The results indicate that l,4-BO is a unique 
sedative drug, quite dissimilar to ethanol. 
MATERIALS AN~ METHODS 
Adult, male Sprague-Dawley rats (300-350 g) were obtained from Murphy 
Breeding laboratories, Plainfield, Indiana. Animals were maintained for 
7-10 days prior to experimental use on an ad lib diet of Purina lab Blox and 
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1.4-BO (Research Grade) was purchased from Matheson Coleman and Bell 
and administered by i.p. injection as the pure compound or as solutions in 
distilled water such that the volume of injection was 0.1 ml per 100 g body 
weight. 
spontaneous motor activity was measured in Woodard Actophotometers. 
Liver triglycerides were determineu using Harleco kits. 
RESULTS 
Preliminary results in the rat indicated the i.p. L050 to be 1328 mg/kg. 
a value somewhat higher than that reported by Sprince et. !l. (1966). No 
deaths were seen at doses below 1000 mg; doses of 1600 mg/kg or greater were 
an LD100 ' 
The loss of righting reflex after a single dose was dose dependent. as 
shown by the data in" Table 1. 
TABLE 1 
Loss of Righting Reflex in Rats Given Various Doses of 1.4-BD 
Dose N Duration of L.R.R. 
mg/Kg,T.p. min±S.E.M.---
250 8 0 
500 12 lOSt 4.6 
1000 12 3l8±21.8 
While no loss of righting reflex was observed at 250 mg/kg, a significant. 
effect was seen on rotorod performance at doses as low as 200 mg(~g (Table 2). 
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Rotorod Performance 
Dose 
mg/l<9,T. p. 
50 
100 
200 
300 
400 
in 
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TABLE 2 
Rats Gi 'Jen Various Doses of l,4-BD 
N Failures % 
15 37.4 
11 36.S 
11 55.4 
6 100.0 
6 100.0 
Similarly, significant effects were seen on spontaneous motor activity 
at doses as low as 50 mg/kg, i.p., although the dose-response curve was 
clearly biphasic as shown in Figure 1. with virtually a complete abolition 
of activity at doses of 300 or 400 mg/kg. 
When rats were dosed with l,4-BO daily for periods up to 14 days, a 
peculiar adaptation to the effects of the drug were observed (Table 3). 
The duration of loss of righting reflex was significantly lower with the 
fourth dose; further dosing did not lower the duration of action at all. 
Measurement of liver triglycerides in the rats treated with daily 
doses of 1.4-BO as described in Table 3 indicated no significant change 
from control levels, a sharp contrast to the actions of ethanol under a 
similar dosage regimen. In addition. the effects of 1.4-BO, in ,combination 
with pentobarbital or chlorpromazine. on loss of righting reflex. are merely 
additive. 
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TABLE 3 , 
, 
Variation in Duration of 1.4-BD Narcosis with Repeated Dosage 
Duration of Loss of Righting Reflex 
Day 500 mg/kg. i.p. 1000 mg/kg. IN}· /I of doses min±S.E.M. (N) miniS. E.M. 
105± 4.6 (12 ) 318±21.8 (12) 
4 78±10.3 ( 7)*' 191± 4.5 ( 8)* 
7 87± 5.6 ( 6)* 2l0± 6.0 ( 5)* 
14 79± 5.8 ( 3)* l89± 8.5 ( 2)* 
* (p < 0.05) Significantly different from day 1 
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Although l,4-BD appears structurally to be a dimer of ethanol, the only 
pharmacological similarity between the two compounds appears to be in their 
depressant potency. l,4-BD is active at doses of > 50 mg/kg, i .p.; the activity 
depends on the parameter being measured. Thus, a reduction in spontaneous 
motor activity is seen at 50 mg/kg; retorod performance is imparied at 200 
mg/kg; and loss of righting reflex occurs at 250 mg/kg. The dose-response 
data for rats treated with l,4-BD is most intriguing, reflecting a biphasic 
type of response (Figure 1). At doses of 50, 100 or 200 mg/kg, 1.4-BD causes 
~ significant decrement in activity; at doses of 300 or 400 mg/kg, activity 
levels are zero since the animals lose their righting reflex. 
Another interesting phenomena was observed when rats were given daily 
doses of l,4-BD for 14 days. Under thesE conditions, the duration of loss 
of righting reflex was significantly reduced by the 4th dose, although no 
further reductions in effect were observed over the remainder of the dosage 
period. In this regard, it was of interest that no significant elevations of 
liver triglycerides were observed over this period of treatment, a striking 
contrast to many reports on the actions of ethanol on liver lipids. In this 
regard, it is also interesting that the effects of combined dosages of l,4-BD 
with pentobarbital or chlorpromazine have a merely additive effect on loss of 
righting reflex. Thus, it seems that the CNS actions of l,4-BD may be sufficiently 
unique to justify further examination as a potential pharmacologic"l agent. 
In this regard, the studies of Sprince et. ~. (1966) and Roth and Gairman 
(1968) indicating that the CNS depressant effects of l,4-BD may be mediated 
by its conversion to a-hydroxybutyric acid are most interesting. Certainly, 
the Therapeutic Index in rats as a potential anesthetic (LD50/ED50 for loss 
of right reflex >60 minutes) is intriguing since it appears to be <4.0. 
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In combination with the demonstrated lack of hepatotoxicity. even with 
chronic dosage. this possibility seems to be worthy of further study. 
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Il).tcstinal transport of tryptophan and its v.nalogs 
T.-\L\IAGE R. BOSI:\, DAVID R. HATHAWAY, A:\U ROGER 1', \1.-\It'KEL 
J h}'II'I//1f/Zt of I'I{(mnllwlogy, .\Jedical SC/fIlCI'S Frog/lIlIl, Inrli'll/II Univcrsily, BltllI//1wglo/1, /J,)lana --17--101 
BOSI:>;, T."L~!P'GE R., DAVID R. HATHAWAY, AND ROGER P. 
MAICKEL. lllleslirlal transport of tlJpl!1Jlhnr! alld ils allalogs. Am. J. 
Physiol. 228(2); 496-500. 1975.-A comparative study of the 
intestinal transport of DL-tryptophan and its l-methylindole 
(Iryptophan-I-JJe) and 1)cnzo[b]thiophene (tryptophan-S) ana-
logs has been rarried out in vitro, IIsing the e\'Crted intestinal sac 
of the rat and hanNer. Both tryptophan and tryptop.han-S are 
actively transported across the intestine, while tryptophan-I-Me 
is not actively transported. The active transport of tryptophan is 
competitively inhibited by tryptophan-S, wggesting a similar 
carrier, while tryptophan-i-Me is not an inhibitor of tryptophan 
transport, suggesting little or no interaction with the carricr. 
The transport of tJ-ypwphan and tryptophan-S is dt'pressed at 
concentrations (10 m!l.f), and all three amino acids produce 
subtle a\trrations in the barrier properties of the sacs, as cvidenced 
by increased tetraethylammonium bromide-14C diffusion. 
active transport; aromatic amino acids 
• 
l·methylindole (tryptophan-I-Me) (lb) and benzo[bJthio-
phene (tryptophan-S) (Ie) analogs, we have ~\.Udied the 
role of the indole nucleus in active intestinal transport 
in the rat and goldcn hamster. 
/' ."-_ ,COOl{ 
C~ r--r IH, 
'V--'x'-
la. X = NH 
I b. X = XCII 3 
1(', X S 
MATERIALS A:\D Mt.THODS 
AI aterials, Animals were adult male Sprague. Dawley 
rats, 280 g (Murphy Breeding Laboratories, Plain'field, 
Ind.) and adult malc golden hamsters, 150 g (Engle Lab-
oratory Animals, Inc., Farmersburg, Ind.). DL-Tryptophan 
[side chain-2, 3-:lH] and tetraethylammonium bromide-
J-!4C (TEA) of specific acth'ities I Ci!ml1lol and I mCil 
FOLLOWl:-lG THE RlWIVAL by \Vilson and \\'iseman (22) mInol, rcspecti\Tly, were pu)'rhased from ~cw 
England 
of the e"erted intestinal sac techniques, developed by Reid :i'\uclear Corp., Boston, Ma
ss. DL-Tryptophan-I-Me and 
(18), a great body of literature has accumulated concerning DL-tryptophan-S were uniformly tritium labeled 
by !'ew 
, the carriers involved in the active tl'ansport of amino acids England ~uclear Corp., with resp
ective specific activitics 
across the intestinal epithelium. Antcdating methodology of 193 mCil m1110\ ana 3 Cilm
mol. The purity of alliabcled 
for elucidating active processes, Berg and BaL1gues~ in 1934 compounds was confirmed by thin
-layer chromatography 
(1) were first to note differences in absorption among (2), scanning the plates with a Packard model 7200 rad
io-
tryptophan isomers and aeetylated derivatives in the rat. chromatogram scanner. U
nlabeled DL-tryptophan was 
Wiseman (24), using the everted sac technique, was un- FllIrchased from Sigma Chemical Co., Inc., S
t. Louis, 
:able to demonstrate active accumulation of L-tryptophan :Mo., and DL-tryptophan-I-M
r. and DL-tryptophan-S were 
at a conccntration of 20 rn~1. However, Spencer and prepared by standard procedUl'cs (4, 25). The pur
ity of all 
: Samily (20) showed activc transport of L-tryptophan to unlabeled compounds was confirmed by thin-l
ayer and 
: occur in hamster intestinal sac at low concentrations, with gas chromatography. 
: uptake dropping off to zero at higher concentrations. This Methods, In all cverted sac
 transport studies a modifica-
: phenomenon has been confirmed by other investigators tion of thc method of Wilso
n and Wiseman (22) was em-
I and attributed to toxicity (20), depression (7), and most ployed. Animals were anesthetized with Kcmbu
tal (8-10 
: recently, to a bidirectional flux ,haracteristic of the carrier mg/kg, ip), laparotomy was performed, and 
4'-cm seg-
. mcchanism (Hi). mcnts of ileum beginning 5 em from thc ilcoc
ccal valve 
Despite 20 yr of study of the active transport of amino vI'ere removcd sequentially an
d individually with ligation 
: acids in the intestine, a satisfactory undcrstanding of the of neighboring blood vesse
ls to prevent ('xcess blood loss. 
: role of structural factors in tryptophan transport has not The modification insured t
hc elimination of temporal in-
been forthcoming. At prcsent, investigations have demon- cubation differences among
 ~acs, i.e., the fir.~t sac was 
strated the primary role of the a-carboxyl and a-amino away from an intact blood s
upply the same length of 1illw 
groups (I9) and have shown rathcr conclusively that as the last. Typically, five sacs were prepared fr
om each 
highly polar or chargcd substitutions on the aromatic anin1al.·:JiNs;rsion of sacs wa
s performed in isotonic saline 
ring reduct' transportability (lJ). These findings prompted, at 23°e dh a glass rod; any adventitious succus was gently 
Wiseman (23) to state, in a rece~lrre\'iew of amino acid washed from the mucosal surface. All sacs werc fi
lled with 
tramport, that ths: aromatic SY5t~rl1\eeri-i$'~~0 b~.or com- 0.4 ml of lcst solution, ligatl~d, and placed in incubation 
parati\'cly little intportance, proddcd';fthat if do~~not bear vessels containing 5 ml of identical test solution. lncuba-
a charge. . tiulls wefe carried out in a
n Arninco-DublloIT metabolic 
As I;an of a continuing study of tr)'ptophan (la) and its shaker at 37°e and 30 oscillations/min. A dircct 
OJ-.·vgen 
J _. . 
. '"'f 
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!-lIpply W(JS provided for carl) incubation \T~"cl hy (llll-
tiJ1l1()Us !Jllbbling of 100 (; oxy£,\cn through a Pa~tt'ur pip"ltf' 
~t an approximatc rate of 20 Illl 'min per \·ial. ~J1cllbati()m 
wcre carried out for 30 min. 
En'rted saC's employed in viability inwstigations W('1"(' 
prepared and incubated as above. At 15 min 2 !lei of 
tetraethylammonium bromide-l-HC (0.1 ml) were added 
to each vessel. 
All solutions were pn'pared in a Krcbs-Hemeleit bi-
carbonate bllilcr stock, pH 7.4. To various concentrations 
of unlabeled amino acid, tracer amounts of the labeled 
compounds were added to achieve 0.1 /lCi/mI. Xonab-
sorbable phenolsulfonphthalein, at a final concentration of 
0.014 m!\f, was added to the test solution for purposes of 
"olume corrections. Cpon termination of the experiment, 
O.2-ml aliquots of serosal and mucosal fluids were removed 
and added to counting dais containing the scintillation 
solution predously described (12) and counted in a Packard 
Tri-Carb model 4·322 liquid scintillation system. Aliquots 
of serosal fluid, 0.1 mI, were diluted to 2.0 ml with 0.5 X 
KaOH aJ:c read on a Beckman DU spectrophotometer at 
554 nm. Similar spectrophotometric readings were obtained 
on the original stock solution, and the ratios of initial and 
final absorbance "a lues were used for volume correction. 
Tissue accumulation of amino acid was measured and 
used only for purposes of determining percent recO\'ery of 
the labeled amino acid. Typical recoveries were 96-103 '/c. 
The rates of transport were calculated as described by Lin 
et al. (11). 
Slopes were determined by linear regression analysis. 
Comparisons of individual \'alues were performed by the 
Student t test; slope and intercept comparisons were per-
formed as reported by Cox (8). 
RESULTS 
The data obtained from studies of the everted sac of 
rat or hamster, using DL-tryptophan and its analogs, are 
presented in Table 1. Transport of tryptophan-I-Me was 
not observed. For both tryptophan and tryptophan-S, 
the data do nut follow standard Michaelis-Menten kinetics, 
primarily due to a drastic fall in transport rate at 10 mM. 
This phenomenon has been reported for tryptophan (7, 20) 
and for other neutral amino acids at higher concentration 
(13, 14), 
For tryptophan and tryptophan-S, Km and Vmax were 
determined by the Hofstee method in which the Vmax is 
represented as the y-intercept and -Km is represented by 
the slope. Figure IA presents results for the rat where a 
Km of 1.70 mM and a V max of 2.91 /lmol/g per 30 min for 
tryptophan and Km = 2.03 mM and V maX = 4.10 J.lmol/g 
per 30 min for tryptophan-S were determined. Statistical 
analYiiis of the differences in K m and V max values indicated 
that they were not significant at the 0.05 level. 
A similar plot for the hamster appears in Fig. ) B where 
the K m of tryptophan was found to be 1.96 mM and the 
"max was found to be 3.33 /lIDOl/g per 30 min, whereas 
for tryptophan-S, K m was determined to be 2.49 ml\f and 
"max was determined to be 4.63 J.lmol/g per 30 min. Xo 
statistkally significant difference at the 0.05 b'e! was found 
between the Km and '-max "alues or between respective 
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T.\llJ.J: I. T'rlll.ljmrt qf t~i/'to/J/,(/n and analogs i?J' 
(i'flled SIIC jlll/',lIdliQIlS 
Species 
uJ.·TJ')·ptophan Rat 
DL.Tryptophan·S Rat 
DL·Tryptophan- Rat 
I·Me 
DL.Tf}'ptophan Hamster 
DL·Tryptophan-S Hamster 
DL-Tryptophan- Hamster 
I·Me 
. -. -_._-
+ ......... -_. 
Tnitial Serosal 
Conen, m!ll 
0.1 
0.5 
1.0 
3.0 
5.0 
10.0 
0.1 
0.5 
1.0 
3.0 
5.0 
10.0 
0.1 
1.0 
5.0 
0.1 
0.5 
1.0 
3.0 
5.0 
10.0 
0.1 
0.5 
1.0 
3.0 
5.0 
10.0 
0.1 
1.0 
5.0 
Tr ... n31 lorled, 
"molls pcr 31) min 
0.16::1:0.02 
0.65::1:0.03 
1.1 J ::1:0.03 
1.85::1:0.21 
2.18::1:0.05 
1.90::1:0.09 
0.19::1:0.02 
0.82::1:0.05 
1.28::1:0.04 
2.54;:1:0.14 
2.42::1:0.21 
1.67::1:0.12 
-0.01;:1:0.003 
-0.06::1:0.02 
-0.46::1:0.14 
0.17::1:0.01 
0.63;:1:0.03 
1.15::1:0.10 
2.02::1:0.18 
2.45::1:0.09 
2.03::1:0.10 
0.18::1:0.01 
0.76::1:0.17 
1.30::1:0.06 
2.60::1:0.08 
2.72::1:0.21 
1.94::1:0.13 
-0.02::1:0.005 
-0.06::1:0.03 
-0.88::1:0.11 
Each value is the mean ;:I: SD of five sac preparations. Transport 
(in pmol/g pef 30 min) was calculated a~ described in MATERIALS 
AND METHODS. 
5 A 
5 B 
1 1 
1 2 1 2 
("I~OJo..E:s/G/30 NUIl/(MILWIJl.ES/Ll 
FJG. 1. Hofstce plots of transport of tryptophan {-Do} and trypto-
phan·S ( .•• ) by isolmcd c\encd sacs of rat (Fig. IA) and hamster 
(Fig. lB). Each point is Illl'an of 5 sacs; \crtical bars are ::I: SD. 
I 
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FIG. 2. Hofstee plots of transport of tr)"ptophan in presence of 
varying concentrations; 0 (-0-), I 111M (-3-), and 3 mM (-e-) of 
tryptophan-S by isolated everted sacs of rat (Fig. 2A) and hamster 
(Fig. 2B). Each point is mean of five sacs; vertical bars are ± SD. 
TABLE 2. Transport of tlJptophan in the presence oj 
tlJ'Ptophan-l-Me in the rat and hamster 
Species 
Rat 
Rat 
Hamster 
Hamster 
Tryptophan 
Conen, mM 
0.1 
1.0 
0.1 
1.0 
===== 
Tryptophan·I .. Il. ConeD 
ImM, 10mJlf, 
I'mol!g per 30 min "mol/s per 30 miD 
0.11 ± 0.03 
1.1S ± 0.13 
O.IS ± 0.01 
1.11 ± 0.10 
0.15 ± 0.02 
1.09±0.1O 
0.14 ± 0.02 
1.09 ± 0.14 
.---.. -.-... ----~ .. _-
---.----
Each value is the mean ± SD of five sac preparations. Transport 
(in I'mol/g per 30 min) was calculated as described in MATERIALS 
AND METHODS. 
Km and V mnx "alues of the tryptophans .when compared 
between the two animals. 
Figure 2A presents the kinetics of tryptophan transport 
in the rat in the presence of tryptophan-So Competitive 
inhibition is observed, with the Vmax remaining constant at 
all inhibitor concentrations (indicated by I values on the 
graph) while Km changes. Similar results are obtained in 
the hamster and appear in Fig. 2B. 
Tryptophan-I-Me was unable to inhibit tryptophan 
transport (Table 2). In the presence of 1 or 10 mM trypto-
phan-I-Me, the rate of tryptophan transport at 0.1 or 1.0 
mM does not change. Statistical analysis of these values 
compared to tryptophan at zero inhibitor concentration 
indicates no statistical difference at the 0.05 level. 
Considering the problem of decremental transport at 
high initial concentrations, Table 3 lists experimental 
velocities of tryptophan and tryptophan-S and the cor-
responding predicted values obtained by the use of the 
Michaelis-Menten equation. The last column expresses 
the percent predicted value of the experimentally de-
termined velocity. It can be seen that deviation from pre-
dicted velocity occurs for tryptophan-S at S mM and for 
tryptophan at approximately 10 mM. Statistical compari-
son of the deviation at the 5 roM and 10 roM points indi-
cated a significant difference (P < .05) between the two 
compounds. . 
"iability studies, at high concentration-induced dccre-
mcntal transport, werc conducted by mcasuring the percent 
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T.\HLE 3. Cuillj'(lIisfll/ 4 fX/I!'illlfTi/ul IIlId 
Jlfedlcted 11111/.ll
'
llri l'rlOI il ieS 
ConCIl, 
£xpll Vtlocily Predicted 
Species Compound 
(\'1;), Velocity V 1\' X loa 
roM I'lno\,g per ("p),l'moIiC E ., 
lU min per 30 min 
---------
Rat Tryptophan 5 2.IB±O.OS 2 17 100±2.' 
Rat Tryptophan 10 1.90±0.09 2.50 71i±3.1:1 
Rat Tryptophan 3 2.S4±0.14 2.46 JO·HS.7 
Rat Tryptophan-S 5 2.42::1:0.20 '2.92 B:l.±u.a 
Rat Tr)·ptophan·S 10 I.G7±0.12 3.-W 4~1±3 .5 
Hamster Tryptophan S 2.4S±0.09 2.38 103±3.1 
Hal11~ter Tryptophan 10 2.03±0.1O 2.78 7:l±3.7 
Hamster Tryptophan 3 2.60±0.08 2.51 104±3.2 
Hamster Tryptophan-S 5 Z.72±0.21 3,06 8fl±G,'l 
Hamster Tryptophau·S 10 1.94±0,13 3.68 S3±3,4 
Each value is the mean ± SD of five sac preparations. 
TABLE 4. Transintestinal diiJusion oj telraetll)'lammonium-J-l4C 
(TEA) iTI the presence oj uar,,)'ing concentrations oj 
t~)j}tOP'IQTl and its analogs 
Species 
Rat 
Rat 
Rat 
H.at 
Rat 
Hamster 
Hamster 
Hamster 
Hamster 
Hamster 
Tryptophan Tryptophan.I.M < Tryptophan·S 
Conen, -------~---- ~." .. ---;-- ~-" t .... 
m..\! crt D ?Q D~se In D I 10 Dose (1'1' D s 10 DU ... e 
10 osc ~o Control 10 OSc "(.70 ·C';ntrol J(J 0 e 'Fo Controi 
---. ------ --.- -"- .. _- ---- "---- ---" 
.~.~--. 
-.~ ~-
-
O· 0.65 1.0 0.65 1.0 0.65 (,0 
±0.07 ±0.07 ±O,07 
0.66 1.0 0.64 1.0 0.64 1.0 
±0.04 ±0.06 ±0.07 
5 0.64 1.0 0.64 1.0 1.03 1.6t 
±0.07 ±O.OS ±0.09 
10 1.48 2.3t 0.70 1.1 2.01 3.1 t 
±0.22 ±0.13 ::1:0.30 
20 2.31 3.6t 1.67 1.6t 4.13 Il.:H 
±0.34 ±O.ll ::1:0.45 
O· 3.69 1.0 3.69 1.0 3.69 1.0 
±0.B9 ±0.89 ±0.89 
3.46 1.0 3.63 1.0 3.51 1.0 
±l.OS ±0.91 ±0.80 
S 3.60 1.0 3.38 1.0 6.S6 l.llt 
±0.78 ±0.64 ±0.78 
10 8.29 2.2t 4.02 1.1 10.46 2.St 
±0.77 ±1.02 ±1.09 
20 12.85 3.St 5.86 1.6t 24.30 h.6t 
±l.OO ±0.9S ::I:2.S1 
---~---~--~. -----
Each value is the mean ± SD of five sac preparations. • Con-
trol = diffusion of TEA when alI;;"" acid concentration '" O. 
t Significant difference (P < O.OS) from control and significant 
difference (P < O.OS) from other values in horizontal row. 1: % 
Dose = % total TEA diffusing from mucosal to serosal cOlnpart-
ment in IS min. 
total dose diffusion of the relatively nondiffusable and 
inert compound, TEA, from the mucosal to serosal com-
partment during the last IS-min period of a 3D-min in-
cubation in the presence of varying concentrations of the 
amino acids. These data were then correlated with histo-
logical evidence of sac disintcgration. The premise was that 
a nondisrupted lipid epithelial border should serve as an 
effective barrier to transepithelial diffusion of the highly 
polar TEA; this has recently been confirmed (l7), Similar 
methodology has been l>mployed by GibaJdi and co-
workers (9) in c\'aluating c\'crlcd sac ,'iability with good 
. results. 
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Table 4 shttws the n'~lI11~ nf tll(' inH'l'ligati.on. Th(' column 
percent dost'lwlTl'nt ("ontrol i~ a ratiQ of the mean values 
of TEA diflll~ion at \'ari{l\l~ umillCl acid cOJl(t'ntrations to 
the mean diffusion \'alue at i'('ro amillo arid concentration, 
the control. Slali~tiral cOlilparisons WCft' made between 
the actual percent dose \'alue" shown in the first column 
under each compound. Ratio:, greater than I indicate a 
net increase in difl'usion over thc control. For tryptophan-S, 
a net increase in diITusion i;; seen to begin at 5 mM with 
progressive increase in direct correspondence to concentra-
tion. Significant diffusion in thc presence of tryptophan 
does not begin until 10 mM and for the I-methyl derivath'e, 
increased diffusion is first noted at 20 mM. Histological 
evidence of sac disintegration, observed as epithelial swell-
ing, disruption of cell borders, and sloughing, WdS noted 
only at the 10 and 20 m?\1 concentrations for tryptophan 
and tryptophan-So This will be described in detail in a 
future report. 
DISCUSSION 
Selective molecular alterations might alter transport-
ability in several ways. First, there may be stereochemical 
and electronic effects. The replacement of the indole nu-
cleus by benzo[b]thiophene results in a molecule that is 
similar sterically to indole t>ut electronically distinct due 
to the involvement of 3d orbitals on the sulfur atom (3), 
while the I-methylindole analog resembles indole elec-
tronically but diITers sterically due to the pre~cnce of the 
bulky methyl group. Additionally, indole possesses the 
capability of hydrogcn bonding at the I-position which is 
absent in the analogs. 
A second way in which substitution might alter transport 
would be through alteration of the acid/base properties 
of the a-COOH and a-J\7H 2 groups. Studies by Christensen 
and Oxender (6) have indicated that modest altcrations of 
pKa values have slight eITect on transport. Tryptophan and 
its sulfur and I-methyl analogs do not differ greatly with 
respect to pKa values of the a-carboxyl and a-amino 
groups (5). 
Finally, transportability may be affected through a 
polarity change in the aromatic system, lcading to differ-
ences in lipophilieity. Partition coefficient determinations 
have shown that the ordcr of lipophilicity of the compounds 
is ill the order: tryptophan-S > tryptophan-I-Me > 
tryptophan (5). 
It is evident that steric bulk at the 1-position of the indole 
nucleus differentiates tryptophan and tryptophun-S from 
tryptophan-I-Me. The fact that tryptophan-S and trypto-
phan-I-Me are more lipophilic than tryptophan as indi-
cated by their partition coefficicnts, yet the I-methyl de-
rivative is not actively transported, gives greatest support 
to stcrk factors in the transport mechanism. These findings 
contradict earlier thinking emphasizing the importance 
of aromatic ring system lipophilicity and the unimportance 
of nonpolar structural changes in determining transporta-
bility (I I ). 
''''hen compared to the studies of Cohen and Huang (7) 
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who found transpon of tilt' ·to, 5-, tlnd p-1I11·tll\ I dL'rh'alh I" 
of tryptophan at n ,ill!!!!- rOnt'l'ntrat.:<>n, (IIII' I'C'\IIt~ wOtlld 
tend to SlIgg('Sl lilt' importance of the J -pllsitioll of thl' 
indole nudeus a~ a hilt' fol' sleric ~l1teraction of trrptophan 
with the carrier molecule. 
The results of the inhibition studic~ support the con-
tention that tryptophan and tryptophan-S shan' tlw ~nllle 
carrier and interart in a rompetitiyc fashion. On tht' other 
hand, the absence of any competitive behayior of trypto-
phan-I-Me with tryplophan for transport would J;uggest a 
rather dramatic inertncss of this compound with respect 
to carrier interaction. It must be remembcred that all of 
the data reported in the present paper are for the rarcmic 
mixtures. While the D-isomer of tryptophan is presumably 
not transported (7), the assumption that it has no effect on 
thc transport of the L-isomer when both arc present rannot 
be taken as an absolute phenomenon. 
The depression of transport obseryed at high conre11ll'a-
tions of tryptophan has been reported by several groups 
(7, 16, 20). Our results confirm this }.;I,enomenon for 
tryptophan and tryptophan-S as well. In addition, by com-
parison of actual and predicted velocities, we hayc shown 
'that depression of transport tends to occur cRrlier fol' the 
sulfur analog. Spencer and Samily (20) first ~f'ec111ated that 
damage to sacs might account for the inhibition of transport. 
Cohen and Huang (7), on thc other hand, thought it 
represented some sort of depression but did not suggest a 
specific mechanism. Most recently Munck (16) has re-
opened the issue, and based on the theoretical work of 
Wilbrandt and Rosenberg (21), has attributed the decline 
in transport of tryptophan at high concentrations to a 
bidirectional flux charaetedstic of the transport mech-
anism (15). 
In support of the data presented here, Laster et al. (10) 
reported light and e1ertron microscopic evicence of cellular 
damage to hamster everted sacs incubated in vitro with 40 
mM L-tryptophan. These lesions neither occurred 'with the 
D-isomer nor with II other amino acids tested at the same 
concentration (10). While we also examined histological 
samples and noted gross evidence of destruction at 10-20 
mM DL-tryptophan and DL-tryptophan-S in both the rat 
and hamster, the measurement of TEA diffusion over a 
range of concentrations, when compared to a control, 
indicated that a more subtle alteration in the barrier 
properties of the sacs was occurring at tryptophan-S Con~ 
eentrations as low as 5 mM and tryptophan-I-Me con-
centrations as low as 20 m~1. This we take as e\·.idence of 
toxicity, although the exact nature of thc toxic eiTect is 
at the present time unknown. 
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DIFFERENTIAL EFFECTS OF aMT ON ANORECTIC AND STIMULATORY 
ACTION OF AMPHETAMINES 
Raymond H. Cox, Jr.* and Roger P. Maickel 
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ABSTRACT 
Pretreatment of rats with a dosage regimen of aMT that has no effect on 
the anorectic action of a single dose of 2 mg/kg of d-amphetamine or meth-
amphetamine causes a marked reduction in the rate of continuous avoidance 
responding evoked by that same dose. Similar pretreatment followed by a 
dose of 8.0 mg/kg of benzphetamine was without effect on the drug's action 
on both systems. 
INTRODUCTION 
Since the first studies of tre action of d-amphetamine on anorectic 
and central stimulatory behavior (Lesses and Myerson, 1938; Prinzmetal and 
Alles, 1940), a large amount of research effort has been placed in attempts 
to separate the two actions of drugs in the amphetamine series. A recent 
symposium contains a variety of papers reviewing various aspects of this 
problem (Costa and Garattini, 1970). In addition, Cox and M~ickel (1972) 
have reported a detailed comparison of the two activities of a large number 
*Present Address: Mead Johnson Research Laboratories 
Evansville, Indiana 47721 
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of phenylethylamines, using reduction of deprivation-induced food consumption 
as a measure of anorectic potency and increase of continuous avoidance respond-
ing as a measure of central stimulatory potency. Since Miller, et ~ (1970) 
had reported that aMT pretreatment could' reduce the stimulatory effect of 
d-amphetamine, it seemed reasonable to do a comparative study of several 
amphetamines in animals pretreated with aMT. 
MATERIALS AND METHODS 
Adult, male Sprague-Dawley rats (Hormone Assay Laboratories, Chicago) 
were used in all experiments. Details of animal handling, drug dosage, 
behavioral testing, and statistical processing of data may be found in the 
paper by Cox and Maicke1 (1972). Treatment with aMT was as reported by 
Miller, et ~ (1970). Brain NE and 5HT were determined as described by 
Maickel, et ~ (1968) . 
TABLE 1 
Effect of aMT Pretreatment on Brain Levels of NE and 5HT 
Each value is the mean + S.D. of results obtalned from 4 
animals given 150 mg/kg (i.p.) of aMT as a sus~ension in 
peanut oil at 48, 36, 24 and 12 hours prior to the zero 
time point. 
Hours After Last Injection 
Control 
6 
12 
24 
4& 
Brain NE 
)Jg/g 
0.46 + .05 
0.28 + .09* 
0.20 + .03* 
0.21 + .04* 
0.30 + .03* 
Brain 5HT 
)Jg/g 
0.63 + .06 
0.70 + .09 
0.68 + .09 
0.64 !. .04 
0.62 + .07 
*Significantly different from control (p < .05) as determined 
by the Student "t" test: 
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RESULTS 
The effects of pretreatment with aMT in the dosage regimen described by 
Miller, et!L (1970) are shown in Table 1. As can be seen from the data, a 
maximal reduction (to approximately 45% of control values) was maintained 
over the period 12-24 hours after the last dose. Accordingly, all behavioral 
testing was performed during this time period. 
TABLE 2 
Effect of aMT Pretreatment on Anorectic Action of Amphetamines 
Drugs were administered 12 hours after the final dose of aMT. 
Each value is the mean + S.D. of values obtained from 6 animals. 
each animal serving as its own control. 
Compound (dose-mg/kg) 
Saline 
d-Amphetamine (2.0 mg/kg) 
Methamphetamine (2.0 mg(kg) 
Beniphetamine (8.0 mg/kg) 
No Pretreatment 
% 
100 + 8 
60 + 7* 
53 :!:.13* 
66 + 16* 
aMT Pretreatment 
% 
87 + 1i* 
58 + 121' 
55 + 151' 
68 + 121' 
*Significantly different from saline (p < .05) as determined by the 
Student ~t~ test. 
NNo signigicant difference from non-pretreated animals (p > .05) as 
determined by the Student ~t" test. 
1'No Significant difference from non-pretreated animals (p > .05) as 
determined by the Student "t" test, but si9nificant1y different 
from saline with aMT pretreatment (p < .05). 
When animals were pretreated with aMT, then given a single dose of 
d-amphetamine, methamphetamine, or benzphetamine, the results obtlined on 
deprivation-induced food consumption are shown in Table 2. It is clear that 
the aMT pretreatment had no effect on the anorectic activity of the amphet-
amin,vs. The pretreatment itself had a slight, but non-significant. action 
on food consumption. 
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Effect of aMT Pretreatment on Stimulatory Action of Amphetamines 
Drugs were administered 12 hours after the final r.~se of aMT. 
Each value is the mean t S.D. of values obtained from 6 animals, 
each animal serving as its own control • 
Compound (dose-mg/kg) No Pretreatment aMT Preatment 
% % 
Saline 100 + 17 94 + 11 
d-Amphetamine (2.0 mg/kg) 259 + 49* 67 + '20# 
Methamphetamine (2.0 mg/kg) 287 + 51* 63 + 23# 
Benzphetamine (8.0 mg/kg) ·97 + 12 93 + 17 
*Significant1y different from saline (p < .05) as determined by the 
Students "t" test. 
#Significant1y different from non-pretreated animals (p < .05) as 
determined by the Students lit" test. 
In sharp contrast to these results are those obtained for continuous 
avoidance responding. The data obtained (in response to amphetamines) when 
animals were pretreated with aMT are presented in Table 3. Pretreatment 
with aMT had no significant effect on the rate of avoidance responding per 
se, but such pretreatment completely abolished the increased responding 
usually evoked by d-amphetamine and methamphetamine. Benzphetamine did not 
evoke stimulation in control animals; aMT pretreatment did not alter these 
results. 
DISCUSSION 
The ability of amphetamines to produce two different pharmacological 
effects: appetite depression and central stimulation, has been known for 
many years. The precise ro1e(s} of norepinephrine in these actions of 
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amphetamines has also been a continuing area for research. Weissman, et ~ 
(1966) have shown that aMT pretreatment antagonized the effect of amphetamine 
on conditioned avoidance behavior. Moore, et ~ (1967) in a subsequent publi-
cation, attributed some effects of aMT to non-specific toxicological phenomena 
of the agent, especially when given ;n massive single doses. A previous 
publication from this laboratory (Miller, et ~, 1970) has shown that use of 
a multiple-dosage schedule of more modest doses of a~T permits marked reduction 
in brain NE levels to be achieved, with no toxicity and only a slight perturba-
tion of normal behavior. 
The possible ro1e(s) of brain NE in mechanisms related to food consumption 
have also been the subject of some study. Many-of the studies have been 
reviewed in the publications by Morgane (1969), Grossman (1967), and Myers 
(1974). In this regard, it is of interest to note that the actions of amphet-
amine on food consumption can be altered by hypothalamic lesions (Cole, 1966) 
and that aMT treatment can reduce the rate of lever pressing for food by rats 
(Seaton and Crow, 1969), although this latter effect may be confounded by a 
concommitant decrease in motor activity. 
The data presented herein show that a pretreatment regimen of aMT that 
lowers brain NE by approximately 55% has clearly separable effects on the 
anorectic and stimulatory actions of several amphetamines. Under these condi-
tions, the central stimulatory actions of d-amphetamine and methamphetamine 
are completely abolished, while benzphetamine, which has no stimulatory acti-
vity at the dose tested, is not influenced by the aMT treatment. In contrast, 
the lowered brain NE levels have no effects on the anorexigenic actions of all 
three agents. The obvious question to be raised with regard to these results 
is whether they point to the possibility of developing new anorectic agents 
making use of this differential effect. 
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ABSTRACT 
Pretreatment of rats with the MAO-inhibitor pargyline prevents the 
metabolic destruction of 5HT and NE released in the brain by a subsequent 
dose of reserpine, and high levels of the amines remain in the brain. Under 
these conditions, the hypersecretion of ACTH usually evoked by reserpine does 
not occur. The elevated levels of brain 5HT and NE produced by MAO inhibition 
do not cause ACTH hypersecretion nor do they prevent the ACTH hypersecretion 
caused by exposure to cold or administration of sedative doses of chlorpromazine. 
Previous reports have indicated that sedative doses of reserpine evoke 
a hypersecretion of ACTH in rats, similar to that produced by exposure to low 
environmental temperatures (Maickel et ll" 1901; Westermann et~, 1962). The 
charactel'istic response includes decreased adrenal ascorbic acid and increased 
plasma corticosterone, liver tryptophan pyrrolase (TPO) and adrenal gland weight. 
Similar effects were produced in rats by sedative doses of the Rauwolfia alkaloids 
raunescine and rescinnamine, the reserpine analogue syrosingopine, or the 
benzoquinolizine Ro 4-1284 (2-hydroxy-2-ethyl-3-isobutyl-9, lO-dimethoxy-l,2,-
3,6,7-hexahydrobenzo(a)quinolizine). 1D contrast, isoreserpine, the 
pharmacologically inactive stereoisomer of reserpine, failed to evoke a 
pituitary-adrenal response. 
The ACTH hypersecretion evoked by reserpine was shown to be independent 
of the sedation caused by the drug (Martel et ~, 1962). For exampl e, pretreat-
ment of animals with desmethylimipramine antagonized the reserpine-induced 
. sedation without preventing the decline in brain amines or the hypersecretion 
of ACTH. The current paper explores the antagonism of reserpine-induced ACTH 
hypersecretion by the monoamine oxidase (MAO) inhibitor pargyline (MO 911, 
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N-methyl-N-benzyl-2-propynylamine). Evidence is presented that this antagonism 
is related to the level of brain biogenic amines maintained during the cOUrse 
of action of the drug. Pretreatment with MAO inhibitors does not affect the 
ACTH hypersecretion evoked by cold-exposure or chlorpromazine, lending further 
support to the hypothesis that reserpine-induced ACTH hypersecretion is related 
to brain amine changes. 
MATERIALS AND METHODS 
Experimental procedures were performed with unanesthetized adult male 
Sprague-Dawley rats (250-300 g). The animals were allowed food and water ad 
lib. and maintained as previously described (Maickel et !i, 1961). Reserpine, 
as the lyophilized phosphate salt, was dissolved in 0.5 ml water and injected 
into.the tail vein. Chlorpromazine, pargyline, and Ro 4-1284 were dissolved 
in distilled water and injected intraperitoned1ly. Control animals were 
injected with saline or distilled water. Animals were stunned and then 
immediately decapitated. Blood was collected into beakers containing heparin, 
transferred to tubes, and centrifuged immediately. Plasma samples for corti-
costerone assay were stored at -lOoC. For the assay of liver TPO, adrenal 
ascorbic acid, and brain 5HT, NE and NAO, tissues were removed and stored at 
Chemical methods. Adrenal ascorbic acid was determined by the method 
of Maicke1 (1960); plasma corticosterone by the method of Guil1emin (1959) 
and liver TPO Knox (1951); brain 5HT and NE by the method of Maicke1 et al , 
--(1968); and brain MAO activity by the method of Weissbach et !L (1960). 
Parameters of pituitary-adrenal stimulation. The following indices of 
pituitary-adrenal stimulation \'/ere measured; a fall in the level of adrenal 
ascorbic acid, a rise in the level of plasma corticosterone, and an increased 
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activity of liver TPO. The limitations and advantages of each of these indices 
have been discussed in a previous paper (Maickel et ll, 1961). In sqme 
experiments the changes in plasma corticosterone levels were used as the sole 
index of pituitary-adrenal hyperactivity. 
RESULTS 
Effects of pargyl ine Q!!. brain levels of SHT and NE and on pituitary-
adrenal system. The administration of a single dose of pargyline (25 mg/kg. 
i.p.), or two doses 18 hours apart, did not affect the levels of adrenal 
ascorbic acid, plasma corticosterone, or liver TPO (Table 1). Brain levels 
of 5HT and NE were markedly increased and brain MAO activity was inhibited 
by> 95%, as determined by the method of Weissbach et !!. (1960). 
. Effects of pretreatment with pargyline Q!:!" reserpine-induced ACTH hyper-
secretion. A previous communication reported that pretreatment of rats with 
pargyline prevented both the sedation and the ACTH hypersecretion induced by 
reserpine (Martel et a1. 1962). The results in Table 2 show that administration 
of reserpine to rats pretreated with pargyline (25 mg/kg. i.p.) caused little 
change in brain SHT and NE levels in 6 hours. The animals did not show the 
sedation characteristic of reserpine ana there was no evidence of ACTH 
.hypersecretion. 
When rats were pretreated with smaller doses of pargyline, the subsequent 
admin1strat1on of reserpine produced a variety of results (Table 3). In some 
animals. MAO inhibition was not sufficient to prevent the immediate metabolism 
of the amines released by reserpine. These animals became deeply sedated in 
~ hours. At that time, brain levels of SHT and NE had fallen markedly and 
there was a pronounced hypersecretion of ACTH. In other animals, the MAO 
inhibitor was only partially effective in protecting the released amines; 
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o in these animals, the sedative action of reserpine \'ias delayed. In 6 hours, 
sedation was apparent; however. the brain levels of 5HT and HE had not fallen 
to minima} values and no ACTH hypersecretion was observed. Finally, a 
third group of animals was observed in which the MAO inhibitor protected 
most of the released amines from destruction; 6 hours after reserpine. the 
animals showed only a slight sign of sedation. In these animals. reserpine 
had no s.ignificant effect on pituitary-adrenocorticalactivity./ 
Dose-response relationship of pargyline antagonism of reserpine-induced 
ACTH hypersecretion. Previous papers have shown that a number of reserpine-
like compounds lower brain amine levels and cause ACTH hypersecY'etion in rats 
(Maickel et!i. 1961; Westermann et!i. 1962). One striking simi1arity in 
these data is that the brain levels of amines must be depleted belciw 50% of 
the normal level ~n order to observe hypersecretion of ACTH .. When rats pre-
treated with varying doses of pargyline were given reserpine, only those 
animals in which the level of brain amines fell below 50% of the control animals 
showed ACTH hypersecretion (Table 4). If the dose of pargyline was sufficient 
to protect the reserpine-released amines to the extent that the levels of 5HT 
did not fall to values below 50% of normal, there was no measurable pituitary-
adrenal stimulation. 
~ack of effect of pargyline pretreatment on ACTH hypersecretion induced 
Bl other stressful stimuli. Previous papers from this laboratory have described 
the ACTH hypersecretion evoked by cold~exposure or administration of chlor-
promazine (Maickel et!i, 1961; Smith et!i, 1963). From the data in Table 5 
it is evident that pretreatment of rats with pargyline had no effect on the 
o ACTH hypersecretion induced by cOld-exposure or chlorpromazine. r:lis is in 
striking contrast to the antagonism of reserpine action produced by pargyline 
and lends further weight to the hypothesi's that the action of reserpine on 
the pituitary-adrenocortical system is mediated through an effect of the drug 
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on brain ami nes. 
DISCUSSION 
The studies presented in this paper lend further evidence that the 
ACTH hypersecretion caused by reserpine and rese.rpi!ne-l i ke drugs is related 
to the effects of the drugs on brain monoamine storage. A previous 
pipet (Westermann et !I, 1962) has noted that these drugs produce ACTH hyper-
secretion only when given 1.n doses that lower the amine stores below 50% of 
normal, regardless of whether this was achieved by administration of a single 
large dose or repeated smaller doses. In animals pretreated with pargyline 
(in doses which block brain MAO activity by 95%) administration of reserpine 
does not lower the level of brain amines. Although reserpine impairs the 
storage of 5HT and NE, the liberated amines are protected from the degradative 
action of HAO; due to their poor lipid solubility they can d.iffuse across the 
blood-brain barrier into the blood stream only very slowly. Thus, high levels 
of free amines remain in the brain for a long period of time. 
The relationship of pituitary-adrenal hyperactivity to depletion of brain 
am1nes to values below 50% of normal, first noted with reserpine alone, has 
also been observed in pargyline-treated animals. The possible significance 
of this is not immediately apparent. In the rat, the whole brain is used for 
the determination of 5HT and NE; the assay method measures the amines as if 
they were uniformly distributed throughout the entire brain. 'Perhaps this 
level of amines in a brain homogenate is equivalent to a complete depletion 
of the amine~ In one or more specific areas of the brain, or perhaps it is 
related to an imbalance of amines and consequently of neural function in some 
specific neuronal circuits. 
o 
-6-
i 
The observation that pretreatment of rats-with an MAO inhibitor does not 
prevent the stimulatory effects of cold-exposure or chlorpromazine on the 
pituitary-adrenal axis may also suggest that the hypersecretion of ACTH 
evoked by reserpine is due to interference with storage processes for brain 
biogenic amines. 
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'TABLE 1 
'Effects of Pargyline on B~ain Levels of 5HT and NEand On Pituitary-Adrenal Parameters 
Numbers in parentheses represent number of animals studied. All values are means ~ S.D.; 
underlined values are significantly different from controls (p < .05). Measurements were made 
18 hours after the last dose of pargyline. 
I Adrenal Plasma 
Ascorbic Corticosterone 'Liver TPO Bra;n 
Acid 5HT NE 
mg/100 9 Ilg/m1 llmol/g 11ver/hr llg/9 Ilg/g 
Control (20) 447 + 41 0.15 + .05 3.2 + .36 0.45 + .04 0.46 + .04 
Pargyline (13) 451 + 40 0.16 + .05 2.9 + .38 0.69 ±. .06 0.60 + .04 
one dose 
25 mg/kg 
Pargyline (15) 453 + 46 0.19 + .04 3.0 + .27 0.80'-tJ .06 0.72 + .07 
- - - -two doses 
25 mg/kg Lp. 
18 hours apart 
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TABLE 2 
Antagonism of Reserpine-Induced Sedation and ACTH 
Hypersecretion by Pargyline 
Numbers in parentheses represent number of animals studied. All values 
are mean + S.D.; underlined values are significantly different from controls 
(p > <.05). Animals were pretreated with pargyline (25.mg/kg i .p.) at 36 
and 18 hours prior to administration of reserpine (1 mg/kg i.v.). Brain 
am1nes and plasma corticosterone were measured 6 hours after reserpine. 
Plasma Brain 
Corticosterone 5HT NE Sedation 
~g/m1 llg/g llg/g 
Control (20) 0.15 + .05 0.45 + .04 0.46 + .04 --
Pargyl ine (15 ) 0.19 + .04 0.80 + .06 0.72 + .07 No 
I{eserpine ( 11) 0.44 + .04 0.08 + .02 0.07 + .03 Yes -, 
Pargy1 ine + 0.12 + .03 0.76 + .03 0.55 + .05 No 
Reserpine (9) - - -
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,TABLE 3 
'Effect of a Borderline Dose of Pargyli'ne on Reserpine-induced Sedation 
and ACTH Hypersecretion 
c 
Numbers in parentheses represent number of animals studied. All values are mean + S.D.; under
-
lined values are significantly different from controls (p <.05). Animals were given a single dose 
of pargyline, 18 mg/kg i.pq 18 hours before administration of reserpine (1 mg/kg Lv.). All animals 
were killed 6 hours after reserpine. 
Sedation Plasma Brain I 
3 hours after 6 hours after Corticosterone 5HT NE 
Reserpine Reserpine 
~g7m1 \1g/g \19/9 
Control (20) - - 0.15 + .05 0.45 + .04 0.46 + .04 
Pargyline (6) - - 0.16 + .03 0.62 + .03 0.57 + .04 
Reserpine (ll) Deep Deep 0.44 + .04 0.08 + .02 0.07 + .03 
Pargyline 
* + Reserpine 
I (10) Deep Deep 0.39 + .03 0.20 + .03 0.19 + .04 
II (10) Slight Deep 0.18 + .05 0.40 + .03 0.34 + .03 
III (11) 1 None Slight 0.17 +" .05 . '0-.53 +" .03 0.45 + .05 
-- -~ ... - --------- ---.------'..~ .. 
- --------
* Groups I, II and III were selected by visual observation of degree of sedation at 3 hours af
ter reserpine 
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TABLE 4 
Dose-response of Pargyline Antagonism of 
Reserpine-induced ACTH Hypersecretion 
Numbers in parentheses represent number of animals studied. All values 
are mean! S.D.; underlined values are significantly different from controls 
(p <.05). Reserpine was administered 18 hours after pargyline. Animals 
were killed 6 hours after reserpine. 
Plasma I , 
Pargyline 'Reserpine 'Cart i cos terone 5HT 'NE Sedation 
mg/kg. l.p. mg/kg, 1. v. ~g/ml lJg/g lJg/g 
- -
(20) 0.15 + .05 0.45 + .04 0.46 + .04 
-;-
-
10 
- ~ ~l 0.14 + .03 0.58 + .03 0.50 ±. .02 -10 1 0.37 ±: .03 0.21 ±. .02 o. 1 is + .02 Yes 
25 - (13 ) 0.13 + .03 0.69 ±. .04 0:60 ± .02 -
25 1 ( 9) 0.15 + .04 0.57 ± .03 0.49 ±. .03 No 
-
25 x 2 days 
-
(15) 0.14 + .04 0.80 ± .06 0.72 ± .07 
-
25 x 2 days 1 ( 9) 0.12 + .03 0.76 ± .03 0.55 ±. .05 No 
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TABLE 5 
Failure of Pretreatment with Pargyline to Block 
ACTH Hypersecretion Induced by Cold-exposure 
or Chlorpromazine 
Numbers in parentheses represent number of animals studied. All values 
are mean ~ S.D.; underlined values are significantly different from 
corresponding controls (p <.05). Animals were exposed to cold (40 C) or given 
chlorpromazine (15 mg/kg, i.p.) 18 hours after pretreatment with pargyline 
(2 doses, 25 mg/kg, i.p., 18 hours apart), then killed 3 hours after chlor-
promazine or after 2 hours of cold-exposure. 
Control 
" 
II 
+ Cold-Exposure 
+ Chlorpromazine 
Pargyline 
.. + Cold-Exposure 
II + Chlprpromazine 
(20) 
(7) 
(10) 
(15 ) 
(13 ) 
( 9) 
138 
Plasma 
Corticosterone 
\!g/ml 
0.15 + .05 
0.42' I .04 
0.39 ± .04 
0.14 + .04 
0.40 ±: .03 
0.38 ± .03 
'~~,--:": .... -,", _~-i>-~· .• _::ij,{!~:.:~_ ~"'-'-____ w.-...... "'-" 
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PRESSOR EFFECTS OF TRYPTAMINE ANALO
GUES 
T.R. BOSIN, E. JANE HIXSON & R.P. MAICKE
L 
Department of Pharmacologv. Medical Sciences
 Program. Indiana University. 
Bloomington, Indiana 47401, U.S.A. 
J Methylation of tryptamine in the I-position ha
d little elTect on the potency of the drug as a pres
sor 
agent in the intact anaesthetized rat. 
1 In contrast, substitution of a benzo[b]thiophene rin
g system for the indole ring decreased the 
pressor activity. 
3 Pretreatment of the animals with reserpin
e redt "ed the pressor elTect of tryptamine an
d its 
benzo(b}thiophene analogue while increasing the elTect of the
 I-methylindole. analogue. 
4 Pretreatment with phenoxybenzamine reduce
d the pressor elTect of all three compounds. 
. . 
Introduction 
Since the elTects of tryptamine on guinea-pig is
olated 
ileum were not inhibited by atropine or antihistam
ines, 
and, since a strip desensitized by tryptamine
 was 
insensitive to 5-hydroxytryptamine and vice v
ersa, 
Gaddum (1953) concluded there must be a specific 
tryptamine receptor. Rocha e Silva, Valle & Pica
relli 
(1953) defined a 5-hydroxytryptamine receptor in 
guinea-pig ileum dilTering from those for acetylch
oline, 
bradykinin, histamine, nicotine and piloca
rpine. 
Gaddum & Hameed (1954) reported similar receptors 
in rat uterus and in the vasculature of the r
abbit 
isolated ear. Gaddum & Picarelli (1957) defined two 
types of tryptamine receptor in the guinea-pig 
ileum, 
one blocked by morphine and the other by ph~.nox
y­
benzamine. 
The elTect of tryptamine on blood pressure was f
irst 
noted by Laidlaw (1912). The elTectsoftryptamine as 
a pressor substance have been compared to those
 of 5-
hydroxytryptamine by Reid (1951), Reid & Rand 
(1951) and Page (1952) and ourselves (Hixson, Bosin, 
Zabik & Maickel, 1973). More recently, Winter, 
Gessner & Godse (1967) examined the elTects of a 
series of amines on the rat isolated fundus prepar
ation, 
and found that tryptamine and its benzo[b}thiophene 
analogue had higher relative intrinsic activitie
s but 
lower affinities than 5-hydroxytryptamine. 
Method. 
Adult, male Sprague-Dawley rats (300-3S0 g) were 
obtained from Murphy Breeding Laborat
ories, 
Plainfield, Indiana, U.S.A. and maintained on P
urina 
Lab Chow and tap water ad lib for 7-10 days b
efore 
experimental use. Pentobarbitone sodium (Nembutal), 
reserpine (Serpasil), heparin, and tryptamine 
hydrochloride were purchased from comm
ercial 
sources. Phenoxybenzamine hydrochlo
ride 
(Dibenzyline) was kindly supplied by Smith-Kline 
and French Laboratories. 3-(2-Amino-
ethyl)benzolb]thiophene (tryptamine-S), and 1-
methyl-3-(2-aminoethyl)-indole (tryptamine-I-Me) 
were synthesized and supplied by Dr E. ~ampaigne
, 
Department of Cher.listry, Indiana University. 
Surgical procedure 
Animals were anaesthetized with pentobarbiton
e, in-
traperitoneally as follows: controls-60 mg
/kg; 
reserpine pretreat::!i-SO mg/kg; phenoxybenza
mine 
pretreated-45 mg/kit. When pinching the tail eli
cited 
no response, the rats Were placed on their backs
 on a 
small animal operatin,~ board (Interex Corp.). The 
trachea was cannulated to insure a free airway an
d the 
common carotid artery was ligated at the superio
r end 
then damped at the inferior end. A cannula of P
E 50 
tubing ~ ... as inserted into the artery through a small 
incision, l>ttached to 1'. 23 gauge needle, and conn
ected 
via a three-way ~topcock to a Statham strain gaug
e 
model P23AA and to the pressure bottle of a me
rcury 
manometer system. The system was filled with 0
.93% 
wlv NaCI solution containing heparin 1000 u/m!. 
The 
strain gauge was connected to the coupler of an O
ffner 
Type RB Dynograph (Beckman Instrument, Inc.), or, 
via a Bridge Preamplifier (Narco Biosystems, Inc.) to 
a Physiograph model PMP-4A (Narco Biosystems, 
Inc.). The system was flushed brieRy with the 
heparin/saline solution, and blood pressure reco
rded 
to confirm the intact system. 
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Figure 1 Pressot effects of tryptamine and analogues. Baseline blood pressure values were 110 ± 5 mmHg 
in control ratS. 60 ± 4 mmHg in reserpine-pretreated rats, and 86 ± 5 mmHg in phenoxybenzamine-pretreated 
rats. (a) Effects of tryptamine and analogues in control rats; (b) effects of pretreatments on pressor responses 
to tryptamine; (c) tryptamine-So and (d) tryptamine-'-Me. Vertical bars indicate S.e. mean. 
The external jugular vein was then exposed for a 
distance of 1 to 1.5 cm. A cannula of PE 50 tubing 
was inserted, attached to a 23 gauge needle and 
connected via a three-way stopcock to a 3 mI syringe 
containing a flushing solution of the heparin/saline 
solution used above, and a 1 ml syringe containing the 
test drug. 
Testing method 
Test drugs were made up in the heparin/saline solution 
such that a volume of 0.1 mI contained a specific dose 
of the drug. Each of four animals was given four doses 
of drug four times, in a Latin square design, over a 
period of 1-2 hours. In addition, a Latin square was 
designed based on the sequence of the four cycles, so 
that each animal received a different sequence of 
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cycles. Reserpine (10 mg/kg i.p.) was given 22-26 h 
before testing. Phenoxybenzamine (5 mg/kg i.p.) was 
given 1.5 h before testing. 
Results 
In control animals tryptamine caused a significant 
pr\~ssor response over a range of 125-toOO v.g/kg. 
Both of the analogues also showed a pressor effect; 
tryptamine-S was less potent than tryptamine, while 
tryptamine-I-Me had a similar potency to tryptamine 
(Figure I a). Transitory respiratory paralysis was seen 
occasionally after 500 v.g/kg and usually after 
1000 v.g/kg of tryptamine and tryptamine-So 
Tryptamine-I-Me was more toxic; 1000 and 
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500llg/kg invariably caused a fatal cessation of 
respiration. 
Pretreatment of rats with a single dose of reserpine 
reduced the pressor effects of typtamine and 
trypamine-S significantly (Figures I b, c). Respiratory 
paralysis of brief duration occurred after the higher 
doses with both tryptamine and tryptamine-So In 
contrast, the pressor respohses to the doses of 
tryptamine-I-Me given to reserpine-treated animals, 
62.5, 125 and 250Ilg/kg, were greater in the same 
doses than in normal animals (Figure Ic). 
In animals pretreated with phenoxybenzamine, the 
pressor effects of all three compounds were 
significantly reduced when compared to their actions 
in control animals (Figures 1 b, c, d). Of particular 
interest is the fact that respiratory paralysis due to the 
pressor agents was a rare occurrence after phenoxy-
benzamine pretreatment. 
Discussion 
The scientific literature contains a variety of references 
to the existence of tryptamine receptors (Erspamer, 
1954). However, it is difficult to extrapolate from 
responses of isolated preparations to those of the 
vasculature in the intact animal. While tryptamine 
may interact with its own specific peripheral 
receptor(s) to increase blood pressure, one cannot rule 
out the possibility of a centrally-mediated component. 
Since the dose-response curves were not parallel the 
relative potencies of the analogues depended to some 
extent on the dose. Tryptamine-S was less potent than. 
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INTERACTIONS OF CAFFEINE \VITH VARIOUS 
AMPHETAMINES ON RAT FOOD CONSUMPTION 
AND AVOIDANCE RESPONDING* 
R. H. Cox, JR.t and R. P. MAICKEL 
Department of Pharmacology, Medical Sciences Program, Indiana University, Blooming
ton. IN 47401 
(Accepted 29 April 1976) 
Summary-Pretreatment of rats with caffeine potentiated the actions of the p-chloro-
and p-methyl 
analogues of amphetamine and benzphetamine as depressants of deprivation-induced food 
consumption, 
although no such effects were seen with the unsubstituted compounds. Similar caffeine 
pretreatment 
completely antagonized the stimulant effect of amphetamine and p-chloroamphetamine o
n continuous 
avoidance responding. In contrast, combined dosage of caffeine potentiated the actions
 of p-methyl-
amphetamine, or benzphetamine, drugs normally showing decreased avoidance respond
ing. Caffeine, 
in comhin'ation with benzphetamine. caused a slight decrease in avoidance responding. 
Caffeine is generally considered to be a stimulant 
drug. with actions not too dissimilar in man from 
those of the amphetamines (Weiss and Laties, 1962). 
Since caffeine is chemically a member of the structural 
series known as xanthines, it also has the ability to 
inhibit the phosphodiesterase enzyme known to be 
responsible for the degradation of cyclic 3'5'-adeno-
sine monophosphate (cyclic AMP) (Robison, Butcher 
and Sutherland 1971a; Robison, Nahas and Triner, 
1971b). A previous report from this laboratory (Cox 
and Maickel. 1972) compared the effects of a variety 
of phenylethylamines on deprivation-induced food 
consumption and continuous avoidance responding 
in rats, Substitution of a chlorine atom in the para-
position of amphetamine increased the anorexigenic 
potency with little effect on avoidance responding. A 
p-methyl group rl!duced anorexigenic potency and 
changed the effects on avoidance responding from 
stimulant to depressant. Substitution of either a 
chlorine or methyl group in the para-position of benz-
phetamine reduced the anorexigenic potency and con-
ferred significant depressant activity on the com-
pound. Thus. it secmed of interest to examine the 
effects of the com hi nation of caffeine and several 
amphetamines on the dual test system of deprivation-
induced fooJ consumption and continuolls avoidance 
responding. 
"'ATERIALS A:">:O METHODS 
AlI experiments were performed using adult, male 
Sprague-Dawley rats (Hormone Assay Lahoratories, 
Chicago) weighing 250-300 g and maintained on a 
diet of Purina laboratory chow and tap water ad lib. 
for at least 10 days prior to the beginning of exper-
• Supported in pari by NASA grant NGL 15-003-117. 
t Present address: l\·lead Johnson Re,earch Center. 
Evans\ i1le. IN 47721. 
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imental use. The behavioural methods and statistical 
procedures used were identical to those previously 
reported (Cox and Maickel, )972). 
Free:feedin9 
The rats were housed in individual metabolism 
cages (20.3 x 24.1 x 17.8 cm) with continuous access 
to water. Rats were deprived of food for 22 hr; thus, 
being required to consume their total daily ration in 
the remaining 2 hr. Dry Purina chow was available 
during this time in spill-proof jars and the rats were 
required to put their heads through a small hole in 
order to obtain the food. This feeding schedule was 
used for the duration of a particular experiment (8-10 
weeks). The establishment of a consistent day-to-day 
intake (15-20 g) took 10-14 days, during which time 
the rats lost 15-20~o of their initial body weight. After 
base-line weights were attained, the weight of the rats 
did nol change significantly for the duration of the 
experimental session. 
Groups of 24 rats were conditioned to the feeding 
schedule as described above. After base-line weights 
were established, the rats were divided into four 
groups of six rats each. Each group was tested with 
four doses of a single drug. All drug, were adminis-
tered by intraperitoneal injection in volumes of 0.1 
ml/IOO g of body weight. 30 min before the scheduled 
feeding time in order to allow sufficient time for onset 
of action of the drugs. Solutions of the drugs were 
prepared in distilled water in concentrations such that 
0.1 ml/IOO g of body weight resulted in the correct 
dose in terms of miIIigrams of free base per kilogram 
of body weight. 
Results were calculated in terms of percentage of 
control with each animal serving as its own control. 
The control value was the mean intake for the three 
sessions immediatel) prior to drug administration. 
Dose responses curves were determined with each 
data point repre~l!nting mean ± S.E.M. of five or six 
animals. 
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Experiments were carried out in four ho"cs 
\\ ith 
sides. back and top of metal and a Plexigla
s door 
to permit viewing of the subject. Each box had a grid 
floor 28.0 cm long and 26.7 em wide with 1.0
 cm 
grids placed 2.0 cm aparl(centre to centre) for delher-
ing shock to the feet and was equipped wi
th two 
levers on the wall at one end. mounted 7.6 cm 
above 
the floor and 14.0 cm aparllcentre to centre). Pressing 
the lever near the front wall postponed shock 
(avoid-
ance response); pressing the lever ncar the back wall 
terminated the shock (escape response). Shock (350 
V and 0.6 mA short-circuit current provided 
by a 
Grason-Stadler E-I064 GS shock generator) was deli-
vered to the grids. walls and levers via a
 shock 
scrambler circuit. The boxes were enclosed i
n insu-
lated shells to isolate them from external visual
 stimu-
li. Extraneous auditory stimuli were masked b
y con-
tinuous 'white' noise in each box and in the
 room. 
Programming and recording of experiment
s were 
accomplished by automatic switching and tim
ing cir-
cuit~, cumulative recorders and electrical impulse
 
counters. 
The response-shock interval was 40 sec: shock 
onset was delayed for 40 sec each time; the rat 
pressed 
the avoidance lever when the shock was n
ot on. 
Whenever the time since the last avoidance re
sponse 
exceeded 40 !iec. shock came on and remained
 on 
until the rat pressed the escape lever or un
til the 
shock terminated automatically after 3 sec. 
The 
shock-shock interval was 20 sec: after a shock fu
rther 
shocks were presented at 20-sec intervals un
til the 
rat once again pressed the avoidance lever, wh
en the 
shock was not ongoing, to return to the re
sponse-
shock interval. 
Individual rats were trained and tested at five
-day 
intervals at the same time of day and in th
e same 
experimental box. The duration of each sessi
on was 
4.5 hr with the initial 30 min serving as a 'wa
rm-up' 
period. Approximately 30% of the rats were dis
carded 
because they failed to acquire the appropri
ate re-
sponses; i.e. eSC:lpe anti avoidance by the thi
rd ses-
sion. The performance of the remaining ra
ts was 
stable enough for drug testing after six sessions
, which 
included two saline treatment sessions. Bas
e lines 
were considered stable when the avoidance ra
te was 
consistent (160 ± 30 responsesjhr) for each animal 
over the period t == 1 hr to t :=: 3 hr of three consec
u-
tive sessions. All drugs were administered by
 intra-
peritoneal injection, in solutions as described above, 
immediately following the 30 min 'warm-up' 
period. 
Dose-response curves were determined; each c
urve 
was based on four rats with each data point
 repre-
senting mean ± S.E.M. of four or five replic
ations. 
The dose for each rat on a particular sessio
n was 
dictated by a balanced 4 )( 5 Latin square. With this 
technique. each rat received each dose of th
e drug 
in a different sequence. As a result, carryover
 effects 
could be determined if they e)(isted. The results were 
calculated as percentage of control avoidan
ce rate 
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with each animal serving a~ it~ own control. The co
n-
trol avoidance rate was the mean of the avo
idance 
rates for the three sessions immediately prior
 to the 
drug administration. The period of time select
ed was 
that equivalent to the time in the free-fceding
 situa-
tion (i.e. 30 min-2.S hr after drugl. 
Statistical met/IUds 
With the determined data points. linear dose
-res-
ponse curves were fitted for each drug, in bo
th the 
free-feeding and the continuous avoidance sit
uation, 
by the method of least square:.. 
In order to compare the various drugs. a resp
onse 
-dose 50 (RDso) has been estimated for each drug. 
This is the estimated dose of a particular drug
 which 
would be required to produce a 50% decrease in
 food 
intake or a 50~o change in avoidance rate. The more 
familiar term is the effective dose 50 (ED so) which 
is an estimate of the dose which is effective i
n 50% 
of the animals. The EDso l'~tjmate is based on quan-
tal data and is therefore amenable to statistical
 mani-
pulations. However, the RDso estimate is ba
sed on 
a graded response and cannot be compared d
irectly 
to determine significant differences. However, 
it does 
permit comparison of the relative potency 
of the 
drugs being studied. 
Caffeine (free base) was dissolved in 1.0 M aqueous 
solutions of sodium benLOate (both obtained from 
commercial suppliers and of reagent grade) such that 
injections of 0.1 mJ of the resulting solution per 100 
g body weight resulted in the appropriate d
ose in 
mgfkg. The effect of caffeine on food intake was
 deter-
mined by administering the drug intraperitonea
lly, 30 
min prior to the point of food access. In th
e con-
tinuous avoidance situation, caffeine was ad
minis-
tered immediately after the 30 min 'warm-up' 
period. 
RESULTS 
Effects of caffeille 011 food intake and avoidance res-
ponding 
The data obtained on food intake with dose
s of 
caffeine over'the range 12-108 mgfkg are pr
esented 
in Figure lA. As can be seen, caffeine had no 
signifi-
cant effect on food intake at doses Jess than 60 mg
fkg; 
above this dose, a rapid decrement in food con
sump-
tion was observed. In the continuous avoidance
 situa-
tion, no evidence for stimulation (in the form of in-
creased avoidance responding) was seen at intraperi-
toneal doses of caffeine as low as 8 mgikg (Fig. 1 B). 
In fact, doses of less than 16 mgfkg signif
icantly 
reduced the rate of avoidance responding in a
 dose-
dependent manner. This effect was not accom
panied 
by decreased escape responding or gross over
t seda-
tion as would be expected for a typical dep
ressant 
drug. 
Effects of caffei/le pretreatmel1! 0/1 a/lorectic actio/J of 
ampltelamines 
An intraperitoneal dose of caffeine of 4S mg/kg
 was 
chosen as the interaction dose since it had no 
signifi-
t 
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Fig. 1. Dose-response data for caffeine on food consl)mption (A) and avoidance responding (B) test 
systems. Each point is the mean value of 5-6 rats treated as described in the text; vertical bars
 are 
S.E.M. Lines drawn are those obtained from linear regression analysis. 
cant action on food consumption while causing a sig-
nificant reduction (approx. 50%) in avoidance res-
ponding. This dose was administered to groups of 
rats 60 min prior to exposure to food in the consum-
matory system previously described (Cox and 
Maickel. 1972). The amphetamines were given 30 min 
after the caffeine at 3 dose levels, in the ratio 11:2n:411. 
This permitted comparison with noncaffeine-pre-
treated animals over a similar dose-response range. 
The results obtained. presented in terms of RDso 
values and slopes of the dose-response curves, are 
shown in Table 1. For both amphetamine and benz-
phetamine, caffeine pretreatment had no significant 
effect on anorectic activity. However, in the case of 
all four para-substituted compounds. the caffeine pre-
treatment produced a significant potentiation of anor-
ectic activity. Pretreatment with a dose of caffeine (9 
mgjkg, i.p.) that was ineffective on both food con-
sumption and avoidance responding had no effects 
on the actions of a subsequent dose of any of the 
agents. Pretreatment with intraperitoneal doses of caf-
feine larger than 45 mgjkg could not be tested due 
to obvious signs of toxicity. 
Effects of caffeine p"elrealmeni on (j[loidance respond-
ing action of ampllelamines 
Pretreatment of rats with a dose of 45 mgjkg of 
caffeine prior to administration of the amphetamines 
was also tested on continuous avoidance responding. 
This dose of caffeine alone would cause an approxi-
mately 50~o reduction in the rate of avoidance res-
ponding (see Fig. 1). The results obtained with the 
drug combinations are shown in Table 2. These 
results are more complex to interpret than the anorec-
tic data, since the slopes change significantly for all 
of the compounds. Both amphetamine and its 
p-chloro analogue increased the rate of avoidance res-
ponding, and these actions were completely anta-
gonized by caffeine pretreatment. In contrast, p-meth-
ylamphetamine caused a decreased rate of avoidance 
responding, all effect that was slightly potentiated by 
caffeine. 
Table 1. Effects of caffeine pretreatment on anorectic action of amphetamines 
Treatment 
Amphetamine 
Amphetamine + Caffeine 
p-Chloroamphetamine 
p-Chloroamphetamine + Caffeine 
p-Methylamphelamine 
p-Methylamphetamine + Caffeine 
Benzphetamine 
Benzphetamine + Caffeine 
p-Chlorobcnzphetamine 
p-Chlorobenzphetamine + Caffeine 
p-Methylbcnzphetamine 
p-Methylbenzphetamine + Caffeine 
6 
6 
6 
6 
5 
6 
6 
6 
5 
6 
6 
5 
RD,o (95% C.L.) 
(mg/kg) 
1.9 (1.7-2.0) 
1.4 (1.0-2.0) 
1.5 (1.3-1.7) 
0.6 (0.4-0.8)t 
8.8 (7.3-10.6) 
2.7 (2.2-3.3)· 
12.5 (10.8-13.9) 
12.2 (6.7-18.2) 
19.7(16.0-23.7) 
3.4 (2.8-3.9)· 
27.8 (19.4-39.7) 
15.3 (10.8-21.8)* 
Slope + S.E. 
-84 ± 6 
-103±23 
-178 ± 26 
-93 ± 23 
-111 ± 16 
-125 ± 20 
-103 ± 8 
-93 ± 27 
-138±20 
-103±12 
-\06 ± 22 
-85 ± 13 
* Caffeine pretreatment significantly different from no pretreatment (P < 0.05) and slopes 
are parallel. 
t Slopes of drug and drug + caffeine arc not parallel. Student ,-comparison of all three 
doses with and without caffeine pretreatment were significant (P < 0.05). 
Drugs "'ere admini~tered as indicated in the text. RD50 values, 95% confidence limits 
(eL.1 and slopes ± S.E. ",ere determined as described by Cox and Maickel (1972). 
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Tabk 2. En'eet~ of cafTl:in<: pretreatment lll1 aHlidanec responding action of amphetaJ1lllw~ 
RDso (95~~ C.L.) 
Treatment n (mg/kg) Slope ± S.E. 
Amphetamine 5 0.8 (0.J-2.31 +232:t li2 
Amphetamine + Caffeine 5 32.5 (27.2-37.7) 
-33 ± 12 
r-Chluroamphetamine 5 0.8 10.7-0.9) +186 ± 41 
r-Chloroamphct:unine + Caffeine 5 20.6 (17.7-23.3) -9 ± 5 
r-Methylamphetamine 5 2.4 (1.~.5) 123 ± 39 
r-Mcthylamphetamine + Caffeine 4 1.8 (1.J-2.9) -66 ± 20 
Benzphctamine 5 >32.0 0 
Benzphetamine + Caffeine 4 6.2 (5.1-7.4) +58 ± 17 
r-Chlorobcnzphctamine 5 25.1 (22.J-28.1) -246 ± 35 
r-Chlorobenzphetamine + Caffeine 4 16.0 (11.1-21.1) -17 ± 11 
r-Methylbenzphetamine 4 38.5 (20.3-72.91 -70 ± 15 
l'-Methylbenzphetamine + Caffeine 5 2.4 (1.7-3.0) -17 ± 9 
Drugs were administered as indicated in the tex\. RDso values. 95~·o confidence limits 
(CL.). and slopes ± S.E. were determined as described by Cox and Maickel (1972) 
In the bcnzphctamine series. the parent compound 
had no effect on the rate of avoidance responding 
at doses up to 32 mg,'kg. Pretreatment with caffeine 
caused a decrement in avoidance response rate: how-
ever, the positive slope creates the possibility for two 
RDso values. one of 6.2 mg/kg for a SO~o decrease 
in responding and a theoretical additional one of 
326 mglkg for a 50~(I increase in responding. Both 
p-chlorobcnzphetamine and p-methylbenzphetamine 
depressed a\'oidance responding rates themselves: 
these effects were potentiated by the caffeine pretreat-
ment. As with the food consumption studies, attempts 
to utilize a lower dose of caffeine (9 mg/kg ) were 
ineffective. Similarly. the combination of ampheta-
mines with doses of caffeine of 60 mgjkg 01 ;.lgher 
caused severe toxicity and some deaths. 
D1SCl'SSION 
The mecha!,1ism(~') by which phenylethylamines 
such as amphetamine and bcnzphetamine produce 
anorexia in man and animals has been the basis for 
an extensive amount of research in recent years 
(Costa and Garattini, 1970). In particular, much 
emphasis has been placed ,on the possible role of 
brain norepinephrine in control of feeding behaviour 
(Morgane, 1969) and the likelihood that ampheta-
mines may act by interacting with brain noradrener-
'gic function (Modell, 1960). In addition. any consider-
ation of biochemical phenomena related to catechola-
mines must consider the possibility that the adenyl 
cyclase-cyclic AMP system is somehow involved 
(Robison et al., 197111, b). 
With this background in mind, the present paper 
teports on the interactions of caffeine and several 
phenylethylamines with deprivation-induced food 
consumption and continuous avoidance responding. 
The former may be consideted as a measure of anore-
tic activity (Cox and Maickel, 1972: Heise. 1964), and 
the latter as a measure of central stimulatory and 
depressant acti\'ity (Heise and Boff, 1962). 
Caffeine itself is anoretic. although the doses 
required are so large that the action of this drug may 
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be considered as related, not to a specific depression 
of appetite, but, to a general depression of activity. 
This conclusion is supported by the data in Figure 
1 which show that intraperitoneal doses of caffeine 
greater than 12 mgjkg caused a significant reduction 
in avoidance responding. This depressant action on 
responding resembles that of chlorpromazine rather 
than a barbiturate. since there is no concurrent im-
pairment of escape responding (Heise and Boff. 1962). 
Caffeine has also been shown to have a depressant 
effect. alone or in combination with ethanol, on other 
behavioural test systems (Alstot\ and Forney, 1971). 
The two parent compounds chosen for this study 
were amphetamine and benzphetamine (N-methyl-N-
benzylamphetamine), both of which are clinically used 
as anoretic agents (Costa and Garattini. 197m. In 
addition, the p-chloro and p-methyl analogues of 
these compounds were also studied. The results 
obtained in the deprivation-induced food consump-
tion test are clear cut. Caffeine pretreatment, at a dose 
which was, by itself, ineffective was without effect on 
the activity of the parent compounds while markedly 
potentiating the effects of the para-substituted ana-
logues (Table 1). 
The actions of amphetamine and its p-chloro ana-
logue, normally stimulants of avoidance responding, 
were completely antagonized by caffeine pretreat-
ment, while action of the p-methyl analogue, normally 
a depressant of avoidance responding, was slightly 
potentiated (Table 2). Benzphetamine, normally with-
out efft:cl on avoidance responding at doses up to 
24 mgjkg. showed significant depression of avoidance 
responding at low doses « 16 mgjkg) in caffeine pre-
treated animals. Extrapolation of the dose-response 
line would suggest that doses greater than 200 mg,lkg 
would cause increased avoidance responding. A pre-
liminary test of 45 mgjkg of caffeine plus 72 mgjkg 
of benzphetamine led to severe toxicity and death of 
2 out of 6 animals. The p-chloro and p-methyl ana-
logues of benzphetamine are both depressants of 
avoidance responding of themselves: caffeine pretreat-
ment significantly potentiated this action {Table 21. 
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The results are both interesting and compli~ated. 
The lack of effects of ~arreine on the non-para-5uhsli-
tuted amphetamine and benzphetamine (in terms of 
:!ppetite depression I is in sharp contrast to the actions 
of caffeine 011 all four para-substituted compounds 
where the dose-re5ponse curve is shifted markedly to 
the left. The effects on continuous avoidance respond-
ing suggest a preponderance of the caffeine effect to 
negate the potent stimulatory effect of amphetamine. 
Alternatively. one may consider that amphetamine 
was able to partially o\'ercome the depressant actions 
of caffeine. Attempts to confirm either of these 
hypotheses with other doses of caffeine were unsuc-
cessful. This dissociation of avoidance and anorectic 
actions lends further credence to the hypothesis that 
they are under separate controlling systems. The spe-
cific differences between the amphetamine (primary 
amine) series and the benzphetamine (tertiary amine) 
series will obviously require additional study. In the 
case of the para-substituted compounds. the marked 
potentiation of their anorectic action by caffeine sug-
gests a possible role for cyclic AMP and such a possi-
bility also deserves further study. 
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SU~1MARY 
Six tricyclic antidepressant drugs, representing both secondary 
and tertiary amines and four different ring systems, were elamined for 
their effects on deprivation-induceo fluid consumption by rats in a 
standardized test system. All compcunds reduced fluid consumption with 
a potency ran ki ng of: des i prami ne > amitri pty 1 i ne' dOlep in' nortri p-
tyline' imipramine' protriptyline. In a similar test situation, 
pretreatment with PCPA markedly reduced fluid consumption at 24 hours; 
fluid consumption levels had.not returned to normal by 15 days after 
dosage. 
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Hf ;WDUCTlON 
The tricyclic antidepressant dr~gs have become very popular clinical 
agents since their introduction into therapeutic use some twenty years ago. 
Their clinical activity has often been attributed to interactions with central 
noradrenergic mechanisms, since they potentiate the peripheral response to 
exogenous catecholamines (5igg, et ~, 1963) and sympathetic nerve stimulation 
(Thoenen, et ~,1964). In addition, the tricyclic compounds have been shoym 
to inhibit the uptake of exogenously administered NE (Hertting, ~~, 1961). 
In this regard, Lahti and Maickel (1971) have shown that this effect is also 
shown by several phenothiazine tra~~uilizers and correlates with chemical 
stru~ture rather than pharmacological activity. 
A variety of behavioral actions have been shown to occur with tricyclic 
antidepressants. For example, Stein and Seifter (1961) showed that imipramine 
increased, in both magnitude and duration, the methamphetamine-induced increase 
in the rate of response of rats working for rewarding hypothalmic stimulation. 
In this test system, chlorpromazine had an opposite effect. Previous studies 
from this laboratory had demonstrated that phenothiazine tranquilizers 
(Maickel, et ~, 1968a), as well as cholinergic blockers and cholinergic 
stimulants (Gerald and Maickel, 1969) were effective in reducing the volume of 
floid consumed by deprived rats.' Since some of the widely observed clinical 
side effects-of the tricyclic antidepressants represent anticholinergic actions 
such as blurred Vision, dry mouth, and urinary retention, it seemed'of interest 
to test a variety of these agents for their effects on fluid consumption. In 
addition, the pO'ss;bility of , examining the role of biogenic amines in the 
ac.tions of the tricycl ic antidepressants by using drug interaction studies 
also seemed a feasible route for experimental design. 
i 
1 
j 
i 
~'~~u ............ ------~-------------------------------------i :i 
~1ATER 1/\'. SAND METHODS 
Adult (300-350 g) male, Sprague-Dawley rats (Murphy Breeding Laboratories, 
Plainfield, Indiana) were used in all experiments. The animals were maintained 
on tap water and Purina Rat Chow ad lib, for at least 1 week after arrival in 
the laboratory. All solutions for injection were made in glass distilled 
water such that a dose. volume of 0.1 ml per 100 g body \-Ieight contained the 
desired dose; all injections were given intraperitoneally, 15 min prior to 
placing the animals in the drinking cages. 
The procedures used to measure deprivation-induced water consumption 
were basically those of Gerald and i~aickel (1969). Rats I'Jere placed in 
cages, 7 x 7 x 14 inches, identical to the home cages of the animals. The 
cages were suspended in individual compartments of a sound-proofed box with 
uniform fluorescent lighting. Constant circulation of air by blo'lJers.main-
tained uniform temperature in the compartments; the noise level of bloweri 
served as a "white noise ll • Each ca;e contained a (kinking tube connected 
to an external 50 ml buret filled \-Jith distilled water at the start of each 
test run and stoppered. As the animal consumed water, the change in volume 
was measured visuallY to the nearest 0.1 ml. The front door of each compart-
. ment was equipped with an eye-piece 1ense to permit visual observations of 
the rats without disturbing their behavioral performance. For at least 1 
week prior to testing drug effects, rats were deprived of water daily for 
23 hr prior to testing,·then placed in the IIdrinking cages" and allowed to 
drink for 1 hr .. Food was available ad lib. ill the home cages but was not 
available in the drinking cages. 
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'Drug trials were started only ~fter the animals demonstrated stable 
baselines (less than 5% daily variat~on) of water intake. The schedule 
for drug studies was arranged so t~~~ the rats were run daily, with drugs • 
administered every fifth day, and placebo doses on the intervening days. 
Water intake was recorded at 15, 30 and 60 min of the consummatory sessions; 
the greatest proportion of drinking occurred in the first 15 min in all' 
cases. 
Brain levels of serotonin (5HT) and norepinephrine (NE) were determined 
in whole brain as reported by Maickel, et.!l (.l968b). p-Chlorophenyla1anine 
,(PCPA) and a-methyltryosine (aMT) were purchased from Regis Chemical Company. 
G~oups of 8 rats were run in each system; an n of < 8 rat~ indicates 
that a value or values was discardeo because of equipment malfunction. All 
data are reported as means ± S.D. Statistical comparisons were carried out 
by the correlated t-test for paired scores. The day prior to each drug day 
was used as the pre-drug value for :hat drug run. Each anima' served as 
its own contro'l; per cent of pre-drug values are the mean of values calculated 
for each animal. Dose-response curves Were determi ned 'by 1 i near regress 1 on 
. analysis and s16pes and RD50 values were calculated as described by Cox 
(1970) and Maickel and Webb (1972). 
RESULTS 
Effects of Tricyclic Compounds on Deprivation-Induced Fluid Consumption. 
The results obtained from dose-response studies of single acute dosages of six 
. tricY~li~ antidepressants are presented in Table 1. With t~e exception of 
the lowest doses of nortriptyline and protripty1ine. all doses of each drug 
tested sig~ificantly decreased the volume ·of fluid consumed by the deprived 
rats. When the data weresu~jected to linear regression analysis, semilo-
garithmic plots yielded straight 1ines with slope and Rd50 values as presented 
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in Table 2; several striking relat~~1ships ca~ be seen. First of all, 
although the potency ranking for the RD50 values shows a tenfold range 
(from 31.6 ]Jmoles/kg for desipramin,e to 3Q.O.3 ].:moles/kg for imipramine) 
the compounds fall into two groups. Four of the drugs (desipramine, amitrip-
tyline, doxepin, nortriptyline) have molar RD50 values in the'range of 31.6 
to 59.7. In contrast, the molar RD~G values for protr~ptyline and imipramine 
are much higher, 158.2 and 300.3 ~mo1es/kg, respectively. Secondly, when 
the slopes of the dose-response cur~2S are compared, the compounds fall 
~nto three distinct groups: imipra~ine and protriptyline (the most shallow), 
amitriptyline and desimpramine (inter~ediate), and doxepin and nortriptjline 
(the steepest slopes). Tests for ~10pe parallelism indicate that the 
, groups are significantly different from each other although the curves 
within a group are not significantly non-parallel. 
In addition to these findings, Jle other aspect should be mentioned. 
On the post-drug day, a significant carryover effect, i.e., a reduction in 
fluid consumption, was seen with desimpramine (at the 20 mg/k~ dose} and with 
protriptyline (at the 20 and 30 mg/kg doses). 
Effects of aMT Pretreatment on A:tions of Protriptyline. 
In order to assesg the effects of alterations in brain norepinephrine 
(NE) on ~he actions of protriptyline, rats were pretreated with aMT (150 
mg/kg, in oil ,i.p. at 12 hour intervals) with the last dose 6 hrs prior to 
testing, as reported by Miller, et .!!l (1970). This regimen reduced brain 
NEvalues by 66%; the animals also showed a significantly reduced fluid 
intake 'as compared to pre-drug baseline (Table 3). Administration of pro-
triptylioe had no effects on brain NE or 5HT levels. The reduction in 
fluid consumption in. aMT and protriptyline rats was approximately additive 
for the eff~cts of the individual drugs. 
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Effects of PCPA Pretreatment C" i\ctions of Pl'otriptyline 
The situation with PQPA was more complex, since Miller and Maickel 
(l96~) have shown that differential effects on brain 5HT and NE aith respect 
to time after dosage. Rats were treated with PCPA (400 mg/kg, i.p., in 
0il) as described by Miller and Maictel (1969) then dosed "lith protriptyline 
on days 1 ,8, and 15. The results ~Table 4) show that on day 1 there was 
a significant reduction in fluid consumption; this response was essentially 
normal on days 8 and 15 after PCPA treatment. The effects of protriptyline 
in the PCPA-pretreated animals were not significantly different from those 
seen in controls. On day l, this ~sans that the effect of protriptyline 
were antagonized by the PCPA. The effects of PCPA on brain biogenic amines 
were similar to those previously reported, namely a reduction in both 5HT 
and NE on day l, a reduction in 5HT only on day 8, and a return of both 
amin.es to normal values by da..}' 15. 
DISCUSSION 
The results presented herein 12~d further credence to the conclusion 
that the effects of drugs on deprivation-induced fluid consumption refl~ct 
the complexity of the thirst-consumption system. Certainly, the data 
presented in Tables land 2 clearl) demonstrate that all of the tricyclic 
antidepr~ssant drugs tested are able to produce a dose-dependent decrement 
in the volume of water consumed by deprived rats. Several facets of the 
data, however are difficult to explain on the basis of known pharmacological 
actions df the drugs. For example, the dose-response curves for imipramine 
and protriptyline are parallel to each other; the dose-response curves for 
amitriptyline and desipramine, and for doxepin and nortriptyline represent 
similar parallel pairs. 
The lack of overall parallelism makes it difficult to draw potency 
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comparisons vlithin the series as hil"; been done for cholinergic blockers by 
Gerald and r~aickel (1969) or antihistamines (Gerald and Maickel, 1972). 
Nonetheless, the R050 values preserted in Table 2 indicate that imipramine 
and protriptyline are considerably 1ess potent than the other four compounds 
tested. In this regard, it should De noted that, in these acute studies, no 
correlation could be observed betweEl the three compounds that are tertiary 
amines (amitriptyline, doxepin, imipramine) or the three that are secondary 
amines '(desipramine, nortriptyline, pr'otriptyline) in terms of slope or ROSO' 
Pretreatment of rats with PCPA caused a time-differential alteration 
of brain biogenic amines similar tc that reported by ~1iller and Maickel 
(1969), that is, a significant reduction of both brain 5HT and brain NE 
at one day after administration of PCPA, a reduction only of brain 5HT at 
eight days, and normal brain levels ~f both amines at 15 days after PCP~. 
Tests of deprivation-induced fluid consumption over this period showed a 
marked reduction (to 58.9% of pre-drug levels) in fluid intake on 'the first 
day post PCPA, follm'Jed by a return to levels approaching normal (80-90% 
of pre-drug) by the third day post PCPA and a plateau effect at these levels 
through the 17th day (Table 4). Administration of protriptyline (20 mg/kg, 
i.p.) on days 1, 8, or15 after PCPA evoked no additional reductions in 
fluid consumption; however, the values observed were not significantly 
differ~nt from protriptyl~ne alone. 
Pre,treatment of animal s with c,MT led to a reduction in brain NE similar 
to that reported by Miller, et ~ (1970), and a concommitant reduction in 
deprivation-induced fluid consumption (Table 3). Administration of protrip-
tyline (20 mg/kg, i.p.) to these animals caused a further reduction in the 
volume of fluid that was significant]y greater than that seen ~/ith either 
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nt-iT or protriptyline alone. In fal.:., the reduction observed with the 
drug combination seemed to approxin8te what might be expected on the basis 
of a simple additive action of the two compounds. 
Based on these studies, one may infer that the actions of protriptyl~ne 
on deprivation-induced fluid consumption are not greatly influenced by 
" modest alterations in brain NE caused by ~MT. The results with PCPA are 
" difficult to interpret. It does, hGI'I~ver, seem that the PCPA effect is 
manifested by a reduction in the ability of protriptyline to reduce fluid 
consumption on day 1, that is, when both brain 5HT and brain NE are decreased. 
Several recent reviews of the general area of thirst and fluid con-
sumption have discussed the overall problems of drug effects on these systems 
(Epstein, et ~,1973; Fitzsimons, 1972). If one assumes that the deprivation 
schedule used has produced an extrace11ular dehydration with a consequent 
drinking elicited by the hypertensi'/e response produced by th!2 angiotensin 
system, subsequent administration of agents elevating blood pressure might 
be expect~d to increase fluid consumption, while hypotensive agents should 
cause a reduction in consumption. This might explain the "reduced consumption 
cau~ed by the aMT pretreatment, since lowered.body NE stores should result 
in a modest hypotension. However, the effects of the tricyclic antidepressants 
should be hypertensive; nevertheless, these compounds also depress fluid 
consumption. The effects of PCPA at 1 day after dosage could also reflect 
decreased central and peripheral NE and a consequent hypotensive state. 
By 8 and 15 days, this would be expected to disappear as Nt levels return 
to normal va"lues. The inabi1ity to find simple explanations for the actions 
of the tricyc1ic antidepressants alone and their interactions with aMT and 
PCPA would seem to confirm thecompleiity of thirst mechanism(s), especially 
in terms of their neural control, as concluded by Fitzsimons (1972). 
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TI~8LE 1 
. 4~. Effects of Tricyclic Antidepressants on Deprivation-Induced Fluid Consumption. 
Animals were treated as described in Materials and Methods section; 
drug was administered 15 min prior to start of drinking session. 
Results are expressed as mean i S.D. of the values obtained. Statis-
tical comparisons were made by the correlated t-test for paired scores; 
significant differences from the corresponding pre-drug values 
(p < 0.05) are indicated by*. 
Volume Consumed 
Drug N Dose Pre-dru 9_ Drug. % of Pre-drug 
mg/kg m1 ml 
Amitriptyline 8 5 20.1 ± 2. "1 14.9 !: 3.0 74.2 ± 15.6* 
"15 10 22.6 ± 3.4 13.9:L 3.8 60.5 ± 17.9* 
16 20 20.6 ± 4.4 7. , ± 5.1 36.7 ± 27.' * 
Desipramine 16 5 21.9 :: 3.0 13. 1 ± 4.9 66.2 ± 18.5* 
16 10 21.0 ± 2.9 8.7 ± 4.1 40.8 :: 16.8* 
8 20 20.3 .... 2.7 5.8 ± 2.0 29.1 ± 11.8* .. 
Doxepin 8 5 19.2 ,. 3.0 15.2 ± 3.5 80.8 ± 17.0* 
8 10 22.7 ± 3.8 16.02:4.1 70.3 :: 10.6* 
20 22.0 3.2 10.8 ± 5.1 48.3 ± 17.1* 8 ± 
8 30 2l. 2 ± 3.0 4.7 ± 3.5 2l.7 ± 14.7* 
Imipramine 16 5 21.1 ± 3.8 17.6 ± 4.3 83.8 ± 14.4* 
15 10 19.1 ± 3.4 13. 1 :: 3.1 72.7 ± 11.3* 
8 20 19.2 ± 3.9 12.0 ± 2.1 62.4 ± 11.7* 
Nortriptyline 16 5 20.5 ± 2.1 18.0 ± 3.6 88.7 ± 11.3 
16 10 21. 1 ± 3.8 14.8 ± 2.4 70.7 ± 11.0* 
8 20 22.4 ± 4.3 7.9 ± 2.5 39.0 ± 16.2* 
Protripty1ine 8 5 18.8 ± 1.9 19.2 ± 3.1 102.1 ± 12.5 
8 10 19.2 ± 2.5 16.2 ± 1.8 84.1 ± 10.1* 
8 20 18.0 ± 4.4 12.8 ± 1.8 73.9 i 16.1* 
8 30 15.1 ± 4.6 10.5 :!: 2.3 69.5 ± 13.4* 
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fABLE 2 
Analysis of Dose-Response Effects of Tricyclic Antidepr,2ssants 
On Deprivation-Induced Fluid Consumption 
Slopes were determined' by linear regression analysis of 
the data presented in Table 1. RD50 values represent 
the dose estimated to cause a 50% reduction in fluid 
consumption and have been der~ved mathematically from 
the linear regression analysis. 
RD50 
Drug Slope mg/kg \lmo1es/kg 
Desipramine -61.6 8.4 31.6 
Amitriptyline -62.3 13.0 48.0 
Doxepin -78.3 15.5 55.6 
Nortriptyline -82.5 15.7 59.7 
Imipramine -35.5 44.3 158.2 
Protriptyline -41.6 79.0 300.3 
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TABLE 3 
Effects of a~1T on Act; on of Protr; ptyl ;ne on Deprivati on-Induced 
Fluid Consumption 
,.' 
Animals were pretreated with aMT as described in the text. Results are expressed as mean 
± S.D. of the values obtained. Statistical comparisons were made by the correlated t-test for 
paired scores; significant differences from the corresponding control values (p < .05) are indicated 
~ * Animals were killed at the termination of the drinking session for brain amine determinations. 
Volume Consumed Brain Amines 
Treatment I Treatment II N Pre-Drug Drug % of Pre-Drug, 5HT NE 
ml ± S.D. ml ± S.D. mean ~~ ± S.D. ugfg ug/g 
:·Iater Hater 8 21.7;~2.9 21.4~.2.1 97 .'h5. 5 0.10-l:.06 0,49±. O~ 
Hater Protriptyline S 19.3±3.6 13.1±1.5 67.6±13.3* 0.6S±.06 0.50±.04 (20 mg/kg) 
ZtMT vJater 6 20.S±2.0 16.1:.':2.7 77. O± 13.4* O. 7l:i. OS 0.24±.O5* 
:;MT Protriptyline 
(20 mg/kg) 
6 17.9±1.8 9. 2±3. 6 44.8±14.5* 0.69±.04 0.23±.05* 
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TABLE 4 
l,e Effects of aMT on Action of Protriptyline on Oeprivation-Indu,ced 
Fluid Consumption 
Animals Vlere pretreated with PCPA as described in the text. Results are expressed as mean ± 
S.D. of the values obtained. Statistical comparisons were made by the correlated t-test for paired 
scores; significant differences from the corresponding control values (p < .05) are indicated by *. 
Animals were killed at the tenmination of the drinking session for brain amine determinations. 
Treatment I 
Peanut oil 
Pean.lt oil 
PCPA-l 
PC?A-8 
PCPA-15 
PCPA-1 
PCPA-8 
PCPA-1S 
Volume Consumed 
Treatment II N Pre-Drug Drug 
l~ater 
Protriptyline 
(20 mg/kg) 
~later 
Water 
t-Jater 
Protriptyline 
(20 mg/kg) 
Protripty1ine 
(20 mg/kg) 
Protriptyline 
ml ± S.D. ml ± S.D. 
8 19.3·1.9 
8 19. 6±3. 1 
8 17.0±3.4 
8 19.9.t2.9 
8 20.2::.3.1 
6 14.3:1:3. 1 
6 20.8:::1.3 
6 22.T±3.S 
19.7.:2.7 
12. 8±2. 1 
13.1 ±2. 7 
19.2±2.5 
18.9±2.3 
9.1 ±2. 0 
13.5±5.1 
12.6±4.6 
% of Pre-Drug 
mean % i: S.D. 
1 01 . 2~: 1 2 . 0 
65.8:1"10.1* 
79.2±20.4* 
97.0.t10.4 
94.9:1"06.4 
66.7£19.7 
6S.3i24.8 
57.9±22.1* 
Brain Amines 
5HT 
ug/g 
NE 
ugTg 
0.71~.04 0.d8~.04 
0.73t.08 0.49~.07 
0~29±.05* 0.32t.06* 
0.37±.03* 0.47:::.08 
O.67±.07 0.Sl±.05 
0.30=.05 0.31:::.07* 
0.39±.04* 0.46~.06 
0.69±.08 0.47±.03 
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STRUCTURE-ACTIVITY RELATIONSHIPS IN COMPOUNDS 
ANAlAGOUS TO 5,6-DIHYDROXYTRVPTAMINE 
Roger P. Maickel, Talmage R. Bosin, Alan C. Donelson 
Section on Pharmacology 
Medical Sciences Program 
Indi ana University School of ~'edicine Bloomington, IN 47401 
Ernest Campaigne, Richard B. Rogers 
Department of Chemistry 
Indiana University 
Bloomington, I~ 47401 
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The disruption of normal neuronal transmission by interference 
with some aspect of neurotransmitter synthesis, uptake, storage, 
release, or metabolism is considered an important mode of drug action. 
Indeed, the use of drugs which block peripheral nervous transmission 
was indispensable in first establishing, then proving the very nature 
of neuromuscular transmission (1-3), as well as in the study of the 
autonomic nervous system (2,4). The method of blocking transmitter 
utilization has also been used in attempts to clarify the specific 
fUnctions of putative neurotransmitters in the brain, and to substan-
tiate hypotheses linking the effects of psychoactive drugs to their 
interactions with neurochemical systems (5,6) • 
Of greatest interest centrally have been the monoamines serotonin 
(5-HT) and norepinephrine (NE). Literally thousands of publications 
have covered their occurrence in nature; their distribution in various 
systems of vertebrate and invertebrate species; the nature of their 
nervous function; and the subcellular aspects of their utilization by 
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nerves (7-9). Their role, individually or together, in the neural 
processes underlying behavior remains controversial and largely unresolved 
(lO). Present-day monoamine research seeks to provide the final, direct 
evidence confirming the status of NE and 5-HT as brain neurotransmitters, 
a goal heavily dependent on technological advances; and to link directly 
the central function of monoamine-containing neurons to behavior. 
Hypotheses which emphasize the role of HE and 5-HT as neurotrans-
mitters in the normal function of the eNS are of two varieties: 
I. Those which attempt to show evidence of this role, i.e., fulfill 
criteria necessary for the complete recognition of the compounds as 
neurotransmitters; and II. Those which, assuming NE and 5-HT to be 
neurotransmitters, postulate aberrations in their metabolism or neuronal 
release mechanisms as causes for mental disorders or drug effects. 
The technique of selective depletion of central monoamines as 
a means by \,/hi~,:.their functional role in behavior may be studied preStJ\l-
ably has its origin in traditional biology. The surgical destruction 
or extirpation of an organ as a method of investigating its physiological 
si-gnificance in a body has been a mainstay in biological research. The 
practical laboratory difficulties associated with surgical denervation 
in an organ as complex as the central nervous system encouraged a shift 
to the use of chemical means of differentiating the roles of the neuro-
transmitters (ll). 
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In 1959, Senoh and co-workers (12-14) reported that the adminis-
tration of DA to rabbits resulted in the auto-oxidative and enzymatic 
formation of 6-hydroxydopamine (6~HDA).. The peripheral admini.stration 
,i 
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of 6-HDA in the mouse led initially to the discovery that the compound 
produced a long-lasting depletion of NE in the heart (15). Further 
studies showed that while 6-HDA had a lower EDSO than either reserpine 
or metaraminol, its NE-depleting effects lasted considerably longer 
than those of the other compounds tested (16). It was originally 
suggested that 6-HDA damaged amine storage sites (15,17); electron-
microscopic studies indicated that the long-term loss of NE resulted 
from the destruction of adrenergic nerve terminals (18) and concomitant 
loss of activity of NE-synthesizing enzymes was also found (19). 6-HDA's 
Si 
effects have been termed "chemical denervation" (20); the compound has 
been widely used in studies concerned with the synthesis, uptake, storage, 
and functional aspects of both peripheral and central catecholamines 
(21) • 
Follmling central administration of 6-HDA, long-lasting, selective 
decreases in catecholamine levels were observed without significant 
effect on 5-HT or GABA levels (19,22,23). Generally, behavior of 
animals given 6-HDA did not differ significantly from control (19,22,23). 
However, injections of 6-HDA into localized brain regions have been 
used to induce specific lesions of central monoamine neurons (24). 
Spontaneous rotational behavior was observed in rats with unilateral 
6-HDA lesions in the nigro-striatal DA system (25,26). Bilateral injection 
of 6-HDA inh'1 the lateral hypothalamus caused adipsia and aphagia, 
while animals lesioned in the SUbstantia nigra showed marked hyperactivity 
. 
with behavioral reversal after one week (27). 
In 1971; the apparent discovery of a "serotonergic 6-HDA" was 
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reported; intraventricular administration of 5,6-dihydroxytryptamine 
(5,6-DHT) resulted in the long-lasting depletion of brain 5-HT with 
only transient effects on the levels of DA and NE (28,29). The percent-
age loss of 5-HT and the dose-dependency of the effect varied in 
different brain regions. Subsequent fluorescent histochemical and electron-
microscopic studies revealed selective degeneration of indoleamine 
terminals and axons similar to the cytotoxic effects of 6-HOA on adrenergic 
neurons (30,31). The tendency of 5-HT leve1s to recover after the 
initial phase of depletion led to the discovery of axonal regenera~ion 
by the damaged serotonergic neurons (32,33). 
In contrast to 6-HDA, the intraventricular injection of 5,6-HDT 
caused dramatic behavioral changes (34). The acute disturbances have 
been described as "sedation during the first two hours after the injection 
(ether anesthesia), an increased irritability and hyper-reactivity against 
any type of sensory stimulation and bizarre social behavior (fighting 
in a stereotyped position and manner), and increased copulatory activity 
when kept in the same cage inbetween the 1st and 3rd day after 5,6-DHT. 1I 
(35) Frequent fighting episodes as well as increased muricidal behavior 
have been reported, and decreased foodconsump~t;on and loss of weight 
have also been observed. 
, I, 
Intraventricular injection of 5,6-DHT produced 
significant hypothermia thirty minutes after administration (36). 
I 
The advent of a selective neurotoxic agent such as 5~6-DHT opens 
I , 
. fresh avenues for the functional differeriti~tJon of central monoamines, 
and for possible discernment of their role in mediating behavior. The 
availability of such chemicals offers an alternative to the non-selective 
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destruction of brain regions with heterogeneous cell populations, e.g., 
by electrocoagulation or surgical lesioning. In addition, the functional 
significance of the depression of monoamine levels by selective synthesis 
inhibitors may be resolved through the use of cytotoxic agents. The use 
of chemicals to destroy monoamine nerve terminals may supplement brain 
amine concentrations as criteria for relating monoamine function to 
behavior. 
The synthesis and pharmacological testing of structural analogues 
commonly employed to identify structural features responsible for a 
primary effect; to elucidate mechanisms of action; and/or to establish 
a rational basis for the development of more specific agents. The 
recent synthesis (37) of 3-(e-aminoethy1)-5,6-dihydroxybenzo[b]thiophene 
(5,6-DHT-S), the sulfur isostere of 5,6-DHT, offered the opportunity 
to investigate the relative importance of the indo1ic nitrogen in the 
action of 5,6-DHT. Benzo[b]thiophene isosteres of biologically active 
indoles have been stu~ied previously by this laboratory in an attempt 
to estimate the pharmacological contribution of the indolealkylamine 
ring nitrogen (38-41). The availability of benzo[b]thiopheneand 5,6-
disubstituted tryptamines, permitted a study of the contributions of 
the chemical sub-groupings present in 5,6-DHT to its monoaminergic 
activity and general effects on behavior. The parallel neurochemical 
and behavioral structure-activity relationships make it possible to 
speculate on the relation of monoaminergic activity to behavior in the 
rat. 
CONTRASTING BIOCHEMICAL EFFECTS OF 5,6-DHT AND 5,6-DHT-S IN THE RAT 
NE levels in the heart and spleen were decreased significantly 
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by the interperitoneal injection of 30 mg/kg of each compound to adult male rats. ~'inimum levels in Vi.::! heart were reached by the second hour; each compound produced a 55-60% depletion of NE. Values returned to control levels by 16 hours. 
1. 
In the spleen, NE levels were similarly reduced, differing only in that 5,6-DHT caused a longer lasting reduc-ticn (up to 16 hours) than in the heart. 5-HT levels in the spleen were reduced to 50% by 5,6-DHT at 16 hours, and \'/ere sti 11 decreased at 24 hours. 5,6-DHT-S, however, actually increased levels of 57'HT by 50% two hours after injection. No decrease i.l 5-HT levels was observed in the 24-hour period after 5,6-DHT-S. The data on spleen 5-HT and NE are presented in Figures la and lb. In contrast to these effects, the i.p. dosages had absolutely no effects on the levels of 5-HT and NE in the brain of the animals. 
The results obtained following intraventricular injection of 80 119 of the compound', were most dramatic. 5,6-DHT significantly decreased the 5-HT content of the three brain regions: cerebral hemispheres, cerebellum, and brainstem. The decline differing only in the time course of the effect. A rapid drop of 25-35% was observed in the cerebral hemispheres by 4 hours after dosage; this persisted for at least 16 days. Brainstem 5-HT was lm/ered by 20-30% in a similar fashion, \'1hile cerebellar 5-HTshmJed a 25% decrease only over the period 16 hours - 4 days after dosage. The data for the effects of 5,6-DHT and 5,6-DHT-S on brainstem 5-HT and ME are shown in Figure 2. 
In contrast to their effects on 5-HT, both compounds decreased levels of NE in the three brain regions. The decline in the cerebral 
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hemispheres of approximately 30% was less sha
rp and more prolonged than 
in the brainstem, where similar decreases were
 last observed at 4 hours. 
Decreased levels of NE in the cerebellum reach
ed 75% of control briefly, 
at 1 - 2 hours post-injection. (Figure 2). 
Both 5,6-DHT and 5,6-DHT-S produced a transien
t increase in 5-HIAA 
levels. By eight hours, 5,6-DHT had reduced 5
-HIAA levels 20-30% of 
control in all three brain regions, parallelin
g similar reductions of 
5-HT. 5,6-DHT-S, on the other hand, demonstra
ted an ability to increase 
5-HIAA levels, which returned to control value
s by 24 hours. 5,6-DHT ' s 
effects on 5-HIAA paralleled its decrease of 5
-HT in the brainstem and 
cerebral hemispheres, and likewise in the cere
bellum, where 5-HIAA 1evels 
returned to control levels after the 4th day. 
In contrast, 5,6-0HT-S 
J 
caused a significant elevation in 5-HIAA level
s 2 - 4 days after injection. 
Maximum increases of 40-50% were observed in th
e brainstem and cerebral 
hemispheres, 12-20% in the cerebellum. 5-HlAA 
levels returned to near 
normal leve1s by the J6th day. lower doses (20 119/rat o
r 40 l-Ig/rat) of 
both 5,6-DHT and 5,6-0HT-S had similar effects
 though lesser in magnitude 
and duration. 
BEHAVlURAL EFFECTS OF 5,6-0HT AND 5,6-0HT-S IN
 THE RAT 
Peripheral injections of 5,6-DHT dnd 5,6~DHT-S in the rat e
licited 
similar behavior. When administered intraperi
tonea1ly (30 mg/kg), both 
compounds produced peripheral signs such as ex
ophthalamous, piloerection, 
rigid alert stance, and increased i,rritability
, indicating sympathetic 
autonomic stimulation. No increase in motor 
activity, indicative of 
central activity, \-/as observed. 
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When administered centrally, "S,6-DHT and S,6-DHT-S differed in 
their behavioral effects. Injection of 80 pg S,6-DHT-S into the lateral 
ventricle produced a behaviorally depressed animal; the sedated state 
could be described as a semi-conscious stupor, lasting 30-4S minutes. 
After recovery, animals could not be distinguished from controls. Central 
administration of 5,6-DHT in doses of 80 pg caused initial behavioral 
depre~sion which, after 40 - 120 minutes, was usually succeeded by a 
perioJ of sudden, intense activity. 
The distinct~ve behavior after S,6-DHT was characterized by explosive 
jumping (rats at times leapt through covered cages to heights of 18 
inches); erratic running behavior, in which the back legs, in a flipping 
motion, propelled the rat in large circles in open space, or along the 
walls of an enclosure (the animal appeared to ignore barriers in its 
frantic movement and at times bloodied its head and cut its feet); vocal-
ization was often present as high-pitched squeals or shrieks; convulsions 
during which the animal literally behaved as a fish out of water, unable 
to breathe or make sound; and death in 2S-35% of the rats entering into 
this type of behavior. Each such outburst lasted about 30-90 seconds 
in confined spaces, but could continue much longer in open spaces. 
Milder episodes were interspersed among the more intense, and consisted 
of compulsive running and leaping at barriers, appearing to be a form 
of escape behavior. After each outburst the animal lay still, breathing 
deeply, but \'1as alert and hyper-responsive to external stimulation. As 
many as thirty mild and intense outbursts have. been recorded in the two 
hours following injection of S,6-DHT; the period of 4S-75 minutes after 
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injection contained the greatest frequency of such episodes. It was 
observed that those rats which did not enter into the second phase of 
behavior, but which remained behaviorally depressed and stuporous, were 
less likely to recover than those animals which underwent the violent 
behavioral spasms and lived. 
Long-term behavioral effects were observed after central adminis-
tration of S,6-DHT, but not 5,6-DHT-S. Following the period of intense 
activity, rats given S,6-DHT either recovere<;i sufficiently to feed and 
water themselves, or remained adipsic and aph~gict dying within 2 - 4 
days post-injection. Those which recovered tended to weigh less than 
control animals, and were often irritable and defensive when approached 
or handled. The long-term behavioral effects of 5,6-DHT \'/ere character-
ized by more frequent vocalization; unusual social interactions between 
cage-mates; and fighting episodes. One particular form of behavior was 
especially striking: two rats, standing on hind legs facing each other, 
would squeal, "hiss,". or "spitl! at each other, but would not make physical 
contact. At times, this behavior lasted as long as an hour or more. 
BIOCHEMICAL AND BEHAVIORAL EFFECTS OF 5-HYDROXY-6-METHOXYTRYPTAMINE (SH6MT) 
AND S-METHOXY-6-HYDROXYTRYPTAMINE (5M6HT) IN RAT~ 
Each of tl~ese analogues was ~dministered into the lateral ventricle 
of rats at a dosage of :TOO l1g/rat. No significant changes were seen 
in levels of S-HTor NE in any of the brain regions over the period I . - .,. ---
1 - 2~ hours after.dosa1ge. SH6MT di'd cause a significant ircrease (20-
j • ' 
25%) in SHIM levels at 2 hours after dosage, while 5H6MT did cause a 
significant increase (:W~2S%) in SHIM levels at 2 hours after dosage, 
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while 5M6HT caused a significant decrease (25-35%) in 5-HIAA levels at 
1 hour post dosage. 
Within 15 minutes following intraventricular injection of 5H6MT, 
a behavioral syndrome identical to that caused by 5,6-0HT was manifested. 
Brief, periodic (3 - 8 minute), convulsive episodes were combined with 
erratic running behavior and vocalizations. The behavioral effects 
differed from those of 5,6-UHT in that they were quicker in onset and 
lasted less than one hour. There was evident an increased alertness 
over control animals following this syndrome, then the animals could 
not be differentiated behaviorally. 
In contrast, 5r~6HT produced no dramatic behavioral effects. Some 
increased exploratory activity soon after injection was observed, as 
well as increased motor activity and alertness. However, these effects 
were slight, and the animals could not otherwise be differentiated 
from controls. 
BroCHEr~ICAL AND BEHAVIORAL EFFECTS OF 5,6-DIMETHOXYTRYPTAtHNE (5,6-DMT) 
AND 3- (6-AMINOETHYL) -5,6-ISOPROPYLlNOENDIOXYBENZO[b]THIOPHENE (IPST) IN 
THE RAT 
Each compound was itije~ted intraventricularly at a dose of lOa 'I1g/ 
rat. 5,6-DMT apparently elevated 5-HT levels, with no significant effect 
on 5-HIAA or NE. HO\'/ever, since 5,6-Dt·1T is active in the method for 
the determination of 5-HT (42), the increased fluorescence persisting 
to 24 hours, suggests, a -continued presence of 5,6-0MT in significant 
amounts. IPST, which does not interact with the assay methods, elevated 
5 .. HT levels at 2 hours (33%) and 24 hours (44%) in the cerebral hemispheres; 
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by 48 hours, hO\'lever, these levels had declined to 59% of control. Brain-
stem levels of 5-HT were increased by 20-30% at 24 hours post-injection 
with a concommitant decrease in 5-HIAA. In the cerebral hemispheres. 5-HIAA 
levels were depressed for 48 hours after injection. Levels of NE remained 
essentially unchanged throughout the 48 hour period after administration 
of IPST. 
Both IPST-and 5,6-0HT-S were behaviorally active. IPST, in contrast 
to its parent comp~;und 5,6-DHT-S, increased motor activity; the most 
prominent feature of the behavioral effect was :ompulsive cage circling 
interrupted by brief pauses. The effect commenced shortly after injection 
and lasted nearly two hours. Paradox;cally, IPST when administered 
p~ripherally (40 mg/kg, i.p.) depressed all behavior. The rat given 
IPST would lay prone and stuporous, but would lick a water bottle spout 
, 
brought near to its mouth. 
Rats given 100 lJ9' S,6-Dl4T intraventricularly exhibited a disoriented, 
groping behavior, \'/h11.e rolling over and over. The latter behavioral 
effect could be elicited upon moving the animal's cage. This behavior 
lasted up to 2.5 hours after injection, after which the animals could 
not be distinguished from controls. No convulsive behavior similar 
to that produced by S,6-DHT was observed. 
Cor~PARATIVE EFFECTS OF 5,6-DHT AND ANALOGUES IN THE RAT 
A summary of the biochemical and behaviora'l effects of the various 
compounds tested is presented in Table 1. 
Although S,6-DHT is generally considered as a selective depletor 
of brain S-HT, the results obtained from both peripheral and brain 
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ti ssues demonstr'i'I.te an abi 1i ty of the compound to 10\'/er both NE and 
5-HT. That 5,6-DHT might share" properties of both monoamines, and there-
fore have the potential to interact with either catecholaminergic or sero-
tonergic systems, may be deduced readily from its structure. 5,6-DHT 
itself is the 6-hydroxy derivative of serotonin; the o-dihydroxyphenyl 
portion of the 5,6-DHT molecule is isomeric with catechol, a sub-group 
shared by the catecholamines norepinephrine and dopamine. In fact, 
prior to the di scovery of its neurotoxic properties, 5,6-DHT \'/as found 
to be as active at 5-HT in the contraction of smooth muscle preparations 
(43) as well as a potent releaser of heart NE (44). The diploid nature 
of 5,6-DHT
'
s monoaminergic activity in vivo has therefore been confirmed 
here for peripheral anc brain tissues. 
Using 5,6-DHT
'
s structure as the basis for making comparisons, 
the relation of chemical structure to monoaminergic activity may be 
summarized as follows. Replacement of the indolic nitrogen by sulfur 
abolishes 5-HT depleting activity in spleen and in brain, but does not 
alter NE depleting activity in the heart, spleen, or brain. Methylation 
, 
of either the 5- or 6-hydroxyl groups of 5,6-DHT removes monoamine 
depletion activity. However, increased and decreased levels of 5-HIAA 
soon after injection indicate serotonergic interactions are not completely 
absent. t1ethylation of both hydroxyls on 5~6-DHT results in a complete 
abolition of monoaminergic depleting activity, although considerable 
behavioral activity is -retained. In contrast, conversion of 5,6-DHT-S 
to its isopropylidene derivative produces a complex action on brain 5-HT 
and NE systems and causes a generalized stimulatory behavioral effect. 
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COUCLUSIONS 
The indolic nitrogen of 5,6-DHT appears to be an absolute require-
ment for the 5-HT neurotoxic effects of the compound, at least insofar 
as substitution of a sulfur atom is concerned. Similar specificity 
appears to be demanded in terms of the 5- and 6-hydroxyl groups both 
existing in the phenolic state. In contrast, the similar ability of 5,6-
DHT-S to lower stored NE levels for a transient period appears to be 
related only to the catechol characteristics associated with an 
aryl ethyl amine. The overall behavioral actions of the compounds are 
complex and suggest a multiplicity of effects including amine release/ 
depletion and direct receptor interactions. 
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COMPOUND 
HO~ 
.HO~N..!J NHa 
H 
5,6-DHT 
::~H~ 
S,6-DHT-S 
HO'~' 
CHJO~NjJ 'NH2 
H 
. -~ SH6MT· 
CHjO~.1 "."'-HO~NjJ . NH z 
H 
6HSMT 
CHJO~ 
CH:,oM N-)l-· - NH2 
H 
5,6-DMT 
HjC, /Ux:t:1l' 
C I I·· .. _, ,. 
HjC"'" '0 ~ . S NHz 
IPST 
BIOCHEMICAL EFFECTS 
Prolonged (20-30%) decrease in 5HT; initial 
increase, then prolonged decrease in SHIAA; 
brief initial decrease in NE. 
No effect on SHT; increased 5HIAA levels at 
2-4 days post-injection; brief initial decrease 
in NE. 
No effect on 5HT; brief initial increase in 5HIAA; 
no effect on N E. 
No effect on SHT; brief initial decrease in 5HIAA; 
no effect on NE. 
No significant effects on 5HT, 5HIAA or NE. 
Initial increase, then prolonged decrease in 
SHT; generally decreased SHIAA; brief initial 
decrease in NE. 
BEHAVIORAL RESUL TS 
Initial behavioral depression, 30-45 min., then 
explosive jumping and erratic running behavior, 
convulsive episodes, vocalization. 
Behavioral depression lasting up to 30 min. 
post-injection; sedation, animal lying prone. 
Brief, periodic (3-8 min.) convulsive episodes 
within 15 min. injection, associated with er-
ratic running behavior, vocalization; followed 
by period of increased alertness and responsivity . 
Some increased exploratory activity within 15 
minutes of injection, but otherwise no differ-
ence from control animals. 
Disoriented, groping behavior; animals exhibit 
much rotational behavior and hyperreactivity 
to sensory stimulation. 
Increased motor activity; cage circling with 
periodiC pauses, lasting two hours following 
injection. 
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FIGURE lao Levels of 5-HT in rat spleen at various times after a sin9le 
dose (30 mg/kg, i.p.) of 5,6-0HT (--~---) or 5,6-DHT-S (--~---). 
Each value is the mean of 4 animals; control values (N = 8) were 1.40 ± 
.09 (SD) llg/g· 
FIGURE lb. Levels of NE in rat spleen at various times after a single 
dose (30 mg/kg, i.p.) of 5,6-DHT (-~---) or 5,6-0HT-S (--~--). 
Each value is the mean of 4 animals; control values (N = 8) were 0.42 ~ 
.07 (SO) llg/g· 
FIGURE 2a. Levels of 5HT in rat brainstem at various times after a single 
dose (80 llg/rat, intraventricularly) of 5,6-0HT (~---) or 5,6-0HT-S 
(--0--). Each value is the mean of 4 animals; control values (N = 8) 
were, 1.13 ± .17 (SO) llg/g· 
FIGURE 2b. Levels of NE in rat brainstem at various times after a single 
dose (80 119/rat , intra~entricularlY of 5,6-0HT (~) or 5,6-0HT-S 
(:.-0--) . .Each value is the mean of 4 animals; control values (N = 8) 
\'Jere 1.01 ± .11 (SO) l1g/g. 
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ABSTRACT 
In an .11l vitro system of purified hog kidney aromatic-L-amino acid 
decarboxylase, the benzo[b]thiophene analogue of 5-hydroxytryptophanwas 
found to be an effective inhibitor of DOPA decarboxylation, with a 
potency almost twice that of a-methyl-DOPA. When administered to mice 
prior to a dose of 3H-L-DOPA, the benzo[b]thiophene analogue of 5HTP led 
to significant elevations in brain levels of DOPA, dopamine, and metabo-
lites one hour later. 
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INTRODUCTION 
Aromatic-l-amino acid decarboxylase (EC 4.l.l.26) has been 
characterized as the enzyme responsible for the conversion of 3,4-
dihydror.yphenylalanine (DOPA) to 3,4-dihydroxyphenylethylamine (DA), a 
reaction first demonstrated by Holtz, rt ~ [1] in 1938 with kidney ex-
tracts of rabbits and guinea pigs. rhe enzyme has subsequently been 
shown to be widely distributed in various mammalian tissues, and to 
require pyridoxal phosphate as a co-enzyme [2]. The enzyme has been 
partially purified from hog kidney by Christenson, et ~ [3] and character-
ized in terms of optimal cofactor and substrate concentrations as well 
as medium pH by these authors and by Werle and Aures [4]. In addition, 
a variety of aromatic-L-amino acids (both natural and unnatural) have 
been shown to have activity as substrates for the enzyme [3,5-7]. 
One of the more interesting aspects of this enzyme has been the 
controversy surrounding its ability to act as the decarboxylation system 
for indolealanines such as tryptophan as well as for phenylalanines [8,10]. 
There is no doubt that aromatic-L-amino acid decarboyxlase preparations 
purified from hog kidney [3] have considerable activity tm'tards a variety 
of aromatic-L-amino acids, ·! .... ,c111dinn analogues of tryptophan [3,9,11-13]. 
Some analogues of tryptophan that are poor substrates for decarboxylation 
have been shown, not unexpectedly, to be inhibitors of the decarboxylation 
of tryptophan, as \'/ell as other amino acids [13,14]. 
The finding of Ehringer and Hornykiewicz [15J that patients with 
Parkinson's dh;ease had sUb"lIlJli,iJl levels of DA in the SUbstantia nigra 
and the subsequent discovery and development of l-DOPA as a therapeutic 
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agent have stimulated interest in inhibitors of the decarboxylation 
of this amino acid [16-18]. A variety of compounds have been found to 
be inhibitors of the decarboxylation system ~ vitr~, including hydrazine 
derivatives [18-20], a-methyl amino acids [10,21], and by hydroxycinnamic 
acids [22-24]. A recent report from this laboratory has indicated that 
the benzo[b]thiophene and 1-methy1indo1e analogues of tryptophan are 
effective inhibitors of the decarboxylation of tryptophan and phenylala-
nine in vitro [13]. The present paper reports on the activity of several 
analogues of tryptophan as inhibitors of the decarboxylation of L-DOPA. 
MATERIALS AND METHODS 
Materials 
D,L-DOPA-2- 14C(256 ~Ci/mg) and DA-2-14C(300 ~Ci/mg) were purchased 
from Amersham/Sear1e Corporation~ Chicago, IL and L-DOPA-3H (general label, 
30 mCi/mg) and DA-3H (general label, 61 mCi/mg) were purchased from New 
Engl and Nuclear Corp., Boston, MA. DL-DOPA and DL-tryptophan and ,yridoxal 
phosphate were purchased from Sigma Chemical Co., St. Louis, MO, DA was 
purchased from Nutritional Biochemical Corp., Cleveland, OH, and 5-hydroxy-
tryptophan, a-methyl tryptophan, L-DOPA, 3,4-dihydroxyphenyl-acetic acid, 
3,4-dihydroxyphenylethano1, 3-methoxy-4-hydroxyphenylethanol, and hcmo-
vanillic acid were purchased from Regis Chemical Co., Chicago, IL. The 
benzo[b]thiophene analogues of tryptophan, 5-hydroxytryptophan, and a-methyl-
tryptophan and the l-methylindole analogue of tryptophan were supplied 
as racemates by Dr. Ernest Campaigne, Chemistry Department, Indiana University. 
Pargyline hydrochloride was kindly supplied by Abbott Laboratories. 
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All chemicals and reagents used were purchased from commercial sources. 
Ion exchange resin (CG-50. Type 2, 200-400 mesh) was obtained from Mallin-
ckrodt Chemical Co., St. Louis, MO. Adult, male, Swiss-Webster mice 
(18-25 g) were purchased from Murphy Breeding Laboratories, Plainfield, 
IN. Hog kidneys were obtained fresh from the Hinterlein Meat Packing 
Co., Bloomington, IN. 
Enzyme Preparation 
The procedure of Christenson et !l [3], was followed through the 
second ammonium sulfate precipitation with modifications. All work was 
done at 4° C. Defatted hog kidney (300 g) was homogenized with 900 ml 
0.005 M NaH2P04 pH 7.2 containing 0.01 M 2-mercaptoethanol in a Sorva11 
Omnimixer at high speed for one minute. This homogenate was centrifuged 
at 10,000 rpm (16,000 x 9 Sorval1 RC2-B refrigerated centrifuge, rotor 
type GSA) for .30 min. The supernate vias decanted and was brought to 37% 
saturation by the dropwise addition of pH 8.0 saturated ammonium sulfate 
solution. After stirring for 20 min., it was centrifuged as above for 
20 min. The supernate was again decanted and was brought to 55% satura-
tion with saturated ammonium sulfate. After stirring for a further 20 
min., the solution was centrifuged under the above conditions for 20 
min. The supernate was discarded, and the precipitate was dissolved in 
150 m1 of 0.01 M 2-mercaptoethanol. The enzyme was dialyzed overnight 
against 0~01 M 2-mercaptoethano1 and then frozen until use. Enzyme protein 
was determined by the method of Lowry, et ~ [25]. 
Incubation Procedure 
The frozen enzyme \lIas allowed to thaw at room temperature prior to 
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use. All incubations were done in triplicate, using an incubation mixture 
modeled after Creveling and Daly [26] and consisting of: 0.2 ml 0.5M 
NaH2P04 buffer (pH 7.0), 0.1 ml pyridoxal-5-phosphate (final concentration 10-~M), 0.01 ml pargyline HCl (final concentration 1.25 x 10-5M), 0.02 
m1 enzyme, O.Olml DOPA, and d{sti11ed water or inhibitor to a final volume 
of 1.0 ml. All incubations were done at 37 0 C for 10 min. under air in 
an Aminco constant temperature shaking incubator. The mixture was pre-
incubated for 3 min. before addition of substrate. Each incubation 
14 
vessle contained 0.2 pCi DL-DOPA-2- C. Inhibitors, when used, were 
added in 0.5 ml volume 1 min. prior to the addition of the substrate; 
0.5 m1 of H20 was deleted from the original reaction mixture to allow 
the final volume to remain at 1 ml. The enzymatiC reaction \'1as stopped 
_3 
by the addition of 0.1 ml 50% TCA. After addition of 0.1 ml of 1 x 10 
M DA as a carrier plus 10 mg ascorbic acid, 2 ml of 0.5 M KH2P04 (pH 6.5) 
and NH40H to obtain a pH of 6.5 was then added. The mixture was trans-
ferred to centrifuge tubes and spun at 37,000 rpm in a lEe Model HN centri-
fuge for 15 min. One ml of the incubate was then added to the io~ exchange 
columns. Zero time points were prepared by the addition of 0.1 ml 50% 
TCA just prior to substrate addition. 
Analytical Procedures 
The columns were 1 ml disposable pipets cut to 12 cm in length with 
a 12 cc disposable syringe used as a reservoir. A three-way plastic 
stopcock connected the reservoir to the pipet. The resin (Amber1ite CG-50) 
150 mg/co1umn was prepared by the method of Hirst et ~ [27] and used in 
the Na+ form at pH 6.5. 
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After the 1 ml sample loading, the columns were washed with 8.0 m1 
of distilled water, then with 1 m1 2N HCl and 0.5 ml of the eluant was 
pipetted into a polyethylene vial containinq 15 ml scintillation fluid. 
Each sample \'/as counted twice for 10 min. in a Packard Tricarb Liquid 
Scintillation Spectrometer, Model 2425. Scintillation fluid was prepared 
by mixing 14 9 880T (2,5-bis-2-(S-tert-buty1benzoxazoly1)-thiophene, 280 g 
napthalene, 2000 ml toluene and 14·00 ml 2-methoxyethanol. 
The ability of the ion exchange columns to separate DOPA from DA 
was tested by adding a1iquots of DOPA (14C) to one set of columns and 
_4 _7 
DA (14C) to another set at concentrations of 1 x 10 M to 1 x 10 M. 
The columns were then eluted and a1iquots were collected and counted as 
_7 _4 
described above. Recovery of DA over the range 10 - 10 M was 82 - 93% 
under these conditions. 
In Vivo Studies 
For in vivo experiments, drugs were made up in 0.5% methyl cellulose 
suspensions. Pretreated mice received 300 mg/kg of inhibitor i.p. 1.5 hrs. 
prior to a dose of 200 mg/kg L-DOPA (spec. act. 1.97 mCi/mmo1e) p.o. 
Control mice received only 200 mg/kg L-DOPA (3H-G) p.o. All mice were 
sacrificed by decapitation 1 and 2 hours after DOPA administration. 
Tissue samples were removed, rinsed with saline and frozen immediately. 
The samples were assayed by a procedure modified after Taylor and Laverty 
[28]. Tissues were homogenized (Sorvall Omnimixer) for one minute in 4 ml 
0.4 M HC104 with 0.1 ml 10% EDTA and 5.2
 mg ascorbate. The homogenate 
was centrifuged for 10 min. (IEC Model B-20) at 4° C and 10,000 rpm. The 
precipitate \lIas then washed with 2 ml of 0.4 M HC104, centrifuged, decanted 
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and then washed again with 2 ml HC104• The two washes were combined 
with the first centrifuqation and the pH was brought to 6.5 with SN 
KOH. The sample was then centrifuged (lEC Model HN) for 5 min. at 3,700 
rpm to remove KC104 precipitate. An aliquot (8 ml) was then added to an 
ion exchange column prepared as described above. The 8 ml load was col· 
lected for further analysis. 
The column was washed with 8 ml H20 and the rinse combined with the 
liquid collected from the load. This fraction contains DOPA, and its 
acid and neutral (alcohol) metabolites. This was taken to dryness and 
dissolved in 2 ml 0.01 N HC1. Sufficient 2 N HC1 was added to bring 
the pH to 1 prior to washing with 3 volumes of chloroform. A1iquots of 
0.5 ml of the aqueous phase (DOPA)were then pipetted to scintillation 
vials and counted. 
The remaining aqueolAs phase was aspirated off and the chloroform 
phase containing the alcohol -and acidic metabolites was taken to dryness 
and reconstituted in 2 m1 of 0.01 N Hel; 0.5 ml of this fraction was 
counted. The rinsed columns containing the DA and NE were eluted with 
1 ml 2 N Hel and 0.5 'ml was transferred and counted. 
This extraction process was tested with authentic DOPA, 3-methoxy-
4-hydroxyphenylethanol, was chosen to represent the neutral (alcohol) 
metabolites, and homovanillic acid (HVA), chosen to represent the acidic 
class. Concentrated samples of each phase described above were spotted 
adjacent to these spots. The papers were developed us i ng blo solvent 
systems, butanol/acetic acid/H20 (25:4:10) and isopropanol/2N Hel (65:35) 
and scanned {Packard Model 7200 Radio-chromatogram Scanner. Authentic 
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compounds were detected with iodine vapor. The scan from the water 
fraction contained one major peak at Rf - 0.5 while the scan from the 
chloroform phase also showed one peak but of much less intensity at 
Rf - 1. Authentic DOPA ran in the butanol/acetic acid/H20 solvent 
1 ~' 
, 
" 
.. 
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system at an Rf of 0.29 and at an Rf of 0.85 in the isopropanol/Hel system. 
Authentic 3-methoxy-4-hydroxypheny1ethanol and HVA ran at an Rf of 0.93 
in both solvent systems. 
Data Processinq 
Km, Vmax, and Ki \'/ere calculated using linear regression analysis 
of unweighted double reciprocal (l/V vs 1/[5]) data, using computerized 
procedures. 
RESULTS 
Initial Studies of DOPA Decarboxylation 
Using this system and purified hog kidney enzyme, initial studies 
showed the reaction for the decarboxylation of DOPA to be linear over the 
period of 2 - 10 minutes of incubation. The K ranged from 1.96 x 10-4 
m 
_4 
to 2.38 x 10 when derived from data obtained over a range of substrate 
. _5 _3 
concentrations of 5 x 10 to 1 x 10 M. Using a substrate concentration 
5 3 
of5 x 10- M and inhibitor concentration of 10- M a preliminary series 
of inhibition studies was performed. The results, presented in Table 1, 
show that the benzo[b]thiophene analogue of5-hydroxytryptophan was the 
most potent inhibitor of the test series, almost twice as effective as 
a-methyl DOPA, while 5-hydroxytryptophan itself was only slightly less 
potent. 
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Inhibition of DOPA Decarboxylation ~ Vitro 
Detailed kinetic studies were performed with 5-hydroxytryptophan, 
a-methyl-5-hydroxytryptophan, and the benzo[b]thiophene analogues of 
these two compounds. The results, presented in Table 2, indicate that 
the benzo[b]thiophene analogue of 5-hydroxytryptophan ,",'as the most potent 
inhibitor of DOPA decarboxylation in the test system. In the case of 
a-methyl tryptophan, replacement of the indolic nitrogen with a sulfur 
atom led to a slight decrease in potency. The lineweaver-Burke plot 
_3 
for the inhibition of DOPA decarboxylation by the 10 concentrations 
of the various compounds is shown in Figure 1. 
Studies of ~ Vivo Inhibition of DOPA Decarboxylation 
In an attempt to furthe'r test the efficacy of the most potent in vitro 
inhibitor, mice were pretreated with the benzo[b]thiophene analogue of 
5-hydroxytryptophan prior to the administration'of l-DOPA, and brain and 
kidney were removed at 1 and 2 hours for the assay of DOPA, DA and metabo-
lites as described in Materials and Methods. Brain levels of total radio-
activity \-Jere 44% higher after 1 hour in mice pretreated with the inhibitor; 
this was reflected in significantly elevated levels of DOPA, DA, and 
metabolites (33%, 58% and 32%, respectively). No significant elevations 
were seen in brain levels of radioactivity at 2 hours, nor were any of 
the kidney levels significantly elevated. 
DISCUSSION 
The initial screening results presented in this paper indicate that 
the benzo[b]thiophene analogue of 5-HTP 1s the most potent inhibitor of 
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DOPA decarboxylation (Table 1), followed in order by a-methyl-DOPA, the 
benzo [b]thiophene and l-methylindole analogues of tryptophan, and trypto-
phan itself. These results are consistent with previous findings that a 
5-hydroxy function considerably increases the affinity of tryptophan for 
the enzyme [5,16,29]. One can also compare this to the relative rates 
of decarboxylation of 5HTP, tyrosine isomers and tryptophan. 5HTP and 
tyrosine isomers are decarboxylated at a rate of 10 - 40% that of DOPA 
while tryptophan is decarboxylated 1 - 10% that of DOPA [5]. On this 
basis, the benzo[b]thiophene analogue of 5HTP should have the highest 
affinity followe~ by a-methyl DOPA, tryptophan, and derivatives not having 
! 
the 5-hydroxy group. The fact that the benzo[b]thiophene analogue of 
tryptophan is considerably more lipid-soluble than tryptophan [30], 
combined with the fact that it is sterically similar to tryptophan may 
facilitate binding to the active site of the enzyme. 
Lipid solubility would also expl~in why a-methyl tryptophan has 
more affinity for the enzyme than tryptophan. l-Methyltryptophan is 
practically as lipid soluble as the benzo[b]thiophene analogue which 
would also facilitate binding to the enzyme. The fact that the bulk of 
the methylated indole nitrogen may prevent the compound from being as 
strongly bound to the enzYme probably dictates the order of affinity 
indicated in Table 1. 
From the kinetic studies presented in Figure 1 and Table 2, it is 
clear that substitution of sulfur for the indolic nitrogen increases the 
affinity of the enzyme for the 5-hydroxylated compounds, with virtually 
the opposite effect for a-methyltryptophan. The bu1kiness of the a-methyl 
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group may greatly effect the positioning of the structure within the 
active site thereby limiting the interaction of the benzo[b]thiophene 
nucleus with a specific area of the protein. Therefore, when looking 
at a-methylated compounds steric hinderance may be the limiting factor 
rather than the lipid solubility of the compounds. 
The small duration of effect seen ~Ihen the benzo[b]thiophene analogue 
of 5HTP was used as an in vivo pretreatment prior to administration of 
L-DOPA is somewhat disconcerting in view of the potency of this compound 
as an in vitro inhibitor. However, only a single dose combination was 
tested, and nothing is known of the rate of degradation and excretion of 
the inhibitor. Further studies are needed to explore the possible signifi-
cance of these compounds as inhibitors of DOPA decarboxylation. 
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TABLE 1 
Inhibition of DOPA Decarboxylation by Various Compounds 
Purified hog kidney enzyme was used as described in r·1aterials and 
Methods. Inhibition values were calculated on the basis of 4 - 6 replicate 
runs with 10 mins.of incubation. 
Comoound 
Tryptophan 
l-Methyltryptophan 
B - (3-Benzo[b]thienyl )-cl-a 1 ani ne 
5-Hydroxytryptophan 
a-(4-HydroxY-3-benzo[b]thienyl)-a_alanine 
a-Methyl DOPA 
201 
% Inhibition 
0.0% 
10.8% 
31.1% 
83.2% 
93.5% 
51.7% 
r ) 
TABLE 2 
Inhibition of DOPA Decarboxylation by 5-0H and a-CH3 Analogues 
Values foy' KI were determined as described in Materials and Methods, 
using substrate concentrations from 5 x 10- 5 M to 10- 3 M and inhibitor 
concentrations of 10-1t and 10- 3 M. Each point was derived from 4 - 6 
replicate runs with 10 min. incubation. 
Compound 
a-~'ethy1 DOPA 
B- (3-Benzo[b ]thi eny1)-a-a 1 ani ne .. 
a-t~ethyl tryptophan 
a-Methy1-B-(3-Benzo[b]thieny1)-a-a1anine 
5-Hydroxytryptophan 
B-(5-Hydroxy-3-benzo[b]thieny1)-a-a1anine 
202 
KI 
_4 
7.7 x 10 
_3 
1.9 x 10 
_It 
3.7 x 10 
_It 
7.0 x 10 
_4 
2.1 x 10 
_It 
5.8 x 10 
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LEGEND 
Figure 1: Lineweaver-Burke plots of inhibition of DOPA (5 x 10-5M) 
decarboxylation by various compounds (lO-3M). DOPA alone ( ), 
methyl-~-(3-benzo[b]thieny1)-a-alanil1e (- - -), a-methyl tryptophan 
( •••.•• ), 5-hydroxytryptophan (-- •• --), and e-(S-hydroxy-3-benzo[b]-
thienyl)-a-alanine (_a -). 
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Because of its unique structure, trjptophan occupies a central position 
among amino acids and has stimulated interest in the study of the role of 
aromatic and heteroaromatic amino acids in the living organism. Since its 
discovery as one of ten essential amino acids (l)t numerous investigations 
of tryptophan metabolism have appeared in the literature, including one 
monograph (2). Considering only the initial reaction involved in tryptophan 
metabolism, these investigations have defined four distinct pathways: 
1. conversion to N-formylkynurenine by tryptophan pyrrolase; 2. conversion 
to 5-hydroxytryptophan by tryptophan 5-hydroxylase; 3. conversion to 
tryptamine by aromatic L-amino acid decarboxylase; and 4. conversion to 
indole-3-pyruvic acid by tryptophan aminotransferase or 0- and L-amino 
acid oxidase. The significance and scope of these pathways have been 
examined in relation to their role in carcinoid tumor syndrome, Hartnup1s 
disease, phenylketonuria, and maple syrup urine disease (3,4). 
An interesting aspect of tryptophan research has been the synthesis 
, 
and biological evaluation of bioisosteric analogs of the molecule. The 
concept of bioisosterism (5) has provided a rationale for the design of 
compounds possessing similar spatial and electronic properties and has 
provided the basis for our study of bioisosteres of biologically active 
indole derivatives (6,7). As part of that study we have undertaken the 
investigation of the metabolic fate in the rat of OL-2(3-benzo[b]thienyl)-
1-aminopropionic acid (1) , the sulfur analog of tryptophan which constitutes 
the subject of this report. 
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Materials and Methods 
Materials 
Animals 
Mal e Sprague-Dawley rats (~'urphy Breedi ng laboratories, Pl a infield, 
IN), each weighing 350-400 g, were housed in separate metabolic cages 
(Maryland Plastics, Inc., New York, NY) designed to permit the separate 
collection of urine and feces. The animals were maintained on Purina lab 
chow and tap water ad libitum during the course of the experiment. 
Chemicals 
Compound I was synthesized by the method of Avakian, et ~ (8) and 
was tritium-exchange labeled (New England Nuclear Corp., Boston, MA) to 
give a specific activity of 3 Ci/mmole. The radiochemical purity of I 
t/as confirmed to be 98% by TlCl (9) and scanning with a Packard model 7200 
radiochromatogram scanner. 
Authentic samples of Dl-2-(5-hydroxy-3-benzo[b]thienyl)-1-aminopro-
pionic acid, 5-hydroxybenzo[b]thiophene-3-acetic acid, 3-(2-aminoethyl)-
benzo[b]thiophene, 3-(2-hydroxyethyl)benzo[b]thiophene, and benzo[b]thio-
phene-3-acetic acid (II) were supplied by Dr. E. Campaigne, Department of 
Chemistry, Indiana University, Bloomington, IN. Benzo[b]thiophene-3-pyruv;c 
acid (III) and Dl-benzo[b]thiophene-3-1actic acid (IV) were prepared from 
I by known procedures (lO,ll). N-(Benzo[b]thiophene-3-acetyl)glycine (V) 
was synthesized by the following procedure: 
N-(Benzo[b]thiophene-3-acety1)-glycine (V). 
In a 50ml round bottom flask was placed 1.0 g (5.2 mmol) 
of II and 5.0 ml of thionyl chloride, and the resulting 
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solution gently refluxed for 2.5 hr. Excess thionyl chloride was 
removed under reduced pressure and the reaction mixture was 
dried by azeotropic benzene co-distillation. The resulting 
dark oil was dissolved in 4 ml of dry acetone and added to a cold 
solution of 1.5 9 (20.0 mmol) of glycine in 30 ml of IN NaOH. 
The reaction mixture \'/as allowed to warm to room temperature, 
decolorized (Norit), filtered, and acidified with concentrated 
HCl to give a yellow oil which was extracted with 3 x 25 ml 
ether. The combined extracts were washed with 0.2N HCl (20 m1), 
H20 (2 x 20 ml), dried (MgS04) and evaporated under reduced pressure 
to leave an amorphous yellow-white solid which \'/as recrystallized 
from water to yield 0.47 9 (36%) of white plates, m.p. 162-163° C. 
Molecular weight: Calculated: 249.0460, Found: m/e 249.0460. 
Chromatographic and mass spectral data: see Table 2. The identity 
of this material with metabolite V was based on the correspondence 
of their TLC, GC, and GC/MS properties. 
Methods 
In Vivo Metabolism 
Five rats of equal age and weight were placed in individual metabolism 
cages inside a standard fume hood and were maintained on a light-dark 
schedule providing 0700 hr - 2300 hr light and 2300 hr - 0700 hr dark. 
At 0900 hr and 1500 hr animals were injected ip with a solution of I at a 
dose of (100 mg/kg) and (100 ~Ci); control animals were injected ip with 
an equal volume of O.OOlN HC1. 
Urine was collected under toluene for periods of 24 and 48 hr following 
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injection and was used immediately for the isolation and/or quantitation 
of metabolites, or was stored under N2 at _5° C. For the determination 
of residual radioactivity at 48 hr, animals were sacrificed and exsangu-
inated, samples of plasma, liver, kidney, brain, heart, lung, spleen, 
testis, and epidyma1 fat were collected and frozen. Feces were also collected 
and frozen. 
Radioactivity in each of these samples was measured in a Packard Tri-
Carb model 2425 liquid scintillation spectrometer, with polyethylene vials 
and a cocktail composed of 14 9 of 2,5 bi s2- ( -tert-butyl benzoxazo ly1)-
thiophene and 280 g of naptha1ene in a mixture of 2100 ml of toluene and 
1400 ml of ethylene glycol monomethy1 ether. Duplicate aliquots (0.1 ml) 
of the toluene phase were counted directly, while duplicate aliquots (0.1 ml) 
of urine was diluted to 100 ml prior to counting. Samples of feces or 
tissue were homogenized in 4 volumes of~.OlN HCl and duplicate aliquots 
(0.5 ml) of each homogenate were counted. 
Isolation of Metabolites 
Since the 24 hr urine contained the most concentrated source of metabo-
lites, it was chosen for isolation and characterization of the individual 
metabolites arising from I. Metabolites were isolated by a differential 
pH extraction procedure which gave seven fractions. The procedure (Fig. 1) 
consisted of taking 1 ml of urine and diluting with 1 m1 of distilled water. 
The pH was adjusted to 1.0 by the addition of approximately 0.3 ml of 2N 
HCl and the sample extracted with diethy1 ether (2 x 4 ml). The combined 
ether fractions were extracted with 2 mT of 5% sodium bicarbonate solution 
and the remaining ether solution, which consisted of uncharged lipid soluble 
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and weakly acidic compounds (phenols), was designated Fraction A. The 
sodium bicarbonate solution was adjusted to pH 1.0 by the addition of 
approximately 0.6 ml of 2N Hel and extracted with diethyl ether (2 x 4 ml). 
The ether fraction \A/hich contained carboxylic acids \'las designated Fraction 
B. 
The aqueous urinary fraction was next adjusted to pH 13.0 by the 
addition of approximately 0.70 ml of 2N NaOH and extracted with diethyl 
ether (2 x 4 ml). The resulting ether fraction which consisted of organic 
bases, was designated Fraction C. 
The aqueous urinary fraction was finally adjusted to pH 6.8 by the 
addition of approximately 0.36 ml of 2N HCl and extracted with diethyl 
ether (2 x 4 ml). The ether fraction which consisted of weakly polar ~ 
neutral compounds, was designated Fraction D and the remaining aqueous phase, 
which consisted of polar non-extractable neutral and amphoteric compounds, 
was designated Fraction E. 
In order to obtain a non-aqueous extract of Fraction E, non-ionic 
resin chromatography (NIRC) \-/as employed. Pre-packed "Drug-Skreen®1I XAD-2 
resin cartridge columns (0.9 x 5.0 cm), containing 2.0 ± 0.1 9 of resin 
and sample reservoirs \'lere used (Brinkmann Instrument Co., \4estbury, NY). 
Cartridges were sealed and stored at 5° C and brought to room temperature 
immediately prior to use. After assembly, columns were \'Jetted with methanol 
(20 ml) and water (5 x 20 ml). A 2.0 ml aliquot of Fraction E was diluted 
to 10.0 ml with distilled \'later and passed through the column. The flow 
rate was adjusted to 0.2 ml/min and the sample recycled through the column 
three times to insure adequate adsorption. Columns were washed with water 
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(4 x 5 ml) and aspirated by means of a water aspirator for 5 min prior 
to the elution of the sample with methanol (2 x 5 ml). Column adsorption 
efficiency was 73%. The resulting methanol eluate was designated Fraction 
F and the aqueous phase Fraction G. 
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Duplicate aliquots (0.01 - 0.1 ml) of Fractions A - G were counted. 
Similar fractions were obtained from control urine, and were 
used as blanks. 
Thin-layer Chromatography 
All TLC was done using precoated, prescored unip1ates containing 250 ~ 
silica gel G or GF layers (Ana1tech, Inc., Newark, DL). Plates were developed 
in a solvent system prepared by shaking a mixture of chloroform!methano1! 
fornic acid {75:5:5} with 2.0 m1 of 0.01 N sodium borate (Na 2B407.10H20) 
solution, followed by separation of the organic phase directly into the 
chromatography chamber (30 x 20 x 10 em). The TLC plates were developed 
for a distance of 12 cm, air-dried for 30 min, then re-deve1oped in the same 
direction and chamber for 12 cm. Since the plates were double-developed, 
the apparent retardation factor (Rf ) were expressed as a function of the 
Rf as follows: 
R' - R 2 f - 2R f - f 
Visualization of the TLC plates was accomplished by chemical, fluor-
escent or radiochemical methods. The chemical methods consisted of 12 vapor, 
alkaline KMN04 and ninhydrin sprays (12) and fluorescent visualization was 
achieved by inspection of silica gel GF plates under 254 nm UV light. Radio-
chemical visualization of TLC plates was accomplished using a Packard model 
7200 radiochromatogram scanner. 
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Quantitation of urinary metabolites was achieved by spotting 10 pl 
of unmanipu1ated urine on a silica gel G plate, developing as above, and 
scraping the TLC plate into 2 mm segments using an Isolab TLC plate 
scraper (Isolab, Inc., Akron, OH). The silica gel from each 2 mm segment 
was scraped directly into liquid scintillation vials containing 10 m1 of 
liquid scintillation cocktail and the amount of radioactivity determined. 
Sily1ation 
A1iquots (2.0 m1) of Fractions A - F were evaporated to dryness under 
a stream of N2 in teflon-lined screw-capped tubes. BSA (0.1 ml) was added 
to each tube which was then sealed under N2 and heated at 50 - 60° C for 
5 min (Fractions A - E) or 1 hr (Fraction F). Authentic samples were 
derivatized in the same manner. 
Gas Chromatography 
Ge separations were carried out on a Varian model 1840-3 gas 
chromatograph equipped with a flame ionization detector and model 20 
recorder. The column was a 6' x 1/8" silanized glass column packed with 
3% OV-17 on Gas-Chrom Q (80/100 mesh). The injector temperature was 
240 0 C, the detector temperature 280v C, the N2 flow rate 30 m1/min, and 
the column oven temperature \'las programmed from 70 - .270 0 C; wi th 4 mi n 
pre-program and post-program periods run at constant temperature. The 
GC analyses were obtained by injecting 1 - 2 p1 of si1ylation solution 
with the simultaneous initiation of the temperature program described above. 
Tracings were obtained with an attentuation setting of 16 x 10-10 amps/m volt. 
Gas Chromatography - Mass Spectrometry 
An LKB model 9000-Scombination GC/MS instrument (LKB Instruments, 
Rockville, MD) interfaced with a computer (System Industries, Sunnyvale, CAl 
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was employed for structure determinations. The chromatographic columns 
. used in this system were either a 3' x 1/8" silanized glass column packed 
with 2% OV-17 on Gas Chrom Q (80/100 mesh) at 170 0 C, or a 2' x 1/8 silanized 
glass column containing 3.8% W-98 on Chromosorb W-Hp (BO/100 mesh) at 190 0 c. 
Operating conditions were as follows: H flow, 
o C; column 1700 C or 1900 C; separator, 
ml/min; flash heater, 
°C; accelerating voltage, 
KV; ionization potential, 70 eV; trap current, amp; filament current, 
1.1 amp. 
RESULTS 
Metabolites of I were found in highest concentration (76%) in the 
urine collected during the first 24 hr following administration (table 1). 
An additional 4% of the injected dose was excreted in the 24 - 4B hr urine 
and 5% in the 0 - 48 hr feces. AnalysiS of residual tissue levels of 
radioactivity 48 hr following administration of I indicated that only kidney 
and liver contained significant levels of activity; total tissue content 
was less than 4% of the injected dose. Using urinary and fecal excretion 
data and the residual tissue levels of radioactivity, it was possible to 
account for 89% of the administ:,rt;~ ~ase of I. 
Since the 24 hr urine sample contained the highest concentration of 
metabolites it was selected for the isolation and identification of the 
individual metabolites. Isolation of urinary metabolites was accomplished 
by a differential pH extraction procedure (Fig. 1). Analysis of the radiO-
activity present in Fractions A - E indicated that Fractions Band E 
contained greater than 97% of the urinary radioactivity; Fraction B consisted 
of carboxylic acid metabolites and Fraction E consisted of non-extractable 
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and/or amphoteric compounds. Metabolites present in Fraction E could re~dily 
be isolated in methanolic solution (Fraction F) (16.5%) by means of XAD-2 
column chromatography and the remaining aqueous phase was designated Fraction 
G (16.0%). Fractional distillation of Fraction G (13) indicated that approx-
imately 10% of the urinary radioactivity of I was present in this fraction 
as [3H] water. The bn1y metabolite present in Fraction G was unchanged I 
~'" '1.£1'£1.-'1' 
which failed to beAabsorbed by the XAD-2 column. Only trace amounts of 
urinary radioactivity was found in Fractions A, C, and D. 
The number of metabolites present in Fractions Band F were determined 
by evaluation of their GC profiles. The GC scans of compounds present in 
Fractions Band F, obtained from control and dosed animals, are presented 
in Fig. 2 and Fig. 3, respectively. Examination of Fig. 2 revealed the 
presence of four carboxylic acid metabolites, which when compared to authentic 
materials possessed retention times identical to metabolites II - V.(Table 2). 
Similarly, examination of Fig. 3 revealed the presence of a single metabolite 
which exhibited a retention time identical to I. When the metabolites 
pr~sent in Fractions Band F were examined by TLC, Rf values similar to 
authentic materials were obtained in each instance (Table 2). Complete 
identification of each urinary metabolite was accomplished by GC/MS. Total 
mass spectra were obtained for each metabolite and were computer matched 
against spectra obtained from authentic samples (Table 2); in each instance 
perfect agreement was obtained and the metabolites fragmented according to 
expected pathways. 
The quantitation of urinary metabolites was readily achieved by 
quantitative TLC which depended uport development of a suitable solvent 
216 
, 
; 
. , 
i~. 
, . 
([t 
tern (Table 2). The qlJantitative data (T:3ble 3) indicated !\ietabolite 
. ~o be the major metabolite (46.1%), accounting for more than tWice that 
of unchanged I (20.6%). Metabolites II - IV account for the remaining 
urinary radioactivity. Individual variation of metabol ites \'/as found to 
be minimal; no value for any metabolite level in any animal exceeded 1 S.D. 
from the mean level for the entire population. 
DISCUSSION 
The results presented in this report reveal significant differences 
in the metabolism of tryptophan when the indole nucleus is replaced by 
benzo[b]thiophene. In contrast to tryptophan metabol ism \I/here only small 
amounts of the administered dose are excreted in the first 24 hr (14), the 
bulk of I metabolites (76%) are excreted during this time period. An 
additional 4.2% of the injected I was excreted in the 24 - 48 hr period 
following administration and 4.8% appeared in the feces; thus, greater 
than 85% of the administered dose of I \-/as excreted in the 48 hr following 
administration. 
A review of the literature (14) on the quantitative aspects of trypto-
phan metabolism indicated that the major portion of administered tryptophan 
is metabolized by tryptophan pyrrolase along the hynurenine pathway. 
Metabolites derived from the tryptophan 5-hydroxylase pathway account quanti-
tatively for only a small percpnt of the administered dose, while metabolites 
derived from the aromatic l-amino acid decarboxylase, tryptophan transam-
inase, and 0- and l-amino acid oxidase pathways were insignificant. In 
light of the pGthways av~ilable to I, it was surprisinq that its metabolism 
occurred by only one of these pathways; namely, the a-keto acid pathway 
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(Scheme 1). Thus, the immediate questions which can be posed are of two 
distinctly different types: 1. Vlhat are the characteristics of the a-keto 
acid pathway which make it tne sole route of metabolism?; and 2. Vlhat are 
the characteristics of the other metabolic pathways, which, though antici-
pated, were apparently not involved? 
The a-keto acid pathway of endogen9us tryptophan metabolisnl is one of 
the more complex and least understood pathways. It can occur by either trans-
amination or oxidative deamination; the former being a reversible process 
catalyzed by aminotransferc:!se enzymes which require pyridoxal phosphate, 
and the latter being an irreversible process which liberates ammonia and 
1s catalyzed by 0- or L-amino acid oxidase (15). 
The study of tryptophan animotransferase specificity and multiplicity 
has been actively pursued for nearly two decades. Early studies (16,17) 
presented evidence for the existence of at least blo hepatic enzymes capable 
of transaminating tryptophan, which could be adaptive1y increased (18). 
Recent work (19,20) has both supported and expanded these earlier findings. 
The role of transamination in the metabolism of I is difficult to 
access due to the existence of 0- and L-amino acid oxidases. Even before 
transamination was recognized as a biochemical pathway, Neubauer had shown 
that aromatic amino acids could be ix;datively deaminated to the corres-
ponding a-keto acids. Subsequently, Krebs showed that tissue slice prepar-
ations of liver of kidney from normal animals could catalyze the oxidation 
of either D- or L-isomers of as many as b/enty-five amino acids (22,23). 
Little progress has been made in understanding the chemistry of these two 
enzymes; however, Freter et!l. (24) did demonstrate that 5-hydroxytrypto-
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phan could be oxidized to 5-hydroxyindole-3-pyruv1c acid by L-amino acid 
oxidase and further broken down to 5-hydroxyindole-3-acetic acid, a pathway 
predicted by Blaschko & Hoge (25). 
There remains, of course, the question of the metabolic fate of benzo-
[b]-thiophene-3-pyruvic acid. a-Keto acids are known to be readily decar-
boxylated to aryl acetic acids; a reaction demonstrated for indole-3-pyruvic 
acid. At least two enzyme systems requiring thiamine pyrosphosphate are 
known to catalyze this reaction: one oxidative and the other non-oxidative 
(15). Accordingly, they lead to different products: an acetyl-sCoA and 
acetaldehyde derivative, respectively, which may be hydrolyzed and/or oxi-
dized to the corresponding arylacetic acid. In addition, a-keto acids are 
known to undergo non-enzymatic decarboxylative decomposition. In order to 
determine the stability of III under the conditions of urine collection, 
a sample of III was incubated in control urine and analyzed at frequent 
intervals between 2 - 36 hr. The results indicated that III undergoes 
spontaneous decarboxylation in urine at a sufficiently rapid rate to account 
for the total uri nary content of II. 
Compound III can also be reduced to IV in a reversible reaction cata-
lyzed by lactate dehydrogenase. This enzyme is not highly specific and 
h'as been shown (16) to be capable of reducing arylpyruvic acids. ~'ore 
recently lannoni and Weber (26) have isolated and characterized an aromatic 
a-keto acid reductase from dog heart \'/hich was NADH-dependent and capable 
of reducing indole-3-pyruvic acid. 
The final biotransformation of III involves amino acid conjugation, 
or more specifically glycine conjugation to produce V which was the major 
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urinary metabolite to I. Elvins and laidlaw 
(27) first observed N-(indole-
3-acetyl)glycine (indoleaceturic acid) following the ad
ministration of 
tryptamine to dogs. The ~ vitro biochemistr
y of this reaction has been 
"larked out in detail (28) and the enzyme which catalyze
s the reaction, 
glycine N-acyltransferase, has been purified 
and characterized (29). Prior 
to glycine conjugation, however, II must be activated to th
e corresponding 
acyl CoA derivative, the intermediate in the 
oxidative decarboxylation of 
III acid. 
Finally, one must consider the :haracteristic
s of the tryptophan path-
ways which are anticipated but apparently not
 involved. The first pathway 
was that of decarboxylation which was not hig
hly anticipated since our 
laboratory (30) had shown that I was not a substrate fo
r aromatic l-amino 
acid decarboxylase. A careful search for the
 sulfur analog of tryptamine 
in Fraction C failed to detect its presence a
t levels of 0.1% of the adminis-
tered dose. Nevertheless, the presence of II
 and its glycine conjugate V 
made it difficult to definitively rule out th
at possibility; however, Buckpitt 
(30) using pargyline pretreated rats was unable to de
tect any amine following 
the administration of I. 
While the absence of decarboxylation was expe
cted, the complete absence 
of the tryptophan pyrrolase and 5-hydroxylase 
pathways was somewhat surprising. 
Partial explanation for this observation may 
be the higher electron density 
of the indole nucleus relative to ben~o[b]thio
phene and its propensity for 
electrophilic attack {6}. Presumptive metabolites of th
e tryptophan pyrro-
lase pathway could not be assessed because po
tential metabo" ites are unknm'ln 
compounds. In contrast, the availability of 
three importaht 5-hydroxy 
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derivatives. the benzo[b]thiophene analogs of 5_hydroxytryptophan. 5-hydr
o
xy-
tryptamine and 5_hydroxyindole-3-acetic acid. marle it possible to demonstrate 
that none of these compounds "ere present as urinary metabolites of I at 
levels down to 1.0 ~g/ml (0.1% of the administered dose). 
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TABLE 1 
Excretion and tissue disposition of tryptophan-S and metabolites 
Sample 
Urine (0-24 hr) 
Urine (24-48 hr) 
Feces (0-48 hr) 
Radioactivity 
152.8 pC; 
8.4 pC; 
9.6 pCi 
% of Administered Dosea 
76.4 
4.2 
4.8 
--------------------
--------------------
--------------------
-,----------------------
Plasma 3.52 llCi/ml 1.76 
Liver 1.60 llCi/g 0.80 
Kidneys 0.9 itCi/g 0.45 
Lungs 0.26 llCi/g 0.13 
Heart 0.22 llCi/g 0.11 
Testes 0.34 llCi/g 0.17 
Spleen 0.12 llCi/g 0.06 
Fat 0.16 llCi/g 0.08 
Brain 0.18 llCi/g 0.09 
aMean value of duplicate determinations are shown. 
, ' 
o 
TABLE 3 
Urinary excretion of tryptophan-S 'and metabolites by rats 
The values shown are mean % of dose S.D. for a group of five rats. 
Compound ~ % of dose 
Tryptophan-S (I) 20.6 ± 0.8 
Metabolites 
II 
III 
IV 
V 
225 
1.3 ± 0.1 
14.2 ± 1.4 
4.9 ± 0.3 
46.2 ± 1.7 
I 
COOH 
.. 
i 
j .:' 
I 
Scheme 1. 
The metabolic fate of tryptophan-S in the rat. 
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Fig. 1. Scheme for the isolation of metabolites from rat urine. 
ng. 2. 
Fi g. 3. 
GC separation of TMS derivatives present in Fraction B obtained 
from control (A) and drug-treated rats {B}. Numbers II-V denote 
metabolites. 
GC separation of TMS derivatives present in Fraction F obtained 
from control (A) and drug-treated rats (B). Number 1 denotes 
the parent compound. 
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RAT URINE (0-24 hr) . 
12N HQI tc;> pH 1.Q. Ether t -- 1 
Ether Extract 
15% NaHC03 
r------- '. 1 
Aqueous Layer 
12N NaOH to pH 13.0 Ether ! -------·-·-1 
Eth-er Extract Aqueous Layer Ether Extract 
FRACTION C (1.4%) 
Aqueous Layer 
FRACTION A (0.5%)" 12N HC.ItO-PH 1.0 
Ether .. 
l_---r 
1'03 
N 
00 
Ether Extract Aqueous Layer 
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ABSTRACT 
The effects of 5,6-dihydroxytryptamine (5,6-DHT) and its benzo-
[b]thiophene analogue (5,6-DHT-S) have been compared with regard 
to their ability to influence tissue levels of 5HT and NE in rats. 
After i.p. administration, both compounds caused significant reduction 
in NE levels in heart and spleen, while only 5,6-DHT reduced spleen 
5HT, and neither compound had any effect on brain NE or SHT. When 
administered directly into the lateral ventricle, both compounds 
caused reduced NE levels; the duration of effect was less than 1 day. 
In contrast to the prolonged lowering of brain 5HT and 5HIAA observed 
after 5,6-DHT, the benzo[b]thiophene analogue was without effect. 
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I NTRODUCTI ON 
The search for compounds to use as biochemical tools for 
examining the function of neurotransmitter systems has seen a 
significant volume of publications in the past decade, especially 
in terms of those systems involving biogenic amines. For example, 
the initial discovery of the long-lasting depletion of heart 
norepinephrine (NE) following administration of a single dose 
of 6-hydroxydopamine (6-HDA) [1] led to hundreds of studies of the 
latter compound and culminated in its present characterization 
as an agent capable of producing a "chemical denervation ll of 
adrenergic neurons [2]. Because of the poor ability of 6-HDA to 
penetrate the blood-brain barrier, it was soon found that injections 
into the lateral ventricles or other area(s) of the brain were 
necessary to obtain effects on centtal norepinephrine systems [3]i 
once the blood-brain barrier was bypassed, expected effects were 
obtained [4]. 
In 1971, Baumgarten and coworkers [5] published the first 
report of the actions of 5,6-dihydroxytryptamine (5,6-DHT), a 
compound apparently analagous to 6-HDA, but active only on those 
neuronal fibers containing serotonin (5HT). Since that first 
report, a number of papers have appeared confirming the fact that 
5,6-DHT caused selective degeneration of indoleamine terminals 
in a manner similar to that caused by 6-HDA on adrenergic neurons 
[6-8]. As with 6-HDA, the poor abil i ty of 5,6-DHT to cross the 
blood-brain barrier demanded that the compound be administered 
by 'intraventricular injection in order to obtain an effect on 
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brain 5HT [5-9]. 
Additional efforts by Baumgarten, et !l [10] demonstrated 
that peripheral administration of 5,6-DHT produced a marked decrease 
of NE levels in heart and spleen of rats and mice, although the 
NE levels returned to normal in 24 hours. In this regard, it is 
of interest that Heikkila and Cohen [11] found that 5,6-DHT was 
an inhibitor of 5HT and dopamine uptake by brain slices; in contrast, 
6-hydroxydopamine under similar conditions inhibited dopamine 
uptake but was without effect on 5HT uptake. Decreased uptake of 
5HT by brain synaptosomes in vitro has been domonstrated by 
Baldessarini and Gerson [12] to occur after pretreatment of rats 
with 5,6-DHT; these authors found no reduction in NE uptake .by spinal 
cord synaptosomes. Richardson, et a1 [13] found depletion of brain 
5HT but not brain NE at 14 days after a single dose of 5,6-DHT. 
Against this background, one unusual report is that of Costa, et !l 
[14] who found that samples of 5,6-DHT differed in potency as measured 
by their effects on SHT. 
This laboratory has been interested in the applicathm of 
principles of selective molecular modification as a means of studying 
biological structure-activity relationships of indoHc compounds for 
\ 
a number of years. In particular, efforts have centered on the pharma-
cological effects of the benzo[b]thiopheoe and l-methylindole analogues 
of indoleal kyl amines [lS-17]. the intestinal absorption of simil ar' 
analogues of tryptophan [18-19], and the substrate specificity of 
aromatic-l-amino acid decarboxylase with regard to tryptophan analogues 
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[20]. Recently. the synthesis of 5,6-DHT-S [21] made available 
sufficient materia1 to permit a detailed study of the role of the 
indolic nitrogen in the action of 5,6-DHT on monoaminergic systems. 
MATERIALS AND METHODS 
Adult, male Sprague-Dawley rats (275 - 300 g) were obtained 
from Murphy Breeding laboratories, Plainfield, Indiana and maintained 
for at least five days prior to use on a diet of Purina laboratory 
Chow and tap water ad lib. All chemicals and reagents were purchased 
from commercial sources. 
Drugs given intraperitoneally were made up as solutions in 
distilled water such that the specified dosage in mg/kg was contained 
in a volume of 1 ml/kg body weight. Drugs injected intraventricularly 
were dissolved in diluted mammalian Ringer's solution {1/3 distilled 
water, 2/3 Ringer's solution) containing 0.1 mg ascorbic acid per 
milliliter at concentrations such that the desired dose was given 
in a 10 III volume. 
Intraventricular injections of drugs were accomplished according 
to the method of Noble, et ~ [22] with the following modifications. 
Injection volumes were delivered by Hamilton 50 ~l syringes and 
limited to 10 III maxima. The syringes were equipped with 3/8 11 
27-guage needles and were stereotaxically placed to a depth of 
3.75 ± .05 mm in the lateral ventricle. Following injection, the 
hole in the skull was closed with bone wax, the wound was dusted 
with sulfathiazole and closed with wound clips. 
Rats were sacrificed by decapitation, and tissues were removed, 
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washed in cold 0.9% saline, blotted dry and sto
red at -200 C 
until assay. Brains were dissected just prior to assay into
 three 
sections: cerebral hemispheres, cerebellum, an
d the remainder 
(arbitr-arily referred to as "brainstem"). Tissue levels 
of 5HT. 
NE, and 5HlAA were determined as reported by M
iller, et !l [23]. 
RESULTS 
Effects of Parenteral Administration of 5,6-DHT
 and 5,6-DHT-S 
The results obtained after administration of s
ingle i.p. doses 
of 5,6-DHT and 5,6-DHT-S (30 mg/kg) to rats are presented
 in Table 1. 
The results for heart NE show the compounds to
 be virtually identical; 
an initial decrease to minimal values of appro
ximately 50% of zero 
time values is followed by a return to slightl
y above normal levels 
by 16 hours after dosage. The actions of the t
wo analogues on spleen 
NE were slightly d~fferent. 5,6-DHT reduced sp
leen NE levels to a . 
minimal value of less than 50% of control at B
 hours after dosage; 
at 24 hours values were still only 71% of con
trol. The action of 
5,6-DHT-S \'1as slightly less effective (just reaching the 50%
 level 
of depletion at 4 hours) and shorter in duration, returni
ng to normal 
levels by 16 hours after dosage. 
The results for 5HT in spleen were quite differ
ent in terms of 
the two compounds. 5,6-DHT caused a significan
t and persistent 
decrease, reaching a minimal level of about 50%
 of control at 16 
hours and lasting beyond the 24 hour time poin
t. In contrast, 
5,6-DHT-S produced an initial increase in splee
n 5HT, peaking at 
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2 hours, and returning to normal levels by 4 hours. As might be 
expected, no effects whatsoever were seen with either compound in 
terms of brain 5HT or NE. 
Time Course of Effects of Intraventricular Administration of 5,6-DHT 
and 5,6-DHT-S 
Since the blood-brain barrier prevented the 5,6-dihydroxy 
compounds from having any effects 'on brain biogenic amines, a series 
of studies were performed with the injection of the compounds directly 
into the lateral ventricles of the rat brain. Because of the well-
known differences in amine biochemistry in various brain areas, 
brains were divided into three parts prior to the assay. These 
results are presented in Tables 2, 3, and 4 for NE, 5HT and 5HIAA, 
respectively. 
The effects on HE levels, as shown in Table 2, show that both 
the indole and benzo[b]thiophene compounds are completely inactive 
at the lowest dose of 20 ~g/rat, while some slight but significant 
decreases are seen at the higher doses. In the cerebral hemispheres, 
5,6-DHT causes a significant reduction of HE levels at both 40 and 
80 ~g doses from 2 to 16 hours. In contrast, 5,6-0HT-S si~nificantly 
lowers HE at the 40 ~g dose only at the 4 hour time point, while the 
80 ~g dose of the benzo[b]thiophene compound is effective in lowering 
HE levels at the 4, 8, and 16 hour points. Cerebellar HE levels 
were significantly lowered by 5,6-DHT at 1 and 2 hours after doses 
of 40 or 80 ~g/rat; the only point showing a significant effect of 5,6-
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DHT-S was at 1 hour after the 80 ~g/rat dose, where a decreased NE 
level was observed. In the brainstem portion, neither compound 
had a significant effect on NE levels at the lowest (20 ~g) dose; 
the 1 hour time point showed a modest, though not statistically 
significant lowering of NE. At a dose of 40 ~g/rat, 5,6-DHT 
l~wered brainstem NE significantly at the 1,2, and 4 hour points, 
while at the 80 ~g/rat doses, both 5,6-DHT and 5,6-DHT-S significant1y 
lowered the NE at 1, 2, and 4 hours. 
The effects of the two compounds on 5HT levels were distinctly 
different, as shown in Table 3. 5,6-DHT-S was completely ineffective; 
no significant alterations in 5HT levels were seen in any brain 
area, at any dose or time point. In contrast, the effects of 5,6-
DHT were clearly unique to each brain area. In cerebral hemispheres, 
the lowest dose (20 ~g) of 5,6-DHT was ineffective, the intermediate 
dose (40 ~g/r~t) caused significant lowering of 5HT levels from 2 
hours through 2 days, and the high dose (80 ~g/rat) was effective 
for at least 16 days. Cerebellar 5HT was relatively resistant 
to the effects of 5,6-DHT; a significant lowering was observed 
only at 16 hours, 1 day and 4 days after the highest dose (80 ~g/rat). 
In the brainstem, the low dose (20 ~g/rat) of 5,6-DHT caused a 
significant lowering of 5HT at the 4 hour and 1 day points, while 
at the highest dose (80~g/rat), 5HT levels wer~ significantly 
depressed from the 1 hour point to at least 16 days. The inter-
mediate dose (40 ~g/rat) decreased brainstem 5HT from the 1 hour 
paint through 8 days; the lack of statistical significance at the 
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16 hour, 1 day and 4 day points may be attributed to the larger 
standard deviations obtained. 
The effects an 5HIAA levels in the various brain areas are 
shown in Table 4. With the exception of the 2 hour point after 
the high (80 ~g/rat) dose of 5,6-DHT"S in brainstem, no significant 
changes in 5HIAA levels were seen. A lowering of 5HIAA was seen 
after the high (80 ~g/rat) dose of 5,6-DHT in cerebral hemispheres 
at all time points from 4 hours to 16 days. At the intermediate 
dose (40 ~g/rat) a lowering of hemisphere 5HIAA was seen from 4 
hours to 8 days, although only the 16 hour and 4 and 8 day points 
were statistically significant. No changes were observed after the 
low dose. Cerebellar 5HIAA was resistant to the effects of 5,6-
DHT; only a few time points at the high dose were significantly 
lowered. In general, the effects of the high dose of 5,6-DHT on 
brainstem 5HIAA reflected the actions of the compound on 5HT, that 
is a lowering from 2 hours through 16 days, although the 4 hour 
time point was not statistically significant. The intermediate 
(40 ~g/rat) dose showed a Significant lowering of brainstem 5HIAA 
only at the 4, 8, and 16 hour time points, while the lowest dose 
had a significant effect only at 4 hours and 2 days. 
DISCUSSION 
Since the first report by Baumgarten and co-workers on the 
selective neurotoxicity of 5,6-DHT [5] this compound has been of 
wide interest to investigators dealing with various aspects of 
serotonergic function in animals. Of particular interest has been 
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the selectivity of the compound; its ability to cause damage to 
serotonergic stores without affecting catecho1aminergic stores is 
unique, as is its exceptionally long duration of action [5-13]. 
Although some questions have been raised of its relative potency 
(perhaps due to an impurity in some preparations). 5,6-DHT has, 
in general been shown to be an effective and selective serotonin 
neurotoxin [14]. 
For the past 8 years, this laboratory has had a continuing 
interest in the comparative actions vf benzo[b]thiophene analogues 
of indolic compounds having biological significance. Beginning 
with the comparative effects of serotonin and its benzo[b]thio-
phene analogue [15], and continujng through the pressor effects of 
tryptamine and its benzo[b]thiophene and l-methylindole analogues 
[16] studies have shown that certain similarities and differences 
in pharmacb10gic potency exist with regard to the atom located at 
the l-position of the heterocycle. For example, the substitution 
of a sulfur atom for the ring nitrogen in tryptophan has little 
effect on the active transport of the molecule across the intestine 
[19]; however, the slightly greater lipid solubility of the benzo-
[b]thiophene analogue of tryptophan does lead to a slightly more 
rapid passive diffusion component in the i!l. situ perfused intestine 
[18]. When the analogues of tryptophan were tested as substrates 
for aromatic-L-amino acid decarboxylase, however, replacement of 
the indolic nitrogen by a sulfur atom led to a complete ~loss of 
substrate activity [20]. 
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.The possibility of examining the neurotoxic action of 5,6-0HT 
by use of its benzo[b]thiophene analogue led to its synthesis [21] 
and the comparative studies reported in the present paper. When 
administered parenterally to rats, 5,6-0HT-S had an effect on NE 
in heart and spleen basically similar to that of 5,6-0HT, that is, 
a modest depletion seen over 2 - 8 hours after dosage. No effects 
of either compound could be measured on brain NE or 5HT, nor did 
the benzo[b]thiophene have any effect on spleen levels of 5HT, 
other than a modest elevation at the 2 hour time point (Table 1). 
t~hen administered 'by direct injection into the lateral ventricle 
of the rat brain, 5,6-0HT-S had, in general, effects on NE similar 
to those of the indolic 5,6-0HT (Table 2), although the benzo[b]-
thiophene analogue is only about half as potent. In sharp contrast, 
however, are the data presented in Tables 3 and 4, clearly demon-
strating that the 5,6-0HT-S has no effects on brain 5HT whatsoever; 
The actions of 5,6-DHT,. as reported in the present paper, are basically 
in agreement with previous reports, especially that of Costa, et !l 
[14]. Thus the cerebellum is most resistant to the 5HT-depleting 
actions; no significant effects are seen until the dose of 80 ~g is 
reached. Another similarity is the extent of 5HT depletion seen 
with 5,6-DHT. Th~ material used in this study was obtained from the 
Regis Chemical Company, is presumably similar to that described as 
5,6-DHT-II by Costa, et !l [14], and therefore is slightly less potent 
than the material originally used by BaUmgarten and co-workers [5]. 
Perhaps the most significant aspect of the present report lies in 
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the inability of the benlo[b]thiophene analogue of 5,6-DHT to exert 
any significant effects on levels of 5HT. One explanation for this 
striking difference may lie 1n the possibility that the action 
of 5,6-DHT on 5HT stores requires an intermediate quinone-type 
structure as has been proposed for 6-hydroxydopamine [24]. If one 
considers the structures of 5,6-DHT and its benzo[b]thiophene analogue: 
HO HO 
HO 
HO 
it is reasonable to assume that a likely quinone structure can be 
proposed for the indolic compound that would not be chemically 
feasible for the benzo[b]thiophenet 
o 
HO 
This may be the structure active in causing 5HT depletion and degener-
ation of serotonergic fibers. In this sense, both compounds might 
be expected to have a short-acting effect on NE stores, merely 
since they both contain a catechol function that could act as a non-
specific substitute for catecholamines in their storage processes. 
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TABLE 1 I 
~ 
Effects of Parenteral Administration of 5,6-DHT and 5,6-DHT-S 
J 
Each value is the mean ± S.E.M. of values obtained from 4 animals, I 
except that control values are obtained from 16 rats. Values that 
significantly differ from control (p < .05) are underlined. 
Time ComEound* Heart NE SE1een NE SE1een 5HT Brain NE Brain 5HT 
ThrS) j.ig/g J.lg/g ).1g/g J.lg/g \.I9/9 
a 0.29±.O2 0.42±.O7 1.40±.09 0.49±.04 0.61±.04 
'I'\) 1 N 0.19±.02 O.33±.02 1.35±.16 0.47±.03 O.61±.03 
,~ S O. 2lH. 02 0.28±.01 1.92±.18 0.49±.05 0.64±.07 U"I 
1 
'~ 
2 N O.14±.01 0.25±.02 1.14±.08 0.48±.02 0.58±.07 
S O.1S±.Ol O.28±.O3 2.2i±.28 0.51±.OS O.59±.04 
4 N O.17±.Ol 0.21 ±.Ol 1.16±.13 0.50±.O3 0.60±.06 
S 0.18±.O3 0.21 ±. 04 i.56±.10 0.48±.03 0.58±.05 I-
:\ 
8 N 0.25±.02 0.20±.01 . 0.97±.07 0.51 ±. 06 0 • .57±.03 
.'j 
rj 
S O.23±.Ol O.25±.O4 r.42±.25 O.46±.02 0.62±.02 
16 N O. 33±. 02 O.25±.04 0.72±.05 0.47±.03 0.65±.07 
S 0.30±.O2 O.37±.02 1.64±.21 0.50±.05 0.58±.O3 
24 N 0.31±.01 0.30±.O3 0.85±.06 0.48±.02 0.61 ±.O2 
S O.27±.O3 O.39±.04 1.53±.04 0.45±.05 O.59±.05 
*N = 5,6-DHT; S = 5,6-DHT-S 
~ 
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.. TABLE 2·'· la 
':)tft,J"'" " .. ~: ~ : Effects of Intraventricular Dosage of Compounds on Regional Brain NE 
< '-j 
Time/Dosage* Cerebral Hemispheres Cerebellum Brainstem 1 
20).19 40).19 80).19 20).19 40).19 80flg 20).19 40).19 80).19 j 
------ 1 0 hrs 0.3S±.06 0.43±.04 0.40±.05 o .14±.02 0.17±.01 0.17±.02 0.98±.13 1.05±.08 1.01±.11 
I 
1 hrs N 0.34±.07 0.37±.06 0.36±.04 0.13±.02 O.12±.03 O.13±.02 O. 76±. 19 0.85+.06 0,85+.]0 i 
II S 0.37±.07 0.33±.07 0.39±.07 0.16±,03 0.17±.03 O,13±,02 0, 74±. 19 O,99±,OS 0,70+,13 1 
2 hrs N O,32±.10 o 30+ O~ 0.28+.07 0.13±.03 0.14±,02 0, 13±, 02 0.81±.16 0.85+.09 0.74+.14 
~ 
'I 
II S O,37±.04 0.37±.05 0.37±.04 o ,13±. 03 0.1·6±.02 0, lS±. 03 0, 84±.1l O. 99±. 11 O. 72±, 14 i j 
, 
4 hr.s N O,32±.08 0.31±.07 0,29+.03 0.13±.04 0.17±.03 O. 16±. 02 0.93±.11 0.75+.10 0.77+.06 Il II s 0.43±.12 0.3S±.02 0 .. 3.4±.04 O. lS±. 02 0.1S±.02 0.16±.02 0.92±.06 0.91±.11 0.79+.10 
IJ 8 hrs N 0.41±.OS 0.30±.09 0.30±.OS 0.12±.04 0.16±,04 0.16±.02 
1. 03±. 12 0.99±.08 0.91±.13 
II S 0.37±.03 0.37±.05 0.27+.08 O,lS±.Ol O. 16±. 02 0.16±.03 O. 98±. 11 O. 92±. 13 0.93±.16 
16 hrs N 0.42±.'lQ 0.30±.09 0.27+,03 0.13±.03 0.15±.04 0.14±.03 0.88±.09 1 . 07±. 17 O. 93±. 11 
'J Ii S 0.36±.09 0.43±.04 0.32±.04 o .12±. 02 0.19±'.02 0.15±,02 0.97±.09 1. 07±. 09 1. 04±. 11 1 
1 day N 0.36±.03 0.3S±.05 0.34±.09 0.11±.D3 0.lS±.02 O,14±,03 ] • 02±, , 7 ] • 08±, 06 O,94±,10 ,1 
II S 0.39±.06 0.39±.04 0.30±.09 0.13±,03 O,17±.02 O,17±.01 O,93±,15 1. 03±, 14 O. 93±, 11 1 2 days N 0.33±.08 0.35±.OS O,43±.05 o .15±. 02 O,17±,02 0.lS±.03 0.90±.11 1. 13± .14 O. 93±, 11 
II S O,3S±,11 0.34±.OS 0.37±.02 0.13±.03 0.lS±,03 0.16± .02 0.94±.15 O,97±,)6 O,90±.17 • ~ 
4 days N O,37±.06 0.41±.06 0.41±.11 0.12±.02 0.18±.03 0.17±,Ol 0.92±,19 1. 08±, 11 0.93±,13 
I 
I 
II S O,33±,06 0.36±.04 0.43±.09 0.1l±.03 0.16±.02 0.17±.02 o .89±.17 1. 09±. 11 0.89±.14 'i ! 
8 days N 0.40±,08 0.37±.OS 0.18±.03 0.15±.01 1 . 13±. 15 0.92±.09 t j 
II S 0.41±.OS 0.43±.04 0.18±.02 o .16±. 02 1. 12±. 13 1. OS±,11 If 
16 days N 0.3S±.12 0.16±.02 0.98±.07 
j 
1 
II S 0.35±.08 0.15±.03 0.99±.05 
I 
*N = 5,6-0HT; S = .5,6-DHT-S H Each value is the mean ± S.E.M. of values obtained from 4 animals, except that control values are obtained 
from 16 rats. Values that significantly differ from control (p < .05) are underlined. 
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'., ,-\ i I <",.,1 . TABLE 3 r 
;' J 
1 Effects of Intraventricular Dosage of Compounds on Regional Brain SHT 
Time/Dosage* Cerebral Hemispheres Cerebellum Brainstem 
20llg 4~ll9 BOllg 20llQ iOll9 ~ ~ 4~ll9 fOp9 0 hrs 0.34±.04 0.3 .04 0.33±.02 0.20±.03 o. B±.01 0.19± .02 1.09±.ll 1.0±.16 1. 7±.13 
1 hr N 0.35±.03 0.29±.05 0.32±.04 0.19±.02 0.15±.02 0.16±.02 0.96±.16 0.B4±.11 0.85± .13 
II· S 0.31±.03 0.30±.03 fl.33±.05 0.21±.02 0.18± .03 0.96±.17 0.96±.17 , .OO±." 1.1B±.18 
2 ~~·s N 0.29±.03 0.26±.02 0.29±.03 0.20±.04 0.16±.02 0.18±.02 1.00±.17 0.80±.13 0.89±.06 
II S 0.31±.06 0.28±.05 0.311.04 0.22±.05 0.16±.02 0.19±.03 1.17± .15 0.B7±.13 1.11±.11 
4 hrs N 0.29.±.04 0.24±.03 0.26±.03 0.17±.03 0.17±.02 0.17±.02 0.90±.OB 0.75±.12 0.84±.16 
II S 0.34±.02 0.31±.16 0.31±.04 0.20±.03 0.17±.03 0.22±.04 1.13±.07 0.88±.15 1. OS± .11 
8 hrs N 0.31:1:.02 0.25±.03 0.28±.03 0.21±.02 0.16±.04 0.19±.01 0.96±.09 0.80±.14 D.83:t ,~ 
II S 0~32±.02 0.30±.04 0.30±.03 0.22±.04 0.19±.02 0.20±.03 1.04±.10 0.98±.14 1.13±-~ 15-
16 hrs N 0.29±.03 0.24±.04 . 0.22+.Q6 0.20±.02 0.17±.02 0.14±.03 0.9B±.12 0.B9±.15 0.91±.07 
II S 0.34±.03 O.3l±.04 0.37±.03 0.18±.03 0.19±.02 0~20±.03 1.04±.10 1.06±.17 1.17±.06 
1 day N 0.36±.03 0.25±.03 0.26±.02 0.19±.03 0.17±.02 0.14±.02 0.80±.14 0.89±.14 0.97±.10 
II S 0.34±.04 0.33±.04 0.30±.06 0.20±.03 0.17±.04 0.19±.03 1.00±.12 1.11±.11 1.18± .11 
2 days N 0.35±.03 0.24±.03 0.2B±.01 0.19±.03 0.19±.03 0.16±.02 1 .02±.1 2 0.71±.17 '0.95±.11 
.. S 0.36±.03 0.28±.04- 0.32±.03 0.19±.03 0.18±.03 0.21±.02 1.19±.11 0.95±.13 1.05±.12 
4 days N 0.31±.03 0.32±.05 0.'-6±.03 0.18±.04 0.18±.04 0.16±.01 0.96±.11 0,92±.07 0.97±.14 
II S 0.37±.03 0.33±.03 0.32±.03 0.21±.03 0.20±.04 0.18±.02 1.04±.11 l.08±.11 1.19±.13 
8 days N 0.27±.04 0.27±.03 0.19±.03 0.21±.02 0.B01:.07 0.74±.20 
It S 0.29±.04 0.33±.03 0.21±.05 0.18±.03 1.10±.10 1.19±.13 
16 days N 0.23±.03 0.18±.02 0.91±.OB 
II S 0.33±.02 0.lB±.03 1.09±.10 
*N = 5,6-DHT; S : 5,6-DHT-S 
Each value is the mean S.E-M. of values obtained from 4 animals, except that control values are obtained 
from 16 r.ats. Values that significantly differ from control (p c_.05) are underlined. 
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_ I ~ TABLE 4 
Effects of Intraventricular Dosage of Compounds on Regional Brain 5HIAA 
Tinle/D(lsage* Cerebral Hemispheres Cerebell um Brainstem 
o 'ht~s 
20~g 40~ig BO~g 
0.52::.04 0.50::.07 0.56::.06 
20}J9 40 1J.9 SOjJ9 20ug 40\19 BOl-q, 
0.23' .. 01 0.2li: .02 0.2S:t.02 0.76::- . 04 O. 65±. 10 0.77:' . !It! 
1 hl~ N 0.56±.04 0.52:t .. 12 0.62:t.06 O. 25:!. .04 0.2li.03 0.26±.04 O. 82±. 14 0.75:t.16 
O. S6: .12 
" 5 0.57±.04 0.422,.13 0.502:.09 0.241.03 o .18i. 03 0.24±.05 
0.B7±.15 O. 8S±'. 13 O. SO.! .12 
2 ill'S N 0.471.05 0.57.!. .11 0.52.'..11 0.2h.02 o .22±.03 0.20:':.06 O. B6:t. 14 O
. 79±. 12 0.97= 16 
1\ S 0.55:!-.06 O.47±..O9 o .4S±. 12 O.26:t.03 0.22±.03 0.27±.05 O. B9± .14 O. 69±. 11 1
 . 'JO=- .09 
4 hl~S N 0.51±.10 0.441..13 0.43±.09 0.192:.06 0.2li.03 0.lB±.03 O. 55± . 12 0.5
1±.O7 0.87::.17 
., ~ 0.58;..13 OA6.:.09 0.56:..06 ". 0.26i.07 0.23:,:.05 0.28=.05 0.72
::.06 O. 58=-. 11 O. 9f': 1.~ 
S hrs N 0.54J.05 0.421. 11 0.45:1'.05 0.25i.03 0.21::.02 O.20±.04 O. 
65±. 21 0.47:t.07 0.57; .08 
" S O. 54:l. 04 0.43.'.07 0.55::.10 O.25:r.02 0.24±.04 
O.27:!...O3 o .B6±. 15 O. 6B±. 13 0.73= . '-: 
N 16 llY'S 
t; " 
N 0.44J.06 0.3S.!:.07 0.45+.05 
S 0.46±.OB 0.4B:r.07 0.63:".08 
0.21:;:.02 o .1B±. 04 0.20±.05 0.7l±.OB 0.49±.OB 0.59:,,06 
0.202..06 0.23±.02 0.23:!..O3 0.6B1:..07 0.67=.09 0.67.: .. C9 
1 day N 0.45±.06 0.4h.13 0.3B:!:.04 0.23::.02 O.19±.04 0.20::.04 O. 72
±. 07 O. 56± .12 ,O.62! .07 
.j 5 0.53±.OS 0.55±.07 0.50±.07 O.22±.O5 0.19±.04 0.282:.03 0.72±.09 0.68±
.08 0.85.:..02 
2 days H 0.55±.04 0.461:.07 0.44:!'.07 0.19:1..03 0.21±.05 0.lB±.03
 0.59±.05 O.65±.12 0.55=.10 
" 5 0.49i.04 0.53±.09 0.57±.OB 0.23::.02 O.24±
.03 0.28±.06 0.72±.O4 0.63±.16 O. B9~ .07 
4 days N 0.531.11 0.36J.l1 0.39±.02 0.19±.04 0.24±.03 0.23±.04 
O. 79±.11 O.60±.12 O. 59:!.. 11 
It S 0.56.1 .. 09 0.481.12 0.57:1..06 0.25±.03 O. 24±. 04 0.23±.03 O.82±.12 
O. 70± .13 0.79.:.15 
8 days N 0.40i.04 0.342.11 0.21±.02 0.28±.0
3 0.62±.07 0.60=.05 
.t S 0.51 :t.OB 0.61:!..ll 0.24±.03 0.2l±.D6 0.7
3±.OB 0.88::..09 
16 days 
" 
N O,1J.6:!..04 
5 O. 58:!.. 12 
0.21±.04 0.52:t.13 
0.25=.03 0.90:..1 ::f 
*tl. = 5,6-DllT; S :0 5,6 .. 0HT-S 
Each value is the mean ± S.E.M. of values obtained from 4 animals, except that contro
l values are obtained 
from 16 rats. Values that significantly differ from control (p < .05) are underlined. 
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Section on Pharmacology, Medical Sciences Program 
Indiana University School of Medicine 
Bloomington, Indiana 4/401, U.S.A. 
CONTRACTILE RESPotlSES TO TRYPTAr~INE ANALOGUES 
IN ISOLATED S~100TH I~USCLE 
E. Jane Hixson', Gloria V. Lehrmann, and Roger P. Maickel 
Running Title: Effects of tryptamine analogues on smooth muscle. 
lSouthern Research Institute, 2000 Ninth Avenue, Birmingham, 
Alabama 35205. 
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INTRODUCTION 
In 1954. two reviews of the earlier literature on 3-(2-amino ethyl) 
indole (tryptamine) and its 5_hydroxy1ated ana10Que (serotonin) were published 
(1.2); both of these hinted at a unique set of physio109ica1 receptor systems 
for indo 1 ea 1 ky1 ami nes. ~'ost of the support for speel fi c tryptami ne or 
serotonin receptors came from two laboratories who had published the previoUs 
year (3.4). A variety of subsequent studies led to the conclusion that 
receptors with considerable specificity for tryptamine did exist in some 
peripheral smooth muscle sites (5) although there was some question of the 
existence of peripheral receptors specific for serotonin (6). Recently. 
o-'W 00' 
Pinder. et ~ (7) examined some effects of the idene and benzo[b]thiophene 
isosteres of serotonin on the rat stomach fundus preparation. Hore recently. 
this laboratory has reported on the comparative pressor effects of the 
benzo[b]thiophene and l_methy1indole analogues of tryptamine in the intact 
rat (8). The present paper reports on the isolated rat aorta and stomach 
funduS preparations as a test system for comparing the isost~es of t~ptamine. 
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~1ATERIALS AND ~1ETHODS 
Adult, male Sprague-DaVlley rats (180-220 g) were obtained from t1urphy 
Breeding Labs, Plainfield, Indiana, U.S.A. and maintained on a diet of Purina 
laboratory chow and tap water ad lib for 7-10 days prior to experimental use. 
The animals were sacrificed by decapitation. Aortic strips (1.5 to 2 mm wide 
and 3 cm long) were prepared by the method of Furchgott and Bhadrakon (9) 
and suspended in a 60 m1 organ bath. Stomach fundus strips (one strip 1.5 to 
2.0 mm wide and 1 .. 5 cm long from each stomach) vlere prepared by the method of 
Offermeier and Ariens (10), and likewise suspended in a 60 ml organ bath. 
Druas and solutions. The Kreb's bicarbonate solution in which the tissues 
M 
were suspended contai~ed the following compounds in m moles per liter: 
NaCl, 118.5; KCl, 4.8; CaC1 2, 2.5; NaH ZP04, 1.18; MgC1 2, 1.1
8; NaHC03, 24.87; 
O-glucose, 11.1. In addition 10 mg of disodium ethylenediamine tetraacetic 
'acid (Na2EDTA) were added per liter to protect the added 
amines from oxidation. 
The solution was stored at 4° C until use; during the experiment it was 
maintained at 37° C and bubbled with 95% O2/5% CO2, The pH of the solution
 at 
room temperature without bubbling was adjusted to 6.5 with concentrated HC1; 
after warming and bubbling for at least ten minutes the pH increased to 7.4. 
The following drugs were used: 1-norepinephrine hydrochloride (Regis 
Chemical Co.), 5-hydroxytryptamine creatinine sulfate (Regis Chemical Co.), 
tryptamine hydrochloride (Regis Chemical Co.), pargyline hydrochloride 
(EutonylR, Abbott Laboratories), and methysergide tartrate (Sanfert
R
, Sandoz 
Laboratories). In addition, the fol1O\'ling compounds, prepared by Or. E. E. 
Campa;gne (Department of Chemistry, Indiana University, Bloomington, IN) 
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were used: 3-(2-aminoethyl)benzo[bJthiophene (tryptamine-S) and 1-methy1-
3-(2-aminoethy1 indole (t.ryptamine-1-Me). All drugs \</ith the exception of 
~ethysergide were made up in distilled water and the pH adjusted to 6 with 
solid NaHC03. L-ascorbic acid (Fisher Scientific Co.), 0.2 mg/ml, was 
added to the serotonin solution to prevent oxidation. Methysergide was 
dissolved in 1N Hel; the pH was adjusted to 5 with 0.5N NaOH. All drugs were 
kept frozen until just prior to use; concentrations are expressed as weight 
of free base. 
Procedure. A strip of either tissue, attached using silk suture thread to 
an isotonic lever under 2.5 g tension, was connected through an isotonic 
myograph transducer to a recording physiograph (Narco Biosystems, Inc., 
Houston, TX). Eight- to ten-fold ma9nification was used for the aortic 
strips, four-fold for the stomach fundus strips. Aortic tissue was allowed 
to rest for 2 hours prior to study w'ith bath fluid ch~nges at 15-minute 
. -5 lnterva1s. Pargyline at 10 M was added to the bath dUring the first hour 
at rest. Stomach fundus strips were allowed to rest for 50 minutes; pargyline 
at 10-5M was added to the bath four times during this period. 
In all experiments the height of maximal contraction was first determined 
by the cumulative addition of increasing concentrations of the agonist. The 
preparations were then washed at 15-minute intervals until each had returned 
to its previous baseline. Cumulative dose-response curves for the agonist 
(3 or 4 responses, 20 to 8mb maximal) were obtained until two successive 
curves \'Jere simi 1 ar v/ith respe,ct to both the' hei ght of the response for each 
addition and the height of the total responsu, When the tissue had thus 
stabilized, cumulative dose-response curves for the agonist were determined 
r 
! 
I 
I" "'''''''I'~'- -_. -..,..".-~~.. .. ... "=~~-~",, .. -- .. -.,-. 
I_Ii .... 
, . , 
alternately with those for the reference standard. serotonin. 
The tissues were preincubated with antagonist for 15 minutes. On each 
~ortic strip. three concentrations of antagonist were tested alternately with 
the agonist alone; only one-concentration of antagonist was tested on each 
stomach fundus strip. 
Calculations. All responses were recorded as percentage of the maximal 
contraction. log dose-response curves were calculated as the percent of 
response versuS the log dose by the method of least squares. The degree of 
antagonism was ca1cl lated using the dose-ratio of Gaddum, et a1 ~l), 
comparing the log dose-response curve in the presence of antagonist to the 
immediately preceding curve in the absence of antagonist. The pA2 and pAlO 
were determined by the method of Arunlakshana and Schild (12). Student's 
independent t test was used for tryptamine-S and norepinephrine; Student's 
dependent t test was used to compare the intrinsic activities of the test 
compounds to that of serotonin. The 95% confidence limits for the p02' pA2, 
and pAlO values were calculated as described in Documenta Geigy (1970). 
All calculations were performed using a Compucorp Model 445 Computer. 
RESULTS 
Rat Aorta Strips. Norepinephrine, serotonin. tryptamine, and tryptamine-1-r~e 
elicited increasing contractile responses with the cumulative addition of 
increasing concentrations of agonist. The intrinsic activities of norepine-
phrine. tryptamine. and tryptamine-I-Me were the same as that of serotonin 
(p >.40); thus a = 1 for these three test compounds. The pD2 values for 
these three compounds are presented in Table 1. The intrinsic activity of 
tryptamine-S was 0.79 ± .03 (mean ± S.E.M.). Tryptamine-S did not elicit 
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increasing contractile responses with increasing concentration; for this 
reason, no attempt was made to calculate a p02 for tryptamine-S in this 
tissue. The log dose-response curves for norepinephrine. serotonin. trypta-
mine, and tryptamine-1-Me are shown in Figure 1; the slopes of these curves 
are given in Table 1. The curves for the indolealkylamine compounds are all 
parallel; the curve for norepinephrine is parallel to that of serotonin but 
not to those of the other two indo1ea1ky1amines . 
Methysergide at concentrations of 5 x IO-8M to 1 K IO-6M had no signifi-
cant effect on the responses elicited by norepinephrine. Methysergide 
exhibited a dose-dependent antagonism of the effects of serotonin. tyrptamine. 
and tryptamine-1-Me. The pA2 and pAlO values calculated for methysergide 
against these three agonists are presented in Table 2; the pA plots of 
Arun1akshana and Schild (12) are shown in Figure 2; the slopes of these 
plots are given in Table 2. lhese slopes are parallel by statistical test.' 
and all are significantlY different from the theoretical 'value of (-1). 
Rat Stomach Fundus Strips. Serotonin, tryptamine, tryptamine-l-Me, and 
tryptamine-S elicited increasing contractile responses with the cumulative 
addition of increasing agonist concentrations. The maximum responses elicited 
by the three test compounds were not significantly different from that of 
serotonin; thus the intrinsic activity a = 1 for all three test agonists in 
this tissue. The p02 values for these four compounds and the slopes of their 
log dose-response curves are given in Table 3. The tryptamine curve is not 
parallel to any of the others; the serotonin. t~pt~ine-l-Me. and tryptamine-S 
curves are all parallel to each other. The log dose-response curves for 
the four compounds are shown in Figure 3. 
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Methysergide exhibited a dose-dependent antagonism of the effects of 
all four compounds tested. The pA2 and pAlO values calculated for methysergide 
~gainst the four agonists are given in Table 4. The pA plots?'~e shown in 
Figure 4; the slopes of the plots for the four compounds are 9~~en in Table 
4 •. The slope of the serotonin curve is not statistically significantly 
different from the theoretical value of (-1). The slopes of the curves for 
the other three compounds are parallel, and all are ~tatistically significantly 
different from (-1). 
DISCUSSION 
The data in Table 1 shcH'I that norepinephrine had a much higher affinity 
for receptors on the aorta than does serotonin; in fact, the order of affinity 
for the i ndol e compounds was: tryptami ne-l-r~e > tryptami ne > serotoni n. These 
three compounds apparently act by a similar mechanism, as the slopes of their 
. log dose-response curves were parallel. Norepinephrine might .be interpreted 
as acting via the same mechanism as serotonin, as these two curves had 
parallel slopes. However, the use of specific antagonists has shown that 
they act on different receptors (13), illustrating the necessity for the 
use 01 antagonists in addition to the study of the effects of the agonist 
alcine. The intrinsic activities of the two indole test compounds did not 
differ from that of serotonin, suggesting that the5-bydroxyl group and the 
methyl group on the indol e nitrogen have no effect on the abil ity of the 
compound to elicit a response once it reaches the receptor. These changes 
do, hm'Jever, alter the affinity of the t.,lrug for the receptor relative to 
that of the parent compound. 
It is difficult to interpret the action of tryptamine-S on the aortic 
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strip, since the average threshold response was 65.9% and the average maximal 
ie response was 79.3%. This response range (13.4%) is too narro\'/ to yield 
useful dose-response data. A decay in the response to tryptamine-S was 
usually seen; that is, after the contraction elicited by a particular 
concentration had stabilized, it decreased again toward the resting value. 
This type of effect is usually attributed to metabolic breakdO\'In of the 
;. 
agonist; it could not have been due to breakdown by monoamine oxidase as 
serotonin did not produce this effect on the aortic strips. It is possible 
that tryptamine-S is broken dm·m by a pathvJay for which serotinin is not a 
substrate. Another possible explanation for the decay seen with tryptamine-S 
would be a breakdovin of the free amine by the oxygen dissolved in the buffer; 
this breakdown has been shown to take place in the presence of air (14). 
However, this decay was not seen using fundus strips with identical oxygen 
flow through the same buffer. The explanation that fits the results best 
is that tryptami ne-S exhibits properti es ca 11 ed "noncompetitive autoinhibition" 
by Ariens, et ~ (15). In this concept, a single compound might interact 
with the contractile receptor R and"with an inhibitor "receptor" RI. This 
latter "receptor" is the site of action of noncompetitive antagonists, that 
is, the point at which these agonists disrupt the chain of events linking 
stimulus and response. A compound exhibiting this dualism would have a separate 
intrinsic activity and affinity for each of the two receptors. Depending 
upon the equilibrium constants for occupation of the bID types of receptors, 
one or the other of the two effects, contraction or inhibition, may precede 
the other in time. These results have been observed on frog rectu~ abdominis 
'.~J muscle by Ariens, et 2.l (16). In the present case, the results ind!~cate that 
the agonistic effect of tryptamine-S precedes the antagonistic effect. The 
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affinity of such a drug for the contractile receptor may be calculated, although 
with difficulty, by the use of a competitive antagonist; this has not been 
attempted in the present case due to the narrow response range for tryptamine-So 
On stomach fundus strips tryptamine-S elicited increasing contractile 
responses characteristic of a simple agonist, that is, one which does not 
exhibit the dualism described above. This is seen in the case where aI, the 
intrinsic activity of the compound on RI, is equal to zero (15). However, 
on the aorta tryptamine-S has a' > o. Thus, either RI in stomach fundus is 
different from that in the aorta (more specifically, the mechanism for 
translation of stim~lus into response is not the same in stomach fundus as in 
aorta), or tryptamine-S cannot gain access to R' in stomach fundus. 
The intrinsic activities of the three test compounds, tryptamine, trypta-
m;ne-l ... ~le, and tryptamine-S on stomach fundus strips \'/as the same as that of 
serotonin. It would appear that tryptamine does not act by the same mechanism 
as the other three compounds based on the fact that the slope of its 109 dose-
response curve is not parallel to that of any of the others. The order of 
affinity of the four compounds, as seen in Table 3 ,..,as serotonin» tryptamine-
l-r1e > tryptamine> tryptamine-So Serotonin has the greatest affinity for 
receptors in the stomach fundus, while in the aorta it had the least. The 
differences in the two results may be due at least in part to the lipid solu-
bilities of the various compounds versus the lipid content of the two tissues. 
Lipid partition determinations for the four compounds indicate the order of 
solubility in organic solvents to be tryptamine-S > tryptamine-l-Me > trypta-
mine » serotonin (17). In the isolated aorta, exogenous compounds must 
diffuse through either of two layers of tissue which sandwich the smooth 
muscle fibers. The stomach fundus strip prepared by the method of Offermeier 
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and Ariens (10) has the mucous membrane portion remove
d, which might facilitate 
the diffusion of less lipid soluble compound
s. Thus, more lipid soluble 
compounds might have an advantage in gaining
 access to the receptor on aortic 
smooth muscle, in contrast to the case of st
omach fundus with the gastric 
mucosa removed. This \'1ould cause an apparen
tly high affinity of the test 
compounds for aorta as compared to serotonin
, whereas the results Using stomach 
fundus may more accurately represent the "tru
e" affinities of the four compounds 
for serotonin receptors. 
From Tables 2 and 4 it ;s apparent that meth
ysergide fulfills the criteria 
for competitive antagonism only against sero
tonin on stomach fundus, where 
the pA2 - pAlO differe
nce is .92 and the slope is not significantly
 different 
from the theoretical value of (-1). \tIhen tested on the aorti
c strip, methy-
sergide did not act competitively against an
y of the three agonists. The slopes 
of the curves give an n that is significant
ly less than 1 and the pA2 - pAlO 
differences are higher than .95 (Table 6). Marshall (is) has 
suggested that 
such a result may be due to the fact that th
e antagonist has some affinity 
for receptors for other compounds as \'Iell as
 those under study, so that at 
higher concentrations some of the antagonis
t is "\'/asted" by being adsorbed 
onto these other receptors. Garlitz and Fre
y (l3) have shown that methysergide 
has affinity for adrenergic receptors; it do
es block the effect of norepine-
phrine, although at higher concentrations th
an those required for serotonin 
blockade. The slopes of the three pA plots 
are parallel, therefore there is 
no statistically significant difference in t
he values of n for the three 
compounds. Although methysergide is not act
ing competitively against the 
three compounds, it must interact in the. sam
e \'/ay with each of the agonists, 
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as the values of n are the same for each. 
The results using methysergide against tryptamine, tryptamine-l-f.1e, and 
tryptami ne-S on stomach fundus are the opposite o-f those in aorta. The pA2 -
pAlO differences are less than .95, and the slopes give an n greater than 1 
(Table 4). r1arshall (18) suggested that pA2 - pAlO differences less than 
.95 indicate that the antagonist has a general spasmolytic action on contraction 
rather than a specific action at the receptor. If this were the case, the 
methysergide should have also antagonized the effects of serotonin noncompet-
itively. Gaddum (19) and Arunlakshana and Schild (12) suggested that a value 
of n greater than 1 indicates that more than one molecule of antagonist is 
required in order to block each receptor. For example, the pA plot of 
tryptamine has a slope of (-1.77) (Table 4). The value of n is equal to 
(-slope), or 1.77: Then perhaps 1.77 molecules of methysergide must be 
present simultaneously in order to block one receptor. 
Si nce the slopes of the curves for tryptami ne, tryptami ne-l-r'~e, and 
tryptamine-S are parallel, then the value of n for methysergide against all 
three compounds must be the same (The slopes of the three curves are -1.77, 
-2.22, and -2.19, respectively; the value of n probably falls near the mean 
Of. the three slopes, at approximately 2.00). The pA2 and pAlO values for these 
three compounds are also quite similar (Table 4), so it is probable that the 
three test drugs interact \'lith methysergide in the same (noncompetitive) 
fashion. Since methysergide interacted with serotohin competitively, the 
three test drugs, tryptamine, tryptamine-l-Me, and tryptamine-S do not exert 
their effects by the same mechanism as serotinin on rat stomach fundus. It 
is possible that, in addition to a direct effect on serotonin receptors, 
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tryptamine also has an indirect effect in eliciting a contraction. Indirect 
effects of serotonin have been observed in various portions of the gastro-
intestinal-tract in several species {20-22}. Perhaps the lipid solubility 
differences discussed above enable tryptamine and its isosteres to reach a 
site of indirect action more easily than serotonin, thus requiring more 
methysergide per receptor in order to antagonize their effects. 
It is not strictly possible to compare the receptors in the two different 
tissues by use of pA2 and pAlO values if the antagonist does not act competi-
ti vely agai nst the compounds that acti vate those receptors. IIm'/ever, based 
on the values for n which a particular antagonist exhibits against a group of 
compounds in two different tissues, it should be possible to compare the 
members of the group against the standard. Serotonin, tryptamine, and 
tryptamine-l-t,je interact vlith methysergide in the same fashion on the receptors 
of the aorta. On the stomach fundus, hov/ever, tryptami ne and tryptami ne-l-r~e 
apparently do not act on serotonin receptors. Since the test drugs are the 
same and the antagonist is the same, on the basis of the experimental evidence 
presented herein it would seem that serotonin receptors in the aorta are not 
the same as those in the stomach fundus. It would appear that the receptors 
in the stomach are more specific for the serotonin structure than those in the 
to-
aorta, as the loss of 5-hydroxyl group and additi on of a methyl group to, or 
substitution of sulfur for the indole nitrogen leads to a change in the 
mechanism by ~/hich the compound elicits a response in the stomach. Thus, the 
differences in the relative affinities of the test agonists versUS serotonin 
on the blO tissues are not due to diffel~ences in lipid solubility alone, but 
(~) rather reflect a true difference in the interaction of the drugs with the 
receptors in the two tissues. 
260 
;1 
:i 
:f:: j·t: 
if: 
:.'.~ I n 
'.,. 
j 
1 
I 
, . ·1 
1 
J 
't..', "~--~.' 
~ 1 
~ 
~ 
:' 1; j- :~ I 
I 
:f 
;j 
'I 
" .~ 
r 
F:> 
t 
, , 
J , 'I ~ 
~: 
,. }l 
,. 
f1 
~; 
~ 
" ~ 
il 
il! 1~ 
k!l 
I I 
:t. 
;jj 
Another difference in the contractile mechanism in the hID tissues is 
shown by the interaction of tryptamine-S with methysergide on stomach fundus. 
We have seen that tryptamine-S exhibits autoinhibition with intrinsic activity 
a' > 0 for the inhibitory receptor in aorta; on stomach fundus, however, no 
autoinhibition was observed, indicating that either a
1 equals zero, then 
tryptamine-S should act as a competitive antagonist of methysergide (19). 
This would result in a shift of the pA plot for tryptamine-S to the right, 
tDward higher concentrations of methysergide t in order to obtain the desired 
dose-ratio. Tryptamine and tryptamine-S shov>/ed the same intrinsic activity 
and approximately the same affinity for the receptors. If methysergide inter-
acts with both of these agonists in the same fashion, as it does, the pA 
curve for tryptamine-S should be shifted to the ri ght of that for tryptamine 
if tryptamine-S is a competitive antagonist of methysergide. Figure 4 
demonstrates that this is not the case. Therefore, no autoinhibition of 
tryptamine-S is seen in stomach fundus because the inhibitory receptors are 
not the same as those in,aorta, indicating that the events linking stimulus 
and response are not the same in the two tissues. 
In order to uphold these conc1usjons further experimental evidence is 
required. Most importantly, it would be desirable to obtain a compound which 
acts competitively toward serotonin in both aorta and stomach. This would 
provide more conclusive evidence regarding the identity of the receptors in 
the blo tissues. Since methysergide did not act competitively, one cannot 
state conclusively whether the isosteres act on serotonin receptors in aorta. 
If indeed the t\'10 tissues have different serotonin receptors, it may be difficult 
to find an antagonist \'Ihich is competitive against each. This difficulty is 
compounded by the fact that the competitive antagonists of serotonin are often 
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other indole analogs. The results of analog-analog interactions could be 
difficult to interpret. LSD and BOL are probably not the best candidates for 
further receptor studies. as they are so closelY related to methysergide in 
structure that they may only give the same results as those presented herein. 
On the aorta. the analogs should also be tested against phentolamine (an 
a-adrenergic antagonist) and possiblY cyproheptadine (an antagonist of sero-
tonin and histamine Hl receptors) in order to elucidate their mechanism ~re 
fully. It would also be desirable to test antagonists of a different class 
of compounds against the isosteres on stomach fundus in order to determine 
their mechanism; such antagonists should include atropine. and ganglionic 
blockers in order to examine the possibility that the isosteres are acting 
indirectly. 
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SUr~t~ARY 
Tryptamine and its benzo[b]thiophene and l-methylindole analogues had 
a lower affinity for receptors in rat stomach fundus strips than did serotonin; 
the interaction between serotonin and methysergide in this system was competitive, 
\'1hile the interactions bebJeen tryptamine and its analogues and methysergide ,~ 
were noncompetitive. In contrast, the affinity of tryptamine and; l-methy1-
tryptanline for receptors in rat aorta strips was greater than the affinity for 
serotonin; all three compounds showed noncompetitive interactions with me thy-
sergide. The results support the hypothesis of differing serotonin receptors 
in the two tissues. 
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TABLE 1 
pD2 VALUES OF NOREPINEPHRINE AND INDOLEALKYLAMINES 
Compound 
Norepinephrine 
Serotonin 
Tryptamine 
Tryptamine-l-Me 
ON ISOLATED RAT AORTA STRIP 
pD2 ± C.L.* 
8.10 ± .15 
6.57 ± .08 
6.98 ± .21 
7.13 ± .04 
n 
61 
166 
59 
58 
Slope of Log Dose-
Response Curve 
41.51 
34.38 
27.69 
29.17 
*pD2 values ± 95% confidence limits are calculated~s described in 
Methods; n is the total number of responses to all concentrations 
of each compound. 
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Compound 
Serotonin 
Tryptamine 
Tryrtamine-
l-Me 
TABLE 2 
ANTAGONISM OF EFFECTS OF INDOLEALKYLAMINES 
ON RAT AO~TA STRIP BY METHYSERGIDE 
pA2 ± C. L. * pAlO ± C. L. * 
pA2 - pAlO 
10.36 ± .2 8.57 ± .07 1. 79 
9.44 ± .2 6.96 ± :2 2.48 
10.09 ± .3 6.62 ± .2 3.47 
Slope of 
pA p10t 
-.64 
.,..45 
-.38 
*pA2and pAlO values ± 95% confidence limits are calcUlated as described 
in Methods. 
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TABLE 3 
pD2 VALUES OF SEROTININ AND TEST AGONISTS 
ISOLATED RAT STOMACH FUNDUS STRIP 
Slope of Log Dose-
Compound pD2 ± C.L.* n Response Curve 
Serotonin 9.34 ± .16 72 42.49 
Tryptamine 7.60 ± .06 35 82.09 
Tryptamine- 7.91 ± .08 71 47.77 
l-Me 
Tryptami ne-S 7.51 ± .08 66 47.35 
*pD
2 
values ± 95% confidence limits are calculated as described in Methods; 
n is the total number of responses to all concentrations of each compound. 
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TABLE 4 
ANTAGONISM OF EFFECTS OF SEROTONIN AND TEST AGONISTS 
ON RAT STOMACH FUNDUS STRIP BY METHYSERGIDE 
Slope of Compound pA2 ± C.L.* pAlO :i: C.L.* pA2 - pAlO pA plot 
Serotonin 8.80 ± .23 7.88 ± .30 
.92 
-1.26 
Tryptamine 8.77 ± .09 8.22 ± .09 
.55 
-1.77 
Tryptami ne- 8.67 ± .06 8.24 ± .07 .43 
-2.23 l-Me 
Tryptami ne-S 8.85 ± .12 8.39 ± .09 .46 
-2.19 
*pA2 and pAlO values ± 95% confidence limits are calculated as described 
in Methods. 
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FIGURE 1. Effects of Agonists on Isolated Rat Aortic Strips. 
Graphical presentation of data used to obtain the values 
presented in Table 1. The effects of norepinephrine 
(NE, ---0-), serotonin (5HT, -e-)' tryptamine 
(T - -.- -), and 1-methyltryptamine (lMT - . -Q' - .) 
are plotted as log agonist concentration (abscissa) against 
percent contraction (ordinate). Straight lines were 
determined by regression analysis using the method of least 
squares. 
FIGURE 2. Effects of Methysergide on Agonist Action on Rat Aortic Strips. 
• Graphical plesentation of the data used to obtain the 
values pres~nted in Table 2, plotted according to the 
method of Arunlakshana and Schild (1959). The negative 
log of the molar concentrations of methysergide (abscissa) 
are plotted against log X-1, where X is the dose ratio 
for serotonin (5HT, -.-) , tryptamine (T, - -.- -) 
and l-methyltryptamine (lMT, - . -0' - .). Straight lines 
were determined'by regression analysis using the method 
of least squares. 
FIGURE 3. Effects of Agonists on Isolated Rat Stomach Fundus Strips. 
Graphical presentation of data used to obtain the values 
presented in Table 3. The effects of serotonin (5HT, 
-e-), tryptami ne (T, - -. - -), l-methy1 tryptami ne 
(lMT, - . -0' - .), and 3-(2-aminoethyl )benzo[b]thiophene 
(ST, - - -[]- - -) are plotted as log agonist concentration 
(abscissa) against percent contraction (ordinate). Straight 
lines were determined by regression analysis using the method 
of least squares. 
FIGURE 4. Effects of Methysergide on Agonist Action on Rat Stomach 
Fundus Strips. 
Graphical presentation-of the data used to obtain the values 
presented in Table 4, plotted according to the method of 
Arunlakshana and Schild (1959). The negative log of the 
mo1a~ concentrations of methysergide (abscissa) are plotted 
against log X-1, where X is the dose ratio for serotonin 
(5HT, -e-), tryptamine (T, - -.- -), 1-methy1tryptamine 
(lMT, - . -0' - .), and 3-(2-aminoethy1)benzo[b]thiophene 
(ST, - - -0 - - -). Straight lines were determined by 
regression analysis using the method of least squares. 
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DRUG INTERACTIONS ON BODY TEMPERATURE MAINTENANCE 
* IN THE MOUSE 
Carlos M. Quirce#, Richard M. levine and Roger P. Maickel 
Section of Pharmacology 
Medical Sciences Pro~ram 
Indiana University School of Medicine 
Bloomington, Indiana 47401 
ABSTRACT 
Exposure of mice to an environmenta.l temperature 1 eads to a loss of body 
temperature and death in 5 - 6 hours. Intraperitoneal injection of water or 
d-amphetamine exacerbates this effect, while caffeine has a modest antag-
onistic effect. The combination of caffeine and d-amphetamine ;s synergistic 
and leads to a rapid loss in body temperature with death occurring in less 
than 3 hours. 
INTRODUCTION 
When the mammalian organism is placed under environmental conditions 
other than those considered usual or normal, the effects of drugs may be 
considerably altered. Thus, a variety of stresses have been shown to signifi-
cantly influence drug action (Rupe, et ~, 1963; Barry and Buckley, 1966). 
One specific area in which drugs and abnormal environmental conditions are 
known to interact is that of body temperature maintenance. The homeothermic 
mammal maintains its core temperature within a relatively narrow range 
despite wide variations in environmental temperature; the obviously complex 
* Supported in part by NASA grant NGl 15-003-117. 
'Present address: University of Costa Rica, San Jose, Costa Rica. 
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homeostatic mechanisms involved in this process present a wide range of 
targets for drug effects (Whittow, 1971; Weihe, 1973). Of particular interest 
(lJ is a previous study from this laboratory examining the ability .of a variety 
of drugs to interfere with thermoregulation in the cold-exposed rat by actions 
presumed to involve central and peripheral monoaminergic pathways (Maicke1, 
1970) • 
A report by Muller and Vernikos-Danel1is (1970) indicated that a decreased 
environmental temperature reduced the toxicity of d-amphetamine in mice but 
increased the toxicity of caffeine. Since this laboratory had a cont.inuing 
interest in drug interactions with amphetamine in terms of behavioral {Cox 
and Maickel, 1976} and toxicological phenomena (Sokol and Maickel. 1972), 
a study of interactions of d-amphetamine and caffeine in cold-exposed animals 
was undertaken. The r~su1ts, as presented herein, indicate that an inter-
action between the two drugs does indeed occur, but a confounding variable, 
the stress of an intraperitoneal injection, must be taken into account. 
MATERIALS AND METHODS 
Adult, male C57-B16°mice {22 ~ 25g} were obtained from Murphy Breeding 
Laboratories, Plainfield, IN and maintained on an ad lib diet of Purina 
laboratory chow and tap'water for 7 - 10 days prior to experimental use. The 
animals were cold-exposed in individual screen-wire cages (10 x 10 x 15 cm) 
in a walk-in room at 4° C. All drugs were administered by i.p. injections 
in a volume of 0.1 ml/lO g body weight as solutions in distilled water; control 
animals were given distilled water. Rectal temperatures were measured using 
a YSI Te1ethermomete~with a small animal probe. Rate of heat loss (-dQ/ 
dt) was calculated as described by Maickel, et !l {1967} and slope comparisons 
for body temperature decay curves were made as described by Cox (1970). 
Statistical comparisons for -dQ/dt values were performed as in Maicke1 (1970). 
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RESULTS 
Preliminary studies indicated that single i.p.
 doses of 50 mg/kg of 
caffeine and 10 mg/kg of d-amphetamfne caused 
a 3 - 4 fold increase fn the 
rate of body temperature decline in 2 hours of
 exposure of mice at 4° C, so 
these dosage levels were selected for the test
. The data presented in Table 
1 show the effects of single doses of the drug
s. The results clearly demon-
strate that a single f.p. injection of distilled water evok
es a significantly 
greater rate of heat loss as compared to contr
ol (uninjected, but handled) 
animals. In fact, statistical comparisons of
 the -dQ/dt values and the 
slopes for the water and caffeine-treated grou
ps indicate that both of these 
differ significantly from controls but not from
 each other. In contrast, 
dosage with d-amphetamine caused a significant
ly steeper temperature decay 
curve, and significantly greater rate of heat l
oss than any other group. Of 
interest is the fact that caffeine seemed to a
fford some degree of protection 
in that 10 of 12 animals survived for 4 hours 
as compared to 0/12 for water-
injected mice. The enhanced toxicity evoked by d-amphetamin
e is confirmed 
" by the death of 2/12 mice by the 3 hour time p
oint. 
Because of the possible confounding variable o
f water injection, the 
drug interaction studie~ were run as a separat
e experiment; these data are 
presented in Table 2. The effects of two wate
r injections were virtually 
identical to those of a single injection of d-amphetamine (T
able 1) as well 
as to the combination of water plus amphetamin
e injections in terms of the 
rate of heat loss, as well as in the fact tha
t 1/12 animals died by 3 hours 
and all 12 were dead by the 4 hour point. In 
contrast, the combination of 
water and caffeine injections showed a significant protectiv
e effect; 7/12 
mice were still surviving at the 4 hour time 
point, and the rate of heat loss 
and decay slope for body temperature were sign
ificantly reduced. The combi-
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TABLE 1 
Effects of Single Drug Dosage on Body Temperature Maintenance 
by Cold-Exposed 1'1ice 
Mice were given a single i.p. injection as described in Materials and Methods at 25 minutes prior to the 
start of cold exposure. Each value is the mean ± SEM of values obtained; the number in parenthesis indicates 
the N at each time point. Values for -dQ/dt and for the slope of the body temperature decay curves are for 
the period 0 - 2 hours. 
Body Temper~~ure @ Hours of Exposure 
Treatment 0 1 2 3 
4 -dQ/dt Slope Co Co Co Co Co cal/hr 
Control 37.8±O.2(12) 36 .1 ±O . 2 (12 ) 34.4±O.3(12) 29.4±O.3(12) 18.9±O.3(12) 3S.S±2.7 , - .588 
Water 37.8±O.3(12} 33.9±O.4(12) 27.2±O.2(12) 1 6 • 7 ±O • 4 ( 1 2 ) # 11 0 .8±9.3 -.184 
Caffeine 37.0±0.2(12) 32.7±O.3(12) 26.8±O.3(12) 17 .4±O.4(12) l2.6±O .5(1 0) l1S .• D±6.1 -.194 
d-Amphetamine 37.8±O.3(12) 31.1±0.4(12) 21.7±O.3(12) 13.9±0.3(lO) # 168.2± 14.0 - .123 
#All animals dead; body temperatures < 11° C. 
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TABLE 2 
Effects of Drug Interactions on Body Temperature Maintenance 
of Cold-Exposed Mice 
Mice were given i.p. injections as described in Materials and Methods, one at 27 minutes and the other 
at 23 minutes prior to the start of cold exposure. Sequencing was randomized so that half of each group 
received the reverse order. Each v.a1ue is the mean ± SEM of values obtained; the number in parenthesis 
indicates the N at each time point. Values for -dQ/dt and for the slope of the body temperature decay curves 
are for the period 0 - 2 hours. 
Body Temperature @ Hours of Exposure 
Treatments 0 1 2 3 CO CO cO Co 
Water & 
Water 38.3±0.3(12) 32.8±0.4(12) 23.0±0.5(12) 14.4±0.5(11) 
Water & 
Caffeine 37.0±0.4(12) 33.0±0.3(12) 27 • 5±0. 7 (12) 17.6±0.4(12) 
Water & 
d-Amphetamine 37.1±0.3(12) 29.4±0.5(12) 19.2±0.4(12) 12.5±0.6{8) 
Caffeine & 
d-Amphetamine 37.8±0.2(12) 27.8±0.3(2) 1 6 • 1 ±O • 3 (11 ) # 
#A11 animals dead; body temperatures < 11° C. 
" ',~ 
,.." 
4 -dQ/dt Slope Co cal/hr 
# 150.5±8.3 -.136 
12. 5±0. 9 (7) 99.3±5.2 -.209 
# 187.1±9.6 - .111 
226.8±11.3 -.092 
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nation of amphetamine plus caffeine had an etlhanced toxicity, with the most 
rapid rate of hetit loss of any tested group. In fact, the 1/12 mice died in 
2 hours and all 12 were dead at the 3 hour time point. 
DISCUSSION 
The use of an excessive environm~nta1 temperature differential as a 
system to examine drug effects on the ability of a homeothermic animal to 
maintain body temperature within normal limits has been a common technique 
(Chen, et!i, 1943; ~1aickel, 1970; ~Jeihe, 1973). In homeothermic mammals, 
the processes involved in body temperature maintenance in the face of a low 
environmental temperature include both heat conservation and increased heat 
production (Jamira, et!i, 1965; Naickel, et!l., 1967). This entire area 
of temperature regulatory processes has been the subject of several extensive 
reviews (Hardy, et !l., 1970; Cabanac, 1971). 
The studies presented in the present report are of significant value 
in regard to two diverse findings. First of all, a significant potential 
artifact in thermoregulatory studies may exist vlith mice in that the animals 
• lose body heat at a significantly faster rate merely due to an intraperitoneal 
'injection of a small volume (0.1 ml/100 g body weight) of distilled water. 
This effect appears to 5e due to the injection process, since merely punctur-
ing the abdomen or injection of a similar volume of physiological saline 
had a similar action. The effect does not occur in rats (Maickel, 1970) and 
may thus reflect a greater responsivity to stress in the mouse; the additional 
stress having a deleterious effect on thermoregulatory process. 
Administration of caffeine-has a modest antagonistic effect towards the 
injection stress ~ se, whi1e administration of a single dose of d-amphetamine 
appears to exacerbate the stress effect on temperature maintenance. However, 
the combination of caffeine and d-amphetamine had a marked synergistic action 
~,.} ~,.. 
\\' : 
I 
. I 
resulting in a rapid temperature fall and the deaths of one hundred percent 
of the animals in slightly more than 2 hours of exposure to a 4° C environ-
mental temperature. This drug interaction must be considered in the light 
of previous studies from this laboratory showing that, in the rat, caffeine 
had no effects on the anorectic action of d-amphetamine although it did 
antagonize the stimulatory effect of the latter drug on continuous avoidance 
responding. It appears that the interactions of d-amphetamine (a stimulant 
of catecholaminergic function) and caffeine (a blocker of the phosphodies-
terase system that destroys cyc.lic AMP) may be uniquely specific to the test 
system being measured. 
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INTRODUCTION 
The methyl group attached to the a-carbon of 
amphetamine confers on 
. 
the molecule the property of stereoisomel"ism
, giving rise to two enantiomers t 
both of which have significant pharmacologica
l activity (1). For a number 
of years, the generally held belief was that 
d-amphetamine was 3 to 5 times 
more potent than the l-isomer as a stimulant
 of the central nervous system, 
while l-amphetamine'was slightly more potent
 than the d-isomer as a peripheral 
pressor agent (7). However, studies reported in the past fi
fteen years 
give support to the hypothesis that the two 
isomers may have 'actions on 
various behavioral test systems that differ i
n both qualitative and quanti-
tative aspects. Moore (15) has shown that the d-is
omer is more toxic than 
the 1-isomer in both isolated and aggregateci 
mice; this toxicity difference 
paralled the potency of the isomers' in reduci
ng brain norepinephrine., (NE). 
, .... w 
Several laboratories in studying the actions 
of amphetamine isomers on ,: 
; 
10comotor activity have concluded that the d-
isomer is merely more potent 
than the l-isomer (17, 21, 23-25). It should be noted 
that some of these 
studies are confounded by the fact that anim
als were pretreated with a 
monoamine oxidase inhibitor (MAOI).. Studies of the eff
ects of the isomers 
on stereotyped behavior suggested that the ef
fects of d-amphetamine could 
be correlated with actions on NE systems whil
e those of l-amphetamine 
correlated better with actions on dopamine (DA) systems
 (5, 23, 24). 
Sparber and coworkers (18, 27) have reported differenti
al actions of the 
amphetamine isomers 1n operant behavioral sys
tems such as fixed-interval 
and fixed-ratio respond1n~. 
) 
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In addition to these behavioral studies, a number of reports have 
demonstrated differential actions of the amphetamine isomers on brain 
catecholamine uptake, release, and metabolism; these actions show both 
qualitative and quantitative differences in the isomers (4v 19, 26). 
Finally, several studies have suggested that a catecholamine-serotonin 
interaction may exist in the control of locomotor activity in the rat 
(11, 16), although this hypothesis has recently been challenged by Jacobs, 
et ~ (8). 
In terms of the effects of amphetamine isomers on spontaneous motor 
activity in mice, Bainbridge (2) found that d,l-amphetamine had a dose-
dependent effect on SMA; doses < 5 mg/kg were depressant, while doses 
> 10 mg/kg were stimulatory. 
A previous publication from this laboratory (12) demonstrated that 
at low (0.5 mg/kg). and high (8.0 mg/kg) doses, both isomers were stimulants 
of SMA in mice, while,~t intermediate doses (1.0-4.0 mg/kg), the d-isomer 
was stimulatory while the 1-isomer caused a significant depression. 
The present paper examines the actions of d- and l-amphetamines on 
SMA in mice pretreated with agents known to cause alterations in brain 
biogenic amines: a-methyltyrosine (aMT), p-chlorDphenylal~l~ine (PCPA), 
pargy1ine, and reserpine. 
MATERIALS AND ~1ETHODS 
Adult, male, Swiss-Webster mice, weighing 25-30 grams were obtained 
from Murphy Breeding Laboratories, Plainfield, Indiana. The animals were 
maintained on ad lib diet of Wayne Lab Blox and tap water for 7-10 days 
prior to experimental use in an animal room with controlled temperature 
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and a 14:10 light-dark cycle • ..All testing was done between 1000 and 1600 
hours, midway in the 1 ight cycle. Drugs wer.e administered by i .p. injection 
as aqueous solutions (d-amphetamine, 1-amphetamine, pargyline, reserpine) 
or peanut oil suspensions (aMT. PCPA) in a volume of 0.1 m1/l0g body weight. 
All dosages were given and are reported as bat~ weight. 
a~1T and PCPA were purchased from Regi s Chemical Company and Pierce 
Chemi cal Company, respectively. d-Amphetamine su1 fate was kindly supplied 
by Smith-Kline and French; l-amphetamine phosphate was kindly supplied by 
Pennwalt Corporation; pargyline hydrochloride was kindly supplied by Abbott 
laboratories; and lyophylized reserpine phosphate was kindly supplied by 
CIBA-Geigy Corporation. 
SMA activity was measured, using groups of 3 mice, in Woodward acto-
photometers; the procedure was basically that described in a previous 
paper from ~his laboratory (12). The system as utilized has been considered 
as a standardized measurement of psychogenic spontaneous locomotion (9) • 
.. 
It is especially reliable for stimulant drugs sLich as d-amphetamine, yielding 
inverted "U" dose-response curves similar to those obtained with continuous 
avoidance responding. Brain levels of 5HT and NE were determined by the 
method of Maickel, et!l (13). • 
RESULTS 
Standardization of the SMA Test System. Effects of Single Doses of 
Amphetamine Isomers. 
In order to restandardize the test system and provide baseline data 
for interaction experiments, the experiments reported by Maickel, et al 
(12) were repeated, using doses of 1.0 or 4.0 mg/kg of d-amphetamine or 
l-amphetamine. The data obtained are presented in Table 1. As can be seen, 
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both doses of d-amphetamine caused a significa
nt increase in SMA activity 
at all time points. The lower dose of l-amphe
tamine (1.0 mg/kg) caused 
a decrease in activity for the first 10 minute
s and an increase in the 
third and fourth 10 minute periods, while the 
higher dose caused a decreased 
SMA activity in the first three 10 minute peri
ods and an increase in the 
final period. 
Effects of Drug Treatments and Pretreatments o
n Brain levels of 5HT and 
NE. 
In order to have some information on the effec
ts of the various compounds 
studies on brain levels of 5HT and NE, assays 
for, these amines were performed. 
i 
The data are presented in Table 2. As can be 
seen, aMT reduced brain NE 
levels by 64% with no change in SHT, while PCP
A reduced 5HT levels· by 67% 
with no Significant change in NE. Pargyline 
increased 5HT levels by 89% 
. 
and NE levels by 81%, while reserpine reduced 
5HT levels by 82% and NE levels 
by 81%. Neither of the amphetamine isomers ha
d any signific~nt effect on 
either amine. 
Effects of aMT Pretreatment on Actions of Am
phetamine Isomers. 
The data in Table 3 demonstrate the effects o
f aMT pretreatment on 
the actions of d- and l-amphetamine on mouse S
MA activity. The aMT pre-
., 
treatment itself caused a modest, but signific
ant, reduction in S~~ at all 
four time intervals. Both doses of d-amphetam
ine caused an increase in 
SMA in the aMT pretreated mice, although the c
haracteristics of the effect 
differed from that seen in cO!1trol animals (Table 1). For ex
ample, the 
magnitude of the stimulatory effect of the 1.0
 mg/kg dose in the first 
activity interval in the aMT pretreated mice, w
hen estimated by the ratio 
of taunts, did not differ significantly from t
hat seen in contl'ol mice; 
! 
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: Lei however, in the final two intervals, the aMT pretreatment virtually abolished 
the stimulatory effect of the d-amphetamine. At the higher pose (4.0 mg/kg) 
of d-amphetamine, a similar pattern of reduction of response was seen over 
the final two intervals although in the first interval a greater increase 
was observed in the aMT pretreated animals than in the controls. 
! 
i 
With the 1.0 mg/kg dose of the l-isomer, a slight increase in SMA 
(as compared to aMT alone) was observed in the first interval, followed 
by a decrease in the second interval and then two intervals where no drug 
effects were observed. When compared to this dose of l-amphetamine in 
untreated animals, an increased SMA ratio was seen in the first interval, 
followed by slightly lower values for the remaining intervals. The 4.0 
mg/kg dose of l-amphetamine in aMT pretreated mice showed no intervals with 
SMA counts greater than those of pretreatment alone. When comapred to the 
effects of that dose of l-amphetamine in control mice, the only significant 
difference was a marked lessening of activity in the 31-40 minute interval. 
Effects of PCPA Pretrlatment of Actions of Amphetamine Isomers. 
These data are presented in Table 4. Pretreatment with PCPA had no 
significant effects on SMA at any of the intervals. Both doses of d-amphetamine 
increased SMA significantly at all intervals as compared to PCPA pretreatment 
'. 
alone. The magnitude of stimulation evoked by the lower dose of d-amphetamine 
(1.0 mg/kg) was somewhat reduced by the PCPA pretreatment. Ir.! contrast the 
higher dose of d-amphetamine was slightly more effective in the animals 
pretreated with PCPA. 
At the lower dose (1 mg/kg), l-amphetamine acted as a stimulant in PCPA 
pretreated animals; the effect was greater than that of the same dose in 
control animals. The higher dose of l-amphetamine (4.0 mg/kg) had no signifi-
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cant effect on SMA in PCPA pretreated mice • 
Effects of Pargyline Pretreatment on Actions of Amphetamine Isomers. 
The data, as presented in Table 5, show that the pargyline pretreatment 
itself caused a significant decrease in SMA over the last three intervals. 
When compared to these values, both doses 'of d-amphetamine caused increased 
sr~ at all intervals; only the first interval with the lower dose was not 
statistically significant. However, in comparison to the effects in control 
animals, the par'gy1ine-pretreated animals were less responsive to the stimu-
latory action of d-amphetamine at both doses. 
l-Amphetamine had no significant actions at the lower dose (1.0 mg/kg) 
when compared to pargyline pretreatment alone. At the higher dose (4.0 mg/kg), 
a complex pattern was seen, with significantly decreased SMA in the first 
and fourth intervals, a significant increase in the second, and no effect 
in the third when compared to pargyline pretreatment alone. When compared 
to the actions of the 1-isomer in untreated animals, the effects of pargyline 
pretreatment seem to have been those of removal of any stimulatory component. 
Effects of Reserpine Pretre~~ment on Actions of Amphetamine Isomers. 
Table 6 shows that mice treated with a single dose of reserpine (10 
mg/kg, i.p.) 24 hours prior to testing obviously displayed the typical 
• 
sedation syndrome with a virtual absence of SMA. Administration of the 
low dose (1.0 mg/kg) of d-amphetamine evoked a small but significant increase 
in SMA which was far less than that p'roduced by a similar dose in control 
animals. However, the larger ~ose of the d-isomer, when given to reserpine-
pretreated mice, produced counts tt;at were greater, at each interval, than 
those seen in control animals given the same dose. 
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Administration of the low dose (1 mg/kg) of 1-amphetamine to mice pre-
treated with reserpine resulted in a brief stimulatory response of small 
magnitude followed by negligible activity over the last two intervals. 
At the higher dosage, the l-isomer was slightly stimulatory, with the 
effect decreasing with time. 
DISCUSSION 
The effects of amphetamine on various aspects of animal behavior have 
been the subject of literally thousands of experiments. Until about twelve 
years ago, most reports concluded that the two isomers of amphetamine 
differed only in terms of quantitative potency. This was especially true 
in terms of behavioral tests in which the drug effect was manifested as a 
central stimulatory activity, that is, one resu1tin~ in increases in rates 
of activity or responding. More recently, a variety of reports (18, 27), 
including one from this laboratory (12), have suggested that some basic 
qualitative differences may exist in the actions of the amphetamine isomers 
on animal behavior. In extending our previous work, the use of the simple 
actophotometer, with groups of 3 mice per unit, was continued as a measure 
of spontaneous motor activity. The use of naive mice in each test run 
insured a high component of exploratory activity ,'in the overall SMA measure-
ment; the use of 10 minute counting intervals pe~-mitted evaluation of 
varying duration of drug effects as well as enhancing the magnitude of 
specific phenomena of brief duration. 
The data obtained in control (non-pretreated) animals, as presented in 
Table 1, were basically similar to those previously reported by this laboratory 
(12). Thus, d-amphetamine, at both dosages, (1.0 and 4.0 mg/kg), caused a 
marked increase in SMA over control values. The decrease in SMA during the 
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third interval at the higher do~e of d-amphetamine was seen consistently 
and may reflect a temporary fatigue. In contrast to the d-isomer, 1-amphet-
amine showed markedly differing dosage effects. At the lower dose (1.0 
mg/kg), a significant decrease in SMA in the first interval was followed 
by a non-significant action in the second test interval, and a slight 
stimulatory action in the remaining two intervals. In contrast, the higher 
dose of l-amphetamine (4.0 mg/kg) caused a significant reduction in SMA 
activity over the first 3 test intervals. reverting to stimulatory actions 
only in the last ten minutes. 
The first pretreatment studied was that of aMT which produced a 64% 
decrease in whole brain NE at the ti~e of starting the test period with no 
significant alteration in brain SHT (Table 2). Since aMT depletes NE by 
inhibition of tyrosine hydroxylase, it may be assumed that some reduction in 
brain dopamine levels also Dccurred under these conditions (22). With this 
pretreatment, the stimulatory effects of the low dose of d-amphetamine were 
, 
markedly reduced both in magnitude and duration (Tab1e 3), while the higher 
dose had an initial stimulatory effect greater than that seen in controls, 
followed by a rapid abatement of stimulatory activity. These results confirm 
the observations made by Miller, et al (14) that aMT pretreatment had a 
--
. 
marked effect on the abi~ity of d-amphetamine to increase continuous 
avoidance responding in rats. Thus, the stimulatory actions of d-amphetamine 
may be dependent upon the presence of a labile or newly synthesized cate-
cholamine pool. In contrast ·to the actions on d-amphetamine, the aMT 
pretreatment generally caused the l-isomer to have a greater SMA depressant 
effect, especially in terms of duration of action. This would agree with 
the hypothesis that this depressant action may involve systems that are 
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, , functionally antagonistic in terms of controlling SMA; one involving cate-
cholamines, and the other involving some other biogenic amine. 
Pretreatment with PCPA, at a dosage regimen that reduced brain 5HT 
by 67% with only a slight and non-significant action on brain NE, (Table 2), 
had no significant effect on the SMA (Table 4). PCPA pretreatment caused 
a small reduction in the SMA stimulation evokec by the lower dose of d-
amphetamine, but enhanced the stimulatory actions of the higher dose of 
'. 
d-amphetamine. The action of PCPA pretreatment, with its concommitant 
reduction of brain 5HT, was most dramatic on the effects of l-amphetamine. 
The depressant effects of both doses of the l-isomer was completely blocked; 
indeed the lower dose even showed a modest stimulatory effect on SMA. These 
results lend support to the hypothesis that the depressant actions of the 
l-isomer on SMA may involve action on a serotonergic system. 
Pargyline pretreatment, elevating brain levels of 5HT by 110% and NE 
by 81% (Table 2), caused a modest decrease in SMA (Table 5) possibly due to 
an increased serotonergic tone. The stimulatory effects of both doses of 
d-amphetamine were reduced at all intervals; the most dramatic reductions 
\'/ere seen in the periods beyond 20 minutes, where the 3- to 5-fold increase 
in counts seen in control animals was reduced to 2- to 3-fold increases by 
the pargyline pretreatment. In contrast to these observations, the low 
dose of l-amphetamine was without a significant effect on SMA, while the 
high dose depressed S[~A activity in the first and fourth intervals, but 
II 
showed a significant paradoxical increment in the second interval. 
Reserpine pretreatment, on the other hand, reduced brain 5HT levels 
~ by 82% and brain NE levels by 80% (Table 2); under these conditions, SMA 
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lL was virtually abolished (T3.ble 6). Both doses of d-amphetamine had 
stimulatory activity in reserpine pretreated animals (Table 6). In fact, 
the effects of the 4.0 mg/kg dose were similar to or greater than the actions 
of the drug in non-treated controls. This may be a reflection of a central 
nervous system version of "supersensitivlty" (28) or it may reflect a direct 
stimulatory action of d-amphetamine as proposed by Rech (20). ,At the 
lower dose, l-amphetamine had a very small stimulant effect in reserpine-
pretreated animals, while at the higher dose the l-isomer had a modest 
stimulant action, approximately one-fourth as potent a$ that of the d-isomer. 
Of course, since the SMA after reserpine pretreatment was so low, it was 
impossible to elicit any further depression with l-amphetamine. Neverthe-
less, it was of interest to discover that the mixed activity of the l-isomer 
could be so easily converted to purely stimulatory action by virtue of 
reserpine pretreatment. 
When the various results presented in this paper are recomputed in 
terms of "percent control" as described by Jacobs, et ~ (8), a 'most interesting 
set of numbers are generated; these are presented as Table 7. In no instance 
did any dose or count interval in animals treated with~-amphetamine show 
a decrease in SMA; in contrast, with the exception of the animals pretreated 
with reserpine or PCPA, the preponderant response to l-amphetamine was a 
decreased SMA. 
An overview of these results leads to the conclusion that the d-isomer 
of amphetamine, at doses of 1.0 and 4.0 mg/kg, k.p. in miGe, has a net 
stimulant action as reflected by increased SMA, and, that this effect is 
mediated by catecholamine release from freshly synthesized or labile pools. 
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~:;. Ih contrast, the l-isomer of amphetamine appears to have a dual nature. 
In addition to possessing a modicum of catecholamine releas~ng activity, 
it also has an ability to interact with serotonergic systems, perhaps by 
the very nature of its e-phenylethylamine structure. Thus, if one assumes 
that SMA reflects a net activity controlled by a "balance" of 5HT and 
catecholamine functions (3, 6), d-amphetamine will increase SMA by shifting 
the "balance" to the catecholamine side, while l-amphetamine will decrease 
SMA by shifting the "balance ll in favor of the serotonin side. The possible 
role of other biogenic amine systems (such as dopamine) cannot be eliminated, 
although in the present work, the levels of amphetamines used may not have 
had a significant action on dopaminergic systems (10). 
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TABLE 1 
Effects of S;nqle Doses of AmEhetami ne Isomers on Mouse SMA 
Counts per Interval ± SEM* 
Dose N 0-10 min 11-20 min 21-30 min 31-40 min 
mg/kg 
15 818± 25 558± 16 393± 12 297± 10 
1.0 12 1266± 461 l290± 421 1270± 31
1 1257± 451 
4.0 12 1498± 431 1697± 471 1209± 37
1 1508± 411 
1.0 12 690± 220 565± l4NS 460± 17
1 385± 161 
4.0 12 675± 190 303± 140 283± 15
0 409± 191 
Data were obtained as described in Materials and Methods; each "N" 
represents a run of 3 mice. 
*Superscript letters refer to individual comparisons of each interval 
to corresponding control interval by b'o-tai1ed lit" test: 
I = increased counts (p < .001) 
o = decreased counts (p < .001) 
NS = non-sigpificant 
DOne way analysis of variance for drug effect; p values are given for 
F (2,6). 
• 
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TABLE 2 
Effects of Druq Treatments on Levels of 5HT and NE in Mouse Brain 
Brain Levels (pg/g ± SMA) 
Drug Treatment N 5HT NE 
12 0.73 ± .02 0.59 ± .02 None 
ar~T 8 0.77 ± .02 0.21 ± .01
0 
PCPA 8 0.24 ± .02
0 0.51 ± .02 
Pargyline 8 1.38 ± .05
1 1.07 ± .051 
Reserpine 8 0.13 ± .01
0 0 0.11 ± .01 
d-Amphetamine 6 0.71 ± .02 0.58 ± .02 
l-Amphetamine 6 0.73 ± .03 0.59 ± .02 
Each "N" value represents a pool of brains from 2 mice. Pretreatment 
schedules were as follows: 
aMT - 150 mg/kg, i.p. (peanut oil suspension) at 24 hoursilnd 4 
hours prior to sacrifice. 
PCPA _ 400 mg/kg, i.p. (peanut oil suspension) at 48 hours prior 
to sacrifice. 
Pargyline - 40 mg/kg, i.p. (aqueous solution) at 24 hours and 4 
t~urs prior to sacrifice. 
Reserpine ~ 10 mg/kg, i.p. (aqueous solution) at 24 hours prior 
to sacrifice • 
. d- or l-Amphetamine 4 mg/kg, i.p. (aqueous solution) at 30 minutes 
prior to sacrifice. 
Values differing significantly from control (two-tailed "t" test, p < .05) 
are indicated by D = decrease or 1 ~ increase. 
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TABLE 3 
Effects of aMT Pretreatment on Actions of Amphetamine Isomers 
counts per Interval ± SEM* 
Dose N 0-10 min 11-20 min 
21-30 min 31-40 min 
Fff 
mg/kg -
--------
-
--
8 708± 39D 429± 22D 
'297± 17D 237± 16
D <.01 
1.0 4 1157±61
1 8S0± 551 408± 43
NS 317± 231 <.05 
4.0 4 2062±119
1 1239± 861 309± 24
NS 301± 26NS ,~ .05 
1.0 4 856± 43
1 283± 23D 296± 20
NS 276± 28NS <.05 
4.0 4 628± 41
NS 329± 24D 2S4± 27
NS 160± 16D <.05 
Animals were treated with a.MT as described in Table 2; each liN" 
represents a run of 3 mice. 
*Superscript letters refer to individual comparisons of each interval 
to the corresponding control (for aMT alone) or aMT interval by two-
tailed "til test: 
1 = increased counts (p <.05) 
o = decreased counts (p <.05) 
NS = non-significant 
'One way analysis of variance for ar~T effect as compared to control 
data (Table 1) and for each drug effect as compared to aMT alone; 
p values are given for F (2,6). 
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Effects of PCPA Pretreatment on A~tions of Amphetamine Isomers 
Counts per Interval ± SEM* 
Dose N 0-10 min '1-20 min 21-30 min 31-40 min F' 
mg/kg 
16 832± 24NS 559± 23
NS 427± 16NS 310± 15
NS NS 
1.0 4 1167± 66
1 927± 521 867± 361 1008± 35
1 <.01 
400 4 1742± 691 1724± 96
1 1824± 741 1883± 98
1 <.01 
898± 39NS 764± 461 767± 36
1 I <.01 
1.0 4 
726±·48 .. 
4.0 4 809± 49NS 497± 45
NS 392± 49NS 357± 34NS NS 
Animals were treated with PCPA as described in Table 2; each liN" repre-
sents a run of 3 mice. 
*Superscript letters refer to individual comparisons of each interval 
to the cor.responding control (for PCPA alone) or PCPA interval by the 
two-tailed ~It" test: 
I = increas~d counts (p <.001) 
D = decreased counts (p <.001) 
NS = non-significant 
'One way analysis of variance fo·r PCPA effect as compared to control 
data (Table 1) and for each drug effect as compared to PCPA alone; 
p values are given for F (2,6). 
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lJt TABLE 5 
Effects of p~'ine Pretreatment on Actions, of Amphetamine Isomers 
Counts per i nterva 1 ± SEr~* 
Isomer Dose N 0-10 min 11-20 min 21-30 min 31-40 Jtlin 
inQ7kg 
6 901± 32NS 483± 24D 340± 15° 250± 11° 
d 1.0 3 972± 27NS 1075± 581 657± 541 599± 551 
d 4.0 3 1257±1051 1099± 591 697± 621 ' 797± 381 
1 1.0 3 797± 44 NS 483± 46 NS 241± 53NS 209± 42 NS 
1 4.0 3 722± 48° 748± 731 357± 43NS 128± 21° 
Animals were treated with, partyline as described in Table 2; each IINII 
represents a run of 3 mice. " 
*Superscript letters refer to individual comparisons of each interval 
to the corresponding control (for pargy1ine~'alone) or pargyline intervC./l 
by the two-tailed IIt" test: 
I = increased counts (p <.02) 
° = decreased counts (p <.02) 
NS = non-significant 
" 
'One way analysis of variance f~r pargyline effect as compared to control 
data (Table 1) and for each drug effect as compared to pargyline alone; 
p values are given for F(2,6). 
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TABLE 6 
Effects of Reserpine Pretreatment on Actions of Amphetamine Isomers 
Counts per Interval ± SEM* • 
Isomer Dose N 0-10 min 11-20 min 21-30 min 31-40 min F' 
mg/kg 
6 6± 10 s± 10 11± 2
0 12± 40 <.01 
d 1.0 3 191± 161 300± 281 354± 26
1 189± 201 <.01 
d 4.0 3 1631±191 1 1799± 94
1 1838±1141 ,1930± 591 <.01 
1 1.0 3 68± 101 50± 121 18± 6
NS 8± 3NS <.05 
1 4.0 3 485± 461 464± 58
1 330± 281 162± 241 <.01 
Animals were treated with re,serpine as described in Table 2; each "N" 
represents a run of 3 mice. 
*Superscript letters refer to individual comparisons of each interval to 
the corresponding control (for reserpine alone) or reserpine interval by 
the two-tailed "til test: 
I = increased counts (p <.01) 
° = decreased co~nts (p <.01) 
NS = non-significant 
#One way analysis of variance for reserpine effects as compared to control 
data (Table 1) and for each drug effect as compared to reserpine alone; 
p values are given for F (2,6). 
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TABLE 7 
Effects of Various Pretreatments on SMA Actions of Am hetamine Isomers 
Percent Control Counts 
Pretreatment Isomer Dose 0-10 min 
11-20 min 21-30 min 31-40 min 
mg/kg 
None d 1.0 155 
231 323 423 
4.0 183 304 308 
508 
aMT d 1.0 163 
198 137 134 
4.0 291 289 104 
127 ~ I j 
I 
PCPA d 1.0 139 
165 '" 203 325 
" 
1 
; ~ 
4.0 208 308 427 
607 
1 I t Pargyline d 1.0 108 223 193 240 4.0 140 228 205 319 j 
Reserpine d 1.0 3183 
6000 3218 1575 ~ 
4.0 27183 35980 16709 
16083 
k ~ 
None 1 1.0 84 
101 117 130 
l f 
1 
, j , 4.0 83 
54 72 138 l ] 
aMT 1 1.0 121 
66 100 116 
.1 
I 
4".0 89 77 86. 
68 I 1 
fJ 
PCPA 1 1.0 107 
137 180 234 [ 1 
4.0 96 89 92 
115 ~ ",j 
, 
! l 
:! ,. 
! ' 
Pargyline 1 loO 88 
100 71 84  . 
4.0 80 155 105 
51 t , . 
i' ~ , 
Reserpine 1 1.0 1133 
1000 164 67 
, 
, 
" 
4.0 8083 9280 3000 
1350 
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